,datetime,title,source,link,sentiment_class,sentiment_score
0,9/26/2016 4:00:23 PM,BRIEF-Biogen completes submission of new drug application (BIIB),Reuters,/news/stocks/brief-biogen-completes-submission-of-new-drug-application-biib-1001418267,neutral,0.9216691851615906
1,9/28/2016 3:50:23 PM,BRIEF-Anavex signs material transfer agreement with Biogen (BIIB),Reuters,/news/stocks/brief-anavex-signs-material-transfer-agreement-with-biogen-biib-1001423675,positive,0.8786458969116211
2,10/3/2016 12:10:22 PM,"Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001431817,negative,0.6420673727989197
3,10/3/2016 2:20:21 PM,"RPT-Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/rpt-big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001432682,negative,0.5524705052375793
4,10/26/2016 1:56:20 PM,Drugmaker Biogen quarterly profit rises 7 pct (BIIB),Reuters,http://www.businessinsider.com/r-drugmaker-biogen-quarterly-profit-rises-7-pct-2016-10,positive,0.9269185066223145
5,10/26/2016 2:04:18 PM,BRIEF-Biogen Q3 non-gaap EPS $5.19 (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-q3-non-gaap-eps-519-2016-10,neutral,0.9224367141723633
6,10/26/2016 2:42:23 PM,UPDATE 1-Biogen quarterly profit beats on MS drug Tecfidera sales (BIIB),Reuters,http://www.businessinsider.com/r-update-1-biogen-quarterly-profit-beats-on-ms-drug-tecfidera-sales-2016-10,negative,0.7405759692192078
7,10/26/2016 6:36:18 PM,BRIEF-Biogen CEO says search to find successor progressing (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-ceo-says-search-to-find-successor-progressing-2016-10,neutral,0.9099971652030945
8,11/7/2016 3:10:18 PM,Ionis and Biogen's muscular disorder treatment meets main goal (BIIB),Reuters,http://www.businessinsider.com/r-ionis-and-biogens-muscular-disorder-treatment-meets-main-goal-2016-11,neutral,0.8532004356384277
9,11/7/2016 3:46:20 PM,BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-and-ionis-pharmaceuticals-announce-spinraza-meets-primary-endpoint-at-interim-analysis-of-phase-3-cherish-study-2016-11,positive,0.766438364982605
10,11/7/2016 9:50:20 PM,"UPDATE 1-Ionis, Biogen say second study testing muscle drug succeeds (BIIB)",Reuters,http://www.businessinsider.com/r-update-1-ionis-biogen-say-second-study-testing-muscle-drug-succeeds-2016-11,neutral,0.7424211502075195
11,11/15/2016 3:10:20 PM,BRIEF-Biogen announces additional members of management team of hemophilia spin-off company Bioverativ (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-announces-additional-members-of-management-team-of-hemophilia-spin-off-company-bioverativ-2016-11,neutral,0.9318895936012268
12,11/17/2016 5:04:18 PM,"BRIEF-Eisai Co says FDA grants fast track designation for development of E2609 (4523, BIIB)",Reuters,http://www.businessinsider.com/r-brief-eisai-co-says-fda-grants-fast-track-designation-for-development-of-e2609-2016-11,positive,0.6500636339187622
13,11/23/2016 2:44:20 PM,"Lilly Alzheimer's drug fails to slow memory loss in big study (LLY, BIIB)",Reuters,http://www.businessinsider.com/r-lilly-alzheimers-drug-fails-to-slow-memory-loss-in-big-study-2016-11,positive,0.47603246569633484
14,11/23/2016 6:42:20 PM,"Lilly failure a blow for Alzheimer's research, not end of road (LLY, BIIB, AZN)",Reuters,http://www.businessinsider.com/r-lilly-failure-a-blow-for-alzheimers-research-not-end-of-road-2016-11,neutral,0.917626142501831
15,12/8/2016 11:06:03 PM,BRIEF-Positive trends seen with latest study of Biogen Alzheimer's drug (BIIB),Reuters,http://www.businessinsider.com/r-brief-positive-trends-seen-with-latest-study-of-biogen-alzheimers-drug-2016-12,positive,0.9245797991752625
16,12/9/2016 12:00:05 AM,Further promising data seen with Biogen Alzheimer's drug: study,Reuters,http://www.businessinsider.com/r-further-promising-data-seen-with-biogen-alzheimers-drug-study-2016-12,positive,0.7532356977462769
17,12/9/2016 7:16:05 AM,BRIEF-Biogen presents data from Phase 1b study of investigational Alzheimer's Disease Treatment at 2016 clinical trials on Alzheimer's Disease Meeting (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-presents-data-from-phase-1b-study-of-investigational-alzheimers-disease-treatment-at-2016-clinical-trials-on-alzheimers-disease-meeting-2016-12,neutral,0.8461601138114929
18,12/9/2016 3:48:05 PM,"BRIEF-Biogen, AbbVie get Health Canada approval of Zinbryta for MS (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-abbvie-get-health-canada-approval-of-zinbryta-for-ms-2016-12,positive,0.8409057259559631
19,12/9/2016 3:55:11 PM,"We just got some of the most promising Alzheimer's drug data of the year (BIIB, LLY)",Reuters,http://www.businessinsider.com/r-update-1-further-promising-data-seen-with-biogen-alzheimers-drug-study-2016-12,positive,0.7639120221138
20,12/9/2016 4:00:08 PM,"Astra, Lilly stick with Alzheimer's approach despite setback (BIIB, LLY, AZN)",Reuters,http://www.businessinsider.com/r-astra-lilly-stick-with-alzheimers-approach-despite-setback-2016-12,neutral,0.5094074010848999
21,12/10/2016 11:58:05 AM,"BRIEF-Proteostasis Therapeutics - Co received notice from Biogen of termination of collaborative research, development, commercialization, license agreement (BIIB)",Reuters,http://www.businessinsider.com/r-brief-proteostasis-therapeutics---co-received-notice-from-biogen-of-termination-of-collaborative-research-development-commercialization-license-agreement-2016-12,negative,0.5360137224197388
22,12/22/2016 11:12:03 PM,BRIEF-Biogen says separation of Bioverativ to be completed on Feb 1 (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-says-separation-of-bioverativ-to-be-completed-on-feb-1-2016-12,neutral,0.9520241022109985
23,12/23/2016 11:30:03 PM,UPDATE 1-FDA approves Biogen drug for lead genetic cause of infant death (BIIB),Reuters,http://www.businessinsider.com/r-update-1-fda-approves-biogen-drug-for-lead-genetic-cause-of-infant-death-2016-12,positive,0.7890814542770386
24,12/23/2016 11:30:03 PM,FDA approves Biogen drug for lead genetic cause of infant death,Reuters,http://www.businessinsider.com/r-fda-approves-biogen-drug-for-lead-genetic-cause-of-infant-death-2016-12,neutral,0.7391138672828674
25,12/27/2016 2:10:05 PM,US STOCKS-Futures slightly higher after Christmas holiday (BIIB),Reuters,http://www.businessinsider.com/r-us-stocks-futures-slightly-higher-after-christmas-holiday-2016-12,positive,0.8844735622406006
26,1/6/2017 12:00:09 AM,"BRIEF-Biogen enters into exclusive, worldwide license agreement for Factor IX (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-enters-into-exclusive-worldwide-license-agreement-for-factor-ix-2017-1,positive,0.9070213437080383
27,1/12/2017 2:40:03 PM,BRIEF-Biogen spin-off Bioverativ commences when-issued trading of common stock (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-spin-off-bioverativ-commences-when-issued-trading-of-common-stock-2017-1,neutral,0.9580018520355225
28,1/23/2017 3:06:05 PM,BRIEF-Ewopharma partners with Biogen to commercialise Benepali and Flixabi (BIIB),Reuters,http://www.businessinsider.com/r-brief-ewopharma-partners-with-biogen-to-commercialise-benepali-and-flixabi-2017-1,positive,0.7963961362838745
29,1/25/2017 9:02:05 PM,Possible liver injury added to label of Biogen MS drug,Reuters,http://www.businessinsider.com/r-possible-liver-injury-added-to-label-of-biogen-ms-drug-2017-1,negative,0.7554656863212585
30,2/1/2017 2:08:07 PM,"BRIEF-Biogen completes separation of global hemophilia business, Bioverativ (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-completes-separation-of-global-hemophilia-business-bioverativ-2017-2,neutral,0.9025788307189941
31,2/1/2017 3:36:09 PM,BRIEF-Forward Pharma enters license agreement with 2 units of Biogen and other parties (BIIB),Reuters,http://www.businessinsider.com/r-brief-forward-pharma-enters-license-agreement-with-2-units-of-biogen-and-other-parties-2017-2,positive,0.8922913074493408
32,2/9/2017 2:48:16 PM,Forward Pharma Gets $1.25 Bln On Settlement And License Deal With Biogen ,RTTNews,/news/stocks/forward-pharma-gets-1-25-bln-on-settlement-and-license-deal-with-biogen-1001737656,positive,0.8567219972610474
33,2/9/2017 3:30:09 PM,BRIEF-Forward Pharma receives $1.25 bln pursuant to settlement and license agreement with Biogen (BIIB),Reuters,http://www.businessinsider.com/r-brief-forward-pharma-receives-125-bln-pursuant-to-settlement-and-license-agreement-with-biogen-2017-2,positive,0.7715074419975281
34,2/20/2017 2:42:11 PM,"UPDATE 1-Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment (BIIB, WL6)",Reuters,http://www.businessinsider.com/r-update-1-nordic-nanovector-sees-interest-in-its-non-hodgkin-lymphoma-treatment-2017-2,positive,0.9327551126480103
35,2/27/2017 10:40:52 PM,Perrigo To Divest Its Rights To Royalty Stream From Tysabri To Royalty Pharma ,RTTNews,/news/stocks/perrigo-to-divest-its-rights-to-royalty-stream-from-tysabri-to-royalty-pharma-1001787612,neutral,0.9518517851829529
36,2/27/2017 11:06:13 PM,BRIEF-Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion (BIIB),Reuters,http://www.businessinsider.com/r-brief-perrigo-signs-agreement-to-divest-tysabri-royalty-stream-for-up-to-285-billion-2017-2,positive,0.7910255193710327
37,2/28/2017 3:20:41 PM,"The quest to find new drugs to treat Alzheimer's just suffered another blow (MRK, LLY, BIIB, AMGN)",Reuters,http://www.businessinsider.com/r-acceras-alzheimers-trial-fails-in-yet-another-setback-for-disease-2017-2,positive,0.5512122511863708
38,3/1/2017 1:15:00 PM,"Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen",PR Newswire,/news/stocks/biotech-stocks-under-scanner-immunomedics-peregrine-pharma-vericel-and-biogen-1001794343,neutral,0.8020609617233276
39,3/6/2017 9:44:21 AM,Israel's BrainStorm names Biogen senior executive Kern as COO,Reuters,http://www.businessinsider.com/r-israels-brainstorm-names-biogen-senior-executive-kern-as-coo-2017-3,neutral,0.9406853914260864
40,3/16/2017 12:44:42 PM,"US STOCKS-Futures up on Fed's dovish rate-hike outlook (TSLA, BIIB, DG)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-up-on-feds-dovish-rate-hike-outlook-2017-3,positive,0.5905055999755859
41,3/16/2017 2:04:43 PM,"US STOCKS-Wall St to open higher on Fed's 'gradual' rate-hike outlook (TSLA, BIIB, JCI, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-to-open-higher-on-feds-gradual-rate-hike-outlook-2017-3,positive,0.9250993728637695
42,3/16/2017 3:04:45 PM,"US STOCKS-Wall St edges up on gains in tech, bank stocks (IBM, TSLA, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-up-on-gains-in-tech-bank-stocks-2017-3,positive,0.9375530481338501
43,3/16/2017 5:04:45 PM,"US STOCKS-Wall St slightly lower as healthcare stocks weigh (BIIB, TSLA)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slightly-lower-as-healthcare-stocks-weigh-2017-3,negative,0.9582082033157349
44,3/16/2017 6:16:44 PM,"US STOCKS-Wall St edges down as healthcare stocks hit by budget plan (BIIB, TSLA, TSN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-down-as-healthcare-stocks-hit-by-budget-plan-2017-3,negative,0.9686694741249084
45,3/17/2017 1:00:00 PM,5 Biotech Companies Set for Major Breakouts in 2017,PR Newswire,/news/stocks/5-biotech-companies-set-for-major-breakouts-in-2017-1001845732,neutral,0.6153507828712463
46,3/21/2017 5:40:45 PM,Biogen wins ruling in Tecfidera IP case; shares rise (BIIB),Reuters,http://www.businessinsider.com/r-biogen-wins-ruling-in-tecfidera-ip-case-shares-rise-2017-3,positive,0.9305601716041565
47,3/29/2017 3:34:52 PM,"UPDATE 3-U.S. approves Roche drug that targets severe form of MS (MRK, TEVA, BIIB, SAN)",Reuters,http://www.businessinsider.com/r-update-3-us-approves-roche-drug-that-targets-severe-form-of-ms-2017-3,positive,0.825408935546875
48,3/31/2017 6:36:48 PM,BRIEF-US Patent board rules for Biogen in Forward patent case (BIIB),Reuters,http://www.businessinsider.com/r-brief-us-patent-board-rules-for-biogen-in-forward-patent-case-2017-3,neutral,0.9146142601966858
49,3/31/2017 7:30:53 PM,Biogen wins Tecfidera U.S. patent dispute with Forward Pharma,Reuters,http://www.businessinsider.com/r-biogen-wins-tecfidera-us-patent-dispute-with-forward-pharma-2017-3,negative,0.8530128598213196
50,4/13/2017 4:39:05 AM,"UPDATE 1-Apple hires secret team for treating diabetes -CNBC (AAPL, GSK, ETRM, MDT, SAN, BIIB)",Reuters,http://www.businessinsider.com/r-update-1-apple-hires-secret-team-for-treating-diabetes--cnbc-2017-4,neutral,0.7625442147254944
51,4/13/2017 1:21:00 PM,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche ",RTTNews,/news/stocks/bristol-myers-to-get-470-mln-upfront-from-licensing-deals-with-biogen-roche-1001920351,positive,0.9083372354507446
52,4/13/2017 1:23:07 PM,"BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche (BMY, BIIB)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-enters-into-separate-agreements-with-biogen-and-roche-2017-4,positive,0.5764212608337402
53,4/13/2017 1:45:07 PM,"Bristol-Myers to license two of its drugs to Biogen, Roche",Reuters,http://www.businessinsider.com/r-bristol-myers-to-license-two-of-its-drugs-to-biogen-roche-2017-4,neutral,0.7247767448425293
54,4/13/2017 2:07:04 PM,"BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb (BIIB, BMY)",Reuters,http://www.businessinsider.com/r-brief-biogen-licenses-phase-2-anti-tau-antibody-from-bristol-myers-squibb-2017-4,neutral,0.6860154867172241
55,4/13/2017 2:11:12 PM,"UPDATE 1-Bristol-Myers to license two drugs to Biogen, Roche (BMY, BIIB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-to-license-two-drugs-to-biogen-roche-2017-4,positive,0.5787065029144287
56,4/20/2017 5:15:04 AM,"Activist Sarissa says Innoviva backed out of proxy settlement deal (GSK, BIIB, 4502)",Reuters,http://www.businessinsider.com/r-activist-sarissa-says-innoviva-backed-out-of-proxy-settlement-deal-2017-4,neutral,0.5480778813362122
57,4/20/2017 3:51:04 PM,"UPDATE 1-Innoviva director vote drama hands last-minute loss to Sarissa (GSK, BIIB, 4502)",Reuters,http://www.businessinsider.com/r-update-1-innoviva-director-vote-drama-hands-last-minute-loss-to-sarissa-2017-4,negative,0.6912553906440735
58,4/21/2017 8:35:05 PM,"BRIEF-EU Medicines Agency recommendations for April 2017 (BIIB, BMRN, MYL, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommendations-for-april-2017-2017-4,neutral,0.9410563111305237
59,4/24/2017 1:49:24 PM,"Biogen: TECFIDERA, TYSABRI Data Show Improved Outcomes With Early MS Treatment ",RTTNews,/news/stocks/biogen-tecfidera-tysabri-data-show-improved-outcomes-with-early-ms-treatment-1001941824,positive,0.958092987537384
60,4/24/2017 2:15:07 PM,BRIEF-Final phase 3 study data show Spinraza positive results (BIIB),Reuters,http://www.businessinsider.com/r-brief-final-phase-3-study-data-show-spinraza-positive-results-2017-4,positive,0.806469202041626
61,4/25/2017 1:01:59 PM,Biogen Inc. Q1 Earnings Climb 7%,RTTNews,/news/stocks/biogen-inc-q1-earnings-climb-7-1001945862,positive,0.9354208111763
62,4/25/2017 1:21:08 PM,Drugmaker Biogen's revenue rises 3 percent (BIIB),Reuters,http://www.businessinsider.com/r-drugmaker-biogens-revenue-rises-3-percent-2017-4,positive,0.9513281583786011
63,4/25/2017 1:21:08 PM,BRIEF-Biogen Q1 non-GAAP earnings per share $5.20 (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-q1-non-gaap-earnings-per-share-520-2017-4,neutral,0.8626217842102051
64,4/25/2017 1:40:11 PM,"US STOCKS-Futures rise on Trump tax talk; earnings in focus (MCD, CAT, ESRX, BIIB, T)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-rise-on-trump-tax-talk-earnings-in-focus-2017-4,positive,0.8310337662696838
65,4/25/2017 3:11:10 PM,"US STOCKS-Wall St set to open higher as earnings take center stage (CAT, MCD, BIIB, CNC, T, TSN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-as-earnings-take-center-stage-2017-4,positive,0.9364098906517029
66,4/25/2017 3:57:06 PM,"US STOCKS SNAPSHOT-Nasdaq hits 6,000 for first time (BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-snapshot-nasdaq-hits-6000-for-first-time-2017-4,neutral,0.6904081106185913
67,4/25/2017 4:13:10 PM,"US STOCKS-Nasdaq breaches 6,000 mark for first time ever (BIIB, AAPL, MCD, CAT, T, TSN)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-breaches-6000-mark-for-first-time-ever-2017-4,negative,0.8116595149040222
68,4/25/2017 4:45:10 PM,BRIEF-Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-cfo-says-expects-spinraza-adoption-to-ramp-up-going-forward-conf-call-2017-4,positive,0.7817762494087219
69,4/25/2017 7:41:08 PM,"US STOCKS-Nasdaq tops 6,000, Dow surges as earnings impress (AAPL, MSFT, CAT, MCD, DD, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-tops-6000-dow-surges-as-earnings-impress-2017-4,positive,0.8502492308616638
70,5/15/2017 11:38:02 PM,"BRIEF-Paulson & Co Inc takes share stake in Dish Network, Monsanto (DISH, MON, BIIB, AGN)",Reuters,http://www.businessinsider.com/r-brief-paulson--co-inc-takes-share-stake-in-dish-network-monsanto-2017-5,neutral,0.9461640119552612
71,5/16/2017 12:00:00 PM,"Biotech Stocks Under Scanner -- BioCryst Pharma, Biogen, Celldex Therapeutics, and Concordia",PR Newswire,/news/stocks/biotech-stocks-under-scanner-biocryst-pharma-biogen-celldex-therapeutics-and-concordia-1002016131,neutral,0.8961184620857239
72,5/18/2017 3:10:48 PM,Biogen Buys Remedy Pharma' Late-Stage Drug CIRARA ,RTTNews,/news/stocks/biogen-buys-remedy-pharma-late-stage-drug-cirara-1002025398,neutral,0.8644707202911377
73,5/18/2017 3:20:07 PM,BRIEF-Biogen acquires Remedy Pharmaceuticals' late-stage drug cirara (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-acquires-remedy-pharmaceuticals-late-stage-drug-cirara-2017-5,neutral,0.8973274230957031
74,5/22/2017 2:40:05 PM,"Celgene's multiple sclerosis drug succeeds in late-stage trial (CELG, BIIB)",Reuters,http://www.businessinsider.com/r-celgenes-multiple-sclerosis-drug-succeeds-in-late-stage-trial-2017-5,positive,0.9189364910125732
75,5/22/2017 3:16:07 PM,"UPDATE 1-Celgene's multiple sclerosis drug succeeds in late-stage trial (CELG, BIIB)",Reuters,http://www.businessinsider.com/r-update-1-celgenes-multiple-sclerosis-drug-succeeds-in-late-stage-trial-2017-5,positive,0.9091335535049438
76,5/24/2017 7:41:21 AM,Biogen's FAMPYRA Granted MA In EU For Improvement Of Walking In People With MS ,RTTNews,/news/stocks/biogen-s-fampyra-granted-ma-in-eu-for-improvement-of-walking-in-people-with-ms-1002038316,positive,0.9187371730804443
77,5/24/2017 9:44:02 PM,Roche investigating case of patient illness after taking MS drug (BIIB),Reuters,http://www.businessinsider.com/r-roche-investigating-case-of-patient-illness-after-taking-ms-drug-2017-5,neutral,0.5239895582199097
78,5/25/2017 12:26:02 AM,UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation (BIIB),Reuters,http://www.businessinsider.com/r-update-1-deadly-brain-infection-in-german-ms-patient-prompts-roche-investigation-2017-5,negative,0.8412421941757202
79,5/28/2017 11:56:05 PM,CORRECTED-UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation (BIIB),Reuters,http://www.businessinsider.com/r-corrected-update-1-deadly-brain-infection-in-german-ms-patient-prompts-roche-investigation-2017-5,negative,0.8559496402740479
80,5/31/2017 3:10:03 PM,BRIEF-Forward Pharma appeals initial decision in U.S. patent interference to federal circuit (BIIB),Reuters,http://www.businessinsider.com/r-brief-forward-pharma-appeals-initial-decision-in-us-patent-interference-to-federal-circuit-2017-5,neutral,0.8608582019805908
81,6/1/2017 1:46:06 PM,BRIEF-Biogen says Spinraza approved in EU as first treatment for SMA (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-says-spinraza-approved-in-eu-as-first-treatment-for-sma-2017-6,positive,0.6697728037834167
82,6/1/2017 1:51:13 PM,Biogen Reports Marketing Authorization For SPINRAZA In European Union ,RTTNews,/news/stocks/biogen-reports-marketing-authorization-for-spinraza-in-european-union-1002058752,neutral,0.6214375495910645
83,6/1/2017 2:24:06 PM,EU approves Biogen's Spinraza for lead genetic cause of infant death (BIIB),Reuters,http://www.businessinsider.com/r-eu-approves-biogens-spinraza-for-lead-genetic-cause-of-infant-death-2017-6,positive,0.7170398235321045
84,6/5/2017 1:36:05 PM,"Roche combo of breast cancer drugs shows modest benefit (MYL, BIOCON, 068270, BIIB)",Reuters,http://www.businessinsider.com/r-roche-combo-of-breast-cancer-drugs-shows-modest-benefit-2017-6,positive,0.6405401825904846
85,6/13/2017 10:46:05 PM,"BRIEF-Alexion Pharmaceuticals names Paul Clancy as CFO (ALXN, BIIB)",Reuters,http://www.businessinsider.com/r-brief-alexion-pharmaceuticals-names-paul-clancy-as-cfo-2017-6,neutral,0.9483422636985779
86,6/13/2017 10:56:03 PM,"Alexion names Biogen's Paul Clancy as CFO (ALXN, BIIB)",Reuters,http://www.businessinsider.com/r-alexion-names-biogens-paul-clancy-as-cfo-2017-6,neutral,0.9512125253677368
87,6/14/2017 5:05:45 AM,Biogen CFO Paul Clancy To Step Down ,RTTNews,/news/stocks/biogen-cfo-paul-clancy-to-step-down-1002090931,neutral,0.6807736754417419
88,6/14/2017 5:36:43 AM,Alexion Pharma Appoints Biogen Executive Paul Clancy As CFO ,RTTNews,/news/stocks/alexion-pharma-appoints-biogen-executive-paul-clancy-as-cfo-1002090960,neutral,0.9276534914970398
89,6/14/2017 6:58:05 PM,"US STOCKS-Oil drop, weak data weigh on Wall St; Fed move looms (XOM, CVX, JNJ, ALXN, BIIB, HRB)",Reuters,http://www.businessinsider.com/r-us-stocks-oil-drop-weak-data-weigh-on-wall-st-fed-move-looms-2017-6,negative,0.9595026969909668
90,6/14/2017 9:30:03 PM,"US STOCKS-Wall Street edges lower after Fed raises rates (AAPL, BIIB, HRB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-edges-lower-after-fed-raises-rates-2017-6,negative,0.9573737978935242
91,6/14/2017 10:34:03 PM,"US STOCKS-Wall St dips after Fed rate hike; tech slumps again (BIIB, HRB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-after-fed-rate-hike-tech-slumps-again-2017-6,negative,0.9614337086677551
92,6/15/2017 12:00:00 PM,Pharmaceutical Leaders Pave the Way to New Alzheimer's Treatments,PR Newswire,/news/stocks/pharmaceutical-leaders-pave-the-way-to-new-alzheimer-s-treatments-1002095510,neutral,0.638222336769104
93,6/15/2017 12:00:00 PM,Pharmaceutical Leaders Pave the Way to New Alzheimer's Treatments,PR Newswire,/news/stocks/pharmaceutical-leaders-pave-the-way-to-new-alzheimer-s-treatments-1002095497,neutral,0.638222336769104
94,6/19/2017 9:08:05 PM,"US STOCKS-Wall St at record highs on technology, health stocks strength (BIIB, AAPL, MSFT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-at-record-highs-on-technology-health-stocks-strength-2017-6,positive,0.7205073833465576
95,6/19/2017 10:32:03 PM,"US STOCKS-Wall St hits record highs on strong technology, health stocks (AMZN, WFM, AAPL, JPM, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-hits-record-highs-on-strong-technology-health-stocks-2017-6,positive,0.9328801035881042
96,6/20/2017 1:38:05 PM,BRIEF-Biogen appoints Ginger Gregory as chief human resources officer (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-appoints-ginger-gregory-as-chief-human-resources-officer-2017-6,neutral,0.926166832447052
97,6/21/2017 10:48:03 PM,"US STOCKS-S&P, Dow hurt by energy, banks; biotech boosts Nasdaq (CAT, FDX, T, CELG, REGN, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-hurt-by-energy-banks-biotech-boosts-nasdaq-2017-6,negative,0.42568689584732056
98,6/23/2017 1:56:03 PM,"Germany's Merck gets EU backing for oral MS drug (MRK, BIIB, SAN, TEVA, BAYN)",Reuters,http://www.businessinsider.com/r-germanys-merck-gets-eu-backing-for-oral-ms-drug-2017-6,positive,0.8816859722137451
99,6/23/2017 1:58:03 PM,"EU backs second biosimilar copy of Humira, world's top drug (AMGN, BIIB)",Reuters,http://www.businessinsider.com/r-eu-backs-second-biosimilar-copy-of-humira-worlds-top-drug-2017-6,positive,0.8114023804664612
100,6/23/2017 2:07:48 PM,Biogen's IMRALDI Granted Positive Opinion By Europe's CHMP ,RTTNews,/news/stocks/biogen-s-imraldi-granted-positive-opinion-by-europe-s-chmp-1002119557,positive,0.9092308878898621
101,6/23/2017 4:08:05 PM,BRIEF-Biogen’s Imraldi granted positive opinion by committee for medicinal products for human use (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogens-imraldi-granted-positive-opinion-by-committee-for-medicinal-products-for-human-use-2017-6,positive,0.8611496090888977
102,6/23/2017 4:32:05 PM,"High hopes ride on marijuana painkillers amid opioid crisis (ENDP, PFE, BIIB)",Reuters,http://www.businessinsider.com/r-high-hopes-ride-on-marijuana-painkillers-amid-opioid-crisis-2017-6,neutral,0.7061562538146973
103,6/29/2017 1:58:05 PM,BRIEF-Biogen says ‍new data reaffirm clinically meaningful benefit of Spinraza in individuals with spinal muscular atrophy across disease severity​ (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-says-new-data-reaffirm-clinically-meaningful-benefit-of-spinraza-in-individuals-with-spinal-muscular-atrophy-across-disease-severity-2017-6,positive,0.9428821802139282
104,6/29/2017 6:26:06 PM,"U.S. IRS probes drug company-funded patient assistance charity (JNJ, BAYN, TEVA, BIIB)",Reuters,http://www.businessinsider.com/r-us-irs-probes-drug-company-funded-patient-assistance-charity-2017-6,neutral,0.6504508256912231
105,6/29/2017 10:00:03 PM,"UPDATE 1-U.S. IRS probes drug company-funded patient assistance charity (JNJ, BAYN, TEVA, BIIB)",Reuters,http://www.businessinsider.com/r-update-1-us-irs-probes-drug-company-funded-patient-assistance-charity-2017-6,negative,0.6838732361793518
106,7/10/2017 2:12:06 PM,BRIEF-Biogen appoints Amy Chevalier Efantis vice president of government affairs (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-appoints-amy-chevalier-efantis-vice-president-of-government-affairs-2017-7,neutral,0.9325291514396667
107,7/14/2017 1:42:05 PM,BRIEF-Biogen to present data at Alzheimer's Association International Conference (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-to-present-data-at-alzheimers-association-international-conference-2017-7,neutral,0.9297038316726685
108,7/17/2017 1:20:07 PM,BRIEF-Ionis receives $10 mln milestone payment from Biogen (BIIB),Reuters,http://www.businessinsider.com/r-brief-ionis-receives-10-mln-milestone-payment-from-biogen-2017-7,positive,0.9216031432151794
109,7/18/2017 2:28:05 PM,BRIEF-Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders (BIIB),Reuters,http://www.businessinsider.com/r-brief-forward-pharma-announces-planned-distribution-of-eur-1945-per-share-to-shareholders-2017-7,neutral,0.8949310183525085
110,7/25/2017 12:35:02 PM,Biogen Inc. Q2 Income Falls 6%,RTTNews,/news/stocks/biogen-inc-q2-income-falls-6-1002201320,negative,0.9642663598060608
111,7/25/2017 12:50:05 PM,Biogen revenue rises 6.4 pct on Spinraza demand (BIIB),Reuters,http://www.businessinsider.com/r-biogen-revenue-rises-64-pct-on-spinraza-demand-2017-7,positive,0.949357271194458
112,7/25/2017 12:56:04 PM,Biogen Lifts FY17 Forecast As Q2 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-lifts-fy17-forecast-as-q2-results-top-estimates-quick-facts-1002201440,positive,0.7784491181373596
113,7/25/2017 1:12:06 PM,UPDATE 1-Biogen profit smashes estimates on Spinraza demand (BIIB),Reuters,http://www.businessinsider.com/r-update-1-biogen-profit-smashes-estimates-on-spinraza-demand-2017-7,neutral,0.5861349105834961
114,7/25/2017 1:18:06 PM,"US STOCKS-Dow, S&P futures higher; Alphabet weighs down Nasdaq (AMZN, AAPL, T, CMG, CB, BIIB, CNC)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-sp-futures-higher-alphabet-weighs-down-nasdaq-2017-7,positive,0.4989244341850281
115,7/25/2017 2:58:03 PM,"US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open (CAT, MCD, AMZN, AAPL, T, CMG, CB, BIIB, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-caterpillar-mcdonalds-to-lift-sp-dow-at-open-2017-7,positive,0.6481934189796448
116,7/25/2017 4:02:03 PM,"BRIEF-Biogen CEO: ""we will explore deals of all sizes"" (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-ceo-we-will-explore-deals-of-all-sizes-2017-7,neutral,0.8931286334991455
117,7/26/2017 12:44:03 AM,BRIEF-Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-says-in-july-2017-learned-that-prosecution-office-of-milan-is-investigating-interactions-with-some-healthcare-providers-in-italy---sec-filing-2017-7,negative,0.7662655711174011
118,7/26/2017 3:20:35 AM,Milan Prosecutor Investigates Biogen' Interactions With Healthcare Providers ,RTTNews,/news/stocks/milan-prosecutor-investigates-biogen-interactions-with-healthcare-providers-1002204064,neutral,0.4956766664981842
119,7/27/2017 9:12:08 PM,BRIEF-Abarca Health signs reimbursement contract with Biogen for select products (BIIB),Reuters,http://www.businessinsider.com/r-brief-abarca-health-signs-reimbursement-contract-with-biogen-for-select-products-2017-7,positive,0.9214890599250793
120,7/31/2017 3:34:05 PM,"BRIEF-Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-appoints-anabella-villalobos-senior-vice-president-biotherapeutic--medicinal-sciences-2017-7,neutral,0.9371629357337952
121,8/10/2017 1:16:11 PM,AGTC Files IND For Treatment Of X-Linked Retinitis Pigmentosa - Quick Facts ,RTTNews,/news/stocks/agtc-files-ind-for-treatment-of-x-linked-retinitis-pigmentosa-quick-facts-1002248145,neutral,0.7372475862503052
122,8/14/2017 3:07:03 PM,"BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene (JPM, BIIB, CELG, AMGN, RDSA, REGN)",Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-takes-stake-in-jpmorgan-biogen-celgene-2017-8,neutral,0.9486983418464661
123,8/14/2017 11:12:12 PM,"BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen (AAPL, BIIB, GSK)",Reuters,http://www.businessinsider.com/r-brief-paulson--co-takes-share-stake-in-apple-dissolves-share-stake-in-sarepta-biogen-2017-8,neutral,0.9050493240356445
124,8/16/2017 7:45:22 PM,Biogen Added To Goldman's Conviction List On Alzheimer's Promise ,RTTNews,/news/stocks/biogen-added-to-goldman-s-conviction-list-on-alzheimer-s-promise-1002263124,neutral,0.8504654169082642
125,8/17/2017 1:24:59 PM,Race For A New Alzheimer's Drug ,RTTNews,/news/stocks/race-for-a-new-alzheimer-s-drug-1002265169,neutral,0.8672767877578735
126,8/17/2017 5:32:03 PM,"House Democrats launch probe into MS drug pricing (BAYN, BIIB, SAN, TEVA)",Reuters,http://www.businessinsider.com/r-house-democrats-launch-probe-into-ms-drug-pricing-2017-8,neutral,0.9104707837104797
127,8/17/2017 6:02:03 PM,"UPDATE 1-House Democrats launch probe into MS drug pricing (BAYN, BIIB, SAN, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-house-democrats-launch-probe-into-ms-drug-pricing-2017-8,neutral,0.904794454574585
128,8/25/2017 1:32:03 AM,"BRIEF-Imraldi, Biogen's Adalimumab Biosimilar referencing Humira, is approved in EU (BIIB)",Reuters,http://www.businessinsider.com/r-brief-imraldi-biogens-adalimumab-biosimilar-referencing-humira-is-approved-in-eu-2017-8,positive,0.6564626097679138
129,8/25/2017 3:52:03 AM,"Samsung, Biogen version of AbbVie's Humira approved in Europe (BIIB, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-samsung-biogen-version-of-abbvies-humira-approved-in-europe-2017-8,neutral,0.783943235874176
130,8/25/2017 7:02:04 AM,"UPDATE 1-Samsung, Biogen version of AbbVie's Humira approved in Europe (BIIB, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-samsung-biogen-version-of-abbvies-humira-approved-in-europe-2017-8,neutral,0.6772662997245789
131,8/25/2017 8:37:17 AM,"ADMS Soars On FDA Nod, EARS Gets An Earful, Thumbs Up For BIIB's Humira Biosim ",RTTNews,/news/stocks/adms-soars-on-fda-nod-ears-gets-an-earful-thumbs-up-for-biib-s-humira-biosim-1002284421,positive,0.6734223365783691
132,8/25/2017 12:00:00 PM,"Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma",PR Newswire,/news/stocks/technical-snapshots-for-these-biotech-stocks-gilead-sciences-biogen-bluebird-bio-and-biomarin-pharma-1002284948,neutral,0.9466713070869446
133,8/28/2017 1:42:03 PM,BRIEF-Biogen reports new data from phase 1b study of investigational Alzheimer's disease treatment Aducanumab (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-reports-new-data-from-phase-1b-study-of-investigational-alzheimers-disease-treatment-aducanumab-2017-8,neutral,0.700957179069519
134,8/30/2017 1:22:03 PM,BRIEF-Ionis earns $40 million Spinraza regulatory milestone payment from Biogen (BIIB),Reuters,http://www.businessinsider.com/r-brief-ionis-earns-40-million-spinraza-regulatory-milestone-payment-from-biogen-2017-8,positive,0.8651227355003357
135,8/31/2017 5:12:08 PM,"US STOCKS-Wall St higher as data points to strengthening economy (UNH, GILD, CELG, BIIB, DG, CPB, GIS, SCVL)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-higher-as-data-points-to-strengthening-economy-2017-8,positive,0.9424222707748413
136,8/31/2017 7:02:03 PM,"US STOCKS-Wall St gains on data, Mnuchin's remarks on tax reform (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-on-data-mnuchins-remarks-on-tax-reform-2017-8,neutral,0.7451258897781372
137,8/31/2017 9:07:03 PM,"US STOCKS-Wall St gains after Mnuchin's remarks on tax reform (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-after-mnuchins-remarks-on-tax-reform-2017-8,positive,0.6328293681144714
138,8/31/2017 10:27:07 PM,"US STOCKS-Wall St gains on data and Mnuchin tax reform remarks (UNH, GILD, CELG, BIIB, DG, CPB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-on-data-and-mnuchin-tax-reform-remarks-2017-8,positive,0.7359533309936523
139,9/5/2017 11:37:18 PM,BRIEF-Forward pharma says filing in U.S. Court to appeal PTAB decision​ (BIIB),Reuters,http://www.businessinsider.com/r-brief-forward-pharma-says-filing-in-us-court-to-appeal-ptab-decision-2017-9,neutral,0.6607509851455688
140,9/12/2017 2:30:00 PM,Alzheimer's Disease: Cannabis Formulation Shows Promise,PR Newswire,/news/stocks/alzheimer-s-disease-cannabis-formulation-shows-promise-1002361894,positive,0.8793855309486389
141,9/12/2017 2:30:00 PM,Alzheimer's Disease: Cannabis Formulation Shows Promise,PR Newswire,/news/stocks/alzheimer-s-disease-cannabis-formulation-shows-promise-1002361935,positive,0.8793855309486389
142,9/21/2017 4:50:00 PM,Soleil Capital Corp. Announces Qualifying Transaction,PR Newswire,/news/stocks/soleil-capital-corp-announces-qualifying-transaction-561563,neutral,0.9089425206184387
143,9/28/2017 5:45:06 PM,"A congressman just hit out at Trump, tweeting 'companies are charging $87k/yr for a drug YOU own' (BIIB)",Business Insider,http://www.businessinsider.com/elijah-cummings-to-trump-on-ms-drug-prices-2017-9,neutral,0.6280897855758667
144,10/5/2017 4:17:03 PM,"US STOCKS-Wall Street indexes touch fresh record-highs (AAPL, MSFT, AMZN, STZ, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-indexes-touch-fresh-record-highs-2017-10,positive,0.8989015817642212
145,10/5/2017 4:52:03 PM,BRIEF-Biogen updates on new data on treatment with Spinraza (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-updates-on-new-data-on-treatment-with-spinraza-2017-10,neutral,0.8795500993728638
146,10/5/2017 5:22:03 PM,"US STOCKS-Tech stocks power Wall St indexes to fresh record-highs (NFLX, MSFT, AMZN, STZ, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-power-wall-st-indexes-to-fresh-record-highs-2017-10,positive,0.8982329964637756
147,10/8/2017 3:03:03 PM,"It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)",Business Insider,http://www.businessinsider.com/what-alzheimers-disease-drugs-are-in-development-next-trial-2017-10,neutral,0.9026669859886169
148,10/12/2017 2:57:11 PM,"'Double whammy' for Roche as manufacturing patent losses loom (BIIB, MYL, MRK, SAN, GSK)",Reuters,http://www.businessinsider.com/r-double-whammy-for-roche-as-manufacturing-patent-losses-loom-2017-10,negative,0.9509940147399902
149,10/13/2017 1:17:08 PM,BRIEF-IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE (BIIB),Reuters,http://www.businessinsider.com/r-brief-ionis-pharmaceuticals-initiates-ionis-mapt-rx-study-in-patients-with-alzheimers-disease-2017-10,neutral,0.7543997168540955
150,10/23/2017 1:27:13 PM,"BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab (BIIB, 4523)",Reuters,http://www.businessinsider.com/r-brief-biogen-and-eisai-expand-existing-collaboration-agreement-to-develop-and-commercialize-investigational-alzheimers-disease-treatments-including-phase-3-aducanumab-2017-10,positive,0.9334769248962402
151,10/24/2017 1:07:09 AM,"U.S. companies act on climate despite Trump - survey (PM, MSFT, BAC, BIIB, OR, ULVR, UNA)",Reuters,http://www.businessinsider.com/r-us-companies-act-on-climate-despite-trump---survey-2017-10,neutral,0.8901256322860718
152,10/24/2017 1:04:02 PM,Biogen Inc. Q3 Earnings Rise 25%,RTTNews,/news/stocks/biogen-inc-q3-earnings-rise-25-1005437240,positive,0.9337703585624695
153,10/24/2017 1:13:48 PM,Biogen Amends Deal With Neurimmune On Aducanumab; Boosts Profit Potential ,RTTNews,/news/stocks/biogen-amends-deal-with-neurimmune-on-aducanumab-boosts-profit-potential-1005438128,positive,0.95533287525177
154,10/24/2017 1:17:16 PM,Biogen posts 18.7 pct jump in quarterly profit (BIIB),Reuters,http://www.businessinsider.com/r-biogen-posts-187-pct-jump-in-quarterly-profit-2017-10,positive,0.9436120390892029
155,10/24/2017 1:17:16 PM,BRIEF-Biogen Q3 earnings per share $5.79 (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-q3-earnings-per-share-579-2017-10,neutral,0.8426725268363953
156,10/24/2017 1:27:06 PM,UPDATE 1-Biogen profit beats Wall Street view on Spinraza sales (BIIB),Reuters,http://www.businessinsider.com/r-update-1-biogen-profit-beats-wall-street-view-on-spinraza-sales-2017-10,positive,0.8866883516311646
157,10/24/2017 4:07:03 PM,"US STOCKS-3M, Caterpillar lift Dow to record high (MMM, CAT, UTX, MCD, BAC, JPM, GM, WHR, BIIB, CNC, JNJ)",Reuters,http://www.businessinsider.com/r-us-stocks-3m-caterpillar-lift-dow-to-record-high-2017-10,positive,0.907318115234375
158,10/24/2017 5:42:03 PM,"US STOCKS-3M, Caterpillar lift Dow to record high (MMM, CAT, UTX, MCD, BIIB, CNC, JNJ, JPM, WHR)",Reuters,http://www.businessinsider.com/r-us-stocks-3m-caterpillar-lift-dow-to-record-high-2017-10,positive,0.9023404717445374
159,10/24/2017 7:02:06 PM,"US STOCKS-Dow rallies on strong earnings from 3M, Caterpillar (MMM, CAT, MCD, BIIB, CNC, JNJ, BAC, JPM, GM, WHR)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-rallies-on-strong-earnings-from-3m-caterpillar-2017-10,positive,0.9152756929397583
160,10/24/2017 8:42:07 PM,"US STOCKS-Wall St gains on 3M, Caterpillar earnings; Dow jumps (MMM, CAT, GM, MCD, BIIB, WHR)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-gains-on-3m-caterpillar-earnings-dow-jumps-2017-10,positive,0.6523047685623169
161,10/24/2017 10:52:12 PM,"US STOCKS-Dow jumps with upbeat 3M, Caterpillar earnings (MMM, GM, MCD, BIIB, WHR)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-jumps-with-upbeat-3m-caterpillar-earnings-2017-10,positive,0.8919005393981934
162,10/25/2017 2:02:03 AM,"US STOCKS-Dow jumps with upbeat 3M, Caterpillar earnings (MMM, GM, MCD, BIIB, WHR)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-jumps-with-upbeat-3m-caterpillar-earnings-2017-10,positive,0.8919005393981934
163,10/25/2017 7:06:11 AM,Biogen Initiates AFFINITY Phase 2 Trial For Opicinumab In Multiple Sclerosis ,RTTNews,/news/stocks/biogen-initiates-affinity-phase-2-trial-for-opicinumab-in-multiple-sclerosis-1005535573,neutral,0.5172911286354065
164,11/10/2017 2:47:03 PM,Roche MS drug Ocrevus wins European panel backing (BIIB),Reuters,http://www.businessinsider.com/r-roche-ms-drug-ocrevus-wins-european-panel-backing-2017-11,positive,0.9338789582252502
165,11/14/2017 8:52:06 AM,Sandoz says new clinical data support two biosimilars (BIIB),Reuters,http://www.businessinsider.com/r-sandoz-says-new-clinical-data-support-two-biosimilars-2017-11,positive,0.5841268301010132
166,11/17/2017 1:17:03 PM,"BRIEF-Acorda announces royalty monetization transactions for $53 mln (ACOR, BIIB)",Reuters,http://www.businessinsider.com/r-brief-acorda-announces-royalty-monetization-transactions-for-53-mln-2017-11,neutral,0.9294099807739258
167,11/21/2017 1:42:04 PM,BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-appoints-jeff-capello-as-executive-vice-president-and-chief-financial-officer-2017-11,neutral,0.9342581033706665
168,11/21/2017 1:44:11 PM,Biogen Names Jeff Capello CFO ,RTTNews,/news/stocks/biogen-names-jeff-capello-cfo-1008932216,neutral,0.9259564280509949
169,11/21/2017 3:02:03 PM,"Roche, AbbVie leukemia drug superior to older medicine in study (TEVA, BIIB)",Reuters,http://www.businessinsider.com/r-roche-abbvie-leukemia-drug-superior-to-older-medicine-in-study-2017-11,positive,0.9077944159507751
170,11/27/2017 1:12:46 PM,"Biogen In Deal With Alkermes To Develop, Commercialize ALKS 8700 For MS ",RTTNews,/news/stocks/biogen-in-deal-with-alkermes-to-develop-commercialize-alks-8700-for-ms-1009666753,neutral,0.5483065247535706
171,11/27/2017 4:07:03 PM,"Biogen boosts multiple sclerosis holding with Alkermes license (BIIB, ALKS, SAN)",Reuters,http://www.businessinsider.com/r-biogen-boosts-multiple-sclerosis-holding-with-alkermes-license-2017-11,neutral,0.7943246364593506
172,11/28/2017 7:18:22 AM,"BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises ",RTTNews,/news/stocks/biib-alks-team-up-for-ms-drug-regn-s-eylea-combo-fails-again-aezs-rises-1009751989,positive,0.4418775737285614
173,11/30/2017 1:42:03 PM,"BRIEF-Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock (BIIB)",Reuters,http://www.businessinsider.com/r-brief-sarissa-capital-managements-alexander-denner-buys-30000-shares-of-biogens-common-stock-2017-11,neutral,0.9241517782211304
174,12/4/2017 1:47:04 PM,"BRIEF-Biogen Appoints Mark Hernon As SVP, Chief Information Officer (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-appoints-mark-hernon-as-svp-chief-information-officer-2017-12,neutral,0.9368022680282593
175,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12,negative,0.7240304350852966
176,12/14/2017 7:37:04 PM,"UPDATE 1-Germany's Merck to make new bid to enter U.S. MS pill market (MRK, BIIB, SAN, PFE)",Reuters,http://www.businessinsider.com/r-update-1-germanys-merck-to-make-new-bid-to-enter-us-ms-pill-market-2017-12,positive,0.830260694026947
177,12/20/2017 12:42:08 AM,"BRIEF-Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy (BIIB)",Reuters,http://www.businessinsider.com/r-brief-biogen-ionis-collaborate-to-identify-novel-therapies-to-treat-spinal-muscular-atrophy-2017-12,positive,0.7610918283462524
178,12/20/2017 6:11:11 AM,"EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours ",RTTNews,/news/stocks/exel-pfe-once-get-fda-nod-fprx-zlab-team-up-skln-soars-after-hours-1011667355,neutral,0.636665403842926
179,12/20/2017 1:42:08 PM,"US STOCKS-Futures rise as tax overhaul bill nears passage (FDX, MU, BIIB, RHT)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-rise-as-tax-overhaul-bill-nears-passage-2017-12,positive,0.7951755523681641
180,12/20/2017 3:07:03 PM,"US STOCKS-Wall St set for strong open as tax bill nears passage (FDX, MU, INTC, AMAT, LRCX, RHT, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-for-strong-open-as-tax-bill-nears-passage-2017-12,positive,0.901108980178833
181,12/21/2017 1:12:03 PM,BRIEF-Biogen Inc - Results Of Final Analysis On BAN2401 Are Expected During Second Half Of 2018 (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-inc---results-of-final-analysis-on-ban2401-are-expected-during-second-half-of-2018-2017-12,neutral,0.9472861289978027
182,12/21/2017 3:32:03 PM,"Biogen's Alzheimer's drug fails to meet main goal in mid-stage trial (BIIB, 4523)",Reuters,http://www.businessinsider.com/r-biogens-alzheimers-drug-fails-to-meet-main-goal-in-mid-stage-trial-2017-12,negative,0.7165261507034302
183,12/22/2017 10:27:03 PM,BRIEF-Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza (BIIB),Reuters,http://www.businessinsider.com/r-brief-biogen-responds-to-coverage-recommendation-by-the-canadian-drug-expert-committee-cdec-for-spinraza-2017-12,positive,0.714533805847168
184,1/22/2018 3:21:14 AM,WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln ,RTTNews,/news/stocks/wsj-sanofi-nears-deal-to-buy-bioverativ-for-more-than-11-5-bln-1013545019,positive,0.7992337346076965
185,1/22/2018 9:54:43 AM,Sanofi In Deal To Buy Hemophilia Drugmaker Bioverativ For $11.6 Bln; Stock Dips ,RTTNews,/news/stocks/sanofi-in-deal-to-buy-hemophilia-drugmaker-bioverativ-for-11-6-bln-stock-dips-1013571617,negative,0.894507646560669
186,1/25/2018 12:41:49 PM,Biogen Inc. Bottom Line Advances In Q4,RTTNews,/news/stocks/biogen-inc-bottom-line-advances-in-q4-1013983261,positive,0.9359750151634216
187,1/25/2018 12:55:26 PM,Biogen To Acquire Karyopharm's Investigational Oral SINE Compound KPT-350 ,RTTNews,/news/stocks/biogen-to-acquire-karyopharm-s-investigational-oral-sine-compound-kpt-350-1013984186,neutral,0.8777469396591187
188,2/7/2018 1:52:22 PM,Biogen: Primary And Secondary Endpoints Not Met In Natalizumab Phase 2b Study ,RTTNews,/news/stocks/biogen-primary-and-secondary-endpoints-not-met-in-natalizumab-phase-2b-study-1015045127,neutral,0.44162678718566895
189,3/2/2018 12:12:11 PM,"Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts ",RTTNews,/news/stocks/biogen-abbvie-voluntarily-withdraw-worldwide-ma-for-zinbryta-quick-facts-1017686335,neutral,0.7689930200576782
190,3/7/2018 11:07:23 PM,Zinbrynta Now Connected To Brain Inflammation ,RTTNews,/news/stocks/zinbrynta-now-connected-to-brain-inflammation-1018317673,neutral,0.8420150876045227
191,3/12/2018 12:42:25 PM,Biogen To Acquire Phase 2b Ready Asset For Schizophrenia ,RTTNews,/news/stocks/biogen-to-acquire-phase-2b-ready-asset-for-schizophrenia-1018617606,neutral,0.7961347103118896
192,3/12/2018 12:58:32 PM,Biogen Announces New Interim Phase 2 Results From NURTURE ,RTTNews,/news/stocks/biogen-announces-new-interim-phase-2-results-from-nurture-1018617763,neutral,0.8246262073516846
193,4/5/2018 2:26:46 PM,"Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization ",RTTNews,/news/stocks/biogen-samsung-bioepis-announce-deal-with-abbvie-for-imraldi-commercialization-1020573431,positive,0.8017102479934692
194,4/20/2018 1:59:32 PM,"Biogen, Ionis Expand Collaboration; Biogen To Pay $1 Bln To License Therapies ",RTTNews,/news/stocks/biogen-ionis-expand-collaboration-biogen-to-pay-1-bln-to-license-therapies-1021676677,positive,0.9092616438865662
195,4/23/2018 5:24:03 AM,"BHVN In Focus, Fresenius Calls Off Deal To Buy AKRX, Good News For GUD ",RTTNews,/news/stocks/bhvn-in-focus-fresenius-calls-off-deal-to-buy-akrx-good-news-for-gud-1021954677,positive,0.8710291981697083
196,4/24/2018 1:05:47 PM,Biogen Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/biogen-inc-q1-adjusted-earnings-beat-estimates-1022107108,positive,0.8917761445045471
197,5/1/2018 1:51:07 PM,Biogen To Reduce Royalty Rates On Aducanumab; To Pay $50 Mln To Neurimmune ,RTTNews,/news/stocks/biogen-to-reduce-royalty-rates-on-aducanumab-to-pay-50-mln-to-neurimmune-1023005501,positive,0.6940746903419495
198,5/31/2018 1:30:00 PM,"Biogen Appoints Daniel Karp as EVP, Corporate Development",GlobeNewswire,/news/stocks/biogen-appoints-daniel-karp-as-evp-corporate-development-1025972971,neutral,0.9353729486465454
199,6/5/2018 7:55:00 PM,Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months,PR Newswire,/news/stocks/phase-ii-clinical-study-of-elenbecestat-demonstrates-safety-and-tolerability-in-mci-and-mild-to-moderate-alzheimer-s-disease-at-18-months-1026595016,positive,0.9292870163917542
200,6/5/2018 10:00:00 PM,Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases,PR Newswire,/news/stocks/ionis-closes-strategic-collaboration-with-biogen-to-develop-drugs-for-a-broad-range-of-neurological-diseases-1026606821,positive,0.7747113704681396
201,6/6/2018 7:02:45 AM,"BIIB's Alzheimer's Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out ",RTTNews,/news/stocks/biib-s-alzheimer-s-drug-scores-well-exas-heads-higher-vxrt-down-but-not-out-1026659565,positive,0.9441404938697815
202,6/6/2018 1:16:43 PM,Alkermes Receives License Payment From Biogen - Quick Facts ,RTTNews,/news/stocks/alkermes-receives-license-payment-from-biogen-quick-facts-1026695034,neutral,0.843925952911377
203,6/7/2018 1:30:00 PM,Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke,GlobeNewswire,/news/stocks/biogen-enters-exclusive-option-agreement-to-acquire-tms-phase-2-asset-for-acute-stroke-1026779350,positive,0.7846642136573792
204,6/7/2018 1:34:57 PM,Biogen Reaches Option Agreement To Buy TMS' Phase 2 Asset For Acute Stroke ,RTTNews,/news/stocks/biogen-reaches-option-agreement-to-buy-tms-phase-2-asset-for-acute-stroke-1026779352,positive,0.8289265036582947
205,6/13/2018 1:30:00 PM,Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference,GlobeNewswire,/news/stocks/biogen-enhances-commitment-to-sma-research-with-data-presented-at-annual-sma-conference-1026923339,positive,0.9401913285255432
206,6/18/2018 10:30:00 PM,Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education,GlobeNewswire,/news/stocks/biogen-foundation-selects-grantees-to-receive-10-million-investment-for-stem-education-1027177140,neutral,0.7798753976821899
207,6/19/2018 10:01:00 PM,"Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018",GlobeNewswire,/news/stocks/biogen-to-host-investor-webcast-on-its-efforts-targeting-stroke-on-june-28-2018-1027215173,neutral,0.9199446439743042
208,6/25/2018 10:01:00 PM,"Biogen to Report Second Quarter 2018 Financial Results on July 24, 2018",GlobeNewswire,/news/stocks/biogen-to-report-second-quarter-2018-financial-results-on-july-24-2018-1027316044,neutral,0.9360223412513733
209,6/28/2018 10:06:00 PM,Biogen Exercises Option to Increase Ownership in Samsung Bioepis,GlobeNewswire,/news/stocks/biogen-exercises-option-to-increase-ownership-in-samsung-bioepis-1027328700,neutral,0.853800356388092
210,7/3/2018 11:33:36 AM,Remember When Was The Last Time A New Alzheimer's Drug Was Approved? ,RTTNews,/news/stocks/remember-when-was-the-last-time-a-new-alzheimer-s-drug-was-approved-1027337782,neutral,0.9172612428665161
211,7/6/2018 1:30:00 AM,Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months,GlobeNewswire,/news/stocks/eisai-and-biogen-announce-positive-topline-results-of-the-final-analysis-for-ban2401-at-18-months-1027345833,neutral,0.8872866034507751
212,7/6/2018 7:14:13 AM,"BIIB One Step Closer, MBVX To Be Delisted, RGLS In The Red On Pink Slip Woes ",RTTNews,/news/stocks/biib-one-step-closer-mbvx-to-be-delisted-rgls-in-the-red-on-pink-slip-woes-1027346076,positive,0.5973508358001709
213,7/6/2018 3:39:03 PM,Biogen is skyrocketing after its Alzheimer's drug delivers positive results (BIIB),Business Insider,http://markets.businessinsider.com/news/stocks/biogen-stock-price-alzheimers-drug-positive-results-2018-7-1027347586,positive,0.9204380512237549
214,7/18/2018 1:30:00 PM,Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC),GlobeNewswire,/news/stocks/data-to-be-presented-from-biogen-s-alzheimer-s-disease-clinical-development-portfolio-at-the-2018-alzheimer-s-association-international-conference-aaic-1027377672,neutral,0.9374414682388306
215,7/20/2018 2:39:32 PM,"Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018",GlobeNewswire,/news/stocks/biogen-to-host-investor-webcast-to-discuss-alzheimer-s-disease-portfolio-on-july-25-2018-1027385897,neutral,0.9108240008354187
216,7/21/2018 3:45:23 AM,"Week Ahead In Pharmaceuticals - 14 Stocks To Watch (LCI, INSY, TBPH...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-14-stocks-to-watch-lci-insy-tbph-1027387101,neutral,0.8893073797225952
217,7/22/2018 3:01:31 PM,Biogen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/biogen-q2-earnings-preview-stock-1027387748,neutral,0.9350948929786682
218,7/23/2018 1:24:59 PM,Applied Genetic Technologies Earns $10 Mln In Milestone Payment - Quick Facts ,RTTNews,/news/stocks/applied-genetic-technologies-earns-10-mln-in-milestone-payment-quick-facts-1027389428,positive,0.6732248067855835
219,7/24/2018 12:59:48 PM,Biogen Updates 2018 Financial Guidance - Quick Facts ,RTTNews,/news/stocks/biogen-updates-2018-financial-guidance-quick-facts-1027393312,neutral,0.9336510300636292
220,7/25/2018 4:30:00 PM,Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018,GlobeNewswire,/news/stocks/eisai-and-biogen-present-detailed-results-from-phase-ii-clinical-study-of-elenbecestat-in-mci-and-mild-to-moderate-alzheimer-s-disease-at-alzheimer-s-association-international-conference-aaic-2018-1027399519,neutral,0.9106012582778931
221,7/25/2018 10:15:03 PM,We just got more information on the first positive Alzheimer's trial in years — here's what you need to know (BIIB),Business Insider,https://www.businessinsider.com/biogen-and-eisais-alzheimers-data-for-ban2401-2018-7,neutral,0.9238607883453369
222,7/25/2018 10:30:00 PM,Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018,GlobeNewswire,/news/stocks/eisai-and-biogen-announce-detailed-results-of-phase-ii-clinical-study-of-ban2401-in-early-alzheimer-s-disease-at-alzheimer-s-association-international-conference-aaic-2018-1027400607,neutral,0.8977636098861694
223,8/28/2018 1:30:00 PM,Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab,GlobeNewswire,/news/stocks/biogen-and-eisai-report-data-from-long-term-extension-phase-1b-study-of-investigational-alzheimer-s-disease-treatment-aducanumab-1027489565,neutral,0.7642937302589417
224,9/4/2018 1:30:00 PM,Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction,GlobeNewswire,/news/stocks/biogen-enrolls-first-patient-in-global-phase-3-study-of-biib093-iv-glibenclamide-for-large-hemispheric-infarction-1027505458,positive,0.7356874346733093
225,10/2/2018 1:30:00 PM,Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care,GlobeNewswire,/news/stocks/biogen-highlights-at-ectrims-2018-data-on-its-industry-leading-multiple-sclerosis-portfolio-and-a-range-of-initiatives-aimed-at-transforming-patient-care-1027582725,positive,0.6579589247703552
226,10/3/2018 1:30:00 PM,Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS),GlobeNewswire,/news/stocks/biogen-to-present-data-from-its-neurology-pipeline-at-the-2018-international-congress-of-parkinson-s-disease-and-movement-disorders-mds-1027586474,neutral,0.8835742473602295
227,10/6/2018 1:30:00 PM,New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy,GlobeNewswire,/news/stocks/new-spinraza-nusinersen-data-presented-at-annual-congress-of-the-world-muscle-society-demonstrate-benefits-in-treating-presymptomatic-infants-with-spinal-muscular-atrophy-1027595235,positive,0.9313333630561829
228,10/11/2018 1:30:00 PM,Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-advances-research-to-improve-outcomes-for-patients-with-multiple-sclerosis-1027608499,positive,0.8755138516426086
229,10/17/2018 8:00:00 AM,"IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union",GlobeNewswire,/news/stocks/imraldi-biogen-s-adalimumab-biosimilar-referencing-humira-is-launched-in-the-european-union-1027623708,neutral,0.7315526604652405
230,10/18/2018 1:30:00 PM,Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting,GlobeNewswire,/news/stocks/biogen-to-present-data-from-alzheimer-s-disease-portfolio-at-the-2018-clinical-trials-on-alzheimer-s-disease-ctad-meeting-1027629520,neutral,0.9098325371742249
231,10/21/2018 3:01:25 PM,Biogen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/biogen-stock-price-q3-earnings-preview-1027636049,neutral,0.9190120697021484
232,10/23/2018 7:00:00 AM,UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus,GlobeNewswire,/news/stocks/ucb-and-biogen-announce-topline-results-from-a-phase-2b-study-of-dapirolizumab-pegol-in-systemic-lupus-erythematosus-1027641939,neutral,0.5045563578605652
233,10/23/2018 7:19:08 AM,"UCB, Biogen: Dapirolizumab Pegol Phase 2b Study Fails To Meet Primary Endpoint ",RTTNews,/news/stocks/ucb-biogen-dapirolizumab-pegol-phase-2b-study-fails-to-meet-primary-endpoint-1027642003,negative,0.9418011903762817
234,10/23/2018 1:19:01 PM,"Biogen Q3 Profit Rises, Results Beat View - Quick Facts ",RTTNews,/news/stocks/biogen-q3-profit-rises-results-beat-view-quick-facts-1027643553,positive,0.9459795355796814
235,10/25/2018 2:31:23 PM,Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference,GlobeNewswire,/news/stocks/eisai-and-biogen-announce-presentation-of-additional-data-from-the-phase-ii-clinical-trial-of-ban2401-in-early-alzheimer-s-disease-at-the-2018-clinical-trials-on-alzheimer-s-disease-ctad-conference-1027654841,neutral,0.9022693037986755
236,10/26/2018 3:15:00 PM,Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD),GlobeNewswire,/news/stocks/biogen-and-eisai-announce-presentation-of-detailed-analyses-from-the-phase-1b-long-term-extension-study-of-aducanumab-at-clinical-trials-on-alzheimer-s-disease-ctad-1027659585,neutral,0.8656981587409973
237,11/29/2018 1:30:00 PM,International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product,GlobeNewswire,/news/stocks/international-prix-galien-recognizes-spinraza-as-best-biotechnology-product-1027766730,positive,0.8979933261871338
238,12/6/2018 1:30:00 PM,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data,GlobeNewswire,/news/stocks/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-treatment-biib067-for-a-subtype-of-familial-amyotrophic-lateral-sclerosis-als-based-on-positive-phase-1-data-1027786415,positive,0.5757378935813904
239,12/17/2018 1:30:00 PM,Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis,GlobeNewswire,/news/stocks/alkermes-and-biogen-announce-submission-of-a-new-drug-application-to-u-s-food-and-drug-administration-for-diroximel-fumarate-in-multiple-sclerosis-1027813658,positive,0.6020324230194092
240,12/17/2018 1:47:55 PM,Alkermes Submits NDA For Diroximel Fumarate - Quick Facts ,RTTNews,/news/stocks/alkermes-submits-nda-for-diroximel-fumarate-quick-facts-1027813747,neutral,0.8513811826705933
241,12/20/2018 6:19:19 PM,Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients,GlobeNewswire,/news/stocks/biogen-applauds-quebec-decision-to-cover-spinraza-nusinersen-for-a-broad-population-of-sma-patients-1027826461,positive,0.8629516363143921
242,1/3/2019 1:30:00 PM,First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis,GlobeNewswire,/news/stocks/first-patient-enrolled-in-biogen-s-phase-3b-study-to-evaluate-extended-interval-dosing-eid-with-natalizumab-in-multiple-sclerosis-1027841422,positive,0.5439426302909851
243,1/4/2019 1:30:00 PM,Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets,GlobeNewswire,/news/stocks/biogen-and-skyhawk-therapeutics-announce-agreement-to-develop-novel-small-molecule-rna-splicing-modifiers-for-neurological-disease-targets-1027844252,positive,0.870380163192749
244,1/4/2019 1:30:00 PM,Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions,GlobeNewswire,/news/stocks/biogen-and-c4-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-potential-new-treatments-for-neurological-conditions-1027844253,positive,0.8744300007820129
245,1/4/2019 1:46:36 PM,"Biogen, Skyhawk Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/biogen-skyhawk-announce-collaboration-quick-facts-1027844297,neutral,0.8876478672027588
246,1/27/2019 3:01:29 PM,Biogen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/biogen-q4-earnings-preview-stock-1027898626,neutral,0.9350948929786682
247,1/29/2019 1:08:42 PM,Biogen Q4 Results Top Estimates; Sees 2019 Results In Line With View ,RTTNews,/news/stocks/biogen-q4-results-top-estimates-sees-2019-results-in-line-with-view-1027904387,positive,0.8963990211486816
248,2/15/2019 10:11:00 PM,Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.,Moodys,/news/bonds/biogen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-biogen-inc-1027957881,neutral,0.8530017733573914
249,2/25/2019 1:30:00 PM,Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis,GlobeNewswire,/news/stocks/alkermes-and-biogen-announce-u-s-food-and-drug-administration-acceptance-of-diroximel-fumarate-new-drug-application-for-multiple-sclerosis-1027979733,positive,0.7106349468231201
250,2/25/2019 1:46:22 PM,Alkermes Announces NDA Filing Acceptance For Diroximel Fumarate - Quick Facts ,RTTNews,/news/stocks/alkermes-announces-nda-filing-acceptance-for-diroximel-fumarate-quick-facts-1027979812,positive,0.5648212432861328
251,2/28/2019 1:30:00 PM,"Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy",GlobeNewswire,/news/stocks/biogen-further-expands-presence-in-china-with-approval-of-spinraza-nusinersen-the-first-and-only-treatment-for-spinal-muscular-atrophy-1027993077,positive,0.9191110730171204
252,3/2/2019 2:18:44 AM,Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA,GlobeNewswire,/news/stocks/biogen-responds-to-cadth-s-updated-recommendation-regarding-coverage-for-spinraza-1027998361,neutral,0.7499674558639526
253,3/4/2019 8:00:00 AM,Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology,GlobeNewswire,/news/stocks/biogen-announces-agreement-to-acquire-nightstar-therapeutics-to-establish-clinical-pipeline-of-gene-therapy-candidates-in-ophthalmology-1027999735,positive,0.8452911972999573
254,3/12/2019 4:00:00 AM,"Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm",GlobeNewswire,/news/stocks/biogen-enters-into-an-agreement-to-sell-its-large-scale-biologics-manufacturing-site-in-hillerød-denmark-to-fujifilm-1028021613,positive,0.535749614238739
255,3/21/2019 12:00:00 PM,Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease,GlobeNewswire,/news/stocks/biogen-and-eisai-to-discontinue-phase-3-engage-and-emerge-trials-of-aducanumab-in-alzheimer-s-disease-1028048273,neutral,0.880712628364563
256,3/21/2019 12:24:50 PM,"Biogen, Eisai To Discontinue Phase 3 ENGAGE, EMERGE Trials Of Aducanumab ",RTTNews,/news/stocks/biogen-eisai-to-discontinue-phase-3-engage-emerge-trials-of-aducanumab-1028048378,neutral,0.9246971011161804
257,3/21/2019 1:30:04 PM,Biogen is crashing after scrapping its late-stage Alzheimer's drug trials (BIIB),Business Insider,https://markets.businessinsider.com/news/stocks/biogen-alzheimers-disease-aducanumab-eisai-clinical-trial-2019-3-1028048723,negative,0.9594267010688782
258,3/21/2019 3:16:29 PM,Biogen Shares Fall As Late-stage Trials Of Alzheimer's Drug Discontinued ,RTTNews,/news/stocks/biogen-shares-fall-as-late-stage-trials-of-alzheimer-s-drug-discontinued-1028049388,negative,0.9599081873893738
259,3/25/2019 11:45:46 PM,Biogen Announces $5 Bln Stock Buyback ,RTTNews,/news/stocks/biogen-announces-5-bln-stock-buyback-1028057161,neutral,0.8843113780021667
260,4/12/2019 1:30:00 PM,Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference,GlobeNewswire,/news/stocks/biogen-continues-to-advance-innovation-in-sma-with-new-data-in-adults-and-infants-to-be-presented-at-mda-clinical-and-scientific-conference-1028106957,positive,0.8480223417282104
261,4/22/2019 3:01:36 PM,Biogen earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/biogen-q1-earnings-preview-1028126290,neutral,0.9350948929786682
262,4/24/2019 12:56:42 PM,Biogen Inc. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/biogen-inc-q1-adjusted-earnings-beat-estimates-1028133850,positive,0.8917761445045471
263,4/29/2019 1:30:00 PM,Biogen Announces Three New Nominees for Election to Board of Directors,GlobeNewswire,/news/stocks/biogen-announces-three-new-nominees-for-election-to-board-of-directors-1028148030,neutral,0.909838080406189
264,4/30/2019 1:33:55 PM,Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy,GlobeNewswire,/news/stocks/data-published-in-neurology-show-that-treatment-with-spinraza-nusinersen-improved-motor-function-and-provided-long-term-benefit-for-individuals-with-later-onset-spinal-muscular-atrophy-1028152946,positive,0.9524828791618347
265,5/1/2019 1:30:00 PM,Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases,GlobeNewswire,/news/stocks/biogen-to-present-data-at-aan-highlighting-its-innovative-marketed-treatments-and-investigational-pipeline-programs-for-complex-neurodegenerative-diseases-1028157428,neutral,0.7156291604042053
266,5/1/2019 10:30:00 PM,Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS),GlobeNewswire,/news/stocks/biogen-to-present-new-interim-data-from-its-phase-1-2-clinical-study-of-tofersen-biib067-for-the-potential-treatment-of-a-subtype-of-familial-amyotrophic-lateral-sclerosis-als-1028159469,neutral,0.7673538327217102
267,5/6/2019 1:30:00 PM,Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen),GlobeNewswire,/news/stocks/biogen-presents-data-at-2019-aan-annual-meeting-affirming-longer-term-safety-and-durability-of-treatment-with-spinraza-nusinersen-1028170694,positive,0.8230083584785461
268,5/7/2019 1:30:00 PM,Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS,GlobeNewswire,/news/stocks/data-at-aan-demonstrate-biogen-s-leadership-and-commitment-to-innovation-in-ms-1028175843,positive,0.8691011071205139
269,5/15/2019 1:02:00 AM,"Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy",GlobeNewswire,/news/stocks/biogen-s-spinraza-nusinersen-receives-positive-recommendation-from-nice-for-funding-in-the-united-kingdom-for-the-treatment-of-infants-children-and-adults-with-spinal-muscular-atrophy-1028201146,positive,0.951825737953186
270,5/20/2019 1:30:00 PM,Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation,GlobeNewswire,/news/stocks/biogen-recommends-stockholders-reject-the-below-market-mini-tender-offer-by-trc-capital-corporation-1028214161,neutral,0.8761451840400696
271,5/30/2019 1:30:00 PM,New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis,GlobeNewswire,/news/stocks/new-phase-3-interim-results-support-safety-and-efficacy-of-diroximel-fumarate-in-multiple-sclerosis-1028241646,positive,0.8838822245597839
272,6/7/2019 7:49:05 AM,"Pain, Pain Go Away - The Suicide Disease Drug Pipeline ",RTTNews,/news/stocks/pain-pain-go-away-the-suicide-disease-drug-pipeline-1028262468,neutral,0.8754533529281616
273,6/7/2019 11:41:57 AM,Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million,GlobeNewswire,/news/stocks/biogen-completes-acquisition-of-nightstar-therapeutics-for-approximately-800-million-1028263101,neutral,0.8179016709327698
274,6/11/2019 7:16:13 AM,Genentech: Gazyva Meets Endpoints In Phase II Lupus Nephritis Trial ,RTTNews,/news/stocks/genentech-gazyva-meets-endpoints-in-phase-ii-lupus-nephritis-trial-1028268319,positive,0.7323442697525024
275,6/11/2019 3:26:38 PM,Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder,InvestorPlace,/news/stocks/zynerba-zyne-stock-cannabidiol-patent-autism-spectrum-disorder-1028272003,negative,0.5551157593727112
276,6/12/2019 1:05:00 AM,Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019,GlobeNewswire,/news/stocks/biogen-to-present-new-safety-and-efficacy-data-on-biosimilars-and-estimates-1-8-billion-euros-in-savings-for-the-european-healthcare-system-in-2019-1028271715,positive,0.8092413544654846
277,6/19/2019 3:49:28 PM,3 Large-Cap Biotech Stocks to Buy for Massive Gains,InvestorPlace,/news/stocks/3-large-cap-biotech-stocks-to-buy-for-massive-gains-1028293605,neutral,0.7152913808822632
278,6/21/2019 8:30:47 PM,Nasdaq Today: Maintaining Altitude Amid Uncertainty,InvestorPlace,/news/stocks/nasdaq-today-maintaining-altitude-amid-uncertainty-1028299511,neutral,0.5723587870597839
279,6/25/2019 8:46:12 PM,Nasdaq Today: Hard to Keep Track of the Losers,InvestorPlace,/news/stocks/nasdaq-today-hard-to-keep-track-of-the-losers-1028307921,neutral,0.5613378286361694
280,6/28/2019 8:24:19 PM,Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook,InvestorPlace,/news/stocks/nasdaq-today-apple-loses-ive-and-the-nasdaqs-q3-outlook-1028318764,negative,0.9430888891220093
281,7/1/2019 1:30:00 PM,Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients,GlobeNewswire,/news/stocks/biogen-announces-new-data-further-establishing-spinraza-nusinersen-as-a-foundation-of-care-in-spinal-muscular-atrophy-for-a-broad-range-of-patients-1028320844,positive,0.8239752650260925
282,7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970,neutral,0.9275438189506531
283,7/21/2019 3:01:26 PM,Here's what Wall Street expects from Biogen's earnings report,Markets Insider Automation,/news/stocks/biogen-q2-earnings-preview-1028369640,neutral,0.8965476155281067
284,7/22/2019 3:51:50 PM,"Notable Earnings To Watch On July 23 - AN, JBLU, BIIB, CMG, KO, HOG, HAS, TXN ",RTTNews,/news/stocks/notable-earnings-to-watch-on-july-23-an-jblu-biib-cmg-ko-hog-has-txn-1028372290,neutral,0.9243824481964111
285,7/22/2019 5:58:17 PM,"MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock",InvestorPlace,/news/stocks/ms-franchise-spinraza-likely-to-be-key-catalysts-for-biogen-stock-1028374209,positive,0.7163318395614624
286,7/23/2019 1:07:38 PM,Biogen Q2 Profit Rises; Lifts 2019 Outlook ,RTTNews,/news/stocks/biogen-q2-profit-rises-lifts-2019-outlook-1028375491,positive,0.9347787499427795
287,7/23/2019 3:42:23 PM,Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat,InvestorPlace,/news/stocks/biogen-earnings-boost-biib-stock-1028378754,positive,0.9162024855613708
288,7/30/2019 1:30:00 PM,Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis,GlobeNewswire,/news/stocks/diroximel-fumarate-demonstrated-significantly-improved-gastrointestinal-tolerability-profile-compared-to-dimethyl-fumarate-in-patients-with-multiple-sclerosis-1028397993,positive,0.9549914598464966
289,7/30/2019 3:04:43 PM,ALKS : Diroximel Fumarate Shows Superior GI Tolerability On EVOLVE-MS-2 Endpoint ,RTTNews,/news/stocks/alks-diroximel-fumarate-shows-superior-gi-tolerability-on-evolve-ms-2-endpoint-1028398997,positive,0.9570061564445496
290,8/20/2019 1:30:00 PM,Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients,GlobeNewswire,/news/stocks/biogen-and-invitae-announce-availability-of-rapid-results-in-genetic-testing-program-for-spinal-muscular-atrophy-sma-to-improve-speed-of-diagnosis-for-patients-1028458934,positive,0.8986291885375977
291,9/11/2019 11:00:00 AM,New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years,GlobeNewswire,/news/stocks/new-data-presented-at-ectrims-reinforce-long-term-benefits-of-tecfidera-dimethyl-fumarate-over-10-years-1028515466,positive,0.9166748523712158
292,9/12/2019 11:00:00 AM,New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum,GlobeNewswire,/news/stocks/new-research-demonstrate-biogen-s-continued-commitment-to-improve-care-of-patients-with-multiple-sclerosis-across-treatment-spectrum-1028518908,positive,0.9432023763656616
293,9/13/2019 2:15:27 PM,"Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts ",RTTNews,/news/stocks/eisai-biogen-to-discontinue-elenbecestat-phase-iii-studies-quick-facts-1028523088,neutral,0.9349668622016907
294,9/14/2019 10:31:25 AM,"3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector",InvestorPlace,/news/stocks/3-biotech-stocks-that-show-the-good-the-bad-and-the-ugly-side-of-this-sector-1028524601,neutral,0.9101839065551758
295,9/17/2019 1:30:00 PM,Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index,GlobeNewswire,/news/stocks/biogen-ranked-1-biotechnology-company-on-dow-jones-sustainability-world-index-1028529793,positive,0.7805274724960327
296,9/18/2019 1:30:00 PM,Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients,GlobeNewswire,/news/stocks/biogen-advances-spinal-muscular-atrophy-sma-clinical-research-with-new-study-evaluating-a-higher-dose-of-spinraza-nusinersen-and-additional-data-in-a-broad-range-of-patients-1028533574,positive,0.7130200266838074
297,9/23/2019 9:00:00 AM,"Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding",GlobeNewswire,/news/stocks/interferon-beta-treatments-including-plegridy-peginterferon-beta-1a-and-avonex-interferon-beta-1a-receive-positive-chmp-opinion-for-use-during-pregnancy-and-breastfeeding-1028543483,positive,0.9191706776618958
298,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645,neutral,0.9301358461380005
299,10/1/2019 2:00:00 PM,Biogen Announces Leadership Update,GlobeNewswire,/news/stocks/biogen-announces-leadership-update-1028566546,neutral,0.8926394581794739
300,10/1/2019 2:26:58 PM,"Biogen Appoints Alfred Sandrock As EVP, Research And Development ",RTTNews,/news/stocks/biogen-appoints-alfred-sandrock-as-evp-research-and-development-1028566809,neutral,0.9440283179283142
301,10/2/2019 1:30:00 PM,Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders,GlobeNewswire,/news/stocks/landmark-nurture-study-of-infants-with-spinal-muscular-atrophy-sma-treated-pre-symptomatically-with-spinraza-nusinersen-published-in-neuromuscular-disorders-1028570405,neutral,0.6206486225128174
302,10/3/2019 2:41:05 PM,Biogen Canada Reports Positive Results On Spinal Muscular Atrophy Study ,RTTNews,/news/stocks/biogen-canada-reports-positive-results-on-spinal-muscular-atrophy-study-1028574056,positive,0.9501028060913086
303,10/21/2019 1:30:05 PM,Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week,GlobeNewswire,/news/stocks/biogen-and-samsung-bioepis-to-present-data-for-infliximab-and-adalimumab-biosimilars-at-united-european-gastroenterology-week-1028614633,neutral,0.9144085049629211
304,10/21/2019 8:16:27 PM,Stock Market Today: Stocks Rally Ahead of Big Earnings Week,InvestorPlace,/news/stocks/stock-market-today-stocks-rally-ahead-of-big-earnings-week-1028616676,positive,0.9003600478172302
305,10/22/2019 12:30:05 PM,Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies,GlobeNewswire,/news/stocks/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimer-s-disease-based-on-new-analysis-of-larger-dataset-from-phase-3-studies-1028618041,neutral,0.8240936994552612
306,10/22/2019 12:52:00 PM,Biogen Plans To Submit BLA For Aducanumab In Alzheimer's Disease; Shares Jump ,RTTNews,/news/stocks/biogen-plans-to-submit-bla-for-aducanumab-in-alzheimer-s-disease-shares-jump-1028618105,neutral,0.8345834612846375
307,10/22/2019 1:33:13 PM,Biogen Q3 Profit Tops Estimates; Revenue Up 5% - Quick Facts ,RTTNews,/news/stocks/biogen-q3-profit-tops-estimates-revenue-up-5-quick-facts-1028618324,positive,0.9516390562057495
308,10/22/2019 3:33:07 PM,Biogen surges 42% after stunning reversal sees it revive plans for Alzheimer's treatment (BIIB),Business Insider,https://markets.businessinsider.com/news/stocks/biogen-stock-price-soars-on-plan-to-revive-alzheimers-treatment-2019-10-1028619410,positive,0.9400156140327454
309,10/22/2019 5:23:57 PM,5 Healthcare Stocks to Buy,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-2-1028620498,neutral,0.8994203805923462
310,10/22/2019 8:17:39 PM,Stock Market Today: Biogen’s Answer to Alzheimer’s,InvestorPlace,/news/stocks/stock-market-today-biogens-answer-to-alzheimers-1028621067,neutral,0.8794760704040527
311,10/23/2019 1:19:08 PM,"Wednesday’s Vital Data: Biogen, McDonald’s and Lyft",InvestorPlace,/news/stocks/wednesdays-vital-data-biogen-mcdonalds-and-lyft-1028623788,neutral,0.9254962205886841
312,10/23/2019 6:37:15 PM,Biogen CEO Confident Its Alzheimer's Drug Will Get FDA Approval ,RTTNews,/news/stocks/biogen-ceo-confident-its-alzheimer-s-drug-will-get-fda-approval-1028624406,positive,0.9270169734954834
313,10/25/2019 11:49:09 AM,"3 Big Stock Charts for Friday: Microsoft, Texas Instruments, and Box",InvestorPlace,/news/stocks/3-big-stock-charts-friday-microsoft-texas-instruments-box-1028631233,neutral,0.930755078792572
314,10/30/2019 12:30:05 PM,Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-sclerosis-1028643236,positive,0.7381020188331604
315,11/1/2019 6:16:10 PM,"The Good, Bad, and Ugly for Biogen Stock",InvestorPlace,/news/stocks/the-good-bad-and-ugly-for-biogen-stock-1028652569,neutral,0.5726683139801025
316,11/4/2019 10:30:00 PM,"Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019",GlobeNewswire,/news/stocks/biogen-to-host-investor-webcasts-from-clinical-trials-on-alzheimer-s-disease-ctad-congress-on-december-5-2019-1028657218,neutral,0.9362678527832031
317,11/6/2019 1:30:00 PM,Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis,GlobeNewswire,/news/stocks/biogen-to-expand-biosimilars-portfolio-and-gain-access-to-additional-markets-through-new-transaction-with-samsung-bioepis-1028664222,positive,0.9192120432853699
318,11/12/2019 6:50:33 PM,7 Biotech Stocks to Buy With Plenty of Power in the Pipeline,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-1028682538,neutral,0.8071870803833008
319,11/13/2019 4:44:57 PM,3 of 2019’s Best New ETFs to Watch,InvestorPlace,/news/stocks/2019-best-etfs-to-watch-1028686366,neutral,0.6217009425163269
320,11/21/2019 1:30:00 PM,Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder,GlobeNewswire,/news/stocks/biogen-announces-enrollment-completion-of-global-phase-3-gene-therapy-study-for-an-inherited-retinal-disorder-1028707538,positive,0.6729592680931091
321,11/22/2019 1:30:00 PM,Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate),GlobeNewswire,/news/stocks/biogen-presents-data-demonstrating-improved-gastrointestinal-tolerability-with-vumerity-diroximel-fumarate-compared-to-tecfidera-dimethyl-fumarate-1028711092,positive,0.9547349810600281
322,11/22/2019 1:43:58 PM,Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity ,RTTNews,/news/stocks/biogen-s-data-shows-improved-gastrointestinal-tolerability-with-vumerity-1028711117,positive,0.9563114047050476
323,12/3/2019 1:30:00 PM,Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE),GlobeNewswire,/news/stocks/biogen-announces-positive-phase-2-study-results-for-cutaneous-lupus-erythematosus-cle-and-systemic-lupus-erythematosus-sle-1028732988,positive,0.944017231464386
324,12/5/2019 9:17:19 PM,"5 Top Stock Trades for Friday: RH, DG, KR, BIIB",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-rh-dg-kr-biib-1028742734,neutral,0.9211545586585999
325,12/9/2019 1:12:56 PM,"With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell",InvestorPlace,/news/stocks/no-pathway-forward-for-ocugen-stock-1028747917,negative,0.5869523286819458
326,12/13/2019 1:30:00 PM,Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy,GlobeNewswire,/news/stocks/biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy-1028761936,positive,0.5253638029098511
327,12/13/2019 1:54:03 PM,Biogen Stops Development Of Gosuranemab For Progressive Supranuclear Palsy ,RTTNews,/news/stocks/biogen-stops-development-of-gosuranemab-for-progressive-supranuclear-palsy-1028761987,negative,0.9218640327453613
328,12/19/2019 10:16:39 AM,Why Longer-Term Investors Should Buy Amarin Stock on Weakness,InvestorPlace,/news/stocks/why-longer-term-investors-should-buy-amarin-stock-on-weakness-1028775027,neutral,0.9243662357330322
329,12/19/2019 4:19:08 PM,Make the Shift Toward Value Stocks With These 5 Picks,InvestorPlace,/news/stocks/make-the-shift-toward-value-stocks-with-these-5-picks-1028776707,neutral,0.9216774106025696
330,1/13/2020 1:30:00 PM,Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.,GlobeNewswire,/news/stocks/biogen-to-acquire-novel-clinical-stage-asset-with-application-in-alzheimer-s-disease-and-parkinson-s-disease-from-pfizer-inc-1028812151,positive,0.6067082285881042
331,1/13/2020 2:03:26 PM,Biogen To Acquire Clinical Stage PF-05251749 From Pfizer - Quick Facts ,RTTNews,/news/stocks/biogen-to-acquire-clinical-stage-pf-05251749-from-pfizer-quick-facts-1028812254,neutral,0.8417471647262573
332,1/14/2020 7:01:00 PM,Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.,Moodys,/news/bonds/biogen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-biogen-inc-1028817172,neutral,0.8530017733573914
333,1/15/2020 12:16:22 PM,"3 Big Stock Charts for Wednesday: Biogen, Cooper Companies, and Maxim",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-biogen-cooper-companies-and-maxim-1028819357,neutral,0.9438915848731995
334,1/28/2020 2:46:23 PM,7 Big Biotech Stocks to Avoid,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-avoid-1028851372,neutral,0.929349958896637
335,1/29/2020 3:02:11 PM,Biogen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/biogen-stock-quarter-earnings-preview-q4-1028855277,neutral,0.9190120697021484
336,1/30/2020 1:28:08 PM,Biogen Inc. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/biogen-inc-q4-adjusted-earnings-beat-estimates-1028859254,positive,0.9016663432121277
337,1/30/2020 1:30:45 PM,Biogen Guides FY20 In Line With Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-guides-fy20-in-line-with-estimates-quick-facts-1028859297,positive,0.4946634769439697
338,1/30/2020 6:57:09 PM,Biogen is submitting a key Alzheimer's drug it once abandoned for approval 'as soon as possible.' Here's what we just learned and still need to know. (BIIB),Premium,/news/stocks/biogen-alzheimers-drug-aducanumab-fda-filing-update-what-we-know-2020-1,neutral,0.9104498624801636
339,2/5/2020 6:48:56 PM,Biogen up 18% on reported favorable patent ruling for Tecfidera,Seeking Alpha,https://seekingalpha.com/news/3538715-biogen-up-18-on-reported-favorable-patent-ruling-for-tecfidera?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9509204030036926
340,2/5/2020 9:26:28 PM,Stock Market Today: New Record Highs; An $8 Trillion Opportunity,InvestorPlace,/news/stocks/stock-market-today-new-record-highs-an-8-trillion-opportunity-1028878844,positive,0.8038056492805481
341,2/6/2020 1:09:15 PM,PTC Therapeutics down 6% premarket on risidplam data,Seeking Alpha,https://seekingalpha.com/news/3539181-ptc-therapeutics-down-6-premarket-on-risidplam-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9630668759346008
342,2/18/2020 8:22:37 AM,"Stock Alert: Warren Buffett's Berkshire Hathaway Reveals Stake In Kroger, Biogen ",RTTNews,/news/stocks/stock-alert-warren-buffett-s-berkshire-hathaway-reveals-stake-in-kroger-biogen-1028912177,neutral,0.9289048314094543
343,2/18/2020 2:39:16 PM,Biogen up 2% premarket on Berkshire stake,Seeking Alpha,https://seekingalpha.com/news/3542704-biogen-up-2-premarket-on-berkshire-stake?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8430614471435547
344,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9021157026290894
345,2/25/2020 7:34:53 PM,3 Top Stocks You Should Watch to Invest Like Berkshire Hathaway,InvestorPlace,/news/stocks/3-top-stocks-you-should-watch-to-invest-like-berkshire-hathaway-1028938532,neutral,0.9108915328979492
346,2/27/2020 10:06:00 PM,"Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases",GlobeNewswire,/news/stocks/biogen-and-sangamo-announce-global-collaboration-to-develop-gene-regulation-therapies-for-alzheimer-s-parkinson-s-neuromuscular-and-other-neurological-diseases-1028947812,positive,0.8930063843727112
347,2/27/2020 11:03:26 PM,"Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases ",RTTNews,/news/stocks/biogen-sangamo-sign-deal-to-develop-gene-therapies-for-neurological-diseases-1028947929,positive,0.8842382431030273
348,2/27/2020 11:51:47 PM,Sangamo +39% on gene therapy deal with Biogen,Seeking Alpha,https://seekingalpha.com/news/3546882-sangamoplus-39-on-gene-therapy-deal-biogen?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7590684294700623
349,3/6/2020 3:17:34 PM,Biogen tries to nip coronavirus outbreak among staff,Seeking Alpha,https://seekingalpha.com/news/3549429-biogen-tries-to-nip-coronavirus-outbreak-among-staff?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8553805947303772
350,3/12/2020 12:40:49 PM,Vir Biotech up 27% premarket on COVID-19 deal with Biogen,Seeking Alpha,https://seekingalpha.com/news/3551009-vir-biotech-up-27-premarket-on-covidminus-19-deal-biogen?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9408385753631592
351,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6742607355117798
352,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847,neutral,0.895007848739624
353,3/16/2020 9:08:52 PM,Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World,GlobeNewswire,/news/stocks/biogen-foundation-commits-10-million-to-support-covid-19-relief-efforts-in-the-u-s-and-around-the-world-1029001466,positive,0.8056178092956543
354,3/24/2020 11:33:42 AM,"3 Big Stock Charts for Tuesday: Biogen, Activision Blizzard, and Plug Power",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-biogen-activision-blizzard-and-plug-power-1029026899,neutral,0.8960168957710266
355,3/25/2020 12:17:36 PM,More Covid-19-related activity - healthcare,Seeking Alpha,https://seekingalpha.com/news/3555000-covidminus-19-related-activity-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9488641619682312
356,4/2/2020 1:30:00 PM,Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study,GlobeNewswire,/news/stocks/biogen-announces-first-patient-treated-with-higher-dose-of-spinraza-nusinersen-in-phase-2-3-devote-study-1029259405,positive,0.8518861532211304
357,4/3/2020 7:34:50 PM,Investors Are Wondering: Where’s Warren Buffett?,InvestorPlace,/news/stocks/investors-are-wondering-wheres-warren-1029064378,neutral,0.7011396884918213
358,4/9/2020 11:38:04 AM,"3 Big Stock Charts for Thursday: Goldman Sachs, FedEx, and Biogen",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-goldman-sachs-fedex-and-biogen-1029079572,neutral,0.9284935593605042
359,4/15/2020 3:13:45 PM,RemeGen candidate Fast Track'd for lupus,Seeking Alpha,https://seekingalpha.com/news/3560931-remegen-candidate-fast-trackd-for-lupus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.709993302822113
360,4/16/2020 11:53:16 AM,Biogen announces consortium for COVID-19 biobank,Seeking Alpha,https://seekingalpha.com/news/3561227-biogen-announces-consortium-for-covidminus-19-biobank?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5859752297401428
361,4/16/2020 1:30:10 PM,"Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium  to Build and Share a COVID-19 Biobank",GlobeNewswire,/news/stocks/biogen-broad-institute-of-mit-and-harvard-partners-healthcare-launch-consortium-to-build-and-share-a-covid-19-biobank-1029097890,positive,0.7592902779579163
362,4/20/2020 11:45:10 PM,"Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics",GlobeNewswire,/news/stocks/biogen-releases-2019-corporate-responsibility-report-demonstrating-continuous-progress-across-environmental-social-and-governance-metrics-1029109247,positive,0.921155571937561
363,4/21/2020 3:01:27 PM,Here's what Wall Street expects from Biogen's earnings report,Markets Insider Automation,/news/stocks/biogen-q1-quarterly-earnings-preview-stock-1029112308,neutral,0.8965476155281067
364,4/21/2020 8:27:51 PM,"Stock Market Today: Video Games Surge; Amazon to $4,000?",InvestorPlace,/news/stocks/stock-market-today-video-games-surge-amazon-to-4000-1029114543,positive,0.8672993779182434
365,4/22/2020 11:21:40 AM,Biogen down 6% on extended filing timeline for Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3562970-biogen-down-6-on-extended-filing-timeline-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9696952700614929
366,4/22/2020 11:37:50 AM,Biogen Spinraza sales up 24%; non-GAAP EPS up 31%,Seeking Alpha,https://seekingalpha.com/news/3562983-biogen-spinraza-sales-up-24-non-gaap-eps-up-31?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9495054483413696
367,4/22/2020 1:39:42 PM,Biogen Q1 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-q1-results-top-estimates-quick-facts-1029117053,neutral,0.8762961626052856
368,4/22/2020 3:00:10 PM,SmileDirectClub and Immunic among healthcare gainers; Biogen among losers,Seeking Alpha,https://seekingalpha.com/news/3563127-smiledirectclub-and-immunic-among-healthcare-gainers-biogen-among-losers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7027385830879211
369,4/23/2020 11:47:56 AM,"3 Big Stock Charts for Thursday: Snap, Biogen, and L Brands",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-snap-biogen-and-l-brands-1029122409,neutral,0.9367508888244629
370,4/23/2020 1:21:39 PM,A couple of loud downgrades on Biogen,Seeking Alpha,https://seekingalpha.com/news/3563653-couple-of-loud-downgrades-on-biogen?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8921825289726257
371,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761,neutral,0.8712261319160461
372,4/27/2020 3:52:00 PM,Biogen Inc. -- Moody's rates Biogen's notes Baa1; stable outlook,Moodys,/news/bonds/biogen-inc-moody-s-rates-biogen-s-notes-baa1-stable-outlook-1029133380,positive,0.7657926082611084
373,4/27/2020 4:40:56 PM,3 Mega Cap Stocks Earnings Dips to Buy,InvestorPlace,/news/stocks/3-mega-cap-stocks-earnings-dips-to-buy-1029134286,negative,0.9318463802337646
374,4/27/2020 10:06:10 PM,Biogen Prices $3.0 Billion of Senior Unsecured Notes,GlobeNewswire,/news/stocks/biogen-prices-3-0-billion-of-senior-unsecured-notes-1029134708,neutral,0.9484785795211792
375,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.901307225227356
376,5/18/2020 1:30:10 PM,New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients,GlobeNewswire,/news/stocks/new-spinraza-nusinersen-data-reinforce-sustained-efficacy-and-longer-term-safety-across-broad-range-of-spinal-muscular-atrophy-sma-patients-1029210527,positive,0.9561637043952942
377,5/19/2020 1:30:10 PM,New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS,GlobeNewswire,/news/stocks/new-data-at-aan-showcase-biogen-s-commitment-to-advancing-innovation-in-ms-1029214404,positive,0.8656517863273621
378,5/19/2020 4:44:45 PM,Nothing Will Stop Biogen Stock From Moving Higher,InvestorPlace,/news/stocks/nothing-will-stop-biogen-stock-from-moving-higher-1029216839,neutral,0.8043230772018433
379,5/22/2020 1:05:53 PM,7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine,InvestorPlace,/news/stocks/7-top-rated-biotech-stocks-to-buy-1029227095,neutral,0.5756127834320068
380,5/27/2020 7:08:26 PM,"Biotech Stocks Have Been on Fire, But Timing Is Everything",InvestorPlace,/news/stocks/biotech-stocks-have-been-on-fire-but-timing-is-everything-1029239422,neutral,0.6861350536346436
381,5/28/2020 1:30:10 PM,Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science,GlobeNewswire,/news/stocks/biogen-and-mit-launch-new-virtual-learning-lab-for-high-school-students-historically-underrepresented-in-science-1029250215,positive,0.5876320004463196
382,6/4/2020 1:30:10 PM,Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020,GlobeNewswire,/news/stocks/biogen-presents-positive-phase-2-cutaneous-lupus-erythematosus-cle-data-at-european-e-congress-of-rheumatology-eular-2020-1029280307,positive,0.9465526342391968
383,6/8/2020 3:29:14 PM,7 of the Best Blue-Chip Stocks to Buy,InvestorPlace,/news/stocks/7-of-the-best-blue-chip-stocks-to-buy-1029289733,positive,0.6396170258522034
384,6/10/2020 11:58:46 AM,Biogen's Spinraza shows sustained benefit in presymptomatic SMA patients,Seeking Alpha,https://seekingalpha.com/news/3581849-biogens-spinraza-shows-sustained-benefit-in-presymptomatic-sma-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9517838358879089
385,6/10/2020 1:30:10 PM,New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment,GlobeNewswire,/news/stocks/new-results-from-landmark-nurture-study-show-that-pre-symptomatic-sma-patients-treated-with-spinraza-nusinersen-continue-to-demonstrate-sustained-benefit-from-treatment-1029296266,positive,0.9547004103660583
386,6/10/2020 2:21:51 PM,Biogen: New Results From NURTURE Study Reveals Sustained Benefit Of SPINRAZA ,RTTNews,/news/stocks/biogen-new-results-from-nurture-study-reveals-sustained-benefit-of-spinraza-1029296650,positive,0.9419944882392883
387,6/15/2020 6:09:17 PM,Warren Buffett stock screen yields seven picks,Seeking Alpha,https://seekingalpha.com/news/3583116-warren-buffett-stock-screen-yields-seven-picks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7674033045768738
388,6/17/2020 6:50:26 PM,"As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure",InvestorPlace,/news/stocks/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-1029319275,neutral,0.8430030345916748
389,6/18/2020 1:32:38 PM,Biogen under pressure on adverse ruling Tecfidera patent ruling,Seeking Alpha,https://seekingalpha.com/news/3584148-biogen-under-pressure-on-adverse-ruling-tecfidera-patent-ruling?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9041635394096375
390,6/18/2020 4:00:18 PM,Stock Alert: Biogen Tanks 6% ,RTTNews,/news/stocks/stock-alert-biogen-tanks-6-1029322306,neutral,0.8200197219848633
391,6/18/2020 7:58:16 PM,Biogen News: BIIB Stock Battered 7% by MS Drug Patent Ruling,InvestorPlace,/news/stocks/biogen-news-batters-biib-stock-1029323700,negative,0.9700766801834106
392,6/19/2020 3:39:00 AM,Biogen Inc. -- Moody's: Tecfidera patent ruling credit negative for Biogen,Moodys,/news/bonds/biogen-inc-moody-s-tecfidera-patent-ruling-credit-negative-for-biogen-1029324090,negative,0.8000093698501587
393,6/19/2020 7:52:36 AM,"FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars ",RTTNews,/news/stocks/fda-nod-for-epzm-rare-court-rules-in-myl-s-favor-ocuphire-to-hop-onto-nasdaq-alpn-soars-1029324381,positive,0.8128530979156494
394,7/6/2020 10:40:08 AM,Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years,InvestorPlace,/news/stocks/rprx-stock-is-likely-to-reach-new-highs-coming-years-1029368649,positive,0.915957510471344
395,7/8/2020 1:30:10 PM,Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease,GlobeNewswire,/news/stocks/biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as-a-treatment-for-alzheimer-s-disease-1029376017,positive,0.627407431602478
396,7/8/2020 4:00:40 PM,Stock Alert: Biogen Up 5%; Submits Application To FDA For Aducanumab ,RTTNews,/news/stocks/stock-alert-biogen-up-5-submits-application-to-fda-for-aducanumab-1029377035,positive,0.9335790276527405
397,7/8/2020 8:56:55 PM,"4 Top Stock Trades for Thursday: TWTR, NIO, BIIB, SNAP",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-twtr-nio-biib-snap-1029378473,neutral,0.9324886202812195
398,7/8/2020 11:01:10 PM,The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS,GlobeNewswire,/news/stocks/the-new-england-journal-of-medicine-publishes-final-results-from-phase-1-2-study-of-tofersen-for-a-genetic-form-of-als-1029378385,neutral,0.9097334742546082
399,7/10/2020 12:23:01 PM,Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors,InvestorPlace,/news/stocks/potential-alzheimers-drug-not-enough-to-excite-biogen-stock-investors-1029384005,neutral,0.581057608127594
400,7/21/2020 1:30:10 PM,Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec),GlobeNewswire,/news/stocks/biogen-plans-to-initiate-phase-4-study-evaluating-benefit-of-spinraza-nusinersen-in-patients-treated-with-zolgensma-onasemnogene-abeparvovec-1029413908,positive,0.8330497741699219
401,7/21/2020 3:01:34 PM,Biogen earnings: here's what to expect,Markets Insider Automation,/news/stocks/biogen-quarter-earnings-preview-q2-1029414581,neutral,0.9404481053352356
402,7/22/2020 12:00:10 AM,Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer,GlobeNewswire,/news/stocks/biogen-names-michael-mcdonnell-as-executive-vice-president-and-chief-financial-officer-1029416824,neutral,0.9438976049423218
403,7/22/2020 4:52:46 AM,Biogen Appoints Michael McDonnell As EVP And CFO ,RTTNews,/news/stocks/biogen-appoints-michael-mcdonnell-as-evp-and-cfo-1029417049,neutral,0.9382873773574829
404,7/22/2020 1:24:47 PM,Biogen Boosts FY20 Earnings Outlook; Q2 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-boosts-fy20-earnings-outlook-q2-results-top-estimates-quick-facts-1029419403,positive,0.93943852186203
405,7/22/2020 3:44:07 PM,Biogen Earnings: BIIB Stock Jumps 1% Higher on Q2 Beats,InvestorPlace,/news/stocks/biogen-earnings-biib-stock-jumps-1-higher-on-q2-beats-1029421403,positive,0.9460317492485046
406,7/24/2020 10:06:10 PM,Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease,GlobeNewswire,/news/stocks/biogen-to-present-data-at-virtual-2020-alzheimer-s-association-international-conference-highlighting-comprehensive-approach-to-alzheimer-s-disease-1029429808,neutral,0.8649311065673828
407,7/27/2020 6:21:14 PM,Morgan Stanley double-upgrades Biogen and says the stock can surge another 30% (BIIB),Business Insider,https://www.businessinsider.com/biogen-stock-gets-rare-double-upgrade-morgan-stanley-surge-more-2020-7,positive,0.9365360736846924
408,8/6/2020 2:02:30 PM,Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases,GlobeNewswire,/news/stocks/biogen-and-denali-to-collaborate-on-lrrk2-program-for-parkinson-s-disease-and-certain-tv-platform-enabled-programs-for-neurodegenerative-diseases-1029477632,positive,0.7069503664970398
409,8/6/2020 3:50:21 PM,Denali Stock Surges After Biogen Collaboration ,RTTNews,/news/stocks/denali-stock-surges-after-biogen-collaboration-1029478711,negative,0.7081992626190186
410,8/7/2020 1:30:10 PM,FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review,GlobeNewswire,/news/stocks/fda-accepts-biogen-s-aducanumab-biologics-license-application-for-alzheimer-s-disease-with-priority-review-1029481783,positive,0.7064810991287231
411,8/7/2020 2:07:11 PM,Biogen: FDA To Review Biologics License Application For Aducanumab ,RTTNews,/news/stocks/biogen-fda-to-review-biologics-license-application-for-aducanumab-1029481903,neutral,0.8423107266426086
412,8/7/2020 4:13:59 PM,Stock Alert: Biogen Ticking Up ,RTTNews,/news/stocks/stock-alert-biogen-ticking-up-1029482515,neutral,0.579516589641571
413,8/10/2020 3:38:13 PM,The 8 Best Stocks in Warren Buffett’s Pocket Right Now,InvestorPlace,/news/stocks/8-best-warren-buffett-stocks-right-now-1029488304,neutral,0.8635177612304688
414,8/26/2020 3:05:56 PM,7 International Stocks to Buy Growing Faster Than Amazon,InvestorPlace,/news/stocks/international-stocks-to-buy-growing-faster-than-amazon-1029537057,positive,0.8800203204154968
415,9/8/2020 1:30:10 PM,New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS,GlobeNewswire,/news/stocks/new-biogen-data-presented-at-actrims-ectrims-advance-understanding-of-clinical-and-health-disparities-in-ms-1029568845,positive,0.6203202605247498
416,9/11/2020 2:01:10 PM,New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio,GlobeNewswire,/news/stocks/new-data-at-actrims-ectrims-meeting-showcase-safety-and-efficacy-of-biogen-s-industry-leading-ms-portfolio-1029581670,positive,0.6899675726890564
417,9/14/2020 1:30:10 PM,Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health,GlobeNewswire,/news/stocks/biogen-to-invest-250-million-in-a-20-year-initiative-to-eliminate-its-use-of-fossil-fuels-and-improve-public-health-1029585444,positive,0.7503580451011658
418,9/14/2020 2:20:12 PM,"Biogen Announces $250 Mln, 20-yr Initiative To Eliminate Fossil Fuels - Quick Facts ",RTTNews,/news/stocks/biogen-announces-250-mln-20-yr-initiative-to-eliminate-fossil-fuels-quick-facts-1029585807,neutral,0.5148417353630066
419,9/28/2020 6:36:00 PM,Biogen Inc. -- Moody's affirms Biogen at Baa1; outlook revised to negative,Moodys,/news/bonds/biogen-inc-moody-s-affirms-biogen-at-baa1-outlook-revised-to-negative-1029627818,negative,0.49434909224510193
420,10/6/2020 11:14:27 AM,Biogen files application in Europe for Lucentis biosimilar,Seeking Alpha,https://seekingalpha.com/news/3620040-biogen-files-application-in-europe-for-lucentis-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7950215339660645
421,10/6/2020 1:00:10 PM,"Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)",GlobeNewswire,/news/stocks/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis-ranibizumab-1029651449,positive,0.8825892210006714
422,10/6/2020 2:31:23 PM,Biogen teams up with Scribe Therapeutics to develop gene therapy for ALS,Seeking Alpha,https://seekingalpha.com/news/3620162-biogen-teams-up-scribe-therapeutics-to-develop-gene-therapy-for-als?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5100467205047607
423,10/6/2020 2:44:51 PM,The 7 Best New Stocks From 2020 to Buy Now,InvestorPlace,/news/stocks/the-7-best-new-stocks-from-2020-to-buy-now-1029653691,neutral,0.8444294929504395
424,10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673,neutral,0.8608306646347046
425,10/16/2020 4:12:31 PM,3 Biotech Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-right-now-1029689519,neutral,0.9306740164756775
426,10/20/2020 3:01:35 PM,Here's what to expect from Biogen's earnings report,Markets Insider Automation,/news/stocks/biogen-stock-price-quarter-earnings-preview-q3-1029698638,neutral,0.924342691898346
427,10/20/2020 4:11:53 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3623754-notable-earnings-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.855887770652771
428,10/20/2020 5:17:29 PM,Biogen Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3623812-biogen-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7634727358818054
429,10/21/2020 11:11:25 AM,Biogen up 3% on earnings beat,Seeking Alpha,https://seekingalpha.com/news/3624109-biogen-up-3-on-earnings-beat?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9433099031448364
430,10/21/2020 11:56:00 AM,Biogen trims guidance as growth drivers remain elusive,Seeking Alpha,https://seekingalpha.com/news/3624138-biogen-trims-guidance-growth-drivers-remain-elusive?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8834490180015564
431,10/21/2020 1:26:35 PM,Biogen Trims FY20 Earnings Outlook; Q3 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-trims-fy20-earnings-outlook-q3-results-top-estimates-quick-facts-1029703977,negative,0.8910582661628723
432,10/22/2020 11:28:35 AM,Dosing underway for Ionis' ION541 in early-stage movement disorder study,Seeking Alpha,https://seekingalpha.com/news/3624719-dosing-underway-for-ionis-ion541-in-early-stage-movement-disorder-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7222561836242676
433,10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001,neutral,0.7490036487579346
434,10/27/2020 11:59:44 AM,Scholar Rock's SRK-015 shows positive effect in mid-stage spinal muscular atrophy study,Seeking Alpha,https://seekingalpha.com/news/3626322-scholar-rocks-srkminus-015-shows-positive-effect-in-mid-stage-spinal-muscular-atrophy-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9483583569526672
435,10/30/2020 11:11:30 AM,Biogen application for Alzheimer's drug accepted in Europe,Seeking Alpha,https://seekingalpha.com/news/3628974-biogen-application-for-alzheimers-drug-accepted-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5034166574478149
436,10/30/2020 12:00:00 PM,European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease,GlobeNewswire,/news/stocks/european-medicines-agency-accepts-biogen-s-aducanumab-marketing-authorization-application-for-alzheimer-s-disease-1029745717,positive,0.8893802762031555
437,10/30/2020 7:30:23 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3629204-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
438,11/1/2020 11:00:11 AM,"Week Ahead In Pharma: COVID-19 Data Readout, FDA Decisions, CTAD Presentation ",RTTNews,/news/stocks/week-ahead-in-pharma-covid-19-data-readout-fda-decisions-ctad-presentation-1029750301,neutral,0.9415560364723206
439,11/2/2020 11:05:35 AM,3 Biotech Stocks With Eye-Catching Pipelines,InvestorPlace,/news/stocks/3-biotech-stocks-with-eye-catching-pipelines-1029752447,neutral,0.5421436429023743
440,11/3/2020 1:04:33 PM,Biogen announces additional data on lupus candidate BIIB059,Seeking Alpha,https://seekingalpha.com/news/3630299-biogen-announces-additional-data-on-lupus-candidate-biib059?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8876723051071167
441,11/3/2020 1:30:00 PM,Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting,GlobeNewswire,/news/stocks/biogen-to-present-positive-phase-2-systemic-lupus-erythematosus-data-at-american-college-of-rheumatology-2020-meeting-1029758375,neutral,0.7933010458946228
442,11/4/2020 3:45:26 PM,Biogen rallies 31% ahead of Ad Com meeting on Alzheimer's med aducanumab,Seeking Alpha,https://seekingalpha.com/news/3631138-biogen-rallies-31-ahead-of-ad-com-meeting-on-alzheimers-med-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8841754198074341
443,11/4/2020 4:01:38 PM,"Biogen, Digirad leads healthcare gainers; Repro Med Systems, Aptevo Therapeutics among major losers",Seeking Alpha,https://seekingalpha.com/news/3631141-biogen-digirad-leads-healthcare-gainers-repro-med-systems-aptevo-therapeutics-among-major?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7275644540786743
444,11/4/2020 5:12:44 PM,Healthcare rallies as Presidential vote count continues,Seeking Alpha,https://seekingalpha.com/news/3631239-healthcare-rallies-presidential-vote-count-continues?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5205032825469971
445,11/4/2020 5:40:06 PM,"BIIB, XPEV, CXW and PVAC among midday movers",Seeking Alpha,https://seekingalpha.com/news/3631275-biib-xpev-cxw-and-pvac-among-midday-movers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9302337765693665
446,11/4/2020 10:19:11 PM,"4 Top Stock Trades for Thursday: BIIB, PTON, GM, WEN",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-biib-pton-gm-wen-1029767490,neutral,0.9393633604049683
447,11/5/2020 6:11:01 AM,"BIIB Faces FDA Panel Tomorrow, CRSP Climbs On Hemoglobinopathies Trial Data, SAVA On Watch ",RTTNews,/news/stocks/biib-faces-fda-panel-tomorrow-crsp-climbs-on-hemoglobinopathies-trial-data-sava-on-watch-1029767914,neutral,0.7399300932884216
448,11/6/2020 4:20:04 PM,Biogen shares halted pending Ad Com vote on Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3633224-biogen-shares-halted-pending-ad-com-vote-on-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8959824442863464
449,11/6/2020 8:27:23 PM,FDA advisory committee thumbs down on Biogen Alzheimer's candidate aducanumab,Seeking Alpha,https://seekingalpha.com/news/3633299-fda-advisory-committee-thumbs-down-on-biogen-alzheimers-candidate-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8465331196784973
450,11/7/2020 2:15:00 AM,Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease,GlobeNewswire,/news/stocks/update-on-fda-advisory-committee-s-meeting-on-aducanumab-in-alzheimer-s-disease-1029776678,neutral,0.9086185097694397
451,11/7/2020 5:30:00 AM,Biogen's long and winding road in Alzheimer's hits wall,Seeking Alpha,https://seekingalpha.com/news/3633230-biogens-long-and-winding-road-in-alzheimers-hits-wall?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5482166409492493
452,11/7/2020 10:01:19 PM,Weekly Wrap: An election week sees a bulletproof stock market,Seeking Alpha,https://seekingalpha.com/news/3633357-weekly-wrap-election-week-sees-bulletproof-stock-market?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8884294629096985
453,11/8/2020 3:52:03 PM,"Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing ",RTTNews,/news/stocks/week-ahead-in-pharma-fda-decisions-sitc-presentations-13d-sec-filing-1029778637,neutral,0.932803750038147
454,11/9/2020 12:46:30 PM,Biogen down big after FDA advisory committee snub of Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3633564-biogen-down-big-after-fda-advisory-committee-snub-of-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9229716658592224
455,11/9/2020 1:40:06 PM,"Zoom Video Communications, Biogen leads premarket losers' pack",Seeking Alpha,https://seekingalpha.com/news/3633631-zoom-video-communications-biogen-leads-premarket-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.901924729347229
456,11/9/2020 3:58:46 PM,"Aptevo Therapeutics, Sundial Growers leads healthcare gainers; Arcturus Therapeutics, Quidel among major losers",Seeking Alpha,https://seekingalpha.com/news/3633748-aptevo-therapeutics-sundial-growers-leads-healthcare-gainers-arcturus-therapeutics-quidel?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5212963819503784
457,11/9/2020 5:47:22 PM,"BIIB, EPR, QDEL and AMC among midday movers",Seeking Alpha,https://seekingalpha.com/news/3633806-biib-epr-qdel-and-amc-among-midday-movers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.938762903213501
458,11/9/2020 7:17:00 PM,Biogen Inc. -- Moody's review's Biogen's Baa1 ratings for downgrade,Moodys,/news/bonds/biogen-inc-moody-s-review-s-biogen-s-baa1-ratings-for-downgrade-1029782892,negative,0.8763467073440552
459,11/16/2020 1:30:00 PM,Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an  Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership,GlobeNewswire,/news/stocks/biogen-ranked-1-biotechnology-company-by-dow-jones-sustainability-world-index-for-an-industry-record-5th-time-recognition-reflects-longstanding-esg-leadership-1029805664,positive,0.9441733360290527
460,11/18/2020 12:20:18 PM,FDA accepts Biogen's U.S. application for Lucentis biosimilar,Seeking Alpha,https://seekingalpha.com/news/3637415-fda-accepts-biogens-u-s-application-for-lucentis-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5515343546867371
461,11/18/2020 1:00:00 PM,"Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)",GlobeNewswire,/news/stocks/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis-ranibizumab-1029815228,positive,0.8291108012199402
462,11/20/2020 8:30:48 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3638447-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
463,11/27/2020 12:45:28 PM,Biogen teams up with Sage Therapeutics (SAGE) to develop therapies in depression,Seeking Alpha,https://seekingalpha.com/news/3639647-biogen-teams-up-sage-therapeutics-sage-to-develop-therapies-in-depression?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.535872220993042
464,11/27/2020 12:45:28 PM,Biogen teams up with Sage Therapeutics to develop therapies in depression,Seeking Alpha,https://seekingalpha.com/news/3639647-biogen-teams-up-sage-therapeutics-to-develop-therapies-in-depression?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5678023099899292
465,11/27/2020 1:30:00 PM,Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders,GlobeNewswire,/news/stocks/biogen-and-sage-therapeutics-announce-global-collaboration-to-develop-and-commercialize-potential-breakthrough-therapies-in-depression-and-movement-disorders-1029844608,positive,0.9002242088317871
466,11/27/2020 1:58:01 PM,"Biogen, Sage Therapeutics To Jointly Develop And Commercialize Zuranolone, SAGE-324 ",RTTNews,/news/stocks/biogen-sage-therapeutics-to-jointly-develop-and-commercialize-zuranolone-sage-324-1029844669,neutral,0.9011598825454712
467,12/3/2020 4:13:37 PM,3 Under-Loved Biotech Stocks to Buy for Profits Into 2021,InvestorPlace,/news/stocks/3-under-loved-biotech-stocks-to-buy-for-profits-into-2021-1029862758,neutral,0.6799814105033875
468,12/8/2020 9:52:33 PM,The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure,InvestorPlace,/news/stocks/the-7-best-coronavirus-vaccine-stocks-still-in-the-race-for-a-cure-1029875288,positive,0.5180484652519226
469,12/10/2020 4:30:00 AM,Biogen Files New Drug Application for Aducanumab in Japan,GlobeNewswire,/news/stocks/biogen-files-new-drug-application-for-aducanumab-in-japan-1029954885,neutral,0.7105053067207336
470,12/10/2020 4:30:03 AM,Biogen files new drug application for aducanumab in Japan,Seeking Alpha,https://seekingalpha.com/news/3643160-biogen-files-new-drug-application-for-aducanumab-in-japan?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7105053067207336
471,12/10/2020 4:47:35 AM,Biogen Submits NDA For Investigational Therapy For Alzheimer's Disease In Japan ,RTTNews,/news/stocks/biogen-submits-nda-for-investigational-therapy-for-alzheimer-s-disease-in-japan-1029879534,neutral,0.8025884628295898
472,12/11/2020 9:08:05 PM,Cortexyme weighed down by Citi downgrade,Seeking Alpha,https://seekingalpha.com/news/3643837-cortexyme-weighed-down-citi-downgrade?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9270342588424683
473,12/14/2020 6:37:56 PM,7 Biotech Stocks To Buy Beyond Covid Vaccine Plays,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-beyond-covid-vaccine-plays-1029891263,positive,0.5038450956344604
474,12/15/2020 3:50:00 PM,Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.,Moodys,/news/bonds/biogen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-biogen-inc-1029894438,neutral,0.8530017733573914
475,12/18/2020 7:42:23 AM,Biogen Agrees To Pay $22 Mln To Settle Kickback Allegations ,RTTNews,/news/stocks/biogen-agrees-to-pay-22-mln-to-settle-kickback-allegations-1029905101,neutral,0.7875964641571045
476,12/18/2020 4:00:08 PM,AB Science is rising after positive data from Alzheimer’s trial,Seeking Alpha,https://seekingalpha.com/news/3645779-ab-science-is-rising-after-positive-data-from-alzheimer-s-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.94913649559021
477,12/18/2020 4:43:12 PM,Biogen loses bid for appeal of Merck Rebif royalties loss - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3645791-biogen-loses-bid-for-appeal-of-merck-rebif-royalties-loss-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9362956881523132
478,12/21/2020 1:10:32 PM,Europe Ok's intramuscular administration for Biogen's Plegridy,Seeking Alpha,https://seekingalpha.com/news/3646129-europe-oks-intramuscular-administration-for-biogens-plegridy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7383603453636169
479,12/21/2020 1:30:00 PM,The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis,GlobeNewswire,/news/stocks/the-european-commission-grants-marketing-authorization-for-plegridy-peginterferon-beta-1a-intramuscular-administration-for-relapsing-remitting-multiple-sclerosis-1029951702,positive,0.9025323987007141
480,12/21/2020 2:00:27 PM,Biogen's Plegridy Approved In Europe For Intramuscular Injection On RR Multiple Sclerosis ,RTTNews,/news/stocks/biogen-s-plegridy-approved-in-europe-for-intramuscular-injection-on-rr-multiple-sclerosis-1029910278,positive,0.8163531422615051
481,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9501712918281555
482,1/1/2021 9:27:40 AM,Energy and travel among worst S&P 500 performers of 2020,Seeking Alpha,https://seekingalpha.com/news/3648163-energy-and-travel-among-worst-s-and-p-500-performers-of-2020?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6290714144706726
483,1/5/2021 7:39:34 AM,Biogen inks deal for ophthalmic gene therapy development,Seeking Alpha,https://seekingalpha.com/news/3648630-biogen-inks-deal-for-ophthalmic-gene-therapy-development?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5995153188705444
484,1/7/2021 10:50:21 PM,Biotech is attractively valued; Genetic Medicine to outperform in 2021 – Oppenheimer,Seeking Alpha,https://seekingalpha.com/news/3649807-biotech-is-attractively-valued-genetic-medicine-to-outperform-in-2021-oppenheimer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9146185517311096
485,1/8/2021 1:30:00 PM,Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec),GlobeNewswire,/news/stocks/biogen-announces-first-patient-treated-in-respond-study-evaluating-benefit-of-spinraza-nusinersen-in-patients-treated-with-zolgensma-onasemnogene-abeparvovec-1029955209,positive,0.7210730910301208
486,1/8/2021 1:42:53 PM,Biogen moves forward with Spinraza study in SMA patients treated with Zolgensma,Seeking Alpha,https://seekingalpha.com/news/3649898-biogen-moves-forward-spinraza-study-in-sma-patients-treated-zolgensma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8170890808105469
487,1/8/2021 2:07:01 PM,Biogen Begins Phase 4 Study Of SPINRAZA In Patients With Suboptimal Response To Gene Therapy ,RTTNews,/news/stocks/biogen-begins-phase-4-study-of-spinraza-in-patients-with-suboptimal-response-to-gene-therapy-1029943467,neutral,0.7746735215187073
488,1/11/2021 1:30:00 PM,Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone,GlobeNewswire,/news/stocks/biogen-to-launch-pioneering-study-to-develop-digital-biomarkers-of-cognitive-health-using-apple-watch-and-iphone-1029949339,positive,0.6093074679374695
489,1/11/2021 1:33:34 PM,"Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health",Seeking Alpha,https://seekingalpha.com/news/3650238-biogen-apple-collaborate-to-evaluate-device-role-in-digital-biomarkers-of-cognitive-health?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7330794334411621
490,1/11/2021 5:32:08 PM,Alzheimer's peers jump after Eli Lilly's donanemab study meets endpoint,Seeking Alpha,https://seekingalpha.com/news/3650395-alzheimers-peers-jump-after-eli-lillys-donanemab-study-meets-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8135958909988403
491,1/11/2021 5:40:14 PM,"Biogen, Genentech team up for a new neurodegenerative biotech",Seeking Alpha,https://seekingalpha.com/news/3650398-biogen-genentech-team-up-for-new-neurodegenerative-biotech?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5038400292396545
492,1/12/2021 9:36:01 AM,Biogen discloses 10.7% stake in Sage Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3650573-biogen-discloses-10_7-stake-in-sage-therapeutics?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9461405277252197
493,1/14/2021 1:56:59 PM,"The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates",Benzinga,/news/stocks/the-daily-biotech-pulse-alexion-pauses-covid-19-study-nantkwest-readout-organogenesis-jumps-on-guidance-trial-updates-1029968277,neutral,0.9080525040626526
494,1/14/2021 7:45:19 PM,Biogen's stock rises with FDA's action date for Aducanumab fast approaching,Seeking Alpha,https://seekingalpha.com/news/3651565-biogens-stock-rises-fdas-action-date-for-aducanumab-fast-approaching?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8753849864006042
495,1/19/2021 8:44:04 PM,Eli Lilly upgraded to buy at Mizuho on positive donanemab data,Seeking Alpha,https://seekingalpha.com/news/3652410-eli-lilly-upgraded-to-buy-on-positive-donanemab-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9095020294189453
496,1/22/2021 12:55:09 PM,Sage Therapeutics downgraded at BMO citing valuation,Seeking Alpha,https://seekingalpha.com/news/3653498-sage-therapeutics-downgraded-at-bmo-citing-valuation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6162546277046204
497,1/29/2021 12:39:34 PM,Biogen rises 10% after FDA extends review period for aducanumab application,Seeking Alpha,https://seekingalpha.com/news/3656103-biogen-rises-10-after-fda-extends-review-period-for-aducanumab-application?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9229910373687744
498,1/29/2021 1:30:00 PM,Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab,GlobeNewswire,/news/stocks/biogen-and-eisai-announce-fda-s-3-month-extension-of-review-period-for-the-biologics-license-application-for-aducanumab-1030019530,neutral,0.7915614247322083
499,1/29/2021 2:57:06 PM,"Biogen, Eisai Say FDA Extends Aducanumab BLA Review Period By Three Months - Quick Facts ",RTTNews,/news/stocks/biogen-eisai-say-fda-extends-aducanumab-bla-review-period-by-three-months-quick-facts-1030020002,neutral,0.8347177505493164
500,1/29/2021 3:51:02 PM,Biogen upgraded to buy at Stifel on aducanumab optimism,Seeking Alpha,https://seekingalpha.com/news/3656238-biogen-upgraded-to-buy-at-stifel-on-aducanumab-optimism?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7872904539108276
501,1/29/2021 7:19:02 PM,Biogen’s FDA review extension: ‘a positive for Lilly’s Alzheimer perception' – MS,Seeking Alpha,https://seekingalpha.com/news/3656321-biogens-fda-review-extension-a-positive-for-lillys-alzheimer-perception-ms?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7267768979072571
502,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,neutral,0.8783655762672424
503,2/1/2021 1:30:00 PM,Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-announces-fda-approval-of-plegridy-peginterferon-beta-1a-intramuscular-administration-for-multiple-sclerosis-1030027160,positive,0.8863679766654968
504,2/1/2021 1:50:07 PM,Biogen Says FDA Approves PLEGRIDY Intramuscular Administration For MS - Quick Facts ,RTTNews,/news/stocks/biogen-says-fda-approves-plegridy-intramuscular-administration-for-ms-quick-facts-1030027242,positive,0.6821759939193726
505,2/1/2021 3:01:40 PM,Biogen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/biogen-quarter-earnings-preview-q4-1030027804,neutral,0.9190120697021484
506,2/2/2021 8:58:34 AM,"ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch ",RTTNews,/news/stocks/adms-gets-fda-nod-arqt-soars-on-psoriasis-trial-data-dvax-catches-eye-prta-on-watch-1030031352,neutral,0.4898258149623871
507,2/2/2021 5:18:57 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3657287-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.855887770652771
508,2/2/2021 6:00:15 PM,Biogen Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657311-biogen-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7998591661453247
509,2/3/2021 12:15:38 PM,"Biogen EPS misses by $0.18, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3657675-biogen-eps-misses-0_18-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5948824882507324
510,2/3/2021 1:19:59 PM,Biogen Inc. Q4 adjusted earnings Miss Estimates,RTTNews,/news/stocks/biogen-inc-q4-adjusted-earnings-miss-estimates-1030037816,negative,0.9500045776367188
511,2/3/2021 1:24:41 PM,Biogen Guides FY21 Below Estimates; Q4 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-guides-fy21-below-estimates-q4-results-top-estimates-quick-facts-1030037822,neutral,0.8566165566444397
512,2/3/2021 1:31:17 PM,"The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-amgen-earnings-gsk-curevac-vaccine-collaboration-mallinckrodt-fda-decision-1030037844,neutral,0.9407050013542175
513,2/3/2021 4:14:08 PM,Biogen CEO sees 'financial reset in 2021' as Q4 results disappoint,Seeking Alpha,https://seekingalpha.com/news/3657805-biogen-ceo-sees-financial-reset-in-2021-as-q4-results-disappoint?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9669348001480103
514,2/4/2021 9:39:35 AM,"BIIB Pulls Plug On Parkinson's Drug, JAZZ Acquires GWPH, NBIX Ends Deal With VYGR, TYME Flies ",RTTNews,/news/stocks/biib-pulls-plug-on-parkinson-s-drug-jazz-acquires-gwph-nbix-ends-deal-with-vygr-tyme-flies-1030042251,neutral,0.8757729530334473
515,2/4/2021 3:00:00 PM,Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors,GlobeNewswire,/news/stocks/biogen-announces-private-exchange-offer-for-5-200-senior-notes-due-2045-open-to-certain-investors-1030043887,neutral,0.8186339735984802
516,2/4/2021 3:00:00 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030043861,neutral,0.7969077229499817
517,2/4/2021 3:02:00 PM,Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only,GlobeNewswire,/news/stocks/biogen-announces-cash-tender-offer-for-5-200-senior-notes-due-2045-open-to-certain-holders-only-1030043891,neutral,0.8407188653945923
518,2/4/2021 5:10:00 PM,Biogen Inc. -- Moody's assign's Baa1 to Biogen's notes; on review for downgrade,Moodys,/news/bonds/biogen-inc-moody-s-assign-s-baa1-to-biogen-s-notes-on-review-for-downgrade-1030044693,positive,0.4610402584075928
519,2/10/2021 7:00:00 PM,Biogen Announces the Pricing Terms of Its Private Exchange Offer ,GlobeNewswire,/news/stocks/biogen-announces-the-pricing-terms-of-its-private-exchange-offer-1030068182,neutral,0.9313362240791321
520,2/10/2021 7:02:00 PM,Biogen Announces the Pricing Terms of its Cash Tender Offer,GlobeNewswire,/news/stocks/biogen-announces-the-pricing-terms-of-its-cash-tender-offer-1030068179,neutral,0.9234709739685059
521,2/10/2021 7:53:06 PM,Biogen prices cash tender offer,Seeking Alpha,https://seekingalpha.com/news/3660758-biogen-prices-cash-tender-offer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8968913555145264
522,2/11/2021 1:30:00 PM,Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups,GlobeNewswire,/news/stocks/biogen-and-labcentral-award-two-golden-tickets-to-local-and-innovative-science-startups-1030072277,positive,0.8635371327400208
523,2/11/2021 2:00:00 PM,Biogen Announces the Expiration Date Results of Its Private Exchange Offer,GlobeNewswire,/news/stocks/biogen-announces-the-expiration-date-results-of-its-private-exchange-offer-1030072415,neutral,0.9406167268753052
524,2/11/2021 2:03:00 PM,Biogen Announces the Expiration Date Results of Its Cash Tender Offer,GlobeNewswire,/news/stocks/biogen-announces-the-expiration-date-results-of-its-cash-tender-offer-1030072401,neutral,0.9409129619598389
525,2/11/2021 3:14:41 PM,ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today,InvestorPlace,/news/stocks/aciu-stock-why-ac-immune-shares-are-rocketing-higher-today-1030073976,positive,0.8638249039649963
526,2/13/2021 6:54:39 PM,"The Past Week's Notable Insider Buys: Biotech IPOs, Curiositystream, Greenbrier And More",Benzinga,/news/stocks/the-past-week-s-notable-insider-buys-biotech-ipos-curiositystream-greenbrier-and-more-1030079781,neutral,0.8162070512771606
527,2/13/2021 9:00:00 PM,"Pharmas engaged in Alzheimer's, the 'holy grail' of drug development",Seeking Alpha,https://seekingalpha.com/news/3661766-pharmas-engaged-in-alzheimers-the-holy-grail-of-drug-development?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8926677107810974
528,2/16/2021 3:03:14 PM,Cassava shares soar 12% following giant price target increase at Maxim,Seeking Alpha,https://seekingalpha.com/news/3662250-cassava-shares-soar-following-giant-price-target-increase-at-maxim?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9417204260826111
529,2/16/2021 10:56:48 PM,14 AI Stocks to Stay Away From,InvestorPlace,/news/stocks/14-ai-stocks-to-stay-away-from-stocks-to-sell-avoid-1030089444,negative,0.5654575228691101
530,2/24/2021 1:30:00 PM,Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program,GlobeNewswire,/news/stocks/life-science-cares-and-biogen-foundation-help-launch-food-for-free-s-just-eats-program-1030117822,neutral,0.8544171452522278
531,2/26/2021 6:16:37 PM,7 Stocks to Sell for March,InvestorPlace,/news/stocks/7-stocks-to-sell-for-march-1030130711,neutral,0.8999495506286621
532,3/4/2021 1:18:51 PM,Biogen to build new gene therapy facility,Seeking Alpha,https://seekingalpha.com/news/3669331-biogen-to-build-new-gene-therapy-facility?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5665106177330017
533,3/4/2021 1:47:36 PM,"Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina ",GlobeNewswire,/news/stocks/biogen-announces-plans-to-build-a-new-state-of-the-art-gene-therapy-manufacturing-facility-in-research-triangle-park-north-carolina-1030150053,positive,0.8885475993156433
534,3/8/2021 3:19:00 PM,"Alkermes, Inc. -- Moody's assigns Ba3 to Alkermes' term loan; stable outlook",Moodys,/news/bonds/alkermes-inc-moody-s-assigns-ba3-to-alkermes-term-loan-stable-outlook-1030159878,positive,0.8037080764770508
535,3/10/2021 7:41:57 PM,4 Stocks To Buy Ready To Bounce Back From 2020’s Dumpster Fire,InvestorPlace,/news/stocks/4-stocks-to-buy-ready-to-bounce-back-from-2020s-dumpster-fire-1030170582,positive,0.8529170155525208
536,3/15/2021 6:06:24 PM,Biogen nears session lows as Jefferies holds call on Alzheimer's drugs,Seeking Alpha,https://seekingalpha.com/news/3672776-biogen-nears-session-lows-as-jefferies-holds-call-on-alzheimers-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9045403599739075
537,3/16/2021 12:05:44 PM,Biogen expected to receive FDA nod for Alzheimer’s therapy and Solid Bioscience upgraded in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3673052-biogen-expected-to-receive-fda-nod-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.713916003704071
538,3/16/2021 2:17:38 PM,Biogen likely to win approval for Alzheimer's drug: Jefferies,Seeking Alpha,https://seekingalpha.com/news/3673152-biogen-likely-to-win-approval-for-alzheimers-drug-jefferies?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.623925507068634
539,3/17/2021 12:20:24 PM,Cassava initiated with a buy and $110 PT at Jones Trading; sees 111% upside,Seeking Alpha,https://seekingalpha.com/news/3673537-cassava-initiated-with-a-buy-and-110-pt-at-jones-trading?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8866288065910339
540,3/21/2021 1:00:00 PM,Alkermes may see further pressure from activist Sarissa Capital,Seeking Alpha,https://seekingalpha.com/news/3674614-alkermes-may-see-further-pressure-from-activist-sarissa-capital?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9271804690361023
541,4/1/2021 12:51:42 PM,FDA advisers reiterate case against approval of Biogen/Eisai's aducanumab for Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3678502-fda-advisers-reiterate-case-against-approval-of-biogen-eisai-aducanumab-for-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8325456380844116
542,4/6/2021 2:29:11 PM,JP Morgan physician survey finds support for Lilly's donanemab in Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3679541-jp-morgan-physician-survey-finds-support-for-lilly-donanemab-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9133780002593994
543,4/6/2021 6:17:39 PM,Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy,Benzinga,/news/stocks/why-scholar-rock-shares-dropped-despite-positive-apitegromab-data-in-spinal-muscular-atrophy-1030278270,negative,0.9633163809776306
544,4/7/2021 11:41:51 AM,Biogen's TYSABRI wins EC approval for multiple sclerosis indication,Seeking Alpha,https://seekingalpha.com/news/3679768-biogens-tysabri-wins-ec-approval-for-multiple-sclerosis-indication?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9024797677993774
545,4/7/2021 1:30:00 PM,The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis,GlobeNewswire,/news/stocks/the-european-commission-grants-marketing-authorization-for-new-subcutaneous-administration-of-tysabri-natalizumab-to-treat-relapsing-remitting-multiple-sclerosis-1030280745,positive,0.9275522232055664
546,4/7/2021 2:05:09 PM,Biogen: EC Grants Marketing Authorization For Subcutaneous Injection Of TYSABRI ,RTTNews,/news/stocks/biogen-ec-grants-marketing-authorization-for-subcutaneous-injection-of-tysabri-1030280885,neutral,0.5045904517173767
547,4/8/2021 12:14:01 PM,Biogen inks BAT1806 licensing deal in rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3680278-biogen-inks-bat1806-licensing-deal-in-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6225751638412476
548,4/8/2021 1:00:00 PM,Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis,GlobeNewswire,/news/stocks/biogen-and-bio-thera-solutions-announce-commercialization-and-license-agreement-for-proposed-biosimilar-currently-in-phase-3-with-the-potential-to-treat-moderate-to-severe-rheumatoid-arthritis-1030284894,positive,0.9067239165306091
549,4/8/2021 1:41:34 PM,Biogen To Gain Rights To BAT1806 From Bio-Thera - Quick Facts ,RTTNews,/news/stocks/biogen-to-gain-rights-to-bat1806-from-bio-thera-quick-facts-1030285099,neutral,0.8109776973724365
550,4/9/2021 1:11:12 PM,"Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3680680-provention-bio-downgraded-on-fda-feedback-citi-sizes-up-zuranolone-success-on-biogen?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9142313003540039
551,4/9/2021 10:30:00 PM,Biogen Announces Two New Nominees for Election to Board of Directors,GlobeNewswire,/news/stocks/biogen-announces-two-new-nominees-for-election-to-board-of-directors-1030290353,neutral,0.8996530771255493
552,4/12/2021 12:31:31 PM,Sage Therapeutics/Biogen's SAGE-324 meets primary endpoint in essential tremor study,Seeking Alpha,https://seekingalpha.com/news/3680941-sage-therapeuticsbiogens-sage-324-meets-primary-endpoint-in-essential-tremor-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6316429972648621
553,4/12/2021 2:23:08 PM,Sage Therapeutics : Phase 2 Study Of SAGE-324 In Essential Tremor Meets Primary Endpoint ,RTTNews,/news/stocks/sage-therapeutics-phase-2-study-of-sage-324-in-essential-tremor-meets-primary-endpoint-1030293718,neutral,0.8197802305221558
554,4/12/2021 5:59:04 PM,Biogen and Sage trade lower despite positive essential tremor trial,Seeking Alpha,https://seekingalpha.com/news/3681094-biogen-and-sage-trade-lower-despite-positive-essential-tremor-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9604763984680176
555,4/14/2021 10:06:00 PM,"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021",GlobeNewswire,/news/stocks/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021-1030305446,neutral,0.9056475758552551
556,4/15/2021 8:40:59 PM,Biogen's TECFIDERA wins approval in China to treat multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3682388-biogens-tecfidera-wins-approval-in-china-to-treat-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9168655276298523
557,4/15/2021 10:30:00 PM,Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-grows-presence-in-china-with-the-approval-of-tecfidera-dimethyl-fumarate-for-the-treatment-of-relapsing-multiple-sclerosis-1030310435,positive,0.8916447162628174
558,4/16/2021 11:59:58 AM,Biogen’s Tysabri and Vumerity show positive impact in multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3682536-biogens-tysabri-and-vumerity-show-positive-impact-in-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9384950995445251
559,4/16/2021 1:30:00 PM,New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis,GlobeNewswire,/news/stocks/new-data-at-aan-2021-from-across-biogen-s-ms-portfolio-demonstrate-positive-impact-of-treatment-on-people-living-with-relapsing-multiple-sclerosis-1030312194,positive,0.9502638578414917
560,4/17/2021 3:25:15 PM,"The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-johnson-johnson-biogen-earnings-neurology-conference-and-ipos-1030314413,neutral,0.9472426176071167
561,4/19/2021 1:17:32 PM,"Biogen seen to offer a ‘compelling’ risk-reward profile, TG Therapeutics price target lifted after MS data; and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3682936-biogen-seen-to-offer-a-compelling-risk-reward-profile-tg-therapeutics-price-target-lifted?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8940672278404236
562,4/19/2021 1:30:00 PM,Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients,GlobeNewswire,/news/stocks/biogen-advances-leading-research-in-spinal-muscular-atrophy-sma-with-new-data-at-aan-2021-exploring-opportunities-to-improve-outcomes-for-patients-1030317227,positive,0.921610951423645
563,4/20/2021 6:02:34 AM,Biogen/Eisai's lecanemab shows mixed results in mid-stage Alzheimer's Disease study,Seeking Alpha,https://seekingalpha.com/news/3683222-biogeneisais-lecanemab-shows-mixed-results-in-mid-stage-alzheimers-disease-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8567588329315186
564,4/20/2021 3:01:31 PM,Biogen is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/biogen-q1-quarterly-earnings-preview-stock-1030322966,neutral,0.9388397336006165
565,4/21/2021 4:51:00 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3684052-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.882573127746582
566,4/21/2021 5:02:11 PM,Biogen Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3684060-biogen-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6037518382072449
567,4/22/2021 11:05:29 AM,"Biogen EPS beats by $0.39, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3684441-biogen-eps-beats-0_39-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8252130746841431
568,4/22/2021 12:07:25 PM,Biogen boost EPS guidance for 2021; seeks aducanumab approval in additional markets,Seeking Alpha,https://seekingalpha.com/news/3684498-biogen-stock-higher-boosts-eps-guidance-for-2021-seeks-aducanumab-approval?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8637170195579529
569,4/22/2021 1:27:54 PM,Biogen Boosts FY21 Adj. EPS Outlook; Q1 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-boosts-fy21-adj-eps-outlook-q1-results-top-estimates-quick-facts-1030332729,positive,0.9101738333702087
570,4/22/2021 2:08:59 PM,"The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-kempharm-receives-10m-milestone-payment-zymergen-neuropace-debut-on-nasdaq-renalytix-wins-us-government-contract-2-ipos-1030332968,positive,0.795148491859436
571,4/22/2021 3:14:16 PM,Biogen slides as analysts see no major surprises in Q1 results,Seeking Alpha,https://seekingalpha.com/news/3684652-biogen-slides-as-analysts-see-no-major-surprises-in-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9437759518623352
572,4/26/2021 9:48:25 PM,"Following pressure, Biogen to start compassionate use program for ALS drug tofersen",Seeking Alpha,https://seekingalpha.com/news/3685840-following-pressure-biogen-to-start-compassionate-use-program-for-als-drug-tofersen?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6287159323692322
573,4/28/2021 12:43:07 PM,Biogen tying portion of executive pay to ESG metrics,Seeking Alpha,https://seekingalpha.com/news/3686840-biogen-tying-portion-of-executive-pay-to-esg-metrics?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9414471983909607
574,4/28/2021 1:30:00 PM,"Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics",GlobeNewswire,/news/stocks/biogen-releases-2020-year-in-review-demonstrating-its-commitment-to-transparency-and-progress-across-environmental-social-and-governance-metrics-1030357424,positive,0.8468054533004761
575,4/29/2021 12:20:00 AM,Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab),GlobeNewswire,/news/stocks/biogen-provides-regulatory-update-on-the-supplemental-biologic-license-application-sbla-for-subcutaneous-administration-of-tysabri-natalizumab-1030360672,neutral,0.915275514125824
576,4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740,neutral,0.771758496761322
577,4/30/2021 1:28:28 PM,Alkermes reaches agreement with Sarissa giving activist right to designate board member,Seeking Alpha,https://seekingalpha.com/news/3688680-alkermes-reaches-agreement-with-activist-sarissa-to-add-board-member?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5419503450393677
578,5/3/2021 6:50:50 AM,Denali presents positive results from early-stage studies of BIIB122/DNL151 in Parkinson’s disease,Seeking Alpha,https://seekingalpha.com/news/3689024-denali-presents-positive-results-from-biib122dnl151-studies-in-parkinsons-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9493709206581116
579,5/6/2021 1:13:37 PM,Biogen is lower as ICER indicates uncertain benefits of Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3692272-biogen-is-lower-as-icer-indicates-uncertain-benefits-of-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6784558296203613
580,5/10/2021 10:06:00 PM,Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders,GlobeNewswire,/news/stocks/biogen-and-capsigen-announce-collaboration-to-discover-and-develop-novel-aav-capsids-for-targeted-cns-and-neuromuscular-disorders-1030411112,positive,0.8655627369880676
581,5/12/2021 11:49:29 AM,Biogen exercises option to buy stroke treatment from TMS,Seeking Alpha,https://seekingalpha.com/news/3695166-biogen-exercises-option-to-buy-stroke-treatment-from-tms?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7005206942558289
582,5/12/2021 1:30:00 PM,Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data,GlobeNewswire,/news/stocks/biogen-announces-exercise-of-option-to-acquire-the-investigational-drug-tms-007-for-acute-ischemic-stroke-based-on-positive-phase-2a-data-1030420234,neutral,0.5686034560203552
583,5/12/2021 1:51:00 PM,Biogen Exercises Option To Acquire TMS-007 For Acute Ischemic Stroke - Quick Facts ,RTTNews,/news/stocks/biogen-exercises-option-to-acquire-tms-007-for-acute-ischemic-stroke-quick-facts-1030420319,neutral,0.8018330931663513
584,5/13/2021 10:06:00 PM,Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research,GlobeNewswire,/news/stocks/biogen-and-envisagenics-announce-collaboration-to-advance-rna-splicing-research-1030427727,positive,0.7228492498397827
585,5/14/2021 11:49:31 AM,Biogen's gene therapy fails to meet phase 2/3 eye disease main goal,Seeking Alpha,https://seekingalpha.com/news/3696529-biogens-gene-therapy-fails-to-meet-phase-23-eye-disease-main-goal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9534283876419067
586,5/14/2021 1:30:00 PM,Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP ,GlobeNewswire,/news/stocks/biogen-announces-topline-results-from-phase-2-3-gene-therapy-study-for-xlrp-1030430378,neutral,0.5548921227455139
587,5/14/2021 2:31:17 PM,Biogen's Xirius Phase2/3 Study In XLRO Patients Fails To Meet Primary Endpoints ,RTTNews,/news/stocks/biogen-s-xirius-phase2-3-study-in-xlro-patients-fails-to-meet-primary-endpoints-1030430659,negative,0.9431276917457581
588,5/18/2021 4:57:26 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1030442416,neutral,0.9221560955047607
589,5/19/2021 5:08:44 PM,"Why Biogen's June 7 Aducanumab PDUFA Date Is A High-Risk, High-Reward Catalyst",Benzinga,/news/stocks/why-biogen-s-june-7-aducanumab-pdufa-date-is-a-high-risk-high-reward-catalyst-1030447327,neutral,0.8963731527328491
590,5/20/2021 10:06:00 PM,"Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland  ",GlobeNewswire,/news/stocks/swissmedic-grants-good-manufacturing-practice-multi-product-license-to-biogen-biologics-facility-in-solothurn-switzerland-1030453047,positive,0.9411339163780212
591,5/21/2021 11:47:57 AM,Biogen teams up with Ginkgo Bioworks to develop gene therapy manufacturing platform,Seeking Alpha,https://seekingalpha.com/news/3699041-biogen-teams-up-with-ginkgo-bioworks-to-develop-gene-therapy-manufacturing-platform?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6911807656288147
592,5/21/2021 1:30:00 PM,Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform,GlobeNewswire,/news/stocks/biogen-and-ginkgo-bioworks-announce-collaboration-and-license-agreement-to-develop-novel-gene-therapy-manufacturing-platform-1030454690,positive,0.9002165198326111
593,5/21/2021 1:51:03 PM,"Biogen, Ginkgo Bioworks Collaborate To Develop Gene Therapy Manufacturing Platform ",RTTNews,/news/stocks/biogen-ginkgo-bioworks-collaborate-to-develop-gene-therapy-manufacturing-platform-1030454755,neutral,0.6376205086708069
594,5/21/2021 5:12:34 PM,ANVS Stock: The Huge News Sending Annovis Bio Rocketing 200% Today,InvestorPlace,/news/stocks/anvs-stock-the-huge-news-sending-annovis-bio-rocketing-200-today-1030456087,positive,0.9107407331466675
595,5/23/2021 7:25:39 PM,Biotech M&A could soon pick up following slow 2021 start - Jefferies,Seeking Alpha,https://seekingalpha.com/news/3699307-biotech-mergers-acquisitions-could-soon-pick-up-following-slow-2021-start-jefferies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4784913659095764
596,5/23/2021 10:39:21 PM,"'SPACs Attack' Recap: Looking Back At 3 SPAC Deals, SPAC Rumors And The Latest SPAC Headlines And Earnings",Benzinga,/news/stocks/spacs-attack-recap-looking-back-at-3-spac-deals-spac-rumors-and-the-latest-spac-headlines-and-earnings-1030457324,neutral,0.8972042202949524
597,5/25/2021 5:05:13 PM,Biogen investors expect company to win approval for Alzheimer’s drug: RBC survey,Seeking Alpha,https://seekingalpha.com/news/3699963-biogen-investors-expect-company-to-win-approval-for-alzheimers-drug-rbc-survey?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9044347405433655
598,5/26/2021 2:22:44 PM,"Biogen pared loss, back down after speculation on potential activist vulnerability",Seeking Alpha,https://seekingalpha.com/news/3700341-biogen-pared-loss-back-down-after-speculation-on-potential-activist-vulnerability?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5130156874656677
599,5/30/2021 1:02:44 AM,Biogen in the spotlight as FDA action date for Alzheimer’s therapy approaches,Seeking Alpha,https://seekingalpha.com/news/3701441-biogen-in-spotlight-as-fda-action-date-for-alzheimers-therapy-approaches?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5577338933944702
600,6/1/2021 1:30:00 PM,"Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)",GlobeNewswire,/news/stocks/biogen-and-bio-thera-announce-positive-results-from-phase-3-study-of-bat1806-a-proposed-biosimilar-referencing-actemra-tocilizumab-1030481181,positive,0.9332125782966614
601,6/1/2021 2:07:49 PM,"Biogen, Bio-Thera Say Phase 3 Study Of BAT1806 Met Its Primary Endpoints - Quick Facts ",RTTNews,/news/stocks/biogen-bio-thera-say-phase-3-study-of-bat1806-met-its-primary-endpoints-quick-facts-1030481430,positive,0.5467491149902344
602,6/1/2021 11:31:09 PM,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-june-pdufa-dates-1030484849,neutral,0.9476439952850342
603,6/2/2021 12:50:04 PM,"iRhythm downgraded on CEO exit, UBS bullish on aducanumab approval; in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3702278-irhythm-downgraded-on-ceo-exit-ubs-bullish-on-aducanumab-approval-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6011040806770325
604,6/4/2021 7:30:04 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3703423-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
605,6/6/2021 3:52:46 AM,Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3703521-biogen-surges-ahead-of-key-fda-decision-amid-mixed-views-on-potential-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7660930156707764
606,6/7/2021 2:31:25 PM,Biogen investors brace for “mother of all binary events” as FDA is set to decide on Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3703734-biogen-investors-brace-for-mother-of-all-binary-events-as-fda-is-set-to-decide-on-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7174782752990723
607,6/7/2021 2:52:10 PM,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",Benzinga,/news/stocks/the-week-ahead-in-biotech-biogen-alexion-and-vertex-fda-decisions-multiple-conference-presentations-on-the-deck-1030499585,neutral,0.9329092502593994
608,6/7/2021 4:25:54 PM,7 Beaten-Down Stocks to Buy Right Now for a June Rebound,InvestorPlace,/news/stocks/7-beaten-down-stocks-to-buy-right-now-june-rebound-1030500805,negative,0.589763879776001
609,6/7/2021 4:53:06 PM,Analysts bullish on Biogen following Aduhelm approval for Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3703783-analysts-bullish-on-biogen-following-aduhelm-approval-for-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7774261236190796
610,6/7/2021 5:10:01 PM,Biogen stock to resume trading at 1:30 PM,Seeking Alpha,https://seekingalpha.com/news/3703801-biogen-to-resume-trading-at-130p-et?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9522044658660889
611,6/7/2021 5:21:00 PM,"Biogen’s Alzheimer’s drug wins FDA approval, see which ETFs are in play",Seeking Alpha,https://seekingalpha.com/news/3703806-biogens-alzheimers-drug-wins-fda-approval-see-which-etfs-are-in-play?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7666110992431641
612,6/7/2021 5:23:30 PM,Synaptogenix down 5% following Biogen's Alzheimer's drug approval,Seeking Alpha,https://seekingalpha.com/news/3703798-ultra-microcap-synaptogenix-up-10-on-biogen-alzheimers-drug-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9735531210899353
613,6/7/2021 5:43:27 PM,BIIB Stock Alert: The Huge FDA News That Has Biogen Investors Smiling,InvestorPlace,/news/stocks/biib-stock-alert-the-huge-fda-news-that-has-biogen-investors-smiling-1030500796,neutral,0.7891151309013367
614,6/7/2021 5:45:32 PM,Biogen stock surges 41% following aducanumab approval,Seeking Alpha,https://seekingalpha.com/news/3703809-following-trading-hold-biogen-shares-skyrocket-41?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9341280460357666
615,6/7/2021 6:02:20 PM,"iShares Biotechnology Fund Spike Continues Rally, Nears Critical Resistance Level",Benzinga,/news/etf/ishares-biotechnology-fund-spike-continues-rally-nears-critical-resistance-level-1030500451,positive,0.9280399680137634
616,6/7/2021 6:34:19 PM,Eli Lilly hits 52-week high after Biogen wins FDA approval for Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3703836-eli-lilly-hits-52-week-high-after-biogen-won-fda-approval-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7779038548469543
617,6/7/2021 6:42:13 PM,FDA Approves Aduhelm For Alzheimer's Treatment ,RTTNews,/news/stocks/fda-approves-aduhelm-for-alzheimer-s-treatment-1030500634,neutral,0.4948004186153412
618,6/7/2021 7:21:42 PM,Biogen CEO: committed to gathering new data on FDA-approved Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3703844-biogen-ceo-committed-to-gathering-new-data-on-fda-approved-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7497406601905823
619,6/7/2021 7:40:37 PM,"Biogen: Truist sees $846 target, BofA doubts commercial success of Alzheimer's therapy",Seeking Alpha,https://seekingalpha.com/news/3703853-biogen-truist-sees-846-target-bofa-doubts-commercial-success-of-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7337239980697632
620,6/7/2021 7:53:31 PM,"Biogen collaborations with CVS, Cigna seek to boost uptake of Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3703852-biogen-collaborations-with-cvs-cigna-seek-to-boost-uptake-of-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8899663090705872
621,6/7/2021 8:28:28 PM,"Biogen's Aduhelm Gets FDA Approval - A New Drug For Alzheimer's In 18 Years, Priced At $56,000/Yr ",RTTNews,/news/stocks/biogen-s-aduhelm-gets-fda-approval-a-new-drug-for-alzheimer-s-in-18-years-priced-at-56-000-yr-1030500864,positive,0.8798253536224365
622,6/7/2021 9:25:20 PM,5 Top ETFs With Exposure To Biogen,Benzinga,/news/etf/5-top-etfs-with-exposure-to-biogen-1030500950,neutral,0.8830468654632568
623,6/7/2021 9:43:51 PM,"4 Top Stock Trades for Tuesday: Bitcoin, BIIB, YETI, COUP",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-bitcoin-biib-yeti-coup-1030501293,neutral,0.9220055341720581
624,6/7/2021 10:13:51 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-to-catch-up-on-3-1030501422,neutral,0.9254742860794067
625,6/7/2021 11:01:41 PM,Biogen And Norweigan Cruise Line Lead The SPY In A Mixed Day Of Trading,Benzinga,/news/etf/biogen-and-norweigan-cruise-line-lead-the-spy-in-a-mixed-day-of-trading-1030501206,negative,0.9383702874183655
626,6/8/2021 11:17:35 AM,60 Biggest Movers From Yesterday,Benzinga,/news/stocks/60-biggest-movers-from-yesterday-1030502300,neutral,0.7704922556877136
627,6/8/2021 2:06:15 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1030503150,neutral,0.8152948021888733
628,6/8/2021 3:17:38 PM,"The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex",Benzinga,/news/stocks/the-daily-biotech-pulse-hookipa-pds-biotech-report-positive-data-ironwood-cfo-to-depart-decision-day-for-vertex-1030503836,neutral,0.9079675674438477
629,6/8/2021 3:18:10 PM,"Could Lilly's donanemab, others for Alzheimer's get a boost from Biogen approval?",Seeking Alpha,https://seekingalpha.com/news/3704152-could-lilly-donanemab-others-for-alzheimers-get-a-boost-from-biogen-approval?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6547843217849731
630,6/8/2021 4:07:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-8-2021-1030504074,negative,0.5573012828826904
631,6/8/2021 4:08:45 PM,"Thinking About Buying Stock Or Options In Target, Biogen Or Delta Air Lines?",Benzinga,/news/stocks/thinking-about-buying-stock-or-options-in-target-biogen-or-delta-air-lines-1030504073,neutral,0.9304456114768982
632,6/8/2021 4:09:35 PM,"Biogen, Eisai and other Alzheimer's players cool off in afternoon trading",Seeking Alpha,https://seekingalpha.com/news/3704216-biogen-eisai-and-other-alzheimers-players-cool-off-in-afternoon-trading?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6041277647018433
633,6/8/2021 4:45:00 PM,Senator Ron Wyden calls Biogen's Alzheimer's drug price 'unconscionable',Seeking Alpha,https://seekingalpha.com/news/3704227-sen-wyden-calls-biogen-alzheimers-drug-price-unconscionable-in-tweet?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9410052299499512
634,6/8/2021 6:51:45 PM,"5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing",Benzinga,/news/stocks/5-biogen-analysts-on-fda-approval-of-alzheimer-s-drug-aduhelm-broad-label-pricing-1030504841,neutral,0.853453516960144
635,6/8/2021 7:05:43 PM,"A Biotech ETF For Aggressive, Risk-Tolerant Investors",Benzinga,/news/etf/a-biotech-etf-for-aggressive-risk-tolerant-investors-1030504887,neutral,0.7618135809898376
636,6/8/2021 7:46:12 PM,Biogen to start shipping Alzheimer's drug Aduhelm in about two weeks: CEO,Seeking Alpha,https://seekingalpha.com/news/3704306-biogen-stock-drops-amid-plans-to-start-shipping-alzheimers-drug-aduhelm-in-about-two-weeks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8897417783737183
637,6/8/2021 8:03:18 PM,"Biogen, FDA face backlash over aducanumab approval for Alzheimer's",Seeking Alpha,https://seekingalpha.com/news/3704305-biogen-fda-face-backlash-over-aducanumab-approval-for-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9497621655464172
638,6/8/2021 8:15:21 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1030505109,neutral,0.9221560955047607
639,6/8/2021 9:38:24 PM,"5 Top Stock Trades for Wednesday: WEN, FSLY, IWM, CLOV, WKHS",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-wen-fsly-iwm-clov-wkhs-1030505536,neutral,0.9354191422462463
640,6/10/2021 10:59:34 AM,Option Care Health rides on approval for Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3704906-option-care-health-rides-on-approval-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8354968428611755
641,6/10/2021 1:30:00 PM,New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy,GlobeNewswire,/news/stocks/new-data-at-cure-sma-2021-highlight-the-long-term-efficacy-of-spinraza-nusinersen-and-biogen-s-commitment-to-innovation-in-sma-therapy-1030511193,positive,0.8694836497306824
642,6/10/2021 2:49:41 PM,Biogen Gets an Unearned Rip on an Unproven Drug,InvestorPlace,/news/stocks/biib-stock-an-unearned-rip-on-an-unproven-drug-1030512916,negative,0.8146694898605347
643,6/10/2021 4:43:14 PM,UBS sees $13B in peak Biogen Aduhelm sales for Alzheimer's based on doc checks,Seeking Alpha,https://seekingalpha.com/news/3705125-ubs-sees-13b-in-peak-biogen-aduhelm-sales-for-alzheimers-based-on-doc-checks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7501087188720703
644,6/10/2021 4:56:05 PM,What 12 Analyst Ratings Have To Say About Biogen,Benzinga,/news/stocks/what-12-analyst-ratings-have-to-say-about-biogen-1030512640,neutral,0.9447430968284607
645,6/10/2021 10:06:00 PM,"Biogen Announces Investor Day on September 21, 2021",GlobeNewswire,/news/stocks/biogen-announces-investor-day-on-september-21-2021-1030513748,neutral,0.9467548727989197
646,6/10/2021 10:22:25 PM,"With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch",Benzinga,/news/stocks/with-aduhelm-approval-behind-biogen-5-catalysts-for-investors-to-watch-1030513723,neutral,0.8306577205657959
647,6/10/2021 10:53:12 PM,Two FDA Committee Members Resign Over Approval Biogen's New Alzheimer's Drug ,RTTNews,/news/stocks/two-fda-committee-members-resign-over-approval-biogen-s-new-alzheimer-s-drug-1030513789,negative,0.8991596102714539
648,6/11/2021 12:42:00 AM,Biogen Inc. -- Moody's confirms Biogen at Baa1; stable outlook,Moodys,/news/bonds/biogen-inc-moody-s-confirms-biogen-at-baa1-stable-outlook-1030514006,positive,0.9042506814002991
649,6/11/2021 1:33:49 PM,Two more FDA advisory panel members resign over Biogen aducanumab approval,Seeking Alpha,https://seekingalpha.com/news/3705638-two-more-fda-advisory-panel-members-resign-over-biogen-aducanumab-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9029608964920044
650,6/11/2021 2:24:09 PM,BIIB Stock: 9 Things to Know About Biogen’s Alzheimer Drug Approval Controversy,InvestorPlace,/news/stocks/biib-stock-9-things-to-know-about-biogens-alzheimer-drug-approval-controversy-1030516416,neutral,0.9365919232368469
651,6/11/2021 2:49:47 PM,CHWY Stock: What’s Taking a Bite Out of Chewy Shares Today?,InvestorPlace,/news/stocks/chwy-stock-whats-taking-a-bite-out-of-chewy-shares-today-1030516413,neutral,0.6347591280937195
652,6/11/2021 3:15:47 PM,CCXI Stock: 12 Things to Know About ChemoCentryx as Shares Surge Today,InvestorPlace,/news/stocks/ccxi-stock-12-things-to-know-about-chemocentryx-as-shares-surge-today-1030516411,neutral,0.8993551135063171
653,6/11/2021 3:35:25 PM,VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower,InvestorPlace,/news/stocks/vrtx-stock-the-disappointing-news-sending-vertex-pharma-shares-lower-1030516408,negative,0.9724560379981995
654,6/11/2021 5:31:59 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-11-2021-1030516293,negative,0.600886344909668
655,6/12/2021 3:26:11 PM,"Healthcare gainers for the week led by CLOV's meme-stock fever, CureVac falls on delay in regulatory approval for COVID vaccine",Seeking Alpha,https://seekingalpha.com/news/3705832-healthcare-gainers-for-the-week-led-by-clovs-meme-stock-fever-while-curevac-falls-on-delay-in-regulatory-approval-for-covid-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9691377282142639
656,6/12/2021 8:00:43 PM,The road -- and obstacles -- ahead for Biogen's Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3705833-the-road-and-obstacles-ahead-for-biogens-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8098733425140381
657,6/13/2021 6:51:53 PM,"The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-takeda-blueprint-medicines-orphazyme-eton-on-the-radar-ahead-of-fda-decisions-ipos-1030518167,neutral,0.921207845211029
658,6/14/2021 3:01:47 PM,Bullish sentiment for Biogen continues among Wall Street analysts,Seeking Alpha,https://seekingalpha.com/news/3706052-bullish-sentiment-for-biogen-continues-among-wall-street-analysts?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.881667971611023
659,6/14/2021 8:16:35 PM,Biogen's eye disease treatment fails to meet late-stage study main goal,Seeking Alpha,https://seekingalpha.com/news/3706181-biogens-eye-disease-treatment-fails-to-meet-late-stage-study-main-goal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9353043437004089
660,6/14/2021 10:06:00 PM,Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia,GlobeNewswire,/news/stocks/biogen-announces-topline-results-from-phase-3-gene-therapy-study-in-choroideremia-1030521182,neutral,0.5126122832298279
661,6/15/2021 11:11:48 AM,Sage (SAGE) stock drops 12% after disappointing zuranolone secondary data in depression study,Seeking Alpha,https://seekingalpha.com/news/3706316-sage-stock-drops-12-despite-positive-zuranolone-data-in-phase-3-depressive-disorder-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9712927937507629
662,6/15/2021 12:30:00 PM,"Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder",GlobeNewswire,/news/stocks/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone-an-investigational-two-week-once-daily-therapeutic-being-evaluated-for-major-depressive-disorder-1030522749,positive,0.9371654987335205
663,6/15/2021 12:52:53 PM,"Sage, Biogen Announce Positive Pivotal Phase 3 Results For Zuranolone - Quick Facts ",RTTNews,/news/stocks/sage-biogen-announce-positive-pivotal-phase-3-results-for-zuranolone-quick-facts-1030522811,positive,0.928883969783783
664,6/15/2021 2:07:38 PM,"The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-biogen-face-clinical-trial-disappointments-novavax-studies-coronavirus-flu-combo-vaccine-decision-day-for-takeda-1030523320,neutral,0.9001524448394775
665,6/15/2021 3:36:14 PM,Alzheimer's-focused Anavex takes a breather day after gaining 35%,Seeking Alpha,https://seekingalpha.com/news/3706529-alzheimers-focused-anavex-takes-a-breather-day-after-gaining-35?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.42907071113586426
666,6/15/2021 5:24:55 PM,Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug,Benzinga,/news/stocks/biogen-analyst-raises-price-target-on-higher-chance-of-success-for-depression-drug-1030524842,positive,0.9055368304252625
667,6/15/2021 5:29:03 PM,Sage plunges as BofA paints a mixed outlook for depression therapy,Seeking Alpha,https://seekingalpha.com/news/3706567-sage-plunges-as-bofa-paints-a-mixed-outlook-for-depression-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.914418637752533
668,6/16/2021 1:12:59 PM,First patient set to receive Biogen’s Alzheimer’s therapy amid concerns over pricing,Seeking Alpha,https://seekingalpha.com/news/3706873-first-patient-set-to-receive-biogens-alzheimers-therapy-amid-concerns-over-pricing?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.601394534111023
669,6/16/2021 2:02:10 PM,"Cramer Shares His Thoughts On Vertex Pharma, Snap And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-vertex-pharma-snap-and-more-1030527592,neutral,0.932751476764679
670,6/16/2021 2:45:13 PM,Public Citizen demands removal of top FDA officials over Biogen Alzheimer's approval,Seeking Alpha,https://seekingalpha.com/news/3706928-public-citizen-demands-removal-of-top-fda-officials-over-biogen-alzheimers-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8183563947677612
671,6/16/2021 8:45:57 PM,Biogen hurt by setback in mid-stage Alzheimer’s trial for anti-tau antibody,Seeking Alpha,https://seekingalpha.com/news/3707093-biogen-hurt-by-setback-in-mid-stage-alzheimers-trial-for-anti-tau-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9643561244010925
672,6/16/2021 10:30:00 PM,"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease",GlobeNewswire,/news/stocks/biogen-announces-topline-results-from-phase-2-study-of-gosuranemab-an-anti-tau-antibody-for-alzheimer-s-disease-1030529972,positive,0.6068562269210815
673,6/16/2021 11:26:17 PM,First Patient Receives Biogen's Alzheimer's Drug Aduhelm ,RTTNews,/news/stocks/first-patient-receives-biogen-s-alzheimer-s-drug-aduhelm-1030530079,neutral,0.8806081414222717
674,6/17/2021 11:37:53 AM,Biogen starts dosing in late-stage systemic lupus erythematosus study,Seeking Alpha,https://seekingalpha.com/news/3707197-biogen-starts-dosing-in-late-stage-systemic-lupus-erythematosus-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8276504278182983
675,6/17/2021 1:30:00 PM,Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study,GlobeNewswire,/news/stocks/biogen-announces-first-patient-dosed-in-phase-3-systemic-lupus-erythematosus-study-1030531617,neutral,0.6220623254776001
676,6/17/2021 2:31:50 PM,"The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-faces-another-clinical-setback-curevac-s-covid-19-vaccine-study-fails-moment-of-reckoning-for-orphazyme-1030531978,negative,0.9058188199996948
677,6/17/2021 8:36:12 PM,4 Undervalued Biotech Stocks That Belong On Every Investor’s Buy List,InvestorPlace,/news/stocks/4-undervalued-biotech-stocks-that-belong-on-every-investors-buy-list-1030533860,neutral,0.8750114440917969
678,6/17/2021 9:02:15 PM,Biogen’s decision to halt development of anti-tau antibody in Alzheimer’s hurts rivals,Seeking Alpha,https://seekingalpha.com/news/3707507-biogens-decision-to-halt-anti-tau-antibody-in-alzheimers-hurts-rivals?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8681864142417908
679,6/18/2021 1:40:46 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030535141,neutral,0.791632354259491
680,6/18/2021 2:55:08 PM,Biohaven gains on takeover speculation following board appointment,Seeking Alpha,https://seekingalpha.com/news/3707709-biohaven-gains-on-takeover-speculation-following-board-appointment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.657482922077179
681,6/18/2021 6:45:32 PM,"Piper Sandler upgrades shares of Biogen on neurologist survey, reimbursement",Seeking Alpha,https://seekingalpha.com/news/3707788-piper-sandler-upgrades-shares-of-biogen-on-neurologist-survey-reimbursement?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5669464468955994
682,6/18/2021 6:47:26 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-18-2021-1030536179,negative,0.6108731031417847
683,6/20/2021 4:04:37 PM,"The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-incyte-ascendis-fda-decisions-liver-congress-presentations-and-4-ipos-1030537312,neutral,0.9417259097099304
684,6/22/2021 2:01:41 PM,"CVS and Rite Aid get price target cuts, Sage target trimmed on depression drug data, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3708632-price-target-changes-on-drug-store-chains-sage-lowered-on-depression-drug-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8490772247314453
685,6/22/2021 9:07:59 PM,Biogen won approval for Alzheimer’s therapy while FDA staff raised concerns,Seeking Alpha,https://seekingalpha.com/news/3708950-biogen-won-approval-for-alzheimers-therapy-despite-fda-staff-objections?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8649837374687195
686,6/23/2021 12:57:16 PM,"Biogen, Eisai respond to questions surrounding approval of Alzheimer's drug Aduhelm",Seeking Alpha,https://seekingalpha.com/news/3709108-biogen-eisai-respond-to-questions-surrounding-approval-of-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8000758290290833
687,6/23/2021 6:44:55 PM,14 Biotech Stocks To Watch Over The Next 6 Months,Benzinga,/news/stocks/14-biotech-stocks-to-watch-over-the-next-6-months-1030548271,neutral,0.9149301052093506
688,6/23/2021 8:27:02 PM,Biogen and Eisai win FDA’s Breakthrough Therapy tag for Alzheimer’s drug lecanemab,Seeking Alpha,https://seekingalpha.com/news/3709348-biogen-and-eisai-win-fdas-breakthrough-therapy-tag-for-alzheimers-drug-lecanemab?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8334805965423584
689,6/23/2021 10:06:00 PM,"Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease",PR Newswire,/news/stocks/eisai-and-biogen-inc-announce-u-s-fda-grants-breakthrough-therapy-designation-for-lecanemab-ban2401-an-anti-amyloid-beta-protofibril-antibody-for-the-treatment-of-alzheimer-s-disease-1030548686,positive,0.9071661233901978
690,6/24/2021 12:22:38 PM,"BIIB, TALO among premarket losers",Seeking Alpha,https://seekingalpha.com/news/3709501-biib-talo-among-premarket-losers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8970745801925659
691,6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,neutral,0.93064284324646
692,6/24/2021 4:58:13 PM,PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday,Benzinga,/news/stocks/premarket-prep-recap-the-4-stocks-dennis-dick-bought-yesterday-1030551973,neutral,0.9400940537452698
693,6/24/2021 6:04:24 PM,Mizuho enthusiasm for Eli Lilly tempered after talk with company,Seeking Alpha,https://seekingalpha.com/news/3709766-mizuho-enthusiasm-for-eli-lilly-alzheimers-drug-tempered-after-talk-with-company?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9339337348937988
694,6/24/2021 7:23:23 PM,3 Biotech Stocks Ready for Big Breakthroughs Like Biogen,InvestorPlace,/news/stocks/3-biotech-stocks-ready-for-big-breakthroughs-like-biogen-1030552741,positive,0.5007700324058533
695,6/24/2021 9:22:04 PM,"Biogen shares hit by Lilly donanemab Breakthrough Therapy designation, filing plans",Seeking Alpha,https://seekingalpha.com/news/3709984-biogen-shares-hit-by-lilly-donanemab-breakthrough-therapy-designation-filing-plans?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9538450241088867
696,6/25/2021 11:51:13 AM,"Biogen wins positive CHMP opinion for ranibizumab biosimilar, BYOOVIZ",Seeking Alpha,https://seekingalpha.com/news/3710070-biogen-wins-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9055151343345642
697,6/25/2021 1:30:00 PM,"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™",GlobeNewswire,/news/stocks/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz-1030554585,positive,0.9301723837852478
698,6/25/2021 1:51:52 PM,"Samsung Bioepis, Biogen Get Positive CHMP Opinion For Ranibizumab Biosimilar BYOOVIZ - Quick Facts ",RTTNews,/news/stocks/samsung-bioepis-biogen-get-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz-quick-facts-1030554637,positive,0.790392279624939
699,6/25/2021 1:56:41 PM,Two senators call for hearing over impact of Biogen's Aduhelm on Medicare,Seeking Alpha,https://seekingalpha.com/news/3710148-two-senators-call-for-hearing-over-impact-of-biogen-aduhelm-on-medicare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7061121463775635
700,6/28/2021 6:31:35 AM,Arcus Bio ranks in top weekly healthcare gainers amid positive domvanalimab data; Biogen hit by Lilly donanemab Breakthrough Therapy tag,Seeking Alpha,https://seekingalpha.com/news/3710334-arcus-bio-ranks-in-top-weekly-healthcare-gainers-amid-positive-domvanalimab-data-biogen-hit-by-lilly-donanemab-breakthrough-therapy-tag?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9179816246032715
701,6/28/2021 12:50:08 PM,Medicare could restrict access to Biogen’s new Alzhimer’s therapy: WSJ,Seeking Alpha,https://seekingalpha.com/news/3710461-medicare-could-restrict-access-to-biogens-new-alzhimers-therapy-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7724530100822449
702,6/28/2021 2:49:13 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030558925,neutral,0.7998326420783997
703,6/28/2021 5:18:54 PM,New Alzheimer’s Treatment Is A Huge Catalyst for Biogen,InvestorPlace,/news/stocks/new-alzheimers-treatment-is-a-huge-catalyst-for-biiib-stock-1030560044,positive,0.6769978404045105
704,6/28/2021 7:17:40 PM,What 17 Analyst Ratings Have To Say About Biogen,Benzinga,/news/stocks/what-17-analyst-ratings-have-to-say-about-biogen-1030560031,neutral,0.9417726397514343
705,6/29/2021 2:52:29 PM,"Biogen met with key FDA official, launched Project Onyx to gain Aduhelm approval - STAT",Seeking Alpha,https://seekingalpha.com/news/3710999-biogen-met-with-key-fda-official-launched-project-onyx-to-gain-aduhelm-approval-stat?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7237008810043335
706,6/29/2021 2:53:00 PM,Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America,PR Newswire,/news/stocks/enel-x-collaborates-with-biogen-to-electrify-take-home-vehicle-fleet-in-north-america-1030562905,positive,0.8360447287559509
707,6/29/2021 3:41:34 PM,Enel X Partners Biogen To Electrify Its Employee Commercial Fleet - Quick Facts ,RTTNews,/news/stocks/enel-x-partners-biogen-to-electrify-its-employee-commercial-fleet-quick-facts-1030563358,positive,0.746391773223877
708,6/29/2021 4:20:34 PM,3 Better Alzheimer’s Drug Stocks to Buy Instead of Biogen,InvestorPlace,/news/stocks/3-better-alzheimers-drug-stocks-to-buy-instead-of-biogen-1030564044,neutral,0.7046833038330078
709,6/29/2021 7:03:15 PM,Review documents on Biogen's Aduhelm explain why FDA statisticians objected,Seeking Alpha,https://seekingalpha.com/news/3711085-review-documents-on-biogen-aduhelm-explain-why-fda-statisticians-objected?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9263995289802551
710,7/1/2021 11:07:05 PM,Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-july-pdufa-dates-1030573631,neutral,0.9455710649490356
711,7/2/2021 1:32:21 PM,The trend is your friend --  what worked in June,Seeking Alpha,https://seekingalpha.com/news/3712147-trend-is-your-friend-best-worst-stocks-in-june?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9203320741653442
712,7/4/2021 2:00:00 PM,"Pharmas, payers to meet at Duke to hash out how to pay for Alzheimer's drugs - Endpoints",Seeking Alpha,https://seekingalpha.com/news/3712734-pharmas-payers-to-meet-at-duke-to-hash-out-how-to-pay-for-alzheimers-drugs-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9124140739440918
713,7/6/2021 4:46:09 PM,"Doctors, researchers warn against off-label use of Biogen's aducanumab",Seeking Alpha,https://seekingalpha.com/news/3713021-doctors-researchers-warn-against-off-label-use-of-biogen-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6657718420028687
714,7/7/2021 3:23:55 PM,"Cassava, Annovis, and INmune PTs raised at Maxim on aducanumab approval",Seeking Alpha,https://seekingalpha.com/news/3713333-cassava-annovis-and-inmune-price-target-raised-at-maxim-on-aducanumab-approval?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5064277052879333
715,7/7/2021 8:05:41 PM,Big pharma outperforms smaller rivals to lead second quarter gains: Evaluate,Seeking Alpha,https://seekingalpha.com/news/3713436-big-pharma-outperforms-smaller-rivals-to-lead-second-quarter-gains-evaluate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9427438378334045
716,7/8/2021 11:42:56 AM,FDA updated labeling says Biogen's Aduhelm should be used in mild Alzheimer's (updated),Seeking Alpha,https://seekingalpha.com/news/3713551-fda-approves-updated-labeling-for-biogens-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8841833472251892
717,7/8/2021 1:30:00 PM,FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials,GlobeNewswire,/news/stocks/fda-approves-updated-aduhelm-prescribing-information-to-emphasize-population-studied-in-clinical-trials-1030589211,positive,0.5417920351028442
718,7/8/2021 2:01:33 PM,Biogen Says FDA Approves Updated Label For Alzheimer's Drug Aduhelm Injection - Quick Facts ,RTTNews,/news/stocks/biogen-says-fda-approves-updated-label-for-alzheimer-s-drug-aduhelm-injection-quick-facts-1030589327,positive,0.5884510278701782
719,7/8/2021 4:48:34 PM,3 Blue-Chip Stocks to Trade Right Now,InvestorPlace,/news/stocks/3-blue-chip-stocks-to-trade-right-now-1030590867,neutral,0.9188586473464966
720,7/8/2021 8:24:06 PM,FDA was divided on a broader label for Biogen’s Alzheimer’s therapy: Stat News,Seeking Alpha,https://seekingalpha.com/news/3713811-fda-was-divided-on-a-broader-label-for-biogens-alzheimers-therapy-stat-news?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8958137035369873
721,7/8/2021 9:14:31 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-to-catch-up-on-4-1030591542,neutral,0.9254742860794067
722,7/8/2021 10:06:00 PM,"Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease",GlobeNewswire,/news/stocks/collaboration-between-abbvie-biogen-and-pfizer-creates-world-s-largest-browsable-resource-linking-rare-protein-coding-genetic-variants-to-human-health-and-disease-1030591423,positive,0.6106842756271362
723,7/9/2021 1:33:30 PM,"Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-anavex-life-sciences-upstart-and-more-1030592767,neutral,0.9256117343902588
724,7/9/2021 5:08:19 PM,Biogen tumbles as FDA chief calls for a probe on Alzheimer’s drug approval,Seeking Alpha,https://seekingalpha.com/news/3714057-biogen-tumbles-as-fda-chief-calls-for-a-probe-on-alzheimers-drug-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9008743762969971
725,7/9/2021 6:39:01 PM,"Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714076-biogen-fda-probe-on-alzheimers-drug-unlikely-to-have-tangible-impact-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6848840117454529
726,7/11/2021 10:45:12 PM,"The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix",Benzinga,/news/stocks/the-week-ahead-in-biotech-adcom-test-awaits-fibrogen-data-readouts-ipos-in-the-mix-1030595148,neutral,0.9197285771369934
727,7/12/2021 2:20:38 PM,Alzheimer's drug players shake off concerns from Biogen aducanunab probe,Seeking Alpha,https://seekingalpha.com/news/3714334-alzheimers-drug-players-shake-off-concerns-from-biogen-aducanunab-probe?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7501832842826843
728,7/13/2021 1:00:00 AM,"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis",GlobeNewswire,/news/stocks/biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-an-innovative-cns-penetrant-btk-inhibitor-for-the-potential-treatment-of-multiple-sclerosis-1030598911,positive,0.9298813939094543
729,7/13/2021 9:28:04 AM,Biogen inks orelabrutinib licensing deal with InnoCare in multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3714566-biogen-inks-orelabrutinib-licensing-deal-with-innocare-in-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5958999991416931
730,7/13/2021 12:19:07 PM,Biogen asked to submit internal documents by lawmakers in the probe of Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3714647-biogen-asked-to-submit-internal-documents-by-lawmakers-in-the-probe-of-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.872302234172821
731,7/13/2021 2:05:06 PM,"The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data",Benzinga,/news/stocks/the-daily-biotech-pulse-equillium-issues-positive-regulatory-update-biogen-in-licenses-multiple-sclerosis-drug-aridis-releases-covid-19-antibody-cocktail-data-1030601329,neutral,0.7802436947822571
732,7/13/2021 5:53:59 PM,Biogen to benefit from accelerated coverage decision on Alzheimer's therapy: analysts,Seeking Alpha,https://seekingalpha.com/news/3714834-biogen-to-benefit-from-accelerated-coverage-decision-on-alzheimers-therapy-analysts?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9053540825843811
733,7/14/2021 3:54:28 PM,Some Blue Cross Blue Shield affiliates won't cover Biogen's Aduhelm - Boston Globe,Seeking Alpha,https://seekingalpha.com/news/3715204-some-blue-cross-blue-shield-affiliates-wont-cover-biogens-aduhelm-boston-globe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9298245906829834
734,7/14/2021 7:59:40 PM,FDA chief indicates lapses in approval of Biogen’s Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3715282-fda-chief-indicates-lapses-in-approval-of-biogens-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9582750797271729
735,7/15/2021 1:25:25 PM,"Simufilam success already priced in to Cassava, and CONMED a buy in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3715468-simufilam-success-already-priced-in-to-cassava-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7038549780845642
736,7/15/2021 1:43:15 PM,"Cleveland Clinic, Mount Sinai won't administer Biogen's Aduhelm - New York Times",Seeking Alpha,https://seekingalpha.com/news/3715549-cleveland-clinic-mount-sinai-wont-administer-biogen-aduhelm-new-york-times?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9208573698997498
737,7/15/2021 2:38:54 PM,"FDA, Alzheimer's stakeholders look at expediting post-marketing confirmatory trials",Seeking Alpha,https://seekingalpha.com/news/3715573-fda-alzheimers-stakeholders-look-at-expediting-post-marketing-confirmatory-trials?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.896777868270874
738,7/15/2021 5:02:15 PM,UnitedHealth says need more info to determine coverage for Biogen’s Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3715661-unitedhealth-says-need-more-info-to-determine-coverage-for-biogens-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9025853276252747
739,7/15/2021 5:52:59 PM,BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today,InvestorPlace,/news/stocks/biib-stock-the-drug-ban-news-that-has-biogen-stumbling-today-1030612690,neutral,0.8912261128425598
740,7/15/2021 10:12:42 PM,AMD And Biogen Lead The QQQ Lower Thursday,Benzinga,/news/stocks/amd-and-biogen-lead-the-qqq-lower-thursday-1030613067,negative,0.9637587070465088
741,7/16/2021 2:08:26 PM,Biogen shares decline as ICER panel unanimously votes Aduhelm lacks clinical benefit -- STAT,Seeking Alpha,https://seekingalpha.com/news/3715969-biogen-shares-decline-as-icer-panel-unanimously-votes-biogens-aduhelm-lacks-clinical-benefit-cost-effectiveness-stat?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9652925133705139
742,7/16/2021 2:17:21 PM,MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500,InvestorPlace,/news/stocks/mrna-stock-10-things-to-know-about-moderna-as-it-gets-ready-to-join-the-sp-500-1030615504,neutral,0.9003422856330872
743,7/16/2021 3:16:07 PM,FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall,InvestorPlace,/news/stocks/fgen-stock-the-huge-fda-news-causing-fibrogen-shares-to-free-fall-1030615640,negative,0.8264040946960449
744,7/18/2021 1:04:02 AM,Moderna headlines weekly healthcare gainers; FibroGen and Biogen trail,Seeking Alpha,https://seekingalpha.com/news/3716141-moderna-headlines-weekly-healthcare-gainers-fibrogen-and-biogen-trail?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9005435109138489
745,7/18/2021 4:25:56 PM,"The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-earnings-kickstart-with-j-j-and-biogen-albireo-awaits-fda-decisions-more-ipos-1030617574,positive,0.5948061943054199
746,7/20/2021 3:01:32 PM,What Wall Street expects from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-stock-price-q2-earnings-preview-1030625197,neutral,0.9294326305389404
747,7/21/2021 12:27:03 PM,Biogen and Mirimus ink strategic collaboration agreement,Seeking Alpha,https://seekingalpha.com/news/3717330-biogen-and-mirimus-ink-strategic-collaboration-agreement?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5842863917350769
748,7/21/2021 1:41:50 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3717408-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.882573127746582
749,7/21/2021 2:03:00 PM,"Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications",PR Newswire,/news/stocks/mirimus-inc-forms-strategic-collaboration-with-biogen-to-develop-rnai-based-therapeutics-for-neurological-disease-indications-1030630112,positive,0.5996081233024597
750,7/21/2021 5:25:11 PM,SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars,InvestorPlace,/news/stocks/sava-stock-two-dates-cassava-investors-need-to-mark-on-their-calendars-1030631628,neutral,0.9317856431007385
751,7/22/2021 11:03:59 AM,"Biogen EPS beats by $1.08, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3717905-biogen-eps-beats-1_08-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.878646731376648
752,7/22/2021 11:46:08 AM,Biogen raises 2021 guidance; records $2 million quarterly sales from new Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3717945-biogen-raises-2021-guidance-records-2-million-quarterly-sales-from-new-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9114915728569031
753,7/22/2021 1:05:00 PM,"An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.",GlobeNewswire,/news/stocks/an-open-letter-to-the-alzheimer-s-disease-community-from-our-head-of-research-and-development-alfred-sandrock-m-d-ph-d-1030634338,positive,0.5678099393844604
754,7/22/2021 1:33:26 PM,Biogen Boosts FY21 Revenue Outlook; Q2 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/biogen-boosts-fy21-revenue-outlook-q2-results-top-estimates-quick-facts-1030634537,positive,0.9432415962219238
755,7/22/2021 2:18:49 PM,"The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-merck-eisai-seres-ulcerative-colitis-drug-flunks-midstage-study-pfizer-to-invest-in-arvinas-absci-ipo-1030634923,neutral,0.8168379664421082
756,7/22/2021 3:44:11 PM,IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High,InvestorPlace,/news/stocks/igc-stock-the-huge-cannabis-patent-news-that-has-igc-flying-high-1030636057,positive,0.5268210172653198
757,7/22/2021 3:52:10 PM,Biogen R&D chief pens letter to Alzheimer's community defending Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3718136-biogen-research-development-chief-sandrock-pens-letter-to-alzheimers-community-defending-aduhelm-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.871376097202301
758,7/23/2021 10:30:00 PM,Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference,GlobeNewswire,/news/stocks/biogen-to-present-data-from-aduhelm-and-alzheimer-s-disease-portfolio-at-2021-alzheimer-s-association-international-conference-1030640133,neutral,0.9257843494415283
759,7/24/2021 8:00:00 PM,AAIC 2021: What to look for at Alzheimer's biggest annual conference,Seeking Alpha,https://seekingalpha.com/news/3718755-aaic-2021-what-to-look-for-biggest-annual-alzheimers-conference?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9385380744934082
760,7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744,neutral,0.9177685976028442
761,7/26/2021 9:01:36 PM,Biogen and Ionis post promising data from early-stage BIIB080 Alzheimer's disease trial,Seeking Alpha,https://seekingalpha.com/news/3719340-biogen-and-ionis-post-promising-data-from-early-stage-biib080-alzheimers-disease-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9474639296531677
762,7/26/2021 10:10:00 PM,Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021,GlobeNewswire,/news/stocks/biogen-and-eisai-announce-aduhelm-aducanumab-avwa-data-presentations-at-alzheimer-s-association-international-conference-2021-1030646578,neutral,0.8741501569747925
763,7/26/2021 10:35:00 PM,Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC,PR Newswire,/news/stocks/biogen-and-ionis-report-positive-topline-clinical-data-on-investigational-alzheimer-s-disease-treatment-at-aaic-1030646622,positive,0.943282425403595
764,7/27/2021 4:40:16 AM,Biogen : Phase 1b Study On Alzheimer's Disease Meets Primary Objective Of Safety & Tolerability ,RTTNews,/news/stocks/biogen-phase-1b-study-on-alzheimer-s-disease-meets-primary-objective-of-safety-tolerability-1030646958,neutral,0.8280952572822571
765,7/28/2021 2:05:05 PM,3 Diverse Forever Tech Stocks to Buy Today,InvestorPlace,/news/stocks/3-diverse-forever-tech-stocks-to-buy-today-1030657233,neutral,0.8818970322608948
766,7/29/2021 6:27:21 PM,Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation,Benzinga,/news/stocks/annovis-bio-shares-cut-in-half-following-alzheimer-s-data-presentation-1030663679,negative,0.9639384746551514
767,7/29/2021 8:21:06 PM,Biogen and Eisai highlight design for first real world study of Alzheimer’s disease drug Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3721888-biogen-and-eisai-highlight-design-for-first-real-world-study-of-alzheimers-disease-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8171103596687317
768,7/29/2021 10:10:00 PM,"Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021",GlobeNewswire,/news/stocks/biogen-and-eisai-announce-design-of-aduhelm-icare-ad-us-study-the-first-real-world-observational-phase-4-study-in-alzheimer-s-disease-at-aaic-2021-1030664469,neutral,0.7397184371948242
769,7/29/2021 10:30:00 PM,Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401),PR Newswire,/news/stocks/late-breaking-aaic-presentation-explores-potential-clinical-effects-of-lecanemab-ban2401-1030664533,neutral,0.8822758197784424
770,7/30/2021 1:53:58 PM,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-erytech-jumps-on-fast-track-designation-glaxosmithkline-fda-nod-alnylam-s-clinical-collaboration-4-ipos-1030667906,positive,0.7937847971916199
771,7/30/2021 3:51:52 PM,"AbbVie to advance beta-amyloid Alzheimer's candidate, abandons tau asset",Seeking Alpha,https://seekingalpha.com/news/3722486-abbvie-to-advance-beta-amyloid-alzheimers-candidate-abandon-tau-asset?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8751495480537415
772,7/30/2021 5:21:53 PM,Biogen: Does Aduhelm Make it the Next Dendreon?,InvestorPlace,/news/stocks/biib-stock-does-aduhelm-make-it-the-next-dendreon-1030669123,neutral,0.9347943663597107
773,8/2/2021 11:49:11 AM,Biogen highlights results from late-stage natalizumab multiple sclerosis study,Seeking Alpha,https://seekingalpha.com/news/3722850-biogen-highlights-results-from-late-stage-natalizumab-multiple-sclerosis-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8895127773284912
774,8/2/2021 1:30:00 PM,Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-announces-results-from-phase-3b-nova-study-evaluating-every-six-week-dosing-with-natalizumab-in-relapsing-remitting-multiple-sclerosis-1030675752,positive,0.5588036775588989
775,8/2/2021 2:42:57 PM,Biogen: Every Six-week Natalizumab Administration Provides High Level Of Efficacy In Controlling MS ,RTTNews,/news/stocks/biogen-every-six-week-natalizumab-administration-provides-high-level-of-efficacy-in-controlling-ms-1030676152,positive,0.8744229078292847
776,8/2/2021 7:18:33 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1030677545,neutral,0.9187624454498291
777,8/4/2021 4:40:12 PM,"Eisai, Biogen will push for fast approval of another Alzheimer's candidate, lecanemab",Seeking Alpha,https://seekingalpha.com/news/3725115-eisai-biogen-will-push-for-fast-approval-of-another-alzheimers-candidate-lecanemab?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8218268752098083
778,8/4/2021 5:53:09 PM,HHS to review FDA’s accelerated pathway after approval of Biogen’s Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3725217-hhs-to-review-fdas-accelerated-pathway-after-approval-for-biogens-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7389451265335083
779,8/9/2021 10:00:48 AM,What to Do After Cassava Sciences Dropped Off a Cliff,InvestorPlace,/news/stocks/sava-stock-what-to-do-after-cassava-sciences-dropped-off-a-cliff-1030707829,neutral,0.7123355865478516
780,8/16/2021 10:00:06 AM,Cassava Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug,InvestorPlace,/news/stocks/cassaca-sciences-stock-is-a-buy-on-the-strength-of-a-promising-alzheimers-drug-1030733542,positive,0.8587585091590881
781,8/16/2021 10:00:13 AM,"With This Exciting Alzheimer’s Treatment, Cassava Sciences Stock Has Legs",InvestorPlace,/news/stocks/sava-stock-has-legs-1030733537,positive,0.8621016144752502
782,8/16/2021 7:26:06 PM,Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization,Benzinga,/news/stocks/novavax-appoints-new-cfo-amid-inordinate-delay-in-covid-19-vaccine-authorization-1030735356,negative,0.7961598634719849
783,8/16/2021 8:26:50 PM,"Warren Buffett's Berkshire Hathaway exits Axalta Coating, boosts Kroger stake",Seeking Alpha,https://seekingalpha.com/news/3731075-warren-buffetts-berkshire-hathaway-exits-axalta-coating-boosts-kroger-stake?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7038435339927673
784,8/17/2021 6:50:26 PM,"Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q2-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030739447,neutral,0.8887203335762024
785,8/17/2021 7:04:09 PM,7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire,InvestorPlace,/news/stocks/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire-1030739695,neutral,0.938480794429779
786,8/19/2021 4:02:46 PM,"Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk",InvestorPlace,/news/stocks/sava-stock-has-had-an-epic-run-but-getting-in-is-a-serious-risk-1030746748,negative,0.49367067217826843
787,8/21/2021 5:26:59 PM,Expert Ratings For Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1030750233,neutral,0.834668755531311
788,8/23/2021 11:33:55 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-august-23-1030752093,neutral,0.49790605902671814
789,8/30/2021 8:43:24 AM,Biotech Stocks Facing FDA Decision In September 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2021-1030766032,neutral,0.7743744850158691
790,8/31/2021 2:23:28 PM,Wait to See How the Cassava Sciences Allegations Pan Out,InvestorPlace,/news/stocks/cassava-sciences-time-to-buy-sava-stock-on-the-dip-1030770208,neutral,0.9023323059082031
791,8/31/2021 8:00:15 PM,Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-september-pdufa-dates-1030770967,neutral,0.9473286867141724
792,9/2/2021 11:08:18 AM,Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations,InvestorPlace,/news/stocks/cassava-sciences-stock-will-fall-further-on-data-manipulation-allegations-1030776139,negative,0.9686608910560608
793,9/8/2021 4:25:03 PM,7 Busted Biotech Stocks Due for a Rebound,InvestorPlace,/news/stocks/7-busted-biotech-stocks-due-for-a-rebound-1030787940,negative,0.5655410289764404
794,9/9/2021 10:00:22 AM,Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy,InvestorPlace,/news/stocks/sava-stock-still-best-to-tread-carefully-1030789430,negative,0.9286614060401917
795,9/9/2021 9:42:10 PM,"Biogen Admits To ""Slower Than Anticipated"" Launch Of Its Alzheimer's Drug ",RTTNews,/news/stocks/biogen-admits-to-slower-than-anticipated-launch-of-its-alzheimer-s-drug-1030791190,negative,0.7690010666847229
796,9/12/2021 10:04:17 PM,"The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-12-18-calliditas-fda-decision-adcom-review-for-pfizer-biontech-covid-19-vaccine-oncology-conference-and-ipos-1030794269,neutral,0.9348464608192444
797,9/13/2021 10:00:18 AM,Cassava Stock Is a Bold Play That Could Pay Off Soon,InvestorPlace,/news/stocks/cassava-stock-is-a-bold-play-that-could-pay-off-soon-1030795273,positive,0.7781859040260315
798,9/13/2021 4:15:32 PM,3 Quality Stocks to Buy From the Bargain Bin,InvestorPlace,/news/stocks/3-quality-stocks-to-buy-from-the-bargain-bin-1030796320,neutral,0.8965877890586853
799,9/15/2021 1:30:00 PM,Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam),GlobeNewswire,/news/stocks/biogen-plans-to-initiate-phase-3b-study-evaluating-potential-benefit-of-a-higher-dose-of-nusinersen-in-patients-previously-treated-with-evrysdi-risdiplam-1030801198,positive,0.9102874994277954
800,9/16/2021 1:30:00 PM,Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy,GlobeNewswire,/news/stocks/biogen-announces-positive-topline-results-from-phase-2-convey-study-in-small-fiber-neuropathy-1030804252,positive,0.9427865147590637
801,9/16/2021 2:37:23 PM,Biogen Announces Positive Results From Phase 2 Study Of Vixotrigine In Small Fiber Neuropathy ,RTTNews,/news/stocks/biogen-announces-positive-results-from-phase-2-study-of-vixotrigine-in-small-fiber-neuropathy-1030804550,positive,0.942672848701477
802,9/16/2021 7:22:02 PM,Expert Ratings For Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1030805490,neutral,0.834668755531311
803,9/17/2021 1:36:08 PM,"The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-tryst-for-pfizer-biontech-booster-shot-abcellera-s-covid-antibody-treatment-gets-expanded-use-protagonist-slapped-with-clinical-hold-1030806977,positive,0.603901743888855
804,9/17/2021 3:09:31 PM,CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis,GlobeNewswire,/news/stocks/chmp-recommends-vumerity-diroximel-fumarate-for-approval-in-the-european-union-as-a-treatment-for-relapsing-remitting-multiple-sclerosis-1030807336,positive,0.852279782295227
805,9/17/2021 3:51:39 PM,Biogen Announces Positive CHMP Opinion For VUMERITY - Quick Facts ,RTTNews,/news/stocks/biogen-announces-positive-chmp-opinion-for-vumerity-quick-facts-1030807367,positive,0.9184958338737488
806,9/17/2021 7:00:20 PM,"Catalyst watch for next week: FedEx and Nike report, FOMC watch, IPO blitz",Seeking Alpha,https://seekingalpha.com/news/3740930-catalyst-watch-for-next-week-fedex-and-nike-report-fomc-watch-ipo-blitz?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9421775341033936
807,9/20/2021 1:30:00 PM,"FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)",GlobeNewswire,/news/stocks/fda-approves-samsung-bioepis-and-biogen-s-byooviz-sb11-lucentis-biosimilar-ranibizumab-nuna-1030809576,positive,0.7957432866096497
808,9/20/2021 2:13:02 PM,"FDA Approves Samsung Bioepis' Byooviz, A Proposed Biosimilar To Lucentis - Quick Facts ",RTTNews,/news/stocks/fda-approves-samsung-bioepis-byooviz-a-proposed-biosimilar-to-lucentis-quick-facts-1030809769,positive,0.8103951215744019
809,9/21/2021 2:30:00 PM,Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience,GlobeNewswire,/news/stocks/biogen-r-d-day-to-provide-overview-of-diversified-pipeline-and-capabilities-with-potential-for-multiple-novel-therapies-in-neuroscience-1030812704,neutral,0.7390388250350952
810,9/21/2021 2:53:10 PM,Apple looking at new depression detection features for iPhones--report,Seeking Alpha,https://seekingalpha.com/news/3741899-apple-looking-at-new-depression-detection-features-for-iphones-report?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8915746212005615
811,9/22/2021 10:52:32 PM,Biogen Considers Drastic Cost-Cutting Measures As Alzheimer Drug Disappoints ,RTTNews,/news/stocks/biogen-considers-drastic-cost-cutting-measures-as-alzheimer-drug-disappoints-1030817352,negative,0.8306022882461548
812,9/23/2021 3:09:50 PM,"Thinking About Buying Stock Or Options In Tesla, Ballard Power, Bloom Energy Or Biogen?",Benzinga,/news/stocks/thinking-about-buying-stock-or-options-in-tesla-ballard-power-bloom-energy-or-biogen-1030818978,neutral,0.9316520094871521
813,9/23/2021 4:06:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-23-2021-1030819280,negative,0.5392213463783264
814,9/23/2021 6:42:23 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1030819784,neutral,0.9221560955047607
815,9/23/2021 11:04:26 PM,"Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst",Benzinga,/news/stocks/aduhelm-s-blockbuster-potential-is-underappreciated-says-biogen-analyst-1030820408,negative,0.9581800103187561
816,9/24/2021 1:35:37 PM,"Biotech's big fall catalysts to watch out for, from Evercore",Seeking Alpha,https://seekingalpha.com/news/3743858-biotechs-big-fall-catalysts-to-watch-out-for-from-evercore?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7546192407608032
817,9/28/2021 1:30:00 AM,Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway,PR Newswire,/news/stocks/eisai-initiates-rolling-submission-to-the-u-s-fda-for-biologics-license-application-of-lecanemab-ban2401-for-early-alzheimer-s-disease-under-the-accelerated-approval-pathway-1030826591,neutral,0.5236440300941467
818,9/28/2021 2:18:52 PM,"The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive",Benzinga,/news/stocks/the-daily-biotech-pulse-eisai-biogen-pursue-approval-of-second-alzheimer-s-treatment-sanofi-changes-mrna-strategy-gsk-subsidiary-to-develop-long-acting-hiv-preventive-1030827880,neutral,0.5831683278083801
819,9/29/2021 7:21:28 PM,Analyst Ratings For Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1030831958,neutral,0.9187624454498291
820,9/30/2021 3:22:09 PM,See Why Perrigo Shares Are Moving Higher On Thursday,Benzinga,/news/stocks/see-why-perrigo-shares-are-moving-higher-on-thursday-1030834251,positive,0.5362213253974915
821,10/1/2021 2:55:51 PM,Cassava Stock Has Reached a Positive Turning Point,InvestorPlace,/news/stocks/cassava-stock-has-reached-a-positive-turning-point-1030837630,positive,0.9338191747665405
822,10/2/2021 2:00:00 PM,"Moderna, BioNTech top performing pharmas in Q3; Alzheimer's drug developers lag",Seeking Alpha,https://seekingalpha.com/news/3747328-moderna-biontech-top-best-performing-pharmas-in-q3-alzheimers-drug-developers-lag?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5793255567550659
823,10/6/2021 9:57:30 PM,"Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT",Benzinga,/news/stocks/merck-keeps-m-a-mode-on-with-mirati-biogen-mrna-companies-on-radar-ft-1030848508,neutral,0.8931921720504761
824,10/7/2021 6:00:06 PM,3 Stocks to Buy Where Wall Street Is Focused on Fear,InvestorPlace,/news/stocks/3-stocks-to-buy-where-wall-street-is-focused-on-fear-1030851385,neutral,0.8951037526130676
825,10/8/2021 6:11:06 PM,Analyst Ratings For Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1030853401,neutral,0.9187624454498291
826,10/11/2021 9:23:27 PM,"As Supernus acquires Adamas, other Parkinson's players mixed on the day",Seeking Alpha,https://seekingalpha.com/news/3751392-as-supernus-acquires-adamis-other-parkinsons-players-mixed-on-the-day?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6782760620117188
827,10/12/2021 6:22:53 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1030859982,neutral,0.9221560955047607
828,10/13/2021 12:02:00 PM,New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis,GlobeNewswire,/news/stocks/new-ms-paths-data-at-ectrims-2021-confirm-biogen-s-disease-modifying-therapies-do-not-reduce-antibody-response-to-covid-19-vaccines-in-people-with-multiple-sclerosis-1030862195,positive,0.8981995582580566
829,10/13/2021 12:05:00 PM,New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience ,GlobeNewswire,/news/stocks/new-data-at-ectrims-2021-highlight-biogen-s-focus-on-patient-centered-outcomes-and-improving-the-ms-patient-experience-1030862194,positive,0.9037895798683167
830,10/14/2021 9:13:22 PM,Biogen price target cut at Cantor Fitzgerald due to lower expected sales of Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3753063-biogen-price-target-cut-at-cantor-fitzgerald-due-to-lower-expected-sales-of-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9609734416007996
831,10/14/2021 10:06:00 PM,Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting,GlobeNewswire,/news/stocks/topline-results-from-tofersen-phase-3-study-and-its-open-label-extension-in-sod1-als-to-be-presented-at-the-american-neurological-association-annual-meeting-1030867833,neutral,0.8668872714042664
832,10/17/2021 10:20:00 PM,Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS,GlobeNewswire,/news/stocks/biogen-announces-topline-results-from-the-tofersen-phase-3-study-and-its-open-label-extension-in-sod1-als-1030871424,neutral,0.6388666033744812
833,10/18/2021 1:34:17 PM,"The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-18-23-j-j-biogen-kickstart-big-pharma-earnings-regeneron-sanofi-roche-await-fda-decisions-and-ipos-1030873336,neutral,0.7243738174438477
834,10/18/2021 3:01:24 PM,Here's what Wall Street expects from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-q3-quarterly-earnings-preview-stock-1030873639,neutral,0.9258308410644531
835,10/18/2021 4:56:18 PM,Ionis Pharma at a historic low on setback for partner Biogen in ALS study,Seeking Alpha,https://seekingalpha.com/news/3754177-ionis-pharma-at-a-historic-low-on-setback-for-partner-biogen-in-als-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8984904885292053
836,10/19/2021 3:06:57 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3755050-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.855887770652771
837,10/19/2021 8:21:07 PM,Sage plans for depression candidate NDA fail to lift stock; shares close down 8%,Seeking Alpha,https://seekingalpha.com/news/3755221-sage-plans-for-depression-candidate-nda-fail-to-lift-stock-shares-close-down-8?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9625508785247803
838,10/20/2021 1:15:40 PM,Biogen Inc. Q3 Profit Declines,RTTNews,/news/stocks/biogen-inc-q3-profit-declines-1030881244,negative,0.9489604234695435
839,10/20/2021 1:32:26 PM,Biogen Raises FY21 Guidance - Quick Facts ,RTTNews,/news/stocks/biogen-raises-fy21-guidance-quick-facts-1030881347,neutral,0.8239163756370544
840,10/20/2021 2:16:25 PM,"The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-retreats-amid-vaccine-issues-lumiradx-covid-test-approved-in-india-sesen-shines-on-positive-bladder-cancer-review-1030881679,positive,0.555168867111206
841,10/20/2021 4:34:30 PM,Abbot Labs and Biogen Outshine Novavax in the Health Care Sector,Benzinga,/news/stocks/abbot-labs-and-biogen-outshine-novavax-in-the-health-care-sector-1030882395,neutral,0.6113494038581848
842,10/21/2021 1:46:38 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030885393,neutral,0.7969077229499817
843,10/26/2021 3:07:38 PM,Eli Lilly begins rolling submission of Alzheimer's candidate donanemab,Seeking Alpha,https://seekingalpha.com/news/3758158-eli-lilly-begins-rolling-submission-of-alzheimers-candidate-donanemab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9043501019477844
844,10/26/2021 3:17:29 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1030900419,neutral,0.8152948021888733
845,10/26/2021 4:13:44 PM,Teva Pharmaceutical falls 6% on eve of Q3 earnings show,Seeking Alpha,https://seekingalpha.com/news/3758203-teva-pharmaceutical-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9715292453765869
846,10/26/2021 6:36:47 PM,Expert Ratings For Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1030901093,neutral,0.834668755531311
847,11/1/2021 10:00:56 AM,Cassava Stock Could Jump More Than 200 Times,InvestorPlace,/news/stocks/sava-stock-could-jump-more-than-200-times-1030920800,neutral,0.5619463324546814
848,11/2/2021 7:25:48 PM,Blue Cross Blue Shield affiliate considering coverage of Biogen's Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3763243-blue-cross-blue-shield-affiliate-considering-coverage-of-biogen-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7088579535484314
849,11/3/2021 12:30:00 PM,Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting,GlobeNewswire,/news/stocks/biogen-announces-late-breakers-and-additional-new-data-presentations-at-the-2021-clinical-trials-on-alzheimer-s-disease-ctad-meeting-1030931451,neutral,0.9336402416229248
850,11/5/2021 7:00:37 PM,"Catalyst watch for next week: Rivian IPO, Hertz redux, Disney+ Day and AMD event",Seeking Alpha,https://seekingalpha.com/news/3766361-catalyst-watch-for-next-week-rivian-ipo-hertz-redux-disney-day-and-amd-event?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9357773661613464
851,11/8/2021 2:24:25 PM,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-7-nov-13-earnings-taper-off-multiple-conference-presentations-ipos-and-more-1030949001,negative,0.9685659408569336
852,11/9/2021 2:13:10 PM,"The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data",Benzinga,/news/stocks/the-daily-biotech-pulse-double-dose-of-positive-tidings-for-merck-alkermes-slips-on-partial-termination-of-j-j-licensing-deal-amgen-migraine-drug-data-1030953661,negative,0.8833058476448059
853,11/9/2021 6:06:08 PM,Biogen says probe is underway for death following its Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3767927-biogen-says-probe-is-underway-for-death-following-its-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6819204688072205
854,11/10/2021 1:46:22 PM,Roche indicates its Alzheimer's drug would be priced below Biogen's Aduhelm - Reuters,Seeking Alpha,https://seekingalpha.com/news/3768636-roche-indicates-its-alzheimers-drug-would-be-priced-below-biogens-aduhelm-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8013221621513367
855,11/10/2021 8:39:45 PM,Biogen/ Eisai disclose long-term data for Alzheimer’s candidate from mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3768907-biogen-eisai-disclose-long-term-data-for-alzheimers-candidate-from-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9200758934020996
856,11/10/2021 8:57:00 PM,"Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (...",PR Newswire,/news/stocks/eisai-presents-late-breaker-updates-on-lecanemab-clinical-biomarker-and-safety-data-from-phase-2b-study-core-and-open-label-extension-across-five-years-at-clinical-trials-on-alzheimer-s-disease-1030961052,neutral,0.8500461578369141
857,11/11/2021 5:20:00 PM,Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference,PR Newswire,/news/stocks/eisai-presents-new-analysis-of-lecanemab-clinical-efficacy-results-from-phase-2b-study-at-clinical-trials-on-alzheimer-s-disease-ctad-conference-1030966094,neutral,0.8168562650680542
858,11/11/2021 6:00:00 PM,Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Co...,PR Newswire,/news/stocks/introduction-of-first-of-a-kind-plasma-based-biomarker-screening-to-facilitate-identification-of-subjects-for-phase-3-ahead-3-45-trial-presented-at-clinical-trials-on-alzheimer-s-disease-ctad-co-1030966241,neutral,0.6435433626174927
859,11/11/2021 11:10:00 PM,New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease,GlobeNewswire,/news/stocks/new-phase-3-data-show-positive-correlation-between-aduhelm-treatment-effect-on-biomarkers-and-reduction-in-clinical-decline-in-alzheimer-s-disease-1030967029,positive,0.9525265693664551
860,11/12/2021 12:23:52 PM,Biogen gains after indicating its Alzheimer’s drug lowered another key biomarker of disease,Seeking Alpha,https://seekingalpha.com/news/3769972-biogen-gains-after-indicating-its-alzheimers-drug-lowered-another-key-biomarker-of-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9074381589889526
861,11/12/2021 1:40:21 PM,"The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-to-spin-off-consumer-health-business-astrazeneca-earnings-embattled-emergent-to-buy-back-shares-1030969817,neutral,0.8889020681381226
862,11/15/2021 1:30:00 PM,Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year,GlobeNewswire,/news/stocks/biogen-sets-industry-record-with-recognition-on-dow-jones-sustainability-world-index-for-9th-consecutive-year-1030975909,positive,0.7857389450073242
863,11/16/2021 1:44:06 AM,"Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development",GlobeNewswire,/news/stocks/biogen-announces-alfred-w-sandrock-jr-to-retire-as-head-of-research-development-1030978386,neutral,0.7854569554328918
864,11/16/2021 12:07:08 PM,Biogen announces retirement of scientist behind new Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3771275-biogen-announces-retirement-of-scientist-behind-new-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6883324980735779
865,11/16/2021 2:30:12 PM,"The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment",Benzinga,/news/stocks/the-daily-biotech-pulse-kezar-jumps-on-data-biogen-r-d-chief-to-retire-molecular-partners-wilts-on-covid-trial-disappointment-1030980303,neutral,0.6811912059783936
866,11/16/2021 2:48:39 PM,Biogen wins European approval for VUMERITY as multiple sclerosis therapy,Seeking Alpha,https://seekingalpha.com/news/3771450-biogen-wins-european-approval-for-vumerity-as-multiple-sclerosis-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9126964807510376
867,11/16/2021 3:20:00 PM,The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis,GlobeNewswire,/news/stocks/the-european-commission-grants-marketing-authorization-for-vumerity-diroximel-fumarate-as-oral-treatment-for-relapsing-remitting-multiple-sclerosis-1030980905,positive,0.918734073638916
868,11/17/2021 12:47:25 PM,Biogen hurt by setback for European approval of Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3771818-biogen-hurt-by-setback-for-european-approval-of-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9598106741905212
869,11/17/2021 1:24:59 PM,Jim Cramer Likes This Stock Over Cassava Sciences And Biogen,Benzinga,/news/stocks/jim-cramer-likes-this-stock-over-cassava-sciences-and-biogen-1030983909,neutral,0.9125941395759583
870,11/17/2021 1:30:00 PM,Update on Regulatory Review of Aducanumab in the European Union,GlobeNewswire,/news/stocks/update-on-regulatory-review-of-aducanumab-in-the-european-union-1030983935,neutral,0.9218396544456482
871,11/17/2021 8:44:00 PM,Analysts don't see huge impact to Biogen on EMA vote on Alzheimer's drug aducanumab,Seeking Alpha,https://seekingalpha.com/news/3772097-analysts-dont-see-huge-impact-to-biogen-on-ema-vote-on-alzheimers-drug-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6253716945648193
872,11/17/2021 9:17:00 PM,EU Panel Recommends Negative Trend Vote On Biogen's Alzheimer Drug ,RTTNews,/news/stocks/eu-panel-recommends-negative-trend-vote-on-biogen-s-alzheimer-drug-1030985716,negative,0.9206026792526245
873,11/18/2021 4:57:39 PM,"Biogen yet to convince payors for new Alzheimer’s drug, Bloomberg survey reveals",Seeking Alpha,https://seekingalpha.com/news/3772503-biogen-yet-to-convince-payors-for-new-alzheimers-drug-bloomberg-survey-reveals?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5456866025924683
874,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825,negative,0.6235838532447815
875,11/19/2021 5:59:47 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1030992184,neutral,0.9221560955047607
876,11/21/2021 9:06:50 PM,"The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-21-nov-27-takeda-aadi-fennec-fda-decisions-earnings-in-the-spotlight-in-holiday-shortened-week-1030993278,neutral,0.46301308274269104
877,11/22/2021 6:47:54 PM,Biogen’s new Alzheimer’s drug caused brain swelling among 35% of patients in study,Seeking Alpha,https://seekingalpha.com/news/3773490-biogens-new-alzheimers-drug-caused-brain-swelling-among-35-of-patients-in-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8673518300056458
878,11/22/2021 9:59:57 PM,2 Moonshot Biotechs with 10x Potential,InvestorPlace,/news/stocks/2-moonshot-biotechs-with-10x-potential-1030996284,neutral,0.8490810394287109
879,11/30/2021 4:02:31 PM,Biogen drops after losing appeal to revive patent on blockbuster drug,Seeking Alpha,https://seekingalpha.com/news/3775438-biogen-drops-after-losing-appeal-to-revive-patent-on-blockbuster-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9011096358299255
880,12/1/2021 11:56:11 AM,"Sage Therapeutics, Biogen report positive zuranolone data in late-stage depression study",Seeking Alpha,https://seekingalpha.com/news/3775697-sage-therapeutics-biogen-report-positive-zuranolone-data-in-late-stage-depression-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8422839045524597
881,12/1/2021 1:21:34 PM,Viatris Wins Federal Circuit Court Appeal On Biogen's Tecfidera Patent - Quick Facts ,RTTNews,/news/stocks/viatris-wins-federal-circuit-court-appeal-on-biogen-s-tecfidera-patent-quick-facts-1031015535,positive,0.5474846959114075
882,12/1/2021 2:41:54 PM,"The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-backs-merck-s-oral-covid-19-treatment-regulatory-setbacks-for-cti-biopharma-bioxcel-favorable-ruling-for-viatris-in-tecfidera-patent-case-1031016008,positive,0.9288403391838074
883,12/1/2021 2:44:31 PM,"Sage Announces Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder ",RTTNews,/news/stocks/sage-announces-positive-one-year-zuranolone-50-mg-data-on-major-depressive-disorder-1031016016,positive,0.8424033522605896
884,12/6/2021 4:05:46 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-6-2021-1031026544,negative,0.5734044909477234
885,12/6/2021 5:12:59 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1031026720,neutral,0.9221560955047607
886,12/8/2021 12:16:25 PM,"Sage Therapeutics, Biogen reports new analyses from Landscape program of zuranolone in MDD",Seeking Alpha,https://seekingalpha.com/news/3778168-sage-therapeutics-biogen-reports-new-analyses-from-landscape-program-of-zuranolone-in-mdd?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8839704394340515
887,12/8/2021 1:02:53 PM,Sage Announces Presentation Of Analyses From Clinical Program Of Zuranolone In MDD ,RTTNews,/news/stocks/sage-announces-presentation-of-analyses-from-clinical-program-of-zuranolone-in-mdd-1031031811,neutral,0.8971704244613647
888,12/8/2021 2:19:09 PM,"The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-valneva-strikes-deal-to-supply-covid-vaccine-to-bahrain-therapeuticsmd-amneal-settle-patent-lawsuit-reata-awaits-adcom-1031032240,neutral,0.6858615279197693
889,12/8/2021 3:50:56 PM,Biogen eyes layoffs of more than 1K employees - STAT,Seeking Alpha,https://seekingalpha.com/news/3778330-biogen-eyes-layoffs-of-more-than-1k-employees-stat?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9662021994590759
890,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,negative,0.5978409051895142
891,12/11/2021 9:00:00 PM,Biogen's 2021 is a disappointment due to Aduhelm. Is a turnaround possible in 2022?,Seeking Alpha,https://seekingalpha.com/news/3779268-biogen-2021-is-a-disappointment-due-to-aduhelm-is-a-turnaround-possible-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.45848676562309265
892,12/14/2021 12:32:35 PM,Biogen forms alliance to advance digital health for personalized medicine in neuroscience,Seeking Alpha,https://seekingalpha.com/news/3779835-biogen-forms-alliance-to-advance-digital-health-for-personalized-medicine-in-neuroscience?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5080137252807617
893,12/14/2021 1:00:00 PM,Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience,GlobeNewswire,/news/stocks/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance-digital-health-for-personalized-medicine-in-neuroscience-1031083799,positive,0.8471161127090454
894,12/16/2021 1:00:00 PM,Update on the Phase 4 Confirmatory Study of ADUHELM®,GlobeNewswire,/news/stocks/update-on-the-phase-4-confirmatory-study-of-aduhelm-1031084948,neutral,0.9169648289680481
895,12/16/2021 1:32:45 PM,Eli Lilly price target upped at Cantor following new closing high; sees 22% upside,Seeking Alpha,https://seekingalpha.com/news/3780737-eli-lilly-price-target-upped-at-cantor-following-new-closing-high-sees-22-upside?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9425252676010132
896,12/17/2021 12:02:36 PM,Biogen and Eisai suffer setback for European approval of Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3781212-biogen-and-eisai-suffer-setback-for-european-approval-of-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.944159209728241
897,12/17/2021 12:43:58 PM,Update on Regulatory Submission for Aducanumab in the European Union,GlobeNewswire,/news/stocks/update-on-regulatory-submission-for-aducanumab-in-the-european-union-1031085688,neutral,0.9247546792030334
898,12/17/2021 1:38:03 PM,Biogen To Seek Re-examination Of Negative Opinion By EMA For Its 'aducanumab' ,RTTNews,/news/stocks/biogen-to-seek-re-examination-of-negative-opinion-by-ema-for-its-aducanumab-1031053087,neutral,0.6892744302749634
899,12/17/2021 1:54:07 PM,"The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx",Benzinga,/news/stocks/the-daily-biotech-pulse-genfit-spikes-on-liver-disease-drug-licensing-deal-lyell-gets-nod-for-solid-tumor-study-decision-day-for-intra-cellular-argenx-1031053175,neutral,0.743990421295166
900,12/17/2021 8:00:01 PM,"Catalyst watch for next week: Nike and Micron earnings, SPAC votes and Peloton action",Seeking Alpha,https://seekingalpha.com/news/3781417-catalyst-watch-for-next-week-nike-and-micron-earnings-spac-votes-and-peloton-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9215481877326965
901,12/20/2021 12:23:52 PM,Biogen halves price of Alzheimer’s drug in U.S.,Seeking Alpha,https://seekingalpha.com/news/3781562-biogen-halves-price-of-alzheimers-drug-in-us?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.695901095867157
902,12/20/2021 1:00:00 PM,Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/biogen-announces-reduced-price-for-aduhelm-to-improve-access-for-patients-with-early-alzheimer-s-disease-1031086707,positive,0.9344531893730164
903,12/20/2021 1:19:12 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031056019,neutral,0.7998326420783997
904,12/20/2021 1:44:41 PM,Biogen Cuts Price For ADUHELM To Improve Patient Access; To Implement Cost-reduction Measures ,RTTNews,/news/stocks/biogen-cuts-price-for-aduhelm-to-improve-patient-access-to-implement-cost-reduction-measures-1031056089,positive,0.9457595348358154
905,12/22/2021 12:03:39 PM,Biogen/ Eisai trial data on Alzheimer’s drug inconsistent - Japanese health ministry,Seeking Alpha,https://seekingalpha.com/news/3782605-biogen-eisai-trial-data-on-alzheimers-drug-inconsistent-japanese-health-ministry?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9144326448440552
906,12/22/2021 1:30:00 PM,Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review,GlobeNewswire,/news/stocks/japan-s-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-council-seeks-additional-data-aducanumab-remains-under-review-1031084058,neutral,0.9315482974052429
907,12/22/2021 1:51:21 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1031061657,neutral,0.8142688870429993
908,12/22/2021 2:11:58 PM,Biogen: Japan's NDC Seeks Additional Data On Application For Approval Of Aducanumab ,RTTNews,/news/stocks/biogen-japan-s-ndc-seeks-additional-data-on-application-for-approval-of-aducanumab-1031061721,neutral,0.8813257813453674
909,12/22/2021 4:28:57 PM,Expert Ratings For Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1031062160,neutral,0.834668755531311
910,12/22/2021 6:09:49 PM,Biogen price target lowered at Oppenheimer on pricing change for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3782792-biogen-price-target-lowered-at-oppenheimer-on-pricing-change-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.685554563999176
911,12/22/2021 6:50:31 PM,BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today,InvestorPlace,/news/stocks/bad-etf-the-top-sin-stock-holdings-in-the-new-anti-esg-fund-that-debuts-today-1031062665,neutral,0.9194077253341675
912,12/24/2021 12:30:00 AM,INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION,PR Newswire,/news/stocks/investigational-alzheimer-s-disease-therapy-lecanemab-granted-fda-fast-track-designation-1031065150,positive,0.873772919178009
913,12/27/2021 5:12:34 PM,5 Beaten Down Biotech Stocks That Could Bounce Big In 2022,Benzinga,/news/stocks/5-beaten-down-biotech-stocks-that-could-bounce-big-in-2022-1031067132,negative,0.9156028628349304
914,12/29/2021 7:18:22 PM,Biogen surges on potential buyout deal from South Korea's Samsung Group,Seeking Alpha,https://seekingalpha.com/news/3783997-biogen-surges-on-potential-buyout-deal-from-south-koreas-samsung-group?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9144291281700134
915,12/29/2021 9:19:44 PM,Biogen-Samsung deal poses valuation difficulties - Jefferies,Seeking Alpha,https://seekingalpha.com/news/3784019-biogen-samsung-deal-poses-valuation-difficulties-jefferies?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.513816773891449
916,12/30/2021 2:51:08 AM,Samsung says Biogen deal talks report is not true,Seeking Alpha,https://seekingalpha.com/news/3784054-samsung-says-biogen-deal-talks-report-is-not-true?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.82215416431427
917,12/30/2021 7:39:16 AM,Biogen/Samsung Takeover - Deal Or No Deal? ,RTTNews,/news/stocks/biogen-samsung-takeover-deal-or-no-deal-1031070627,neutral,0.8757994771003723
918,12/30/2021 9:58:50 AM,"5 Stocks To Watch For December 30, 2021",Benzinga,/news/stocks/5-stocks-to-watch-for-december-30-2021-1031070771,neutral,0.8999385237693787
919,12/30/2021 12:57:55 PM,20 Stocks Moving in Thursday's Pre-Market Session,Benzinga,/news/stocks/20-stocks-moving-in-thursday-s-pre-market-session-1031071038,neutral,0.7662824988365173
920,12/30/2021 4:03:07 PM,"Angion Biomedica, RedHill Biopharma leads healthcare gainers; Biofrontera, Biogen among major losers",Seeking Alpha,https://seekingalpha.com/news/3784181-angion-biomedica-redhill-biopharma-leads-healthcare-gainers-biofrontera-biogen-among-major-losers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5740028023719788
921,12/30/2021 8:03:03 PM,44 Stocks Moving In Thursday's Mid-Day Session,Benzinga,/news/stocks/44-stocks-moving-in-thursday-s-mid-day-session-1031071786,neutral,0.5729526877403259
922,12/30/2021 8:23:58 PM,"4 Top Stock Trades for Friday: Ethereum, NIO, BIIB, BABA",InvestorPlace,/news/stocks/4-top-stock-trades-for-friday-ethereum-nio-biib-baba-1031071842,neutral,0.9361642003059387
923,12/30/2021 8:48:42 PM,Biogen retraces gains as Street weighs in on deal talks rejected by Samsung,Seeking Alpha,https://seekingalpha.com/news/3784272-biogen-retraces-gains-as-street-weighs-in-on-deal-talks-rejected-by-samsung?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8113289475440979
924,12/31/2021 9:35:01 AM,63 Biggest Movers From Yesterday,Benzinga,/news/stocks/63-biggest-movers-from-yesterday-1031072119,neutral,0.743373692035675
925,1/1/2022 5:00:23 PM,Biogen fizzles despite catalysts after powering Alzheimer’s stocks into 2022,Seeking Alpha,https://seekingalpha.com/news/3784437-biogen-fizzles-despite-catalysts-after-powering-alzheimers-stocks-into-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.49449557065963745
926,1/3/2022 12:59:15 PM,"Biogen price target cut at Canaccord on pricing, labelling and efficacy concerns",Seeking Alpha,https://seekingalpha.com/news/3784511-biogen-price-target-cut-at-canaccord-on-pricing-labelling-and-efficacy-concerns?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5970611572265625
927,1/4/2022 1:01:52 PM,Biogen exercises option with Ionis to develop synthetic nucleotides for spinal muscular atrophy,Seeking Alpha,https://seekingalpha.com/news/3784865-biogen-exercises-option-with-ionis-to-develop-synthetic-nucleotides-for-spinal-muscular-atrophy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7043547034263611
928,1/4/2022 1:30:00 PM,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA,PR Newswire,/news/stocks/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-for-sma-1031075894,positive,0.7143584489822388
929,1/4/2022 1:34:32 PM,Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA,GlobeNewswire,/news/stocks/biogen-exercises-option-with-ionis-to-develop-and-commercialize-investigational-aso-for-sma-1031086153,positive,0.7143584489822388
930,1/4/2022 2:06:59 PM,"Biogen Licenses Global Rights To Develop, Commercialize SPINRAZA From Ionis Pharma ",RTTNews,/news/stocks/biogen-licenses-global-rights-to-develop-commercialize-spinraza-from-ionis-pharma-1031076036,neutral,0.5007259845733643
931,1/4/2022 9:15:57 PM,"Eli Lilly, Bristol Myers in Cowen's list of big pharma with notable catalysts in Q1 2022",Seeking Alpha,https://seekingalpha.com/news/3785213-eli-lilly-bristol-myers-in-cowens-list-of-big-pharma-with-notable-catalysts-in-q1-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5352685451507568
932,1/7/2022 7:00:35 PM,"Catalyst watch for next week: Biogen, Five Below, Tritium and Monster Beverage in the spotlight",Seeking Alpha,https://seekingalpha.com/news/3786173-catalyst-watch-for-next-week-biogen-five-below-tritium-and-monster-beverage-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9277867674827576
933,1/8/2022 5:32:14 PM,"Biogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022",Seeking Alpha,https://seekingalpha.com/news/3786440-biogen-galapagos-and-ultragenyx-among-key-biotech-calls-at-morgan-stanley-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7796732783317566
934,1/8/2022 8:57:16 PM,"Barron's Latest Picks And Pans: Visa, AT&T, Biogen, Robinhood And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-visa-at-t-biogen-robinhood-and-more-1031088840,neutral,0.9415116310119629
935,1/10/2022 3:28:10 PM,Becerra: Medicare premium increase re-evaluation after Biogen Aduhelm price cut,Seeking Alpha,https://seekingalpha.com/news/3786680-becerra-medicare-premium-increase-re-evaluation-after-biogen-aduhelm-price-cut?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6849768757820129
936,1/11/2022 9:34:29 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-cms-severely-limits-coverage-for-biogens-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9214109182357788
937,1/11/2022 9:52:04 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-medicare-severely-limits-coverage-for-biogen-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9214109182357788
938,1/11/2022 10:06:33 PM,"Bed Bath & Beyond, Orphazyme lead postmarket gainers; Gogo, Biogen among losers",Seeking Alpha,https://seekingalpha.com/news/3787303-bed-bath-beyond-orphazyme-lead-postmarket-gainers-gogo-biogen-among-losers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6146512031555176
939,1/11/2022 10:14:59 PM,What 20 Analyst Ratings Have To Say About Biogen,Benzinga,/news/stocks/what-20-analyst-ratings-have-to-say-about-biogen-1031095221,neutral,0.9437344074249268
940,1/12/2022 12:25:56 PM,Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3787408-biogen-extends-losses-as-wall-street-weighs-in-on-medicare-decision-on-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9269968867301941
941,1/12/2022 12:28:16 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-jan-12-1031096507,negative,0.5243474841117859
942,1/12/2022 12:44:17 PM,15 Stocks Moving in Wednesday's Pre-Market Session,Benzinga,/news/stocks/15-stocks-moving-in-wednesday-s-pre-market-session-1031096372,neutral,0.7441522479057312
943,1/12/2022 1:30:17 PM,"Pre-market Movers: IMRN, PIK, NTP, FLUX, MCMJ… ",RTTNews,/news/stocks/pre-market-movers-imrn-pik-ntp-flux-mcmj-1031096504,neutral,0.9524431824684143
944,1/12/2022 1:45:16 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1031096586,neutral,0.8142688870429993
945,1/12/2022 3:02:29 PM,"Immuron, Immix lead healthcare gainers; Philips, Prothena among losers",Seeking Alpha,https://seekingalpha.com/news/3787528-immuron-immix-lead-healthcare-gainers-philips-prothena-among-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7786117196083069
946,1/12/2022 3:44:29 PM,Biogen plans flood of public comments in response to Medicare decision - Endpoints,Seeking Alpha,https://seekingalpha.com/news/3787555-biogen-plans-flood-of-public-comments-in-response-to-medicare-decision-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9283484816551208
947,1/12/2022 4:03:16 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 12, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-12-2022-1031097364,negative,0.5118513703346252
948,1/12/2022 6:00:07 PM,28 Stocks Moving In Wednesday's Mid-Day Session,Benzinga,/news/stocks/28-stocks-moving-in-wednesday-s-mid-day-session-1031097692,negative,0.7145883440971375
949,1/13/2022 11:08:15 AM,50 Biggest Movers From Yesterday,Benzinga,/news/stocks/50-biggest-movers-from-yesterday-1031099460,neutral,0.7799054980278015
950,1/13/2022 1:28:12 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1031099858,neutral,0.7969077229499817
951,1/13/2022 2:52:59 PM,Why Jim Cramer Prefers This Mining Stock Over Vale,Benzinga,/news/stocks/why-jim-cramer-prefers-this-mining-stock-over-vale-1031100220,neutral,0.9281270503997803
952,1/13/2022 4:06:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-13-2022-1031100637,negative,0.5175361633300781
953,1/13/2022 4:27:03 PM,3 Biotech Stocks to Buy That Are Under Severe Pressure,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-that-are-under-severe-pressure-1031100940,negative,0.6681919097900391
954,1/13/2022 7:27:30 PM,Biogen rebounds amid comments on M&A prospects,Seeking Alpha,https://seekingalpha.com/news/3788040-biogen-rebounds-amid-comments-on-ma-prospects?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.908034086227417
955,1/18/2022 12:47:44 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1031108376,neutral,0.8152948021888733
956,1/21/2022 4:12:04 PM,Alzheimer's groups protest CMS decision on Biogen's Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3790363-alzheimers-groups-protest-cms-decision-on-biogen-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9341540336608887
957,1/24/2022 1:39:10 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031122379,neutral,0.7998326420783997
958,1/26/2022 1:46:11 PM,Cortexyme stock plunges 34% after FDA places clinical hold on Alzheimer's drug application,Seeking Alpha,https://seekingalpha.com/news/3791767-cortexyme-stock-plunges-34-after-fda-places-clinical-hold-on-alzheimers-drug-application?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9600628614425659
959,1/27/2022 1:06:51 PM,Biogen/Eisai highlights details for Phase 4 Aduhelm study in Alzheimer's disease,Seeking Alpha,https://seekingalpha.com/news/3792390-biogeneisai-highlights-details-for-phase-4-aduhelm-study-in-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9139934182167053
960,1/27/2022 1:30:00 PM,Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®,GlobeNewswire,/news/stocks/update-on-the-phase-4-envision-confirmatory-study-of-aduhelm-1031135075,neutral,0.9210386276245117
961,1/28/2022 12:50:14 AM,Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion,GlobeNewswire,/news/stocks/biogen-reaches-agreement-with-samsung-biologics-to-sell-equity-stake-in-their-biosimilar-joint-venture-for-up-to-2-3-billion-1031137435,positive,0.8139662742614746
962,1/28/2022 2:24:24 AM,Biogen to sell stake in Samsung Bioepis for more than $2 billion,Seeking Alpha,https://seekingalpha.com/news/3792880-biogen-to-sell-stake-in-samsung-bioepis-for-more-than-2-billion?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.93348228931427
963,1/28/2022 3:43:51 AM,Samsung Biologics To Buy Biogen's Stake In Samsung Bioepis JV For Up To $2.3 Bln ,RTTNews,/news/stocks/samsung-biologics-to-buy-biogen-s-stake-in-samsung-bioepis-jv-for-up-to-2-3-bln-1031137472,neutral,0.868466854095459
964,1/28/2022 1:41:58 PM,Biogen’s plan to sell stake in Samsung Bioepis is “a step in the right direction” - BofA,Seeking Alpha,https://seekingalpha.com/news/3793038-biogens-plan-to-sell-stake-in-samsung-bioepis-is-a-step-in-the-right-direction-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7545375823974609
965,1/28/2022 2:21:16 PM,"The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-liquidates-out-of-biosimilar-jv-provention-bio-plots-diabetes-drug-resubmission-merck-finds-covid-pill-effective-against-omicron-1031139273,positive,0.8550986051559448
966,1/31/2022 1:30:00 PM,Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors,GlobeNewswire,/news/stocks/biogen-announces-nancy-leaming-and-brian-posner-to-retire-from-board-of-directors-1031144097,negative,0.49613189697265625
967,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,neutral,0.9110234975814819
968,1/31/2022 3:02:18 PM,Public comments overwhelmingly support CMS decision on Biogen Aduhelm coverage,Seeking Alpha,https://seekingalpha.com/news/3793530-public-comments-mostly-support-cms-decision-on-biogen-aduhelm-coverage?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6400601863861084
969,1/31/2022 8:21:28 PM,Why did Regeneron Pharmaceuticals stock drop today? Roche gets FDA OK for Eylea rival,Seeking Alpha,https://seekingalpha.com/news/3793704-why-did-regeneron-pharmaceuticals-stock-drop-today-roche-gets-fda-ok-for-eylea-rival?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8744555115699768
970,2/1/2022 1:09:22 PM,Biogen to participate in development of Genentech’s mosunetuzumab,Seeking Alpha,https://seekingalpha.com/news/3793978-biogen-exercises-option-to-participate-in-development-of-genentechs-mosunetuzumab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7140600681304932
971,2/1/2022 1:30:00 PM,Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody,GlobeNewswire,/news/stocks/biogen-exercises-option-to-participate-in-the-development-and-commercialization-of-a-late-stage-bispecific-antibody-1031148738,neutral,0.7469635009765625
972,2/2/2022 3:01:13 PM,Biogen earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/biogen-q4-earnings-preview-stock-1031154141,neutral,0.9190120697021484
973,2/2/2022 3:47:17 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3794923-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.882573127746582
974,2/2/2022 4:37:32 PM,Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes?,Seeking Alpha,https://seekingalpha.com/news/3794972-will-biogen-q4-earnings-bring-positive-surprise-amid-aduhelm-woes?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9053277969360352
975,2/3/2022 12:00:44 PM,"Biogen Non-GAAP EPS of $3.39 beats by $0.02, revenue of $2.74B beats by $120M",Seeking Alpha,https://seekingalpha.com/news/3795390-biogen-non-gaap-eps-of-3_39-beats-0_02-revenue-of-2_74b-beats-120m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5455135703086853
976,2/3/2022 12:56:26 PM,Biogen falls after setting 2022 guidance below consensus,Seeking Alpha,https://seekingalpha.com/news/3795461-biogen-falls-after-setting-2022-guidance-below-consensus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9240421652793884
977,2/3/2022 1:35:30 PM,Biogen Posts Adj. Profit In Q4; Sees FY22 Results Below Market ,RTTNews,/news/stocks/biogen-posts-adj-profit-in-q4-sees-fy22-results-below-market-1031158467,negative,0.8597578406333923
978,2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702,negative,0.928947925567627
979,2/3/2022 6:10:08 PM,Eli Lilly pushes back regulatory submissions for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3795666-eli-lilly-pushes-back-regulatory-submissions-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9197622537612915
980,2/4/2022 1:24:57 PM,Biogen comes under U.S. antitrust probe over new Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3796012-biogen-comes-under-us-antitrust-probe-on-new-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9484918713569641
981,2/4/2022 1:36:13 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1031162385,neutral,0.791632354259491
982,2/4/2022 4:04:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-4-2022-1031162854,negative,0.5035002827644348
983,2/4/2022 4:29:02 PM,Analyst Ratings For Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1031162914,neutral,0.9187624454498291
984,2/4/2022 4:40:08 PM,Biogen downgraded at BMO Capital Markets citing an increasingly challenging outlook,Seeking Alpha,https://seekingalpha.com/news/3796111-biogen-downgraded-at-rbc-citing-an-increasingly-challenging-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.962466299533844
985,2/4/2022 7:31:25 PM,What 24 Analyst Ratings Have To Say About Biogen,Benzinga,/news/stocks/what-24-analyst-ratings-have-to-say-about-biogen-1031163307,neutral,0.9424919486045837
986,2/5/2022 5:00:00 PM,List prices of prescription medicines rise nearly 7% on average in 2022,Seeking Alpha,https://seekingalpha.com/news/3796290-drugmakers-raise-list-prices-by-nearly-7-on-average-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8705558180809021
987,2/7/2022 7:45:49 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1031168330,neutral,0.7998326420783997
988,2/7/2022 9:27:24 PM,Biogen signs licensing deal with Xbrane for potential biosimilar to Cimzia,Seeking Alpha,https://seekingalpha.com/news/3796929-biogen-signs-licensing-deal-with-xbrane-for-potential-biosimilar-to-cimzia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.907293975353241
989,2/7/2022 10:05:00 PM,Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis,GlobeNewswire,/news/stocks/biogen-and-xbrane-announce-commercialization-and-license-agreement-for-proposed-biosimilar-referencing-cimzia-certolizumab-pegol-with-the-potential-to-treat-rheumatoid-arthritis-1031168541,positive,0.9002838134765625
990,2/8/2022 3:11:50 AM,Biogen Reaches Deal With Xbrane For Proposed Biosimilar To Cimzia ,RTTNews,/news/stocks/biogen-reaches-deal-with-xbrane-for-proposed-biosimilar-to-cimzia-1031168956,positive,0.8356348276138306
991,2/8/2022 2:29:54 PM,"The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-amgen-shares-slip-on-earnings-editas-terminates-chief-medical-officer-biogen-licenses-preclinical-rheumatoid-arthritis-biosimilar-1031171617,negative,0.902208685874939
992,2/16/2022 1:46:01 PM,"The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa",Benzinga,/news/stocks/the-daily-biotech-pulse-avenue-tumbles-on-negative-adcom-verdict-moderna-s-expanded-deal-with-rovi-gilead-takes-equity-stake-in-hookipa-1031200248,negative,0.9430138468742371
993,2/16/2022 2:11:27 PM,Sage : Phase 3 Study Of Zuranolone On Major Depressive Disorder Meets Primary & Secondary Endpoints ,RTTNews,/news/stocks/sage-phase-3-study-of-zuranolone-on-major-depressive-disorder-meets-primary-secondary-endpoints-1031200506,neutral,0.6244427561759949
994,2/16/2022 4:35:02 PM,Aurinia Pharma gains after CEO comments on sales outlook,Seeking Alpha,https://seekingalpha.com/news/3800807-auph-stock-gains-after-ceo-comments-on-sales-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8305864334106445
995,2/16/2022 9:21:24 PM,Amylyx announces upcoming AdCom meeting on ALS therapy,Seeking Alpha,https://seekingalpha.com/news/3801036-amlx-stock-unchanged-as-company-announces-upcoming-adcom-meeting?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9140057563781738
996,2/26/2022 9:00:00 PM,How Russia's invasion of Ukraine may impact pharma-biotech R&D,Seeking Alpha,https://seekingalpha.com/news/3806107-how-the-russia-invasion-ukraine-may-impact-pharma-biotech-research-developmment?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8265706896781921
997,3/3/2022 12:53:42 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1031251056,neutral,0.7969077229499817
998,3/3/2022 2:31:01 PM,Biogen raised to Outperform at RBC on potential upside in Alzheimer’s,Seeking Alpha,https://seekingalpha.com/news/3809153-biib-stock-higher-on-upgrade-at-rbc-on-its-potential-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.726061999797821
999,3/3/2022 3:29:34 PM,Senators urge CMS not to restrict coverage of Biogen Alzheimer's drug Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3809184-senators-urge-cms-not-to-restrict-coverage-of-biogen-alzheimers-drug-aduhelm-aducanumab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8730175495147705
1000,3/3/2022 4:03:31 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-3-2022-1031252128,neutral,0.5166980028152466
1001,3/3/2022 6:27:05 PM,Biogen lays off more than 100 in wake of Aduhelm disappointment - Endpoints,Seeking Alpha,https://seekingalpha.com/news/3809255-biogen-lays-off-more-than-100-in-wake-of-aduhelm-aducanumab-disappointment-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.968733012676239
1002,3/3/2022 10:02:46 PM,Expert Ratings For Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1031252913,neutral,0.834668755531311
1003,3/3/2022 10:20:53 PM,Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma,Benzinga,/news/stocks/why-this-analyst-sees-roughly-20-upside-in-this-large-cap-biopharma-1031253028,neutral,0.8598171472549438
1004,3/4/2022 12:30:00 AM,EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL AN...,PR Newswire,/news/stocks/eisai-initiates-submission-of-application-data-under-the-prior-assessment-consultation-system-in-japan-with-the-aim-of-obtaining-early-approval-for-investigational-anti-amyloid-beta-protofibril-an-1031253288,neutral,0.5389968752861023
1005,3/4/2022 2:57:00 AM,"Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022",PR Newswire,/news/stocks/biogen-inc-company-news-berger-montague-investigates-securities-fraud-allegations-against-biogen-inc-nasdaq-biib-lead-plaintiff-deadline-is-april-8-2022-1031253330,neutral,0.8935220837593079
1006,3/4/2022 1:38:12 PM,"The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan",Benzinga,/news/stocks/the-daily-biotech-pulse-ocugen-faces-regulatory-setback-vtv-ceo-quits-biogen-eisai-make-headway-with-second-alzheimer-s-antibody-treatment-in-japan-1031255069,negative,0.8938953280448914
1007,3/5/2022 12:39:00 AM,Charles Schwab Set to Join S&P 100; BellRing Brands to Join S&P MidCap 400; Cerence to Join S&P SmallCap 600,PR Newswire,/news/stocks/charles-schwab-set-to-join-s-p-100-bellring-brands-to-join-s-p-midcap-400-cerence-to-join-s-p-smallcap-600-1031256543,neutral,0.9205849170684814
1008,3/5/2022 3:14:07 AM,Charles Schwab To Replace Biogen In S&P 100 ,RTTNews,/news/stocks/charles-schwab-to-replace-biogen-in-s-p-100-1031256569,neutral,0.927406907081604
1009,3/7/2022 3:50:09 PM,Aurinia Pharmaceuticals gains on report investors pushing for sale,Seeking Alpha,https://seekingalpha.com/news/3810237-aurinia-pharmaceuticals-gains-on-report-investor-pushing-for-sale?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9222245216369629
1010,3/8/2022 1:04:04 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1031262161,neutral,0.8152948021888733
1011,3/8/2022 1:41:50 PM,Biogen downgraded to hold at Stifel on questions on Alzheimer's therapy lecanemab,Seeking Alpha,https://seekingalpha.com/news/3810601-biogen-downgraded-to-hold-at-stifel-questions-alzheimers-therapy-lecanemab?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7993654608726501
1012,3/8/2022 4:04:26 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-8-2022-1031263183,neutral,0.49872344732284546
1013,3/11/2022 10:30:00 PM,Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022),GlobeNewswire,/news/stocks/biogen-to-present-new-research-at-the-international-conference-on-alzheimer-s-and-parkinson-s-diseases-ad-pd-2022-1031274970,neutral,0.8864181041717529
1014,3/14/2022 12:12:01 PM,Early treatment of Biogen's Spinraza leads to improvement in motor function,Seeking Alpha,https://seekingalpha.com/news/3813034-early-treatment-of-biogen-spinraza-leads-to-improvement-in-motor-function?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9418383836746216
1015,3/14/2022 12:30:00 PM,Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference,GlobeNewswire,/news/stocks/biogen-announces-new-updates-across-its-sma-research-program-at-2022-mda-conference-1031277483,neutral,0.7066770792007446
1016,3/15/2022 12:00:00 AM,Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments,GlobeNewswire,/news/stocks/biogen-and-eisai-amend-collaboration-agreements-on-alzheimer-s-disease-treatments-1031279326,neutral,0.45774319767951965
1017,3/15/2022 5:01:09 AM,"Biogen, Eisai Amend Collaboration Agreement On Alzheimer's Disease Treatments ",RTTNews,/news/stocks/biogen-eisai-amend-collaboration-agreement-on-alzheimer-s-disease-treatments-1031279403,positive,0.7952733039855957
1018,3/15/2022 11:10:58 AM,"Biogen to take sole commercial rights for Alzheimer’s drug Aduhelm, Eisai gets royalty",Seeking Alpha,https://seekingalpha.com/news/3813486-biogen-to-take-sole-commercial-rights-for-alzheimers-drug-aduhelm-eisai-gets-royalty?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8539142608642578
1019,3/15/2022 12:19:10 PM,Anavex posts mid-stage biomarker data for lead candidate,Seeking Alpha,https://seekingalpha.com/news/3813543-avxl-stock-rises-on-biomarker-data-for-lead-asset-in-dementia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8721672892570496
1020,3/15/2022 12:46:20 PM,"The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-eisai-amend-aduhelm-agreement-anaptys-acne-drug-flunks-midstage-study-merck-astrazeneca-discontinue-prostate-cancer-trial-1031280887,neutral,0.9103145003318787
1021,3/16/2022 12:10:57 PM,Biogen posts long-term Phase 3 data for Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3814043-biogen-posts-long-term-phase-3-data-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9026975631713867
1022,3/16/2022 12:30:00 PM,Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years,GlobeNewswire,/news/stocks/long-term-phase-3-data-show-aduhelm-continues-to-reduce-underlying-pathologies-of-alzheimer-s-disease-in-patients-treated-for-more-than-two-years-1031284659,positive,0.9502980709075928
1023,3/16/2022 2:07:20 PM,Biogen: ADUHELM Continues To Reduce Underlying Pathologies Of Alzheimer's Beyond Two Years ,RTTNews,/news/stocks/biogen-aduhelm-continues-to-reduce-underlying-pathologies-of-alzheimer-s-beyond-two-years-1031285259,positive,0.9155743718147278
1024,3/16/2022 3:52:16 PM,Biogen ends partnership with Catalyst Biosciences for eye disease candidate,Seeking Alpha,https://seekingalpha.com/news/3814187-biogen-ends-deal-with-catalyst-biosciences-for-eye-disease-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6794542074203491
1025,3/16/2022 4:54:52 PM,Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease,GlobeNewswire,/news/stocks/biogen-announces-peer-reviewed-publication-of-aduhelm-phase-3-emerge-and-engage-data-in-the-journal-of-prevention-of-alzheimer-s-disease-1031286002,neutral,0.8914182782173157
1026,3/16/2022 5:03:20 PM,Biogen continued as a buy at UBS despite Aduhelm agreement change with Eisai,Seeking Alpha,https://seekingalpha.com/news/3814221-biogen-continued-as-a-buy-at-ubs-despite-aduhelm-agreement-change-with-eisai?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6809791922569275
1027,3/18/2022 3:00:20 AM,Viatris Says Defeats Biogen's Attempt To Revive Tecfidera Patent ,RTTNews,/news/stocks/viatris-says-defeats-biogen-s-attempt-to-revive-tecfidera-patent-1031290263,neutral,0.3871126174926758
1028,3/22/2022 12:30:00 AM,"LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING",PR Newswire,/news/stocks/latest-findings-on-lecanemab-clinical-efficacy-aria-rates-biomarkers-relationship-to-clinical-outcomes-and-dosing-regimens-presented-at-ad-pd-2022-annual-meeting-1031296662,neutral,0.9009765386581421
1029,3/22/2022 9:25:32 PM,Why I Sold Kohl’s Corporation Despite Possible Buyout Deal,InvestorPlace,/news/stocks/why-i-sold-kohls-corporation-despite-possible-buyout-deal-1031299764,neutral,0.9167051911354065
1030,3/28/2022 12:04:35 PM,"Biogen, Ionis end ALS clinical program after setback for early-stage trial",Seeking Alpha,https://seekingalpha.com/news/3817921-biogen-ionis-end-als-clinical-program-after-setback-for-early-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6559597849845886
1031,3/28/2022 1:30:00 PM,Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis,GlobeNewswire,/news/stocks/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-amyotrophic-lateral-sclerosis-1031311630,neutral,0.769771158695221
1032,3/28/2022 1:30:00 PM,Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis,PR Newswire,/news/stocks/biogen-and-ionis-announce-topline-phase-1-study-results-of-investigational-drug-in-c9orf72-amyotrophic-lateral-sclerosis-1031311590,neutral,0.769771158695221
1033,3/28/2022 2:17:06 PM,Biogen : Phase 1 Study Of BIIB078 On Amyotrophic Lateral Sclerosis Fails To Meet Secondary Endpoints ,RTTNews,/news/stocks/biogen-phase-1-study-of-biib078-on-amyotrophic-lateral-sclerosis-fails-to-meet-secondary-endpoints-1031311816,negative,0.9233977794647217
1034,3/28/2022 2:17:52 PM,Amylyx in focus as FDA releases briefing docs ahead of AdCom meeting on ALS therapy,Seeking Alpha,https://seekingalpha.com/news/3818017-amlx-stock-in--focus-as-fda-releases-briefing-docs-on-als-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8611409068107605
1035,3/28/2022 5:11:28 PM,"Amylyx has a “very realistic shot”, Evercore says after FDA briefing docs on ALS drug",Seeking Alpha,https://seekingalpha.com/news/3818097-amlx-stock-pares-losses-as-evercore-reacts-to-fda-briefing-docs-on-als-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.76841139793396
1036,3/29/2022 1:20:34 PM,"Biogen ALS candidate failure puts further pressure on commercial portfolio, BofA says",Seeking Alpha,https://seekingalpha.com/news/3818416-biogen-als-candidate-failure-puts-further-pressure-on-commercial-portfolio-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9587132930755615
1037,3/30/2022 12:23:54 PM,Biogen files final protocol with FDA for Alzheimer’s drug Aduhelm confirmatory trial,Seeking Alpha,https://seekingalpha.com/news/3818826-biogen-files-final-protocol-with-fda-for-alzheimers-drug-aduhelm-confirmatory-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5364748239517212
1038,3/30/2022 1:30:00 PM,Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA,GlobeNewswire,/news/stocks/biogen-submits-final-protocol-for-aduhelm-aducanumab-avwa-phase-4-envision-trial-to-fda-1031318484,neutral,0.8444976806640625
1039,3/30/2022 2:31:30 PM,Biogen Submits Final Protocol For Envision Trial Of Aduhelm On Alzheimer's Disease ,RTTNews,/news/stocks/biogen-submits-final-protocol-for-envision-trial-of-aduhelm-on-alzheimer-s-disease-1031318839,neutral,0.859096109867096
1040,4/4/2022 7:28:08 PM,Wave Life gains most in more than a year after early-stage data for ALS drug,Seeking Alpha,https://seekingalpha.com/news/3820515-wve-stock-gains-after-early-stage-data-for-als-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9314283728599548
1041,4/4/2022 10:06:00 PM,New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression,GlobeNewswire,/news/stocks/new-data-at-aan-2022-highlight-real-world-evidence-from-biogen-s-ms-portfolio-and-emerging-research-on-disease-progression-1031331269,neutral,0.7618253231048584
1042,4/7/2022 9:01:11 PM,Biogen lower as Medicare officially limits coverage for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3821868-biogen-falls-as-medicare-officially-limits-coverage-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9627601504325867
1043,4/7/2022 9:35:44 PM,Vir Biotechnology appoints Johanna Friedl-Naderer to COO,Seeking Alpha,https://seekingalpha.com/news/3821882-vir-biotechnology-appoints-johanna-friedl-naderer-to-coo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9390600323677063
1044,4/8/2022 10:57:31 AM,Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks,InvestorPlace,/news/stocks/layoffs-at-blue-stock-highlight-the-current-struggles-of-biotech-picks-1031342692,negative,0.9662711024284363
1045,4/8/2022 12:37:59 PM,Biogen slips as analysts react to final Medicare decision on Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3822004-biib-stock-slips-as-analysts-react-to--medicare-decision-on-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9450897574424744
1046,4/8/2022 2:01:42 PM,Why Is Biogen (BIIB) Stock in the Spotlight Today?,InvestorPlace,/news/stocks/why-is-biogen-biib-stock-in-the-spotlight-today-1031343182,neutral,0.8517703413963318
1047,4/8/2022 2:26:34 PM,Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?,InvestorPlace,/news/stocks/why-is-trevi-therapeutics-trvi-stock-on-the-move-today-1031343248,neutral,0.8141211271286011
1048,4/8/2022 9:02:24 PM,Recession Fears are Creating a Golden Opportunity for Biotech Stocks,InvestorPlace,/news/stocks/recession-fears-are-creating-a-golden-opportunity-for-biotech-stocks-1031343935,positive,0.8096832036972046
1049,4/9/2022 9:00:59 PM,How might the CMS decision on Biogen's Aduhelm impact other Alzheimer's candidates?,Seeking Alpha,https://seekingalpha.com/news/3822173-how-might-the-cms-decision-on-biogen-aduhelm-impact-other-alzheimers-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8164657950401306
1050,4/13/2022 11:36:10 AM,Biogen’s Aduhelm Crashes the Biotech Sector,InvestorPlace,/news/stocks/biib-stock-biogen-aduhelm-crashes-the-biotech-sector-1031353098,neutral,0.6810706853866577
1051,4/18/2022 12:27:49 PM,Biogen raised to Overweight at Wells Fargo on valuation,Seeking Alpha,https://seekingalpha.com/news/3823810-biib-stock-in-focus-after-wells-fargo-upgrade?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5778164863586426
1052,4/18/2022 4:04:01 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-18-2022-1031361238,neutral,0.4997484087944031
1053,4/18/2022 5:19:44 PM,Why This Analyst Believes Biogen Is 'Too Good to Ignore',Benzinga,/news/stocks/why-this-analyst-believes-biogen-is-too-good-to-ignore-1031361347,neutral,0.6422525644302368
1054,4/21/2022 12:10:33 PM,7 Potential Biotech Stocks Buyout Targets in 2022,InvestorPlace,/news/stocks/7-potential-biotech-stocks-targets-in-2022-1031371733,neutral,0.8115261793136597
1055,4/21/2022 8:15:12 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1031373036,neutral,0.9187624454498291
1056,4/22/2022 1:30:24 PM,Biogen pulls EU marketing application for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3825777-biib-stock-lower-as-company-pulls-eu-application-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7558948397636414
1057,4/29/2022 6:03:20 PM,Biogen CEO Vounatsos 2021 compensation down slightly amid Aduhelm woes,Seeking Alpha,https://seekingalpha.com/news/3829594-biogen-ceo-vounatsos-2021-compensation-down-slightly-amid-aduhelm-woes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9709739685058594
1058,5/2/2022 2:26:02 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3830038-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8660826683044434
1059,5/2/2022 2:26:53 PM,"The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-1-7-phathom-fda-decision-pfizer-vertex-pharma-lead-earnings-news-ophthalmology-conference-presentations-and-more-1031408449,neutral,0.9381586909294128
1060,5/2/2022 3:01:13 PM,Biogen is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/biogen-stock-price-q1-earnings-preview-1031408562,neutral,0.9340620636940002
1061,5/2/2022 3:23:49 PM,"Biogen, Scribe to develop additional gene therapy disease target",Seeking Alpha,https://seekingalpha.com/news/3830131-biogen-scribe-to-develop-additional-gene-therapy-disease-target?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7788153886795044
1062,5/2/2022 5:27:58 PM,"Aduhelm woes, performance of multiple sclerosis drugs in focus for Biogen's Q1 earnings",Seeking Alpha,https://seekingalpha.com/news/3830308-aduhelm-woes-performance-of-multiple-sclerosis-drugs-in-focus-for-biogens-q1-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.863426923751831
1063,5/2/2022 6:58:06 PM,"Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder",Benzinga,/news/stocks/sage-therapeutics-biogen-start-rolling-submission-for-zuranolone-in-major-depressive-disorder-1031409925,neutral,0.7016127109527588
1064,5/3/2022 11:04:10 AM,"Biogen Non-GAAP EPS of $3.62 misses by $0.74, revenue of $2.53B beats by $30M",Seeking Alpha,https://seekingalpha.com/news/3830819-biogen-non-gaap-eps-of-3_62-misses-0_74-revenue-of-2_53b-beats-30m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5388479232788086
1065,5/3/2022 11:32:20 AM,Biogen begins executive search to replace CEO,Seeking Alpha,https://seekingalpha.com/news/3830856-biib-stock-in-focus-as-company-begins-executive-search-to-replace-ceo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8417210578918457
1066,5/3/2022 12:48:44 PM,Biogen earnings falls short of consensus amid Aduhelm write-offs,Seeking Alpha,https://seekingalpha.com/news/3830942-biogen-earnings-falls-short-of-consensus-amid-aduhelm-write-offs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9712873697280884
1067,5/3/2022 1:44:20 PM,Biogen Reaffirms FY22 Outlook; Q1 Adj. EPS Misses Estimates ,RTTNews,/news/stocks/biogen-reaffirms-fy22-outlook-q1-adj-eps-misses-estimates-1031413205,neutral,0.8102930188179016
1068,5/3/2022 3:01:06 PM,"The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-s-adcomm-for-acadia-s-pimavanserin-review-issues-for-spero-s-tebipenem-application-cortexyme-layoffs-1031414090,negative,0.5909814238548279
1069,5/3/2022 5:11:30 PM,BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down,InvestorPlace,/news/stocks/biib-stock-treks-higher-amid-news-that-biogen-ceo-michel-vounatsos-is-stepping-down-1031415067,negative,0.8595535159111023
1070,5/4/2022 1:44:39 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1031419302,neutral,0.8142688870429993
1071,5/5/2022 1:30:00 PM,Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis,GlobeNewswire,/news/stocks/biogen-and-medrhythms-to-develop-and-commercialize-a-prescription-digital-therapeutic-targeting-the-treatment-of-gait-deficits-in-multiple-sclerosis-1031425261,neutral,0.5792285799980164
1072,5/10/2022 1:31:00 AM,EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY,PR Newswire,/news/stocks/eisai-completes-rolling-submission-to-the-u-s-fda-for-biologics-license-application-of-lecanemab-for-early-alzheimer-s-disease-under-the-accelerated-approval-pathway-1031438854,positive,0.5368033647537231
1073,5/10/2022 3:23:19 PM,"The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-acquires-migraine-drugmaker-for-11b-biogen-files-for-second-alzheimer-s-drug-approval-longeveron-ceo-leaves-1031442487,neutral,0.898991048336029
1074,5/23/2022 2:36:13 PM,Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?,InvestorPlace,/news/stocks/why-is-catalyst-biosciences-cbio-stock-soaring-170-today-1031482370,neutral,0.7731574177742004
1075,5/26/2022 5:41:17 PM,Ionis Pharmaceuticals' Angelman Syndrome therapy granted orphan drug status,Seeking Alpha,https://seekingalpha.com/news/3843216-ionis-pharmaceuticals-angelman-syndrome-therapy-granted-orphan-drug-status?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4968886375427246
1076,5/31/2022 1:03:00 PM,"Denali Therapeutics, Biogen begin phase 2 study of BIIB122 to treat Parkinson’s disease",Seeking Alpha,https://seekingalpha.com/news/3843921-denali-therapeutics-biogen-begin-phase-2-study-of-biib122-to-treat-parkinsons-disease?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5368688106536865
1077,5/31/2022 5:36:57 PM,Cassava Sciences rallies most since November,Seeking Alpha,https://seekingalpha.com/news/3844084-sava-stock-rallies-most-since-november?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7338777780532837
1078,6/1/2022 11:23:26 AM,"Biogen/Sage's zuranolone helps reduce postpartum depression symptoms, meets main goal of trial",Seeking Alpha,https://seekingalpha.com/news/3844292-biogensages-zuranolone-helps-reduce-postpartum-depression-symptoms-meets-main-goal-of-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.689017653465271
1079,6/2/2022 2:15:53 PM,Biogen & Samsung Bioepis launch in U.S. their biosimilar to Roche's eye drug Lucentis,Seeking Alpha,https://seekingalpha.com/news/3845032-biogen-samsung-bioepis-launch-in-us-their-biosimilar-to-roches-eye-drug-lucentis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6654489636421204
1080,6/3/2022 10:26:34 AM,Biogen/Ionis tofersen slows decline in certain functions in ALS patients in new data,Seeking Alpha,https://seekingalpha.com/news/3845403-biogenionis-tofersen-slows-decline-in-certain-functions-in-als-patients-in-new-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.43354955315589905
1081,6/3/2022 11:20:00 AM,New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS,GlobeNewswire,/news/stocks/new-12-month-tofersen-data-presented-at-encals-meeting-show-clinically-meaningful-benefit-in-people-with-sod1-als-1031507897,positive,0.9536372423171997
1082,6/3/2022 11:40:48 AM,Ionis: Tofersen Slows Disease Progression In Phase 3 VALOR Study ,RTTNews,/news/stocks/ionis-tofersen-slows-disease-progression-in-phase-3-valor-study-1031507911,neutral,0.7684729695320129
1083,6/3/2022 1:11:32 PM,"Biogen, Bio-Thera present positive phase 3 data for their Actemra biosimilar candidate",Seeking Alpha,https://seekingalpha.com/news/3845484-biogen-bio-thera-present-positive-phase-3-data-for-their-actemra-biosimilar-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9333587288856506
1084,6/3/2022 2:00:00 PM,Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022),GlobeNewswire,/news/stocks/biogen-and-bio-thera-solutions-present-positive-phase-3-data-for-tocilizumab-biosimilar-candidate-at-the-annual-european-congress-of-rheumatology-eular-2022-1031508269,positive,0.9102379083633423
1085,6/3/2022 2:40:22 PM,"Biogen, Bio-Thera Presents Positive Phase 3 Data For Tocilizumab Biosimilar In Rheumatoid Arthritis ",RTTNews,/news/stocks/biogen-bio-thera-presents-positive-phase-3-data-for-tocilizumab-biosimilar-in-rheumatoid-arthritis-1031508369,positive,0.9526452422142029
1086,6/6/2022 12:00:13 PM,Biogen inks licensing deal for Parkinson’s disease candidate,Seeking Alpha,https://seekingalpha.com/news/3845856-biogen-inks-licensing-deal-for-parkinsons-disease-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5753825902938843
1087,6/6/2022 1:30:00 PM,"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease",GlobeNewswire,/news/stocks/biogen-and-alectos-therapeutics-announce-license-and-collaboration-agreement-for-al01811-a-novel-gba2-inhibitor-for-the-potential-treatment-of-parkinson-s-disease-1031510624,positive,0.9325862526893616
1088,6/6/2022 1:37:10 PM,Amgen's biosimilar to Roche/Biogen's Rituxan gets FDA approval for rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3845930-amgens-biosimilar-to-rochebiogens-rituxan-gets-fda-approval-for-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.920046329498291
1089,6/6/2022 2:27:39 PM,Quant Ratings Updated on 66 Stocks,InvestorPlace,/news/stocks/quant-ratings-updated-on-66-stocks-1031514810,neutral,0.9267264008522034
1090,6/8/2022 4:09:03 PM,Biogen pulls out of Jefferies Healthcare Conference citing COVID concerns,Seeking Alpha,https://seekingalpha.com/news/3846786-biib-stock-on-watch-as-company-pulls-out-of-jefferies-healthcare-conference?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9456261396408081
1091,6/9/2022 1:58:13 PM,7 No-Brainer Biotech Stocks to Add to Your Buy List,InvestorPlace,/news/stocks/7-no-brainer-biotech-stocks-to-add-to-your-buy-list-1031519703,neutral,0.913317084312439
1092,6/13/2022 1:34:32 PM,"Biogen, Sage to submit a single marketing application for depression candidate",Seeking Alpha,https://seekingalpha.com/news/3848013-biogen-sage-to-submit-single-nda-for-depression-candidate?utm_source=businessinsider&utm_medium=referral,neutral,0.9049574732780457
1093,6/14/2022 1:30:00 PM,The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities,GlobeNewswire,/news/stocks/the-biogen-foundation-and-community-lab-celebrates-20-years-of-serving-our-communities-1031527376,neutral,0.5005673766136169
1094,6/15/2022 1:30:00 PM,New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen),GlobeNewswire,/news/stocks/new-data-presented-at-cure-sma-reveal-residual-unmet-needs-in-young-sma-patients-treated-with-gene-therapy-and-suggest-further-potential-of-using-spinraza-nusinersen-1031530261,positive,0.8100760579109192
1095,6/15/2022 8:22:41 PM,Biogen terminates 2018 asset purchase agreement with Karyopharm Therapeutics,Seeking Alpha,https://seekingalpha.com/news/3849014-biogen-terminates-2018-asset-purchase-agreement-with-karyopharm-therapeutics?utm_source=businessinsider&utm_medium=referral,neutral,0.6217882633209229
1096,6/15/2022 10:52:55 PM,Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement,Benzinga,/news/stocks/karyopharm-therapeutics-shares-slide-after-biogen-terminates-2018-asset-purchase-agreement-1031531870,negative,0.9614120125770569
1097,6/16/2022 3:44:12 PM,Alzheimer’s drug developers are on decline after Roche setback,Seeking Alpha,https://seekingalpha.com/news/3849317-aciu-stock-leads-selloff-in-alzheimers-space-after-trial-setback?utm_source=businessinsider&utm_medium=referral,negative,0.9635190367698669
1098,6/16/2022 4:09:44 PM,"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-s-alzheimer-s-drug-fails-advisors-back-pfizer-moderna-shots-for-youngest-kids-valneva-settles-covid-19-pact-with-uk-1031533533,neutral,0.8402719497680664
1099,6/23/2022 3:04:29 PM,Denali Therapeutics initiated at buy at Berenberg on getting drugs directly into brain,Seeking Alpha,https://seekingalpha.com/news/3851274-denali-therapeutics-initiated-at-buy-at-berenberg-on-getting-drugs-directly-into-brain?utm_source=businessinsider&utm_medium=referral,neutral,0.8123225569725037
1100,6/24/2022 10:42:36 AM,Biogen pulls plug on Aduhelm real-world study on coverage woes,Seeking Alpha,https://seekingalpha.com/news/3851450-biogen-pulls-plug-on-aduhelm-real-world-study-on-coverage-woes-fierce-pharma?utm_source=businessinsider&utm_medium=referral,negative,0.8618502020835876
1101,6/27/2022 10:15:06 AM,7 Biotech Stocks With Key Catalysts Coming in July,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-coming-in-july-1031551243,positive,0.5154509544372559
1102,6/30/2022 6:08:41 PM,EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform,Benzinga,/news/stocks/exclusive-has-biotech-bottomed-nyse-executive-floor-director-says-biogen-and-these-3-stocks-look-poised-to-outperform-1031561237,positive,0.8093796372413635
1103,6/30/2022 7:50:03 PM,Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate,Seeking Alpha,https://seekingalpha.com/news/3853402-acumen-pharmaceuticals-initiated-at-buy-at-hc-wainwright-on-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral,neutral,0.917350172996521
1104,7/5/2022 6:16:38 PM,3 Biotech Stocks to Sell Now,InvestorPlace,/news/stocks/biotech-stocks-to-sell-1031568378,neutral,0.9156689643859863
1105,7/6/2022 1:30:00 AM,THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY,PR Newswire,/news/stocks/the-u-s-fda-accepts-and-grants-priority-review-for-eisai-s-biologics-license-application-of-lecanemab-for-early-alzheimer-s-disease-under-the-accelerated-approval-pathway-1031568696,positive,0.7719578146934509
1106,7/6/2022 9:34:11 AM,"Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review",Seeking Alpha,https://seekingalpha.com/news/3854481-biogen-eisais-alzheimers-therapy-lecanemab-gets-fda-priority-review?utm_source=businessinsider&utm_medium=referral,neutral,0.5544553399085999
1107,7/8/2022 7:53:05 PM,7 Moonshot Investments Upending a $10 Trillion Industry,InvestorPlace,/news/stocks/7-moonshot-investments-upending-a-10-trillion-industry-1031576272,positive,0.575698971748352
1108,7/8/2022 8:12:42 PM,The 3 Leaders of the Gene Editing Revolution,InvestorPlace,/news/stocks/the-3-leaders-of-the-gene-editing-revolution-1031576321,neutral,0.9342885613441467
1109,7/15/2022 2:31:31 PM,"Aurinia Pharma tumbles after takeover speculation cools on new exec hires, exec departure",Seeking Alpha,https://seekingalpha.com/news/3857223-aurinia-pharma-tumbles-after-takeover-speculation-cools-on-new-exec-hires-exec-departure?utm_source=businessinsider&utm_medium=referral,negative,0.8935180306434631
1110,7/15/2022 4:27:23 PM,"Earnings week ahead: Tesla, Twitter, Netflix, Snap, and more",Seeking Alpha,https://seekingalpha.com/news/3857250-earnings-week-ahead-tesla-twitter-netflix-snap-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9304302334785461
1111,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral,positive,0.9346282482147217
1112,7/18/2022 11:06:54 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1031595125,neutral,0.9187624454498291
1113,7/19/2022 2:35:26 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3858105-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.855887770652771
1114,7/19/2022 3:01:13 PM,Here's what Wall Street expects from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-q2-earnings-preview-stock-1031597241,neutral,0.9258308410644531
1115,7/19/2022 5:04:48 PM,Biogen set to report Q2 result amid declining multiple sclerosis drug sales,Seeking Alpha,https://seekingalpha.com/news/3858182-biogen-set-to-report-q2-result-amid-declining-multiple-sclerosis-drug-sales?utm_source=businessinsider&utm_medium=referral,negative,0.6426190137863159
1116,7/20/2022 11:01:44 AM,"Biogen Non-GAAP EPS of $5.25 beats by $1.16, revenue of $2.59B beats by $110M, raises FY22 guidance",Seeking Alpha,https://seekingalpha.com/news/3858411-biogen-non-gaap-eps-of-525-beats-by-116-revenue-of-259b-beats-by-110m-raises-fy22-guidance?utm_source=businessinsider&utm_medium=referral,positive,0.8898476362228394
1117,7/20/2022 11:27:31 AM,Biogen raises guidance citing stronger than expected revenue and cost savings,Seeking Alpha,https://seekingalpha.com/news/3858426-revenue?utm_source=businessinsider&utm_medium=referral,positive,0.9408403635025024
1118,7/20/2022 1:38:35 PM,Biogen Boosts FY22 Outlook As Q2 Results Top Estimates ,RTTNews,/news/stocks/biogen-boosts-fy22-outlook-as-q2-results-top-estimates-1031600624,positive,0.9334572553634644
1119,7/20/2022 4:16:37 PM,"The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study",Benzinga,/news/stocks/the-daily-biotech-pulse-cdc-adcomm-backs-novavax-covid-19-vaccine-european-approval-for-ptc-therapeutics-gene-therapy-merck-s-keytruda-flunks-in-head-neck-cancer-study-1031601508,positive,0.7314309477806091
1120,7/20/2022 5:15:29 PM,Biogen agrees to pay $900M to settle whistleblower lawsuit,Seeking Alpha,https://seekingalpha.com/news/3858655-biib-stock-drops-on-900m-payment-to-settle-whistleblower-lawsuit?utm_source=businessinsider&utm_medium=referral,positive,0.48691508173942566
1121,7/20/2022 5:20:58 PM,Biogen (BIIB) Stock Dips Following Q2 Earnings Report,InvestorPlace,/news/stocks/biogen-biib-stock-dips-following-q2-earnings-report-1031602032,negative,0.9664575457572937
1122,7/21/2022 8:33:24 AM,"ABT Raises Earnings Forecast, BIIB Provides Rosy Revenue Outlook, ELV Q2 Revenue Up 15.6% ",RTTNews,/news/stocks/abt-raises-earnings-forecast-biib-provides-rosy-revenue-outlook-elv-q2-revenue-up-15-6-1031603549,positive,0.9477339386940002
1123,7/21/2022 10:40:37 AM,Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-baker-hughes-shares-dropped-8-here-are-64-biggest-movers-from-yesterday-1031603798,negative,0.8563471436500549
1124,7/21/2022 1:20:05 PM,"Tesla to $1,175? Here Are 5 Other Price Target Changes for Thursday",Benzinga,/news/stocks/tesla-to-1-175-here-are-5-other-price-target-changes-for-thursday-1031604257,neutral,0.8808194398880005
1125,7/21/2022 9:05:24 PM,Scientist casts doubt on amyloid theory for Alzheimer's; sees issues with Cassava images,Seeking Alpha,https://seekingalpha.com/news/3859403-scientist-casts-doubt-on-amyloid-theory-for-alzheimers-sees-issues-with-cassava-images?utm_source=businessinsider&utm_medium=referral,negative,0.6803069710731506
1126,7/21/2022 9:44:28 PM,"With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat",Benzinga,/news/stocks/with-all-eyes-on-lecanemab-read-out-in-alzheimer-s-uncertainty-overshadows-biogen-s-q2-beat-1031605813,neutral,0.506310224533081
1127,7/25/2022 9:31:21 AM,Novartis-Polpharma's biosimilar of Biogen's MS drug Tysabri gets FDA review,Seeking Alpha,https://seekingalpha.com/news/3859879-novartis-polpharmas-biosimilar-of-biogens-ms-drug-tysabri-gets-fda-review?utm_source=businessinsider&utm_medium=referral,positive,0.6394329071044922
1128,7/26/2022 1:14:02 PM,Biogen/Ionis ALS therapy tofersen gets FDA priority review,Seeking Alpha,https://seekingalpha.com/news/3860495-biogenionis-als-therapy-tofersen-gets-fda-priority-review?utm_source=businessinsider&utm_medium=referral,positive,0.7062106728553772
1129,7/26/2022 1:30:02 PM,"FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS",GlobeNewswire,/news/stocks/fda-accepts-biogen-s-new-drug-application-and-grants-priority-review-of-tofersen-for-a-rare-genetic-form-of-als-1031614917,neutral,0.7291331887245178
1130,7/26/2022 2:23:05 PM,"Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate",Benzinga,/news/stocks/daily-biotech-pulse-eu-approval-for-abbvie-s-ulcerative-colitis-treatment-angion-biomedica-evaluates-alternatives-clinical-hold-for-immuron-s-bacterial-infection-candidate-1031615201,positive,0.6602172255516052
1131,7/26/2022 3:50:03 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinias-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral,negative,0.8486039042472839
1132,7/26/2022 4:08:38 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinia-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral,negative,0.8486039042472839
1133,7/27/2022 12:24:04 AM,Recap Of Tuesday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031617287,neutral,0.9340888261795044
1134,7/28/2022 1:30:00 PM,The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus,GlobeNewswire,/news/stocks/the-new-england-journal-of-medicine-publishes-positive-phase-2-data-on-litifilimab-biib059-in-cutaneous-lupus-erythematosus-1031625313,positive,0.9095458984375
1135,8/4/2022 1:32:00 AM,EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFE...,PR Newswire,/news/stocks/eisai-presents-new-findings-on-lecanemab-s-investigational-subcutaneous-formulation-and-modeling-simulation-of-apoe4-genotype-on-aria-e-incidence-at-the-alzheimer-s-association-international-confe-1031647844,neutral,0.8952435255050659
1136,8/12/2022 6:30:25 PM,7 F-Rated Stocks to Avoid Now,InvestorPlace,/news/stocks/7-f-rated-stocks-to-avoid-now-1031680604,neutral,0.665632963180542
1137,8/15/2022 11:45:46 AM,BrainStorm to seek FDA approval for ALS therapy despite Phase 3 setback,Seeking Alpha,https://seekingalpha.com/news/3872785-bcli-stock-higher-as-company-plans-fda-approval-for-als-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9456670880317688
1138,8/26/2022 2:14:55 PM,Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock,InvestorPlace,/news/stocks/insider-richard-barry-is-betting-big-on-cassava-sava-stock-1031708518,neutral,0.9136545658111572
1139,8/30/2022 12:10:21 PM,Canadian drug agency declines to recommend reimbursement for Biogen SMA drug Spinraza,Seeking Alpha,https://seekingalpha.com/news/3877788-canadian-drug-agency-declines-to-recommend-reimbursement-for-biogen-sma-drug-spinraza?utm_source=businessinsider&utm_medium=referral,negative,0.48799416422843933
1140,9/1/2022 12:53:57 PM,BofA names top 10 stock options overwriting candidates,Seeking Alpha,https://seekingalpha.com/news/3879333-bofa-names-top-10-stock-options-overwriting-candidates?utm_source=businessinsider&utm_medium=referral,neutral,0.9246936440467834
1141,9/5/2022 6:00:11 AM,"Which Biotech Stock Is Best: BIIB, BNTX, or ILMN?",TipRanks,/news/stocks/which-biotech-stock-is-best-biib-bntx-or-ilmn-1031723744,neutral,0.9398435354232788
1142,9/7/2022 11:45:26 PM,The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus,GlobeNewswire,/news/stocks/the-new-england-journal-of-medicine-publishes-second-manuscript-reporting-positive-phase-2-results-for-biogen-s-litifilimab-biib059-in-lupus-1031730620,positive,0.7835679650306702
1143,9/12/2022 12:49:24 PM,3 Undervalued S&P 500 Stocks to Buy Before Wall Street Catches On,InvestorPlace,/news/stocks/7-undervalued-sp-500-stocks-to-buy-before-wall-street-catches-on-1031620245,positive,0.7329070568084717
1144,9/12/2022 8:49:32 PM,Biotech Stocks Stand to Benefit as Biden Announces Support for Industry,InvestorPlace,/news/stocks/biotech-stocks-stand-to-benefit-as-biden-announces-support-for-industry-1031738367,positive,0.9459112882614136
1145,9/12/2022 9:09:21 PM,Expert Ratings for Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1031738180,neutral,0.834668755531311
1146,9/13/2022 3:30:00 PM,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm,PR Newswire,/news/stocks/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm-1031740197,negative,0.7863238453865051
1147,9/13/2022 6:51:27 PM,Hurry! It’s Time to Take Your Profits From These 7 Stocks,InvestorPlace,/news/stocks/hurry-its-time-to-take-your-profits-from-these-7-stocks-1031741080,neutral,0.8191995024681091
1148,9/17/2022 4:00:04 PM,Only 75% of accelerated non-cancer drug approvals led to full approvals - study,Seeking Alpha,https://seekingalpha.com/news/3883565-only-three-quarters-of-fda-accelerated-non-cancer-drugs-won-full-approvals?utm_source=businessinsider&utm_medium=referral,neutral,0.7804610729217529
1149,9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358,neutral,0.6688132882118225
1150,9/21/2022 11:15:12 PM,"The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS",GlobeNewswire,/news/stocks/the-new-england-journal-of-medicine-publishes-pivotal-tofersen-data-that-show-benefits-in-rare-genetic-form-of-als-1031757838,neutral,0.8826962113380432
1151,9/22/2022 1:35:19 PM,Eli Lilly raised to Buy at UBS; named top large cap pick,Seeking Alpha,https://seekingalpha.com/news/3885286-lly-stock-raised-to-buy-at-ubs-named-top-large-cap-pick?utm_source=businessinsider&utm_medium=referral,positive,0.5208810567855835
1152,9/22/2022 4:12:36 PM,"Novavax Price Target Cut By Around 80%, Plus This Analyst Predicts $129 For NIKE",Benzinga,/news/stocks/novavax-price-target-cut-by-around-80-plus-this-analyst-predicts-129-for-nike-1031759673,positive,0.5004124641418457
1153,9/23/2022 8:25:13 AM,Mizuho Securities Reaffirms Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-hold-rating-on-biogen-biib-1031761258,neutral,0.6382446885108948
1154,9/23/2022 4:44:30 PM,"Biogen sells 271K square foot Cambridge, Mass. property for $592M",Seeking Alpha,https://seekingalpha.com/news/3885701-biogen-sells-271k-square-foot-cambridge-mass-property-for-592m?utm_source=businessinsider&utm_medium=referral,neutral,0.9488263726234436
1155,9/26/2022 9:50:23 PM,U.S. Department of Justice says Biogen agrees to $900M drug kickback settlement,Seeking Alpha,https://seekingalpha.com/news/3886174-us-department-of-justice-says-biogen-agrees-to-900m-drug-kickback-settlement?utm_source=businessinsider&utm_medium=referral,positive,0.6711550354957581
1156,9/27/2022 3:45:33 AM,Biogen Agrees To Pay $900 Mln Over Kickback Allegations ,RTTNews,/news/stocks/biogen-agrees-to-pay-900-mln-over-kickback-allegations-1031765686,neutral,0.5618696808815002
1157,9/27/2022 6:33:34 AM,Biogen Coughs Up $900M to Settle Litigation,TipRanks,/news/stocks/biogen-coughs-up-900m-to-settle-litigation-1031766058,neutral,0.4471821188926697
1158,9/28/2022 12:09:00 AM,"Biogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trial",Seeking Alpha,https://seekingalpha.com/news/3886585-biogen-eisai-alzheimers-candidate-lecanemab-meets-primary-endpoint-in-late-stage-trial?utm_source=businessinsider&utm_medium=referral,positive,0.913377046585083
1159,9/28/2022 1:30:00 AM,"LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WI...",PR Newswire,/news/stocks/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary-endpoint-showing-highly-statistically-significant-reduction-of-clinical-decline-in-large-global-clinical-study-of-1-795-participants-wi-1031768464,positive,0.9334579706192017
1160,9/28/2022 2:45:05 AM,Positive Report for Biogen (BIIB) from Mizuho Securities,TipRanks,/news/stocks/positive-report-for-biogen-biib-from-mizuho-securities-1031768512,positive,0.8841939568519592
1161,9/28/2022 3:57:17 AM,Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial ,RTTNews,/news/stocks/biogen-and-eisai-s-lecanemab-slows-progression-of-alzheimer-s-disease-in-phase-3-trial-1031768497,neutral,0.7794701457023621
1162,9/28/2022 6:35:54 AM,Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock,Benzinga,/news/stocks/alzheimer-s-progression-slowed-down-by-biogen-s-new-drug-in-late-stage-study-analyst-sees-25-upside-for-stock-1031768776,positive,0.8013479113578796
1163,9/28/2022 9:45:07 AM,Biogen (BIIB) Gets a Buy from Needham,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-needham-1031769369,neutral,0.5348629355430603
1164,9/28/2022 10:43:14 AM,"Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial",Seeking Alpha,https://seekingalpha.com/news/3886651-biogen-eisai-spark-rally-in-alzheimers-stocks-on-late-stage-lecanemab-data?utm_source=businessinsider&utm_medium=referral,positive,0.8227691054344177
1165,9/28/2022 11:27:57 AM,"US Stock Futures Down Ahead Of Fed Speakers, Economic Data",Benzinga,/news/stocks/us-stock-futures-down-ahead-of-fed-speakers-economic-data-1031769238,negative,0.9030975699424744
1166,9/28/2022 11:39:13 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-sept-28-1031769744,negative,0.5243474841117859
1167,9/28/2022 12:09:47 PM,2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data,Benzinga,/news/stocks/2-sympathy-plays-to-watch-for-in-the-wake-of-biogen-s-positive-alzheimer-s-drug-data-1031769371,positive,0.5770570039749146
1168,9/28/2022 12:13:38 PM,"Biogen, Eli Lilly And Some Other Big Stocks Moving Higher In Today's Pre-Market Session",Benzinga,/news/stocks/biogen-eli-lilly-and-some-other-big-stocks-moving-higher-in-today-s-pre-market-session-1031769388,positive,0.9157373905181885
1169,9/28/2022 12:50:41 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), HCA Healthcare (HCA)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-hca-healthcare-hca-1031770069,positive,0.7374993562698364
1170,9/28/2022 12:53:05 PM,"Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… ",RTTNews,/news/stocks/pre-market-movers-silo-prta-biib-nxpl-abos-1031769509,neutral,0.9539187550544739
1171,9/28/2022 1:17:23 PM,Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket,Benzinga,/news/stocks/why-mindmed-is-trading-lower-by-around-35-here-are-31-stocks-moving-premarket-1031769653,negative,0.7719112634658813
1172,9/28/2022 2:02:06 PM,"Prothena, bioAffinity top healthcare gainers; Mind Medicine, Gamida lead losers' pack",Seeking Alpha,https://seekingalpha.com/news/3886758-prothena-bioaffinity-top-healthcare-gainers-mind-medicine-gamida-lead-losers-pack?utm_source=businessinsider&utm_medium=referral,positive,0.660448431968689
1173,9/28/2022 2:22:32 PM,Prothena climbs 80% as Bofa upgrades after rivals’ Alzheimer’s data,Seeking Alpha,https://seekingalpha.com/news/3886766-prothena-climbs-80-as-bofa-upgrades-after-rivals-alzheimers-data?utm_source=businessinsider&utm_medium=referral,positive,0.8883491158485413
1174,9/28/2022 2:42:02 PM,Why Is Biogen (BIIB) Stock Up 40% Today?,InvestorPlace,/news/stocks/why-is-biogen-biib-stock-up-40-today-1031770573,positive,0.8844352960586548
1175,9/28/2022 3:02:10 PM,Why Is Cassava Sciences (SAVA) Stock Heating Up Today?,InvestorPlace,/news/stocks/why-is-cassava-sciences-sava-stock-heating-up-today-1031770608,neutral,0.8180983662605286
1176,9/28/2022 3:22:12 PM,Netflix To Rally Around 24%? Here Are 5 Other Price Target Changes For Wednesday,Benzinga,/news/stocks/netflix-to-rally-around-24-here-are-5-other-price-target-changes-for-wednesday-1031770271,neutral,0.9242811799049377
1177,9/28/2022 3:28:14 PM,What's Going On With Prothena Stock Up Over 60% Today,Benzinga,/news/stocks/what-s-going-on-with-prothena-stock-up-over-60-today-1031770308,positive,0.7238381505012512
1178,9/28/2022 3:54:05 PM,"These Analysts Boost Price Targets On Biogen Following Positive Alzheimer's Drug Data, Shares Jump",Benzinga,/news/stocks/these-analysts-boost-price-targets-on-biogen-following-positive-alzheimer-s-drug-data-shares-jump-1031770434,positive,0.8997616171836853
1179,9/28/2022 3:54:55 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogens-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral,positive,0.9412574768066406
1180,9/28/2022 4:01:56 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-28-2022-1031770432,neutral,0.5031872391700745
1181,9/28/2022 4:04:37 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogen-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral,positive,0.9412574768066406
1182,9/28/2022 4:08:33 PM,14 Analysts Have This to Say About Biogen,Benzinga,/news/stocks/14-analysts-have-this-to-say-about-biogen-1031770458,neutral,0.9312993288040161
1183,9/28/2022 4:33:19 PM,Why Is Acumen (ABOS) Stock Up 95% Today?,InvestorPlace,/news/stocks/why-is-acumen-abos-stock-up-95-today-1031770880,positive,0.7826732993125916
1184,9/28/2022 4:52:05 PM,Why Is Prothena (PRTA) Stock Up 75% Today?,InvestorPlace,/news/stocks/why-is-prothena-prta-stock-up-75-today-1031770910,positive,0.7963075637817383
1185,9/28/2022 5:19:36 PM,Why Acumen Pharmaceuticals Stock Is Soaring Today,Benzinga,/news/stocks/why-acumen-pharmaceuticals-stock-is-soaring-today-1031770635,positive,0.7809367179870605
1186,9/28/2022 5:39:12 PM,"Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results",InvestorPlace,/news/stocks/biotech-stocks-lly-esaly-biib-gain-on-biogen-positive-trial-results-1031771015,positive,0.917136549949646
1187,9/28/2022 6:10:40 PM,7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%,Benzinga,/news/stocks/7-biogen-analysts-on-alzheimer-s-drug-success-as-stock-skyrockets-37-1031770806,positive,0.36163878440856934
1188,9/28/2022 6:15:20 PM,BMO Capital Upgrades Biogen: Here's What You Need To Know,Benzinga,/news/stocks/bmo-capital-upgrades-biogen-here-s-what-you-need-to-know-1031770834,neutral,0.9414299726486206
1189,9/28/2022 6:30:05 PM,This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval,Benzinga,/news/stocks/this-analyst-believes-biogen-s-lecanemab-data-not-slam-dunk-for-complete-cms-approval-1031770867,neutral,0.7880455255508423
1190,9/28/2022 6:40:47 PM,"Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session",Benzinga,/news/stocks/why-prothena-corporation-shares-are-trading-higher-by-76-here-are-53-stocks-moving-in-wednesday-s-mid-day-session-1031770887,neutral,0.8901486992835999
1191,9/28/2022 7:18:17 PM,Medicare costs to decline for first time in a decade,Seeking Alpha,https://seekingalpha.com/news/3886863-medicare-costs-to-decline-for-first-time-in-a-decade?utm_source=businessinsider&utm_medium=referral,negative,0.5771294832229614
1192,9/28/2022 7:43:19 PM,Acumen Pharma at 11-month high on rivals’ Alzheimer’s data,Seeking Alpha,https://seekingalpha.com/news/3886867-abos-stock-surges-on-rivals-alzheimers-data?utm_source=businessinsider&utm_medium=referral,positive,0.7593686580657959
1193,9/28/2022 8:59:59 PM,Why did Biogen stock surge today? Alzheimer's drug data,Seeking Alpha,https://seekingalpha.com/news/3886914-why-did-biogen-stock-surge-today-alzheimers-drug-data?utm_source=businessinsider&utm_medium=referral,neutral,0.8152075409889221
1194,9/28/2022 9:01:15 PM,Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods,Benzinga,/news/stocks/alphabet-to-136-plus-this-analyst-slashes-pt-on-united-natural-foods-1031771105,negative,0.8915141820907593
1195,9/28/2022 10:01:13 PM,"Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data",Seeking Alpha,https://seekingalpha.com/news/3886925-many-alzheimers-drug-developers-close-significantly-higher-thanks-to-biogen-eisai-data?utm_source=businessinsider&utm_medium=referral,positive,0.9467376470565796
1196,9/28/2022 10:17:23 PM,These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win,Benzinga,/news/stocks/these-stocks-are-on-the-radar-after-biogen-eisai-s-surprising-alzheimer-s-trial-win-1031771238,neutral,0.5415459275245667
1197,9/28/2022 11:00:18 PM,"Biogen Stock Is a Winner, But How Much Higher Can It Go?",TipRanks,/news/stocks/biogen-stock-is-a-winner-but-how-much-higher-can-it-go-1031771460,neutral,0.6787208318710327
1198,9/29/2022 12:43:06 AM,7 Growth Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/7-growth-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031771484,neutral,0.8190701007843018
1199,9/29/2022 9:45:49 AM,"Netflix, Biogen And Other Big Gainers From Wednesday",Benzinga,/news/stocks/netflix-biogen-and-other-big-gainers-from-wednesday-1031771992,positive,0.8002161979675293
1200,9/29/2022 11:09:35 AM,Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-nls-pharmaceutics-shares-tumbled-over-66-here-are-68-biggest-movers-from-yesterday-1031772129,neutral,0.6120429635047913
1201,9/29/2022 6:07:42 PM,"Biogen, Eisai cool off after massive run-up following lecanemab Alzheimer's data",Seeking Alpha,https://seekingalpha.com/news/3887223-biogen-eisai-cool-off-after-massive-run-up-following-lecanemab-alzheimers-data?utm_source=businessinsider&utm_medium=referral,negative,0.8865595459938049
1202,9/30/2022 11:59:18 AM,Biogen biosimilar to Roche’s arthritis therapy goes under EU review,Seeking Alpha,https://seekingalpha.com/news/3887435-biogen-biosimilar-to-roches-arthritis-therapy-goes-under-eu-review?utm_source=businessinsider&utm_medium=referral,neutral,0.9301256537437439
1203,9/30/2022 1:00:00 PM,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)",GlobeNewswire,/news/stocks/biogen-announced-ema-filing-acceptance-of-biib800-a-biosimilar-candidate-referencing-roactemra-tocilizumab-1031775355,positive,0.8919745087623596
1204,9/30/2022 1:21:54 PM,Biogen: EMA To Review MAA For BIIB800 - Quick Facts ,RTTNews,/news/stocks/biogen-ema-to-review-maa-for-biib800-quick-facts-1031775387,neutral,0.8995749354362488
1205,10/2/2022 4:00:31 PM,COVID stocks lag U.S. biopharma in Q3; Alzheimer’s theme regains focus,Seeking Alpha,https://seekingalpha.com/news/3887740-covid-stocks-lag-us-biopharma-in-q3-alzheimers-theme-regains-focus?utm_source=businessinsider&utm_medium=referral,negative,0.8604695200920105
1206,10/3/2022 8:30:36 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1031778120,positive,0.552167534828186
1207,10/3/2022 2:18:57 PM,Biogen bid to revive Tecfidera patents denied by U.S. Supreme Court,Seeking Alpha,https://seekingalpha.com/news/3887968-biogen-bid-to-revive-tecfidera-patents-denied-by-us-supreme-court?utm_source=businessinsider&utm_medium=referral,neutral,0.6359103918075562
1208,10/5/2022 10:15:40 AM,2 Signals to Watch Before Buying SAVA Stock,InvestorPlace,/news/stocks/2-signals-to-watch-before-buying-sava-stock-1031784114,neutral,0.9386740326881409
1209,10/5/2022 4:04:05 PM,"Hey Biogen Investors, Don’t Chase BIIB Stock!",InvestorPlace,/news/stocks/hey-biogen-investors-dont-chase-biib-stock-1031785337,neutral,0.9091885089874268
1210,10/6/2022 8:15:35 AM,Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-biogen-biib-1031786584,neutral,0.6464465856552124
1211,10/6/2022 2:58:18 PM,Bipartisan bill aims to get CMS to cover Alzheimer's antibody treatments,Seeking Alpha,https://seekingalpha.com/news/3889267-bipartisan-bill-aims-to-gets-cms-to-cover-alzheimers-antibody-treatments?utm_source=businessinsider&utm_medium=referral,positive,0.7279573678970337
1212,10/7/2022 4:03:24 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-7-2022-1031790246,neutral,0.5318641662597656
1213,10/7/2022 5:40:40 PM,Former J&J executive is tipped to become Biogen CEO – Stat News,Seeking Alpha,https://seekingalpha.com/news/3889747-former-jj-executive-is-tipped-to-become-biogen-ceo-stat-news?utm_source=businessinsider&utm_medium=referral,neutral,0.9377965331077576
1214,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647,positive,0.8603334426879883
1215,10/10/2022 4:03:05 PM,"Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122",Seeking Alpha,https://seekingalpha.com/news/3890066-biogen-denali-begin-dosing-in-late-stage-trial-of-parkinsons-candidate-biib122?utm_source=businessinsider&utm_medium=referral,positive,0.608609676361084
1216,10/12/2022 11:00:23 AM,7 Cheap Blue-Chip Stocks to Buy Before They Rebound,InvestorPlace,/news/stocks/cheap-blue-chip-stocks-2-1031655612,neutral,0.9110720157623291
1217,10/13/2022 3:27:17 PM,Biogen upgraded to buy at Stifel on lecanemab Alzheimer's treatment,Seeking Alpha,https://seekingalpha.com/news/3891135-biogen-upgraded-to-buy-at-stifel-on-lecanemab-alzheimers-treatment?utm_source=businessinsider&utm_medium=referral,positive,0.7770357131958008
1218,10/13/2022 3:30:00 PM,SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About Aduhelm,PR Newswire,/news/stocks/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm-1031803335,negative,0.7863238453865051
1219,10/13/2022 4:05:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-13-2022-1031803524,neutral,0.527847945690155
1220,10/13/2022 7:45:04 PM,"Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts",Benzinga,/news/stocks/analyst-upgrades-biogen-citing-upcoming-conference-competitive-readouts-1031804196,neutral,0.8114142417907715
1221,10/15/2022 1:50:24 AM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Brookdale Senior Living (BKD),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-brookdale-senior-living-bkd-1031807255,neutral,0.9058680534362793
1222,10/17/2022 12:19:39 PM,FDA extends review period for Biogen/Ionis ALS therapy tofersen,Seeking Alpha,https://seekingalpha.com/news/3891774-fda-extends-review-period-for-biogenionis-als-therapy-tofersen?utm_source=businessinsider&utm_medium=referral,neutral,0.6078000664710999
1223,10/17/2022 1:30:10 PM,Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen,GlobeNewswire,/news/stocks/biogen-announces-fda-s-3-month-extension-of-review-period-for-the-new-drug-application-for-tofersen-1031809682,neutral,0.6887023448944092
1224,10/17/2022 1:42:41 PM,Biogen: FDA Extends Review Period Of NDA For Tofersen - Quick Facts ,RTTNews,/news/stocks/biogen-fda-extends-review-period-of-nda-for-tofersen-quick-facts-1031809715,neutral,0.7193766832351685
1225,10/17/2022 2:03:33 PM,"Sage Therapeutics, Biogen Report Further Analyses From Zuranolone Trial In Postpartum Depression ",RTTNews,/news/stocks/sage-therapeutics-biogen-report-further-analyses-from-zuranolone-trial-in-postpartum-depression-1031809795,neutral,0.8982416987419128
1226,10/18/2022 2:20:06 PM,Biogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executive,Seeking Alpha,https://seekingalpha.com/news/3892255-biogen-alzheimers-data-de-risked-beta-amyloid-hypothesis-roche-executive?utm_source=businessinsider&utm_medium=referral,neutral,0.8947479128837585
1227,10/21/2022 5:16:55 PM,"Earnings week ahead: Apple, Alphabet, Amazon, Meta, Boeing and more",Seeking Alpha,https://seekingalpha.com/news/3893730-earnings-week-ahead-apple-alphabet-amazon-meta-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9336963295936584
1228,10/24/2022 2:33:36 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3894130-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8660826683044434
1229,10/24/2022 3:01:13 PM,Biogen earnings preview: what to expect,Markets Insider Automation,/news/stocks/biogen-q3-earnings-preview-1031828467,neutral,0.9184785485267639
1230,10/24/2022 4:31:53 PM,"Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Zymeworks (ZYME)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biogen-biib-zymeworks-zyme-1031829371,positive,0.6790475249290466
1231,10/24/2022 5:20:06 PM,Biogen Q3 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3894221-biogen-q3-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.8290516138076782
1232,10/24/2022 6:28:51 PM,15 Analysts Have This to Say About Biogen,Benzinga,/news/stocks/15-analysts-have-this-to-say-about-biogen-1031829311,neutral,0.9280048608779907
1233,10/24/2022 9:12:31 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1031829601,neutral,0.9221560955047607
1234,10/25/2022 11:06:58 AM,"Biogen Non-GAAP EPS of $4.77 beats by $0.66, revenue of $2.51B beats by $40M, raises FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3894608-biogen-non-gaap-eps-of-4_77-beats-0_66-revenue-of-2_51b-beats-40m?utm_source=businessinsider&utm_medium=referral,positive,0.9257800579071045
1235,10/25/2022 11:46:06 AM,Biogen raises guidance as topline outperforms amid ongoing cost management,Seeking Alpha,https://seekingalpha.com/news/3894636-biogen-raises-guidance-as-topline-outperforms-amid-ongoing-cost-management?utm_source=businessinsider&utm_medium=referral,positive,0.8286418318748474
1236,10/25/2022 1:43:47 PM,Biogen Raises 2022 Guidance ,RTTNews,/news/stocks/biogen-raises-2022-guidance-1031832341,neutral,0.9253495335578918
1237,10/26/2022 12:02:00 PM,New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS,GlobeNewswire,/news/stocks/new-data-at-ectrims-2022-highlight-biogen-s-commitment-to-advancing-individualized-disease-management-for-people-living-with-ms-1031837198,positive,0.682121217250824
1238,10/26/2022 12:05:00 PM,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS,GlobeNewswire,/news/stocks/biogen-data-at-ectrims-2022-highlight-innovation-in-digital-health-focused-on-advancing-treatment-and-personalized-care-of-people-living-with-ms-1031837199,neutral,0.5322114825248718
1239,10/26/2022 12:20:34 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Taysha Gene Therapies (TSHA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-taysha-gene-therapies-tsha-1031837886,neutral,0.9067756533622742
1240,10/26/2022 12:35:55 PM,Atlantic Equities Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-hold-rating-for-biogen-biib-1031838057,neutral,0.6581801772117615
1241,10/26/2022 12:40:52 PM,"Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biogen-biib-timber-pharmaceuticals-tmbr-1031838033,positive,0.6451781392097473
1242,10/26/2022 2:39:42 PM,Biogen raised to Buy at Goldman Sachs as Alzheimer’s prospects return,Seeking Alpha,https://seekingalpha.com/news/3895547-biib-stock-gains-as-goldman-sachs-upgrades-on-alzheimers-prospects?utm_source=businessinsider&utm_medium=referral,positive,0.42892009019851685
1243,10/26/2022 4:07:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-26-2022-1031838805,neutral,0.4896215796470642
1244,10/26/2022 9:55:36 PM,Needham Releases a Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/needham-releases-a-buy-rating-on-biogen-biib-1031840300,neutral,0.8963016271591187
1245,10/27/2022 6:03:06 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Teladoc (TDOC) and Taysha Gene Therapies (TSHA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-teladoc-tdoc-and-taysha-gene-therapies-tsha-1031841928,neutral,0.9118286371231079
1246,10/28/2022 12:00:56 PM,Biogen slips amid reports of death linked to new Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3897190-biib-stock-slips-amid-reports-of-death-linked-to-new-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,negative,0.9501603245735168
1247,11/1/2022 8:15:27 AM,Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-biogen-biib-1031857340,neutral,0.6464465856552124
1248,11/1/2022 1:19:02 PM,Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday,Benzinga,/news/stocks/biogen-to-rally-around-15-here-are-5-other-price-target-changes-for-tuesday-1031858172,neutral,0.9341610074043274
1249,11/2/2022 9:35:12 AM,Biogen (BIIB) Receives a Buy from Needham,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-needham-1031863059,neutral,0.5417353510856628
1250,11/4/2022 2:06:28 PM,Prothena drops 9% as  RBC Capital Markets downgrades citing valuation,Seeking Alpha,https://seekingalpha.com/news/3901961-prta-stock-drops-as-rbc-capital-markets-downgrades-citing-valuation?utm_source=businessinsider&utm_medium=referral,negative,0.9655062556266785
1251,11/7/2022 8:42:12 PM,Former J&J exec no longer seen as frontrunner for Biogen CEO position  - STAT,Seeking Alpha,https://seekingalpha.com/news/3902997-former-johnson-johnson-exec-no-longer-seen-as-frontrunner-for-biogen-ceo-position-stat?utm_source=businessinsider&utm_medium=referral,neutral,0.9084570407867432
1252,11/10/2022 4:21:10 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), BioMarin Pharmaceutical (BMRN) and Intellia Therapeutics (NTLA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biogen-biib-biomarin-pharmaceutical-bmrn-and-intellia-therapeutics-ntla-1031894704,negative,0.9282695055007935
1253,11/10/2022 1:18:55 PM,Biogen names former Sanofi head Chris Viehbacher as new CEO,Seeking Alpha,https://seekingalpha.com/news/3905512-biogen-names-former-sanofi-head-chris-viehbacher-as-new-ceo?utm_source=businessinsider&utm_medium=referral,neutral,0.9143286943435669
1254,11/10/2022 1:30:00 PM,Biogen Names Christopher Viehbacher President and Chief Executive Officer,GlobeNewswire,/news/stocks/biogen-names-christopher-viehbacher-president-and-chief-executive-officer-1031898198,neutral,0.9405853152275085
1255,11/10/2022 2:29:59 PM,Biogen Appoints Christopher Viehbacher As President And CEO ,RTTNews,/news/stocks/biogen-appoints-christopher-viehbacher-as-president-and-ceo-1031898555,neutral,0.9338034987449646
1256,11/10/2022 7:10:43 PM,"Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Apyx Medical (APYX) and Phathom Pharmaceuticals (PHAT)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-biogen-biib-apyx-medical-apyx-and-phathom-pharmaceuticals-phat-1031900154,negative,0.747076153755188
1257,11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660,negative,0.944724440574646
1258,11/14/2022 9:51:32 AM,"Roche faces another setback in Alzheimer's as gantenerumab fails phase 3 trials, MorphoSys plunges 32%",Seeking Alpha,https://seekingalpha.com/news/3906886-roche-faces-another-setback-in-alzheimers-as-gantenerumab-fails-2-phase-3-trials?utm_source=businessinsider&utm_medium=referral,negative,0.9631323218345642
1259,11/14/2022 1:17:31 PM,"Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus",Benzinga,/news/stocks/nasdaq-s-p-500-futures-pullback-at-start-of-new-trading-week-as-rate-fears-return-to-haunt-amd-tesla-biogen-eli-lilly-jd-in-focus-1031909736,negative,0.7648298144340515
1260,11/14/2022 1:35:28 PM,Needham Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/needham-remains-a-buy-on-biogen-biib-1031910219,neutral,0.9322506785392761
1261,11/14/2022 3:16:49 PM,Why Is Biogen (BIIB) Stock Up Today?,InvestorPlace,/news/stocks/why-is-biogen-biib-stock-up-today-1031910786,neutral,0.7774216532707214
1262,11/14/2022 3:30:24 PM,Dow gains while S&P and Nasdaq slide after last week's major surge,Seeking Alpha,https://seekingalpha.com/news/3906922-sp-500-nasdaq-dow-jones-stock-market?utm_source=businessinsider&utm_medium=referral,negative,0.9243873357772827
1263,11/14/2022 3:39:59 PM,Why Is AST SpaceMobile (ASTS) Moving Today?,InvestorPlace,/news/stocks/why-is-ast-spacemobile-asts-moving-today-1031910825,neutral,0.9248577952384949
1264,11/14/2022 3:39:59 PM,Why Is AST SpaceMobile (ASTS) Moving Today?,InvestorPlace,/news/stocks/why-is-ast-spacemobile-asts-stock-moving-today-1031911525,neutral,0.9248577952384949
1265,11/14/2022 4:59:20 PM,"Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback",Seeking Alpha,https://seekingalpha.com/news/3907250-cassava-biogen-lead-alzheimers-stocks-higher-following-roches-gantenerumab-setback?utm_source=businessinsider&utm_medium=referral,positive,0.9394574165344238
1266,11/14/2022 7:18:45 PM,"Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers",Benzinga,/news/stocks/roche-s-alzheimer-s-flop-trial-removes-one-competitor-but-reimbursement-debate-lingers-1031911345,negative,0.7577299475669861
1267,11/14/2022 7:38:47 PM,Why Is Cassava Sciences (SAVA) Stock Up Today?,InvestorPlace,/news/stocks/why-is-cassava-sciences-sava-stock-up-today-1031911445,neutral,0.807410717010498
1268,11/14/2022 9:12:50 PM,"Dow, S&P, Nasdaq snap last week's massive rally as traders mull Fed comments",Seeking Alpha,https://seekingalpha.com/news/3907226-nasdaq-dow-jones-sp-500-stocks-retail-earnings?utm_source=businessinsider&utm_medium=referral,negative,0.6229842305183411
1269,11/14/2022 11:10:01 PM,"Steve Cohen's Point72 enters Dell, EOG, Intuit, exits Nike, McDonald's, Coca-Cola",Seeking Alpha,https://seekingalpha.com/news/3907568-steve-cohens-point72-enters-dell-eog-intuit-exits-nike-mcdonalds-coca-cola?utm_source=businessinsider&utm_medium=referral,neutral,0.9439740180969238
1270,11/15/2022 4:40:52 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Idexx Laboratories (IDXX) and Arcutis Biotherapeutics (ARQT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-idexx-laboratories-idxx-and-arcutis-biotherapeutics-arqt-1031915983,neutral,0.9034608006477356
1271,11/15/2022 11:04:32 PM,Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage,Benzinga,/news/stocks/successful-alzheimer-s-data-would-have-placed-roche-at-two-year-competitive-advantage-1031916589,positive,0.8776633739471436
1272,11/17/2022 1:45:37 AM,RBC Capital Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-biogen-biib-1031920445,neutral,0.931504487991333
1273,11/21/2022 3:37:52 PM,TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO,InvestorPlace,/news/stocks/teva-stock-alert-what-to-know-about-teva-pharmaceuticals-new-ceo-1031929031,neutral,0.9291258454322815
1274,11/21/2022 5:25:13 PM,Biogen (BIIB) Receives a Buy from Mizuho Securities,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-mizuho-securities-1031929310,neutral,0.5102506279945374
1275,11/28/2022 5:20:25 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1031940489,positive,0.552167534828186
1276,11/28/2022 5:30:17 PM,"Analysts Are Bullish on These Healthcare Stocks: Edesa Biotech (EDSA), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-edesa-biotech-edsa-biogen-biib-1031940488,neutral,0.7033971548080444
1277,11/28/2022 5:40:17 PM,"Analysts Are Bullish on Top Healthcare Stocks: Edesa Biotech (EDSA), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-edesa-biotech-edsa-biogen-biib-1031940525,neutral,0.5558503866195679
1278,11/29/2022 9:15:31 PM,"Eisai, Biogen Hit By 2nd Death Related To Alzheimer Trial Drug ",RTTNews,/news/stocks/eisai-biogen-hit-by-2nd-death-related-to-alzheimer-trial-drug-1031943207,negative,0.9304069876670837
1279,11/30/2022 1:50:00 AM,EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE,PR Newswire,/news/stocks/eisai-presents-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-alzheimer-s-disease-at-clinical-trials-on-alzheimer-s-disease-ctad-conference-1031943531,neutral,0.8928577303886414
1280,11/30/2022 1:50:00 AM,ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGL...,PR Newswire,/news/stocks/eleven-experts-from-leading-medical-institutions-and-eight-experts-from-eisai-publish-full-results-of-lecanemab-phase-3-confirmatory-clarity-ad-study-for-early-alzheimer-s-disease-in-the-new-engl-1031943530,neutral,0.6912438869476318
1281,11/30/2022 3:18:18 AM,Eisai Clarifies Lecanemab Not Associated With Two Deaths In Alzheimer's Disease Treatment Trial ,RTTNews,/news/stocks/eisai-clarifies-lecanemab-not-associated-with-two-deaths-in-alzheimer-s-disease-treatment-trial-1031943556,neutral,0.8464645743370056
1282,11/30/2022 4:20:48 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), IVERIC bio (ISEE) and Crinetics Pharmaceuticals (CRNX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-iveric-bio-isee-and-crinetics-pharmaceuticals-crnx-1031943735,neutral,0.899934709072113
1283,11/30/2022 11:20:29 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Horizon Therapeutics (HZNP) and Kala Pharmaceuticals (KALA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-horizon-therapeutics-hznp-and-kala-pharmaceuticals-kala-1031944547,neutral,0.9041885137557983
1284,11/30/2022 1:55:19 PM,Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday,Benzinga,/news/stocks/alphabet-to-135-here-are-10-other-price-target-changes-for-wednesday-1031944728,neutral,0.8858572840690613
1285,11/30/2022 2:00:59 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), uniQure (QURE)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-uniqure-qure-1031945256,positive,0.7849375605583191
1286,11/30/2022 2:07:16 PM,26 Analysts Have This to Say About Biogen,Benzinga,/news/stocks/26-analysts-have-this-to-say-about-biogen-1031944772,neutral,0.9265189170837402
1287,11/30/2022 2:40:15 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Horizon Therapeutics (HZNP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-horizon-therapeutics-hznp-1031945255,neutral,0.8871387243270874
1288,11/30/2022 3:00:18 PM,BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen,InvestorPlace,/news/stocks/biib-stock-alert-what-the-latest-alzheimers-drug-data-means-for-biogen-1031945227,neutral,0.9067272543907166
1289,11/30/2022 3:26:14 PM,CrowdStrike (CRWD) Stock Sinks on Weak Guidance,InvestorPlace,/news/stocks/crowdstrike-crwd-stock-sinks-on-weak-guidance-1031945291,negative,0.948762834072113
1290,11/30/2022 7:03:22 PM,"Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate",Benzinga,/news/stocks/despite-safety-concerns-analysts-are-bullish-on-biogen-s-second-alzheimer-s-candidate-1031945951,positive,0.907336950302124
1291,12/1/2022 5:38:36 AM,"MRNA, BIIB, or IQV: Which Biotech Stock Earns the Street’s “Strong Buy” Rating?",TipRanks,/news/stocks/mrna-biib-or-iqv-which-biotech-stock-earns-the-street-s-strong-buy-rating-1031946927,neutral,0.8603473901748657
1292,12/2/2022 3:05:34 AM,SVB Securities Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/svb-securities-remains-a-buy-on-biogen-biib-1031949345,neutral,0.934866726398468
1293,12/3/2022 1:50:15 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), UnitedHealth (UNH) and Morphic Holding (MORF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-unitedhealth-unh-and-morphic-holding-morf-1031951265,neutral,0.9146159887313843
1294,12/5/2022 11:15:30 AM,"Even After This Year’s Melt-Up, Runway Remains for LLY Stock",InvestorPlace,/news/stocks/even-after-this-years-melt-up-runway-remains-for-lly-stock-1031952582,positive,0.796991765499115
1295,12/5/2022 2:01:22 PM,"Biogen's Tofersen MAA Accepted In Europe To Treat Rare, Genetic Form Of ALS ",RTTNews,/news/stocks/biogen-s-tofersen-maa-accepted-in-europe-to-treat-rare-genetic-form-of-als-1031952861,neutral,0.6742370128631592
1296,12/6/2022 12:20:56 PM,"Sage, Biogen complete rolling filing with FDA for depression therapy zuranolone",Seeking Alpha,https://seekingalpha.com/news/3914235-sage-biogen-complete-rolling-filing-with-fda-for-depression-therapy-zuranolone?utm_source=businessinsider&utm_medium=referral,neutral,0.6893850564956665
1297,12/8/2022 7:38:51 PM,"Biogen, Eisai prompt Medicare to reevaluate Alzheimer’s coverage after new data",Seeking Alpha,https://seekingalpha.com/news/3915449-biogen-eisai-prompt-medicare-reconsider-alzheimers-coverage?utm_source=businessinsider&utm_medium=referral,positive,0.6903255581855774
1298,12/9/2022 1:06:38 PM,Biogen granted FDA review for Actemra biosimilar,Seeking Alpha,https://seekingalpha.com/news/3915670-biogen-granted-fda-review-for-actemra-biosimilar?utm_source=businessinsider&utm_medium=referral,positive,0.7962744235992432
1299,12/9/2022 1:45:01 PM,"Biogen : FDA Accepts BLA For BIIB800, Biosimilar Candidate Referencing ACTEMRA ",RTTNews,/news/stocks/biogen-fda-accepts-bla-for-biib800-biosimilar-candidate-referencing-actemra-1031962636,positive,0.817238450050354
1300,12/18/2022 2:04:41 PM,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-healthcare-stocks-to-own-for-2023-and-beyond-1031978729,neutral,0.89500492811203
1301,12/19/2022 10:50:38 AM,Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-atricure-atrc-and-biogen-biib-1031979574,neutral,0.889303982257843
1302,12/19/2022 2:16:08 PM,Biogen Signs Agreement With Genentech For Royalties On Glofitamab ,RTTNews,/news/stocks/biogen-signs-agreement-with-genentech-for-royalties-on-glofitamab-1031979965,positive,0.9218754172325134
1303,12/20/2022 7:55:11 PM,Mizuho Securities Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-biogen-biib-1031983358,neutral,0.9223442077636719
1304,12/22/2022 5:48:44 PM,"Biogen, Lilly potential Alzheimer's drugs given lukewarm review by drug evaluation group",Seeking Alpha,https://seekingalpha.com/news/3919908-biogen-lilly-potential-alzheimers-drugs-given-lukewarm-review-by-drug-evaluation-group?utm_source=businessinsider&utm_medium=referral,positive,0.7613863348960876
1305,12/23/2022 12:45:00 AM,EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA,PR Newswire,/news/stocks/eisai-initiates-bla-submission-of-data-for-lecanemab-in-china-1031988029,neutral,0.934428870677948
1306,12/23/2022 12:21:27 PM,Eisai starts filing seeking approval for Alzheimer's drug lecanemab in China,Seeking Alpha,https://seekingalpha.com/news/3920193-eisai-starts-filing-seeking-approval-for-alzheimers-drug-lecanemab-in-china?utm_source=businessinsider&utm_medium=referral,neutral,0.5236753225326538
1307,12/23/2022 2:42:02 PM,Biogen/ Eisai deserve $30K price tag for new Alzheimer’s drug – Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3920318-biogen-eisai-deserve-30k-price-new-alzheimers-drug-wells-fargo?utm_source=businessinsider&utm_medium=referral,positive,0.7993872165679932
1308,12/23/2022 5:29:30 PM,"Biogen, Eisai Alzheimer's candidate lecanemab linked to third patient death",Seeking Alpha,https://seekingalpha.com/news/3920430-biogen-eisai-alzheimers-candidate-lecanemab-linked-to-third-patient-death?utm_source=businessinsider&utm_medium=referral,neutral,0.6797540187835693
1309,12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral,neutral,0.7464397549629211
1310,12/27/2022 3:11:57 PM,"Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors",Benzinga,/news/stocks/biogen-s-2nd-alzheimer-s-antibody-beigene-s-cancer-drug-label-expansion-adcom-test-for-regeneron-and-more-january-pdufa-catalysts-for-biotech-investors-1031991144,neutral,0.86749267578125
1311,12/29/2022 6:34:52 PM,"Biogen, FDA faulted in congressional inquiry into Alzheimer’s drug approval",Seeking Alpha,https://seekingalpha.com/news/3921177-biogen-fda-faulted-in-congressional-inquiry-into-alzheimers-drug-approval?utm_source=businessinsider&utm_medium=referral,negative,0.6882864236831665
1312,12/30/2022 12:28:33 PM,7 Cheap Large-Cap Stocks to Buy Before They Surge Higher,InvestorPlace,/news/stocks/cheap-large-cap-stocks-1031607723,neutral,0.8062046766281128
1313,12/30/2022 7:00:00 PM,"Catalyst watch: Tesla deliveries, CES reveals and healthcare updates lead off 2023",Seeking Alpha,https://seekingalpha.com/news/3921300-catalyst-watch-tesla-deliveries-ces-reveals-and-healthcare-updates-lead-off-2023?utm_source=businessinsider&utm_medium=referral,neutral,0.8818861842155457
1314,12/30/2022 10:25:21 PM,Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug ,RTTNews,/news/stocks/congress-report-says-fda-broke-protocols-in-approval-of-biogen-alzheimer-s-drug-1031995274,negative,0.6231312155723572
1315,1/4/2023 2:03:47 PM,Biogen Announces License Agreement With Alcyone For ThecaFlex DRx System ,RTTNews,/news/stocks/biogen-announces-license-agreement-with-alcyone-for-thecaflex-drx-system-1031999763,positive,0.8450496792793274
1316,1/4/2023 5:35:28 PM,"Biogen, Alcyone in agreement for medical device for antisense oligonucleotide therapies",Seeking Alpha,https://seekingalpha.com/news/3922044-biogen-alcyone-in-agreement-for-medical-device-for-antisense-oligonucleotide-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.8301863670349121
1317,1/5/2023 2:02:14 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032002231,positive,0.552167534828186
1318,1/5/2023 9:38:42 PM,Biogen makes changes to R&D department on eve on FDA lecanemab decision,Seeking Alpha,https://seekingalpha.com/news/3922522-biogen-makes-changes-to-rd-department-on-eve-on-fda-lecanemab-decision?utm_source=businessinsider&utm_medium=referral,neutral,0.8957656621932983
1319,1/6/2023 7:07:40 PM,Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?,InvestorPlace,/news/stocks/lecanemab-alert-what-would-alzheimers-drug-approval-mean-for-biogen-biib-stock-1032004993,neutral,0.9419788718223572
1320,1/6/2023 7:17:14 PM,"Biogen, Eisai's Alzheimer's treatment lecanemab approved by the FDA",Seeking Alpha,https://seekingalpha.com/news/3922563-biogen-eisai-alzheimers-treatment-lecanemab-approved-by-the-fda?utm_source=businessinsider&utm_medium=referral,positive,0.7520990371704102
1321,1/6/2023 8:19:28 PM,"Lilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approval",Seeking Alpha,https://seekingalpha.com/news/3922771-lilly-roche-other-alzheimers-drug-developer-rise-modestly-on-biogen-lecanemab-approval?utm_source=businessinsider&utm_medium=referral,positive,0.9446359276771545
1322,1/6/2023 8:30:00 PM,FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease,PR Newswire,/news/stocks/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-pathway-for-the-treatment-of-alzheimer-s-disease-1032005011,positive,0.6993921399116516
1323,1/6/2023 8:47:34 PM,"SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday",Benzinga,/news/stocks/sava-lly-ibb-why-these-alzheimer-s-related-stocks-are-volatile-on-friday-1032005036,neutral,0.7991044521331787
1324,1/6/2023 9:16:10 PM,Mizuho Securities Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-biogen-biib-1032005136,neutral,0.9223442077636719
1325,1/6/2023 10:55:08 PM,Biogen (BIIB) Gets a Buy from Needham,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-needham-1032005179,neutral,0.5348629355430603
1326,1/7/2023 5:30:00 AM,Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease,PR Newswire,/news/stocks/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimer-s-disease-1032005246,positive,0.5276671648025513
1327,1/7/2023 5:31:17 AM,FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment ,RTTNews,/news/stocks/fda-approves-eisai-and-biogen-s-leqembi-for-alzheimer-s-disease-treatment-1032005248,neutral,0.5141104459762573
1328,1/7/2023 5:52:28 AM,Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease  Treatment ,RTTNews,/news/stocks/eisai-submits-sbla-to-fda-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment-1032005249,neutral,0.7644203305244446
1329,1/7/2023 9:00:00 PM,"Biogen, Eisai's lecanemab gets Alzheimer's nod, but how successful it will be is uncertain",Seeking Alpha,https://seekingalpha.com/news/3922809-biogen-eisais-lecanemab-gets-alzheimers-nod-but-how-successful-it-will-be-is-uncertain?utm_source=businessinsider&utm_medium=referral,neutral,0.8341358304023743
1330,1/9/2023 2:44:04 PM,"Ionis, Royalty Pharma ink royalty deal for up to $1.1B",Seeking Alpha,https://seekingalpha.com/news/3922988-ionis-royalty-pharma-ink-royalty-deal-for-up-to-11b?utm_source=businessinsider&utm_medium=referral,neutral,0.7769089937210083
1331,1/10/2023 11:34:49 AM,7 Warren Buffet Stocks to Buy and Hold for the Next Decade,InvestorPlace,/news/stocks/warren-buffett-stocks-to-buy-and-hold-1031558120,neutral,0.9174212217330933
1332,1/10/2023 5:17:04 PM,Sage Therapeutics sees depression treatment zuranolone hitting the market as early as Q3,Seeking Alpha,https://seekingalpha.com/news/3923408-sage-therapeutics-sees-depression-treatment-zuranolone-hitting-the-market-as-early-as-q3?utm_source=businessinsider&utm_medium=referral,neutral,0.6642510890960693
1333,1/11/2023 12:30:00 AM,EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE,PR Newswire,/news/stocks/eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimer-s-disease-in-europe-1032010824,positive,0.648169994354248
1334,1/11/2023 1:32:56 AM,Eisai Submits MAA For Lecanemab As Treatment For Early Alzheimer's Disease In Europe ,RTTNews,/news/stocks/eisai-submits-maa-for-lecanemab-as-treatment-for-early-alzheimer-s-disease-in-europe-1032010855,neutral,0.713384211063385
1335,1/11/2023 9:29:27 AM,Eisai files for approval of Alzheimer's drug lecanemab in EU,Seeking Alpha,https://seekingalpha.com/news/3923568-eisai-files-for-approval-of-alzheimers-drug-lecanemab-in-eu?utm_source=businessinsider&utm_medium=referral,neutral,0.5466753244400024
1336,1/11/2023 11:35:13 AM,Biogen (BIIB) Gets a Buy from Needham,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-needham-1032011961,neutral,0.5348629355430603
1337,1/16/2023 1:30:00 AM,EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN,PR Newswire,/news/stocks/eisai-files-marketing-authorization-application-for-anti-amyloid-beta-protofibril-antibody-lecanemab-for-early-alzheimer-s-disease-in-japan-1032018948,positive,0.8603924512863159
1338,1/16/2023 8:48:03 AM,Eisai files application in Japan for Alzheimer's drug lecanemab,Seeking Alpha,https://seekingalpha.com/news/3924692-eisai-files-application-in-japan-for-alzheimers-drug-lecanemab?utm_source=businessinsider&utm_medium=referral,neutral,0.7611548900604248
1339,1/18/2023 4:50:40 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032023996,positive,0.552167534828186
1340,1/18/2023 4:10:10 PM,"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",Benzinga,/news/stocks/neurodegenerative-diseases-focused-company-goes-public-via-wilbur-ross-backed-spac-joins-alzheimer-s-race-to-compete-biogen-1032025916,neutral,0.6879987716674805
1341,1/20/2023 11:55:27 AM,"Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed",Seeking Alpha,https://seekingalpha.com/news/3926255-dr-reddys-prepare-to-file-for-rituxan-biosimilar-in-us-eu-as-trials-completed?utm_source=businessinsider&utm_medium=referral,neutral,0.8696064949035645
1342,1/20/2023 1:20:25 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Cytokinetics (CYTK) and Legend Biotech (LEGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-cytokinetics-cytk-and-legend-biotech-legn-1032030815,neutral,0.9061134457588196
1343,1/20/2023 3:49:19 PM,Eli Lilly slips while Street defends FDA setback for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3926378-lly-stock-slips-as-street-defends-alzheimers-setback?utm_source=businessinsider&utm_medium=referral,negative,0.8872593641281128
1344,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.9066246747970581
1345,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,positive,0.8150347471237183
1346,1/23/2023 4:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Tenet Healthcare (THC) and Frequency Therapeutics (FREQ)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-tenet-healthcare-thc-and-frequency-therapeutics-freq-1032032646,neutral,0.9126694798469543
1347,1/23/2023 2:29:37 PM,Biogen/ Ionis ALS therapy set for March FDA AdCom meeting,Seeking Alpha,https://seekingalpha.com/news/3926722-biogen-ionis-als-therapy-march-fda-adcom-meeting?utm_source=businessinsider&utm_medium=referral,neutral,0.93522047996521
1348,1/24/2023 4:25:26 PM,Biogen (BIIB) Receives a Buy from Morgan Stanley,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-morgan-stanley-1032037492,positive,0.5905956029891968
1349,1/24/2023 6:00:34 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1032037597,neutral,0.9221560955047607
1350,1/25/2023 11:20:33 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Catalyst Pharma (CPRX) and Nemaura Medical (NMRD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-catalyst-pharma-cprx-and-nemaura-medical-nmrd-1032039794,neutral,0.8956661820411682
1351,1/27/2023 12:30:00 AM,MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY,PR Newswire,/news/stocks/marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimer-s-disease-accepted-by-european-medicines-agency-1032045232,positive,0.5162262320518494
1352,1/27/2023 1:23:36 AM,Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease ,RTTNews,/news/stocks/eisai-ema-accepts-maa-for-lecanemab-as-treatment-for-early-alzheimer-s-disease-1032045263,positive,0.8926591277122498
1353,1/27/2023 9:50:06 AM,"Biogen, Eisai's Alzheimer's drug lecanemab gets review in EU",Seeking Alpha,https://seekingalpha.com/news/3928836-biogen-eisais-alzheimers-drug-lecanemab-gets-review-in-eu?utm_source=businessinsider&utm_medium=referral,neutral,0.7783808708190918
1354,1/27/2023 12:39:46 PM,Mizuho picks its top stocks for 2023,Seeking Alpha,https://seekingalpha.com/news/3928578-mizuho-picks-its-top-stocks-for-2023?utm_source=businessinsider&utm_medium=referral,neutral,0.925223171710968
1355,1/27/2023 12:52:31 PM,J&J pulls Imbruvica combo filing in EU as EMA cites potential 'serious side effects',Seeking Alpha,https://seekingalpha.com/news/3928895-jj-pulls-imbruvica-combo-filing-in-eu-as-ema-cites-potential-serious-side-effects?utm_source=businessinsider&utm_medium=referral,negative,0.9580039978027344
1356,1/30/2023 12:30:00 AM,LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN,PR Newswire,/news/stocks/lecanemab-receives-priority-review-status-in-japan-1032048694,positive,0.49965471029281616
1357,1/30/2023 1:53:21 AM,Eisai : Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment ,RTTNews,/news/stocks/eisai-lecanemab-receives-priority-review-status-in-japan-for-alzheimer-s-disease-treatment-1032048712,positive,0.9255019426345825
1358,1/30/2023 9:51:42 AM,"Biogen, Eisai's Alzheimer's drug lecanemab gets priority review in Japan",Seeking Alpha,https://seekingalpha.com/news/3929247-biogen-eisais-alzheimers-drug-lecanemab-gets-priority-review-in-japan?utm_source=businessinsider&utm_medium=referral,neutral,0.66263347864151
1359,1/31/2023 12:10:35 AM,7 CRISPR Stocks With the Best Long-Term Potential ,InvestorPlace,/news/stocks/7-crispr-stocks-with-the-best-long-term-potential-1032052123,positive,0.8282150030136108
1360,1/31/2023 12:31:10 PM,uniQure inks licensing deal for gene therapy candidate targeting ALS,Seeking Alpha,https://seekingalpha.com/news/3929761-qure-stock-gains-uniqure-inks-licensing-deal-als-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.8200085759162903
1361,1/31/2023 6:29:59 PM,Immunic adds 14% as Wedbush initiates with bullish view on lead asset,Seeking Alpha,https://seekingalpha.com/news/3930040-imux-stock-climbs-wedbush-initiates-with-bullish-view-lead-asset?utm_source=businessinsider&utm_medium=referral,positive,0.8593795895576477
1362,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559,neutral,0.8971438407897949
1363,2/1/2023 9:10:43 PM,The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-nasdaq-stocks-to-buy-in-february-2023-1032060416,neutral,0.7067697644233704
1364,2/2/2023 1:34:18 PM,Anavex gains as trial for Rett syndrome candidate exceeds enrollment target,Seeking Alpha,https://seekingalpha.com/news/3931220-avxl-stock-gains-rett-syndrome-trial-exceeds-enrollment-target?utm_source=businessinsider&utm_medium=referral,positive,0.9464268684387207
1365,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,negative,0.9276774525642395
1366,2/3/2023 11:20:16 AM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Cytokinetics (CYTK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-cytokinetics-cytk-1032065723,positive,0.628406822681427
1367,2/6/2023 12:25:20 PM,"Biogen, Sage win FDA priority review for depression therapy",Seeking Alpha,https://seekingalpha.com/news/3932229-biogen-sage-win-fda-priority-review-for-depression-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.8114627599716187
1368,2/6/2023 12:40:47 PM,Sage Therapeutics: FDA To Review NDA For Zuranolone - Quick Facts ,RTTNews,/news/stocks/sage-therapeutics-fda-to-review-nda-for-zuranolone-quick-facts-1032069974,neutral,0.7556871771812439
1369,2/6/2023 6:14:46 PM,"Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'",Benzinga,/news/stocks/sage-therapeutics-biogen-partnered-depression-candidate-under-priority-fda-review-analyst-says-its-incrementally-positive-1032071046,positive,0.9378432035446167
1370,2/7/2023 5:10:32 PM,Anavex hits two-month high after Q1 FY23 results,Seeking Alpha,https://seekingalpha.com/news/3932982-avxl-stock-hits-two-month-high-after-q1-fy23-results?utm_source=businessinsider&utm_medium=referral,positive,0.9036287665367126
1371,2/9/2023 1:40:04 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Envista Holdings (NVST),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-envista-holdings-nvst-1032083039,neutral,0.895738422870636
1372,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,neutral,0.5336910486221313
1373,2/10/2023 4:49:47 PM,"Earnings week ahead: Coca-Cola, Shopify, Airbnb, Palantir and more",Seeking Alpha,https://seekingalpha.com/news/3934838-earnings-week-ahead-coca-cola-shopify-airbnb-palantir-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9118701219558716
1374,2/10/2023 7:30:55 PM,"Catalyst watch: Inflation reads, Roblox and DoorDash in the spotlight",Seeking Alpha,https://seekingalpha.com/news/3934884-catalyst-watch-inflation-reads-roblox-and-doordash-in-the-spotlight?utm_source=businessinsider&utm_medium=referral,neutral,0.8564732074737549
1375,2/12/2023 10:39:02 PM,"Q4 Reporting Season Pushes Past Halfway Mark: Coca-Cola, Cisco Systems, Palantir, Roku Lead Earnings This Week",Benzinga,/news/stocks/q4-reporting-season-pushes-past-halfway-mark-coca-cola-cisco-systems-palantir-roku-lead-earnings-this-week-1032088248,positive,0.9221210479736328
1376,2/14/2023 3:01:13 PM,Biogen earnings preview: what to expect,Markets Insider Automation,/news/stocks/biogen-stock-price-q4-earnings-preview-1032094835,neutral,0.9184785485267639
1377,2/14/2023 3:01:57 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3935880-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.855887770652771
1378,2/14/2023 4:39:27 PM,All eyes on Biogen Q4 results with focus on future of Alzheimer's drug Leqembi,Seeking Alpha,https://seekingalpha.com/news/3935814-all-eyes-on-biogen-q4-results-with-focus-on-future-of-alzheimers-drug-leqembi?utm_source=businessinsider&utm_medium=referral,neutral,0.90662682056427
1379,2/14/2023 4:51:52 PM,Biogen's Alzheimer's therapy Aduhelm gets updated warning on brain hemorrhage risk,Seeking Alpha,https://seekingalpha.com/news/3935819-biogen-alzheimers-therapy-aduhelm-gets-updated-warning-on-brain-hemorrhage-risk?utm_source=businessinsider&utm_medium=referral,neutral,0.7129017114639282
1380,2/15/2023 12:15:09 PM,Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook,Seeking Alpha,https://seekingalpha.com/news/3936246-biogen-beats-q4-top-and-bottom-line-estimates-initiates-fy23-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.8818645477294922
1381,2/15/2023 1:20:18 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-applied-dna-sciences-apdn-and-provention-bio-prvb-1032098845,neutral,0.8980934023857117
1382,2/15/2023 1:26:33 PM,"Biogen Inc. Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/biogen-inc-q4-profit-increases-beats-estimates-1032098624,positive,0.9417837262153625
1383,2/15/2023 1:30:10 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-chitogenx-otherchnxf-1032098900,neutral,0.881538450717926
1384,2/15/2023 2:00:48 PM,Biogen Q4 Results Top Estimates ,RTTNews,/news/stocks/biogen-q4-results-top-estimates-1032098771,neutral,0.46262219548225403
1385,2/15/2023 4:15:47 PM,Biogen expects new Alzheimer’s drug to weigh on 2023 outlook,Seeking Alpha,https://seekingalpha.com/news/3936422-biogen-expects-new-alzheimers-drug-to-weigh-on-2023-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.7233831882476807
1386,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,neutral,0.42181921005249023
1387,2/16/2023 9:55:12 AM,Biogen (BIIB) Gets a Buy from Morgan Stanley,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-morgan-stanley-1032101907,positive,0.5427836179733276
1388,2/16/2023 10:45:15 AM,Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-hold-rating-for-biogen-biib-1032102084,neutral,0.9009045362472534
1389,2/16/2023 12:25:29 PM,BMO Capital Gives a Buy Rating to Biogen (BIIB),TipRanks,/news/stocks/bmo-capital-gives-a-buy-rating-to-biogen-biib-1032102490,neutral,0.837228536605835
1390,2/16/2023 12:25:33 PM,H.C. Wainwright Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/h-c-wainwright-reaffirms-their-buy-rating-on-biogen-biib-1032102488,neutral,0.7780326008796692
1391,2/16/2023 1:40:10 PM,"Analysts’ Top Healthcare Picks: Alkermes (ALKS), Biogen (BIIB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alkermes-alks-biogen-biib-1032102802,positive,0.6690570712089539
1392,2/16/2023 4:40:08 PM,"Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amedisys-amed-biogen-biib-and-waters-wat-1032103509,neutral,0.9110947847366333
1393,2/17/2023 4:50:18 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biogen-biib-sage-therapeutics-sage-and-karyopharm-therapeutics-kpti-1032104439,negative,0.931009829044342
1394,2/17/2023 3:05:24 PM,Biogen (BIIB) Gets a Buy from SVB Securities,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-svb-securities-1032106406,neutral,0.7008225917816162
1395,2/17/2023 3:21:05 PM,Eisai exec expects full approval of Alzheimer's therapy Leqembi this summer - CNBC,Seeking Alpha,https://seekingalpha.com/news/3937741-eisai-exec-expects-full-approval-of-alzheimers-therapy-leqembi-this-summer-cnbc?utm_source=businessinsider&utm_medium=referral,neutral,0.7042194604873657
1396,2/17/2023 5:54:00 PM,Senators urge swift action to expand Medicare coverage for Alzheimer’s therapies,Seeking Alpha,https://seekingalpha.com/news/3937793-senators-urge-expand-medicare-coverage-for-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.9097912907600403
1397,2/17/2023 7:08:03 PM,"Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved'",Benzinga,/news/stocks/analyst-initiates-coverage-of-ge-healthcare-says-path-to-greatness-well-paved-1032106818,positive,0.8538906574249268
1398,2/18/2023 1:25:20 AM,Barclays Remains a Hold on Biogen (BIIB),TipRanks,/news/stocks/barclays-remains-a-hold-on-biogen-biib-1032107089,neutral,0.9156948328018188
1399,2/23/2023 11:53:25 AM,Medicare says coverage limits on Alzheimer’s drugs is not under review,Seeking Alpha,https://seekingalpha.com/news/3939776-medicare-says-coverage-limits-on-alzheimers-drugs-is-not-under-review?utm_source=businessinsider&utm_medium=referral,neutral,0.8763622641563416
1400,2/24/2023 1:50:51 AM,"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Medtronic (MDT) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-crispr-therapeutics-ag-crsp-medtronic-mdt-and-biogen-biib-1032121545,neutral,0.9075863361358643
1401,2/27/2023 6:39:44 PM,Why Reata Pharmaceuticals Shares Are Falling Monday?,Benzinga,/news/stocks/why-reata-pharmaceuticals-shares-are-falling-monday-1032128597,negative,0.9597981572151184
1402,2/27/2023 7:12:10 PM,Reata in selloff ahead of FDA decision on lead asset as top agency official departs (Update),Seeking Alpha,https://seekingalpha.com/news/3941282-reta-stock-in-selloff-as-top-fda-official-departs?utm_source=businessinsider&utm_medium=referral,negative,0.7177977561950684
1403,2/28/2023 12:30:00 AM,BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION,PR Newswire,/news/stocks/biologics-license-application-for-lecanemab-designated-for-priority-review-by-china-national-medical-products-administration-1032129229,neutral,0.8316234946250916
1404,2/28/2023 8:39:39 AM,Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China ,RTTNews,/news/stocks/biogen-says-bla-for-lecanemab-gets-priority-review-by-nmpa-in-china-1032130239,positive,0.5143750309944153
1405,2/28/2023 9:32:44 AM,"Biogen, Eisai's Alzheimer's therapy lecanemab gets priority review in Chinna",Seeking Alpha,https://seekingalpha.com/news/3941597-biogen-eisais-alzheimers-therapy-lecanemab-gets-priority-review-in-chinna?utm_source=businessinsider&utm_medium=referral,neutral,0.6104445457458496
1406,2/28/2023 9:45:54 AM,Biotech Stocks Facing FDA Decision In March 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2023-1032130420,neutral,0.9167791604995728
1407,3/1/2023 5:53:18 PM,Roche's Genentech sues Biogen over additional patent royalties from Tysabri sales,Seeking Alpha,https://seekingalpha.com/news/3942758-roche-genentech-sues-biogen-over-additional-patent-royalties-from-tysabri-sales?utm_source=businessinsider&utm_medium=referral,negative,0.941439151763916
1408,3/2/2023 1:50:11 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Outset Medical (OM) and Prometheus Biosciences (RXDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-outset-medical-om-and-prometheus-biosciences-rxdx-1032138105,neutral,0.9016881585121155
1409,3/6/2023 12:30:00 AM,FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease,PR Newswire,/news/stocks/fda-accepts-eisai-s-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimer-s-disease-1032145806,positive,0.7559239864349365
1410,3/6/2023 2:13:43 AM,FDA Grants Priority Review For Approval Of Eisai's Leqembi For Alzheimer's Disease Treatment ,RTTNews,/news/stocks/fda-grants-priority-review-for-approval-of-eisai-s-leqembi-for-alzheimer-s-disease-treatment-1032145819,positive,0.6926857233047485
1411,3/6/2023 9:34:16 AM,"Biogen, Eisai's Alzheimer's drug Leqembi gets FDA priority review for traditional approval",Seeking Alpha,https://seekingalpha.com/news/3944299-biogen-eisais-alzheimers-drug-lecanemab-gets-fda-priority-review-for-traditional-approval?utm_source=businessinsider&utm_medium=referral,positive,0.7803711891174316
1412,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,positive,0.5336588621139526
1413,3/8/2023 11:57:03 AM,"FDA to not hold panel meeting for Biogen, Sage's depression therapy zuranolone",Seeking Alpha,https://seekingalpha.com/news/3945236-fda-to-not-hold-panel-meeting-for-biogen-sages-depression-therapy-zuranolone?utm_source=businessinsider&utm_medium=referral,neutral,0.8339474201202393
1414,3/8/2023 12:56:03 PM,Biogen elects new board chairperson,Seeking Alpha,https://seekingalpha.com/news/3945288-biogen-elects-new-board-chairperson?utm_source=businessinsider&utm_medium=referral,neutral,0.910110354423523
1415,3/9/2023 2:35:57 PM,Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock,InvestorPlace,/news/stocks/insider-richard-barry-is-betting-big-on-cassava-sava-stock-2-1032157154,neutral,0.9136545658111572
1416,3/10/2023 7:36:36 PM,Eisai expects $7B sales from Biogen-partnered Alzheimer’s therapy in 2030,Seeking Alpha,https://seekingalpha.com/news/3946569-eisai-sees-biogen-partnered-alzheimers-therapy-to-bring-over-7b-sales-in-2030?utm_source=businessinsider&utm_medium=referral,positive,0.7476333975791931
1417,3/12/2023 2:00:00 PM,Biosimilars expected to save $180B over next five years as more gain approval,Seeking Alpha,https://seekingalpha.com/news/3946583-biosimilars-expected-to-save-180b-over-next-five-years-as-more-gain-approval?utm_source=businessinsider&utm_medium=referral,positive,0.8129684329032898
1418,3/13/2023 2:58:31 PM,Sage upgraded to outperform at RBC on greater confidence in zuranolone approval,Seeking Alpha,https://seekingalpha.com/news/3946885-sage-upgraded-to-outperform-at-rbc-on-greater-confidence-in-zuranolone-approval?utm_source=businessinsider&utm_medium=referral,positive,0.9441965222358704
1419,3/13/2023 6:25:30 PM,"Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone",Benzinga,/news/stocks/analyst-creates-bullish-pitch-for-sage-therapeutics-around-greater-enthusiasm-for-its-depression-drug-zuranolone-1032164018,positive,0.9343584775924683
1420,3/13/2023 6:30:34 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-crinetics-pharmaceuticals-crnx-and-89bio-etnb-1032164178,neutral,0.8998739719390869
1421,3/14/2023 10:11:00 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-illumina-ilmn-and-arcutis-biotherapeutics-arqt-1032165638,negative,0.6894925832748413
1422,3/16/2023 11:01:27 AM,Biogen gets EU court ruling in favor of blocking Tecfidera generic entry,Seeking Alpha,https://seekingalpha.com/news/3948065-biogen-gets-eu-court-ruling-in-favor-of-blocking-tecfidera-generic-entry?utm_source=businessinsider&utm_medium=referral,negative,0.5405267477035522
1423,3/16/2023 1:37:37 PM,Biogen Gets Favorable EU Court Ruling For TECFIDERA Regulatory Data And Marketing Protection ,RTTNews,/news/stocks/biogen-gets-favorable-eu-court-ruling-for-tecfidera-regulatory-data-and-marketing-protection-1032172693,positive,0.9420636892318726
1424,3/17/2023 10:11:31 PM,"Sangamo down post-market as Novartis, Biogen end collaborations",Seeking Alpha,https://seekingalpha.com/news/3948666-sangamo-down-post-market-as-novartis-biogen-end-collaborations?utm_source=businessinsider&utm_medium=referral,negative,0.5980314612388611
1425,3/20/2023 2:49:05 PM,FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting,Seeking Alpha,https://seekingalpha.com/news/3948901-fda-scientists-weigh-potential-effect-of-biogen-als-drug-tofersen-ahead-advisory-meeting?utm_source=businessinsider&utm_medium=referral,neutral,0.8942844271659851
1426,3/20/2023 3:20:47 PM,"Biogen, Eisai Alzheimer's drug Leqembi covered by VA",Seeking Alpha,https://seekingalpha.com/news/3948916-biogen-eisai-alzheimers-drug-leqembi-lecanemab-covered-by-veterans-administration?utm_source=businessinsider&utm_medium=referral,neutral,0.9352534413337708
1427,3/20/2023 3:25:22 PM,Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo,Benzinga,/news/stocks/two-big-pharma-companies-bow-out-of-neurology-drug-partnerships-with-sangamo-1032179260,neutral,0.5198420286178589
1428,3/20/2023 11:00:52 PM,"Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-biogen-biib-sarepta-therapeutics-srpt-and-g1-therapeutics-gthx-1032180438,negative,0.6183700561523438
1429,3/21/2023 12:50:48 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-danaher-dhr-and-blueprint-medicines-bpmc-1032181792,neutral,0.8882130980491638
1430,3/21/2023 8:13:55 PM,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-long-term-growth-and-stability-1032183221,neutral,0.7752801775932312
1431,3/22/2023 9:06:31 PM,Biogen ALS drug tofersen earns mixed voting by FDA advisory panel,Seeking Alpha,https://seekingalpha.com/news/3950163-biogen-ionis-als-drug-tofersen-wins-unanimous-fda-panel-recommendation?utm_source=businessinsider&utm_medium=referral,neutral,0.6810504794120789
1432,3/22/2023 10:05:49 PM,Biogen ALS drug tofersen earns mixed voting by FDA advisory panel,Seeking Alpha,https://seekingalpha.com/news/3950163-biogen-ionis-als-drug-tofersen-earns-mixed-voting-fda-advisors?utm_source=businessinsider&utm_medium=referral,neutral,0.6810504794120789
1433,3/23/2023 5:34:52 AM,Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS ,RTTNews,/news/stocks/biogen-updates-on-fda-advisory-committee-meeting-on-tofersen-for-sod1-als-1032186321,neutral,0.9002088904380798
1434,3/23/2023 10:35:19 AM,Biogen (BIIB) Receives a Hold from BTIG,TipRanks,/news/stocks/biogen-biib-receives-a-hold-from-btig-1032187217,neutral,0.8793240189552307
1435,3/23/2023 10:35:23 AM,Raymond James Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/raymond-james-sticks-to-its-hold-rating-for-biogen-biib-1032187215,neutral,0.850737452507019
1436,3/23/2023 10:40:25 AM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-applied-dna-sciences-apdn-1032187211,positive,0.6621875166893005
1437,3/23/2023 12:30:32 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-regeneron-regn-and-alcon-alc-1032187724,neutral,0.9025923013687134
1438,3/23/2023 5:56:39 PM,7 Blue-Chip Stocks Sitting in the Sweet Spot,InvestorPlace,/news/stocks/7-blue-chip-stocks-sitting-in-the-sweet-spot-1032189016,neutral,0.6686829924583435
1439,3/23/2023 7:01:30 PM,11 Analysts Have This to Say About Biogen,Benzinga,/news/stocks/11-analysts-have-this-to-say-about-biogen-1032189005,neutral,0.9316033124923706
1440,3/24/2023 10:32:42 AM,"5 Best Healthcare Stocks to Invest in Now, According to Analysts",TipRanks,/news/stocks/5-best-healthcare-stocks-to-invest-in-now-according-to-analysts-1032190451,positive,0.5423818826675415
1441,3/28/2023 5:21:30 AM,"VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?",TipRanks,/news/stocks/vrtx-biib-or-iqv-which-biotech-stock-could-deliver-the-highest-return-1032195771,neutral,0.9018274545669556
1442,3/29/2023 3:27:14 PM,Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions ,RTTNews,/news/stocks/biogen-biib080-phase-1b-study-shows-reduction-of-tau-pet-across-brain-regions-1032200596,positive,0.8686668276786804
1443,3/31/2023 1:30:00 AM,EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING,PR Newswire,/news/stocks/eisai-presented-new-analyses-of-aria-and-qol-on-lecanemab-in-clarity-ad-at-the-ad-pd-2023-annual-meeting-1032205100,neutral,0.9014522433280945
1444,3/31/2023 1:31:00 AM,ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS,PR Newswire,/news/stocks/additional-detailed-analyses-from-phase-2-study-201-of-lecanemab-published-as-three-papers-in-peer-reviewed-journals-1032205103,neutral,0.9330966472625732
1445,3/31/2023 7:22:38 AM,"Eisai, Biogen Present Lecanemab New Analyses In Phase 3 Trial; Detailed Analyses In Phase IIb Trial ",RTTNews,/news/stocks/eisai-biogen-present-lecanemab-new-analyses-in-phase-3-trial-detailed-analyses-in-phase-iib-trial-1032205749,neutral,0.807745635509491
1446,3/31/2023 4:34:41 PM,Biotech Stocks Facing FDA Decision In April 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2023-1032207401,neutral,0.9138153195381165
1447,4/3/2023 11:05:32 AM,US to create Alzheimer's research database in ~$300M project - report,Seeking Alpha,https://seekingalpha.com/news/3953520-us-create-alzheimers-research-database-300m-project-report?utm_source=businessinsider&utm_medium=referral,neutral,0.8143214583396912
1448,4/4/2023 4:20:43 PM,Biogen names Adam Keeney to head corporate development,Seeking Alpha,https://seekingalpha.com/news/3954410-biogen-names-adam-keeney-head-corporate-development?utm_source=businessinsider&utm_medium=referral,neutral,0.9434018731117249
1449,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral,negative,0.8911572098731995
1450,4/7/2023 8:28:16 PM,The 3 Best Millionaire-Maker Stocks to Buy for April 2023,InvestorPlace,/news/stocks/the-3-best-millionaire-maker-stocks-to-buy-for-april-2023-1032220912,neutral,0.8748061656951904
1451,4/8/2023 1:45:21 AM,RBC Capital Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-biogen-biib-1032220982,positive,0.5832391977310181
1452,4/10/2023 5:53:43 PM,"Biogen, Eisai to face FDA AdCom in June for full approval of Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3955389-biogen-stock-to-face-june-fda-adcom-for-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.6271350979804993
1453,4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral,negative,0.7583171129226685
1454,4/11/2023 1:46:41 PM,3 Biotech Stocks to Watch for Potential Breakthroughs,InvestorPlace,/news/stocks/3-biotech-stocks-to-watch-for-potential-breakthroughs-1032224599,neutral,0.8524482250213623
1455,4/11/2023 4:40:08 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-centene-cnc-ionis-pharmaceuticals-ions-and-biogen-biib-1032225110,negative,0.922767698764801
1456,4/11/2023 5:01:44 PM,12 Analysts Have This to Say About Biogen,Benzinga,/news/stocks/12-analysts-have-this-to-say-about-biogen-1032224794,neutral,0.9325107932090759
1457,4/12/2023 12:35:13 PM,Biogen licenses amyloid beta-related program from Denali,Seeking Alpha,https://seekingalpha.com/news/3955921-biogen-stock-licenses-amyloid-beta-related-program-from-denali?utm_source=businessinsider&utm_medium=referral,neutral,0.7273128032684326
1458,4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral,neutral,0.5150914192199707
1459,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,positive,0.6195564866065979
1460,4/14/2023 5:30:11 PM,"Catalyst Watch: Earnings season picks up steam, housing data due",Seeking Alpha,https://seekingalpha.com/news/3956620-catalyst-watch-earnings-season-picks-up-steam-housing-data-due?utm_source=businessinsider&utm_medium=referral,neutral,0.5577772855758667
1461,4/14/2023 6:30:56 PM,"Earnings Week Ahead: Tesla, AT&T, Charles Schwab, Netflix, and more",Seeking Alpha,https://seekingalpha.com/news/3956682-earnings-week-ahead-tesla-att-charles-schwab-netflix-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9345334768295288
1462,4/16/2023 10:30:42 AM,7 Sorry Pharma Stocks to Sell in April Before It’s Too Late,InvestorPlace,/news/stocks/7-sorry-pharma-stocks-to-sell-in-april-before-its-too-late-1032234376,neutral,0.8589942455291748
1463,4/16/2023 4:08:24 PM,3 Stocks to Buy That Could Be the Next Biotech Breakthrough,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-that-could-be-the-next-big-breakthrough-1032234593,neutral,0.8774265050888062
1464,4/17/2023 9:00:26 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Prometheus Biosciences (RXDX), Staar Surgical (STAA) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prometheus-biosciences-rxdx-staar-surgical-staa-and-biogen-biib-1032235741,negative,0.934650719165802
1465,4/17/2023 2:03:55 PM,"Biogen's Leqembi has questionable efficacy, cost effectiveness, ICER says",Seeking Alpha,https://seekingalpha.com/news/3956921-biogen-eisai-leqembi-alzheimbers-questionable-efficacy-cost-effectiveness-icer?utm_source=businessinsider&utm_medium=referral,negative,0.9201794266700745
1466,4/17/2023 5:00:44 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-17-2023-1032236863,neutral,0.49481281638145447
1467,4/17/2023 8:08:00 PM,"Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst",Benzinga,/news/stocks/leqembi-sales-to-propel-biogen-stock-to-new-heights-says-bullish-analyst-1032237325,positive,0.9477007389068604
1468,4/19/2023 1:01:34 PM,"Alnylam, Intra-Cellular among potential biotech take-out targets - RBC",Seeking Alpha,https://seekingalpha.com/news/3957656-alnylam-intra-cellular-among-potential-biotech-take-out-targets-rbc?utm_source=businessinsider&utm_medium=referral,neutral,0.5791764855384827
1469,4/21/2023 12:00:53 PM,"Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amerisourcebergen-abc-biogen-biib-1032249758,neutral,0.5846717357635498
1470,4/21/2023 12:10:11 PM,"Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Biogen (BIIB) and Elevance Health (ELV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amerisourcebergen-abc-biogen-biib-and-elevance-health-elv-1032249724,neutral,0.9015927910804749
1471,4/21/2023 12:30:10 PM,Eli Lilly expects Medicare coverage for Alzheimer's drugs - Reuters,Seeking Alpha,https://seekingalpha.com/news/3958637-eli-lilly-expects-medicare-coverage-alzheimers-drugs-reuters?utm_source=businessinsider&utm_medium=referral,neutral,0.742505669593811
1472,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9372533559799194
1473,4/21/2023 7:00:36 PM,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",Seeking Alpha,https://seekingalpha.com/news/3958768-catalyst-watch-earnings-blitz-mobileye-lockup-expiration-and-the-new-one-day-vix-debut?utm_source=businessinsider&utm_medium=referral,neutral,0.9063060879707336
1474,4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,neutral,0.902015209197998
1475,4/24/2023 2:24:40 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3959106-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8660826683044434
1476,4/24/2023 3:01:13 PM,Here's what to expect from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-quarter-earnings-preview-q1-1032254116,neutral,0.9376587867736816
1477,4/24/2023 3:52:38 PM,"Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future",Seeking Alpha,https://seekingalpha.com/news/3959137-biogen-q1-results-focus-amid-leqembi-conundrum-als-drug-future?utm_source=businessinsider&utm_medium=referral,positive,0.8308854699134827
1478,4/25/2023 11:03:28 AM,"Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M",Seeking Alpha,https://seekingalpha.com/news/3959581-biogen-non-gaap-eps-of-3_40-beats-0_12-revenue-of-2_46b-beats-120m?utm_source=businessinsider&utm_medium=referral,neutral,0.7371396422386169
1479,4/25/2023 12:01:00 PM,"Biogen trims down R&D programs, Q1 revenue dips but reaffirms FY23 outlook",Seeking Alpha,https://seekingalpha.com/news/3959628-biogen-trims-down-rd-programs-q1-revenue-dips-but-reaffirms-fy23-outlook?utm_source=businessinsider&utm_medium=referral,negative,0.9499548673629761
1480,4/25/2023 12:05:11 PM,Biogen (BIIB) Gets a Buy from Mizuho Securities,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-mizuho-securities-1032258117,neutral,0.5158860683441162
1481,4/25/2023 1:31:19 PM,Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook ,RTTNews,/news/stocks/biogen-q1-results-top-estimates-reaffirms-fy23-outlook-1032257923,positive,0.7183627486228943
1482,4/25/2023 5:10:31 PM,"Hot Stocks: Earnings sparked movement in PEP, JBLU, NVS, MCD, BIIB and HAL",Seeking Alpha,https://seekingalpha.com/news/3959907-hot-stocks-earnings-sparked-movement-in-pep-jblu-nvs-mcd-biib-and-hal?utm_source=businessinsider&utm_medium=referral,positive,0.9420717358589172
1483,4/25/2023 5:25:23 PM,BTIG Reaffirms Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/btig-reaffirms-their-hold-rating-on-biogen-biib-1032259571,neutral,0.7462924718856812
1484,4/25/2023 7:11:35 PM,"Biogen, Ionis win FDA nod for ALS therapy Qalsody",Seeking Alpha,https://seekingalpha.com/news/3959949-biogen-stock-ionis-stock-win-fda-nod-als-therapy-qalsody?utm_source=businessinsider&utm_medium=referral,positive,0.9275956153869629
1485,4/25/2023 8:30:38 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Cognetivity Neurosciences (OtherCGNSF),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-cognetivity-neurosciences-othercgnsf-1032259964,neutral,0.8695898652076721
1486,4/25/2023 10:05:43 PM,Biogen (BIIB) Gets a Buy from Morgan Stanley,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-morgan-stanley-1032260216,positive,0.5427836179733276
1487,4/26/2023 3:40:53 AM,FDA Grants Accelerated Approval For Biogen's ALS Drug ,RTTNews,/news/stocks/fda-grants-accelerated-approval-for-biogen-s-als-drug-1032260275,positive,0.8479669690132141
1488,4/26/2023 9:10:18 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Centene (CNC) and Danaher (DHR)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-centene-cnc-and-danaher-dhr-1032262473,negative,0.6825053691864014
1489,4/26/2023 10:20:47 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Lineage Therap (LCTX) and Laboratory (LH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-lineage-therap-lctx-and-laboratory-lh-1032262704,neutral,0.8957868814468384
1490,4/26/2023 11:10:27 AM,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Amylyx Pharmaceuticals Inc (AMLX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-amylyx-pharmaceuticals-inc-amlx-1032262907,positive,0.5736332535743713
1491,4/26/2023 12:30:24 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-harvard-bioscience-hbio-and-disc-medicine-iron-1032263395,neutral,0.9072967171669006
1492,4/26/2023 12:35:51 PM,Jefferies Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/jefferies-remains-a-buy-on-biogen-biib-1032263374,neutral,0.9425736665725708
1493,4/26/2023 12:40:14 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Boston Scientific (BSX) and Danaher (DHR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-boston-scientific-bsx-and-danaher-dhr-1032263372,neutral,0.9135190844535828
1494,4/26/2023 2:38:22 PM,These Analysts Revise Price Targets On Biogen Following Q1 Results,Benzinga,/news/stocks/these-analysts-revise-price-targets-on-biogen-following-q1-results-1032263408,neutral,0.9257053732872009
1495,4/26/2023 2:55:03 PM,Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday,Benzinga,/news/stocks/alphabet-to-rally-around-36-here-are-10-other-analyst-forecasts-for-wednesday-1032263428,neutral,0.9081512689590454
1496,4/26/2023 3:32:44 PM,Lilly to report Q1 2023 results with pipeline updates in spotlight,Seeking Alpha,https://seekingalpha.com/news/3960530-lilly-stock-report-q1-2023-results-wth-pipeline-updates-focus?utm_source=businessinsider&utm_medium=referral,neutral,0.9159575700759888
1497,4/26/2023 8:05:11 PM,Biogen gains as Medicare to cover new Alzheimer’s drug with full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3960780-biogen-stock-gains-medicare-cover-new-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,positive,0.9222493171691895
1498,4/27/2023 3:20:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Lineage Therap (LCTX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-lineage-therap-lctx-1032269549,positive,0.5974254012107849
1499,4/28/2023 10:26:31 AM,The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy,InvestorPlace,/news/stocks/the-3-most-promising-biotech-innovations-in-2023-and-the-stocks-to-buy-1032273160,neutral,0.6292579770088196
1500,5/1/2023 12:33:59 PM,Morgan Stanley's Wilson screens for stocks as earnings stabilize but data disappoints,Seeking Alpha,https://seekingalpha.com/news/3962504-norgan-stanleys-wilson-screens-for-stocks-as-earnigns-stabilize-but-data-disappoints?utm_source=businessinsider&utm_medium=referral,negative,0.62675541639328
1501,5/1/2023 12:47:05 PM,Biogen up as Guggenheim upgrades citing full approval for Leqembi,Seeking Alpha,https://seekingalpha.com/news/3962570-biogen-stock-up-guggenheim-upgrades-full-approval-for-leqembi?utm_source=businessinsider&utm_medium=referral,positive,0.8898754119873047
1502,5/1/2023 5:00:43 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-1-2023-1032278640,neutral,0.5625030994415283
1503,5/1/2023 6:54:13 PM,Biotech Is Back With Guggenheim Upgrade: What You Need To Know,Benzinga,/news/stocks/biotech-is-back-with-guggenheim-upgrade-what-you-need-to-know-1032278899,neutral,0.8845245838165283
1504,5/2/2023 3:37:13 PM,Biogen prices ALS therapy Qalsody at $14K a dose - report,Seeking Alpha,https://seekingalpha.com/news/3963469-biogen-prices-als-therapy-qalsody-14k-dose-?utm_source=businessinsider&utm_medium=referral,neutral,0.8993679285049438
1505,5/3/2023 11:13:53 AM,"Lilly stock surges after Alzheimer's drug donanemab slows cognitive decline by 35%, brain swelling seen in some",Seeking Alpha,https://seekingalpha.com/news/3964326-lilly-stock-rises-after-alzheimers-drug-donanemab-slows-cognitive-decline?utm_source=businessinsider&utm_medium=referral,positive,0.811806857585907
1506,5/3/2023 2:04:02 PM,Biogen wins EU exclusivity for Tecfidera until 2025,Seeking Alpha,https://seekingalpha.com/news/3964481-biogen-wins-eu-exclusivity-tecfidera-until-2025?utm_source=businessinsider&utm_medium=referral,positive,0.8352382183074951
1507,5/3/2023 7:37:28 PM,Lilly sends Alzheimer’s drug developers higher after trial data,Seeking Alpha,https://seekingalpha.com/news/3964896-lilly-stock-sends-alzheimers-drug-developers-higher-after-trial-data?utm_source=businessinsider&utm_medium=referral,positive,0.8823214173316956
1508,5/4/2023 9:06:04 PM,"Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen",Benzinga,/news/stocks/analysts-say-eli-lilly-s-donanemab-in-alzheimer-s-is-encouraging-outline-potential-implications-for-biogen-1032294014,positive,0.9320788383483887
1509,5/6/2023 12:15:14 PM,Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-biogen-biib-1032298994,neutral,0.5589914321899414
1510,5/9/2023 7:01:01 PM,Cassava Sciences adds 14% most since September,Seeking Alpha,https://seekingalpha.com/news/3968377-cassava-sciences-stock-gains-most-since-september?utm_source=businessinsider&utm_medium=referral,positive,0.8533794283866882
1511,5/11/2023 9:56:21 AM,"Lundbeck, Otsuka's Rexulti wins FDA approval for agitation linked with Alzheimer's",Seeking Alpha,https://seekingalpha.com/news/3969842-lundbeck-otsukas-rexulti-wins-fda-nod-for-alzheimers-agitation?utm_source=businessinsider&utm_medium=referral,positive,0.889922022819519
1512,5/14/2023 4:00:49 PM,Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study,Seeking Alpha,https://seekingalpha.com/news/3971102-biogen-new-alzheimers-drug-leqembi-raise-medicare-costs?utm_source=businessinsider&utm_medium=referral,positive,0.9365440011024475
1513,5/15/2023 11:15:20 AM,Biogen (BIIB) Receives a Hold from Bank of America Securities,TipRanks,/news/stocks/biogen-biib-receives-a-hold-from-bank-of-america-securities-1032327071,neutral,0.8284618854522705
1514,5/16/2023 5:12:22 AM,Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease ,RTTNews,/news/stocks/biogen-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimer-s-disease-1032329124,positive,0.8895255327224731
1515,5/16/2023 1:07:42 PM,"Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront  cash/equity deal",Seeking Alpha,https://seekingalpha.com/news/3972036-lilly-scribe-team-up-for-neuro-diseases-crispr-therapies?utm_source=businessinsider&utm_medium=referral,neutral,0.6606526970863342
1516,5/17/2023 4:13:55 PM,Prothena adds former FDA neuro chief Billy Dunn to director board,Seeking Alpha,https://seekingalpha.com/news/3972658-prothena-stock-adds-ex-fda-neuro-chief-billy-dunn-board?utm_source=businessinsider&utm_medium=referral,neutral,0.9268184900283813
1517,5/18/2023 3:30:11 PM,Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer’s study,Seeking Alpha,https://seekingalpha.com/news/3973090-cognition-stock-rises-after-ct1812-shows-promise-in-alzheimers?utm_source=businessinsider&utm_medium=referral,positive,0.9288967251777649
1518,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,negative,0.7930808663368225
1519,5/18/2023 7:30:02 PM,"Sen. Wyden presses HHS, CMS on access to new Alzheimer's therapies",Seeking Alpha,https://seekingalpha.com/news/3973210-sen-ron-wyden-presses-hhs-cms-access-new-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral,neutral,0.8973407745361328
1520,5/19/2023 2:00:52 PM,3 Biotech Stocks That Are Revolutionizing Healthcare in 2023,InvestorPlace,/news/stocks/best-biotech-stocks-to-buy-on-the-cusp-of-breakthroughs-1032340011,neutral,0.8015283346176147
1521,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.7357140183448792
1522,5/22/2023 5:26:07 AM,BioArctic : Marketing Authorization Application For Lecanemab Submitted In Great Britain ,RTTNews,/news/stocks/bioarctic-marketing-authorization-application-for-lecanemab-submitted-in-great-britain-1032341440,neutral,0.8690115809440613
1523,5/23/2023 12:30:48 PM,"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-biogen-biib-and-blueprint-medicines-bpmc-1032345266,neutral,0.890754759311676
1524,5/23/2023 12:40:21 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Blueprint Medicines (BPMC) and Cerevel Therapeutics Holdings (CERE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-blueprint-medicines-bpmc-and-cerevel-therapeutics-holdings-cere-1032345246,neutral,0.9070670008659363
1525,5/23/2023 10:02:21 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1032346575,neutral,0.9187624454498291
1526,5/26/2023 10:38:37 AM,Elon Musk's Neuralink gets FDA nod to start human trial of brain implant,Seeking Alpha,https://seekingalpha.com/news/3975338-elon-musks-neuralink-gets-fda-nod-to-start-human-trial-of-brain-implant?utm_source=businessinsider&utm_medium=referral,positive,0.5858261585235596
1527,6/1/2023 2:33:27 PM,Medicare to cover Alzheimer's drugs granted full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3976628-medicare-cover-alzheimers-drugs-granted-full-fda-approval?utm_source=businessinsider&utm_medium=referral,positive,0.8785544037818909
1528,6/1/2023 4:05:06 PM,Biogen (BIIB) Receives a Buy from Mizuho Securities,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-mizuho-securities-1032365263,neutral,0.5102506279945374
1529,6/1/2023 4:55:14 PM,Goldman Sachs Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/goldman-sachs-remains-a-buy-on-biogen-biib-1032365371,neutral,0.9233411550521851
1530,6/2/2023 4:30:52 PM,"Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-stericycle-srcl-biogen-biib-and-acadia-healthcare-achc-1032367908,neutral,0.906990647315979
1531,6/5/2023 2:26:34 PM,"Biogen, Denali to halt late-stage trial for Parkinson’s disease drug",Seeking Alpha,https://seekingalpha.com/news/3977588-biogen-denali-halt-trial-parkinsons-disease-drug?utm_source=businessinsider&utm_medium=referral,negative,0.49954408407211304
1532,6/7/2023 3:45:06 PM,Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-buy-rating-on-biogen-biib-1032376495,neutral,0.5589914321899414
1533,6/7/2023 5:04:36 PM,Biogen gains on “super clean” FDA docs on Alzheimer’s drug ahead of AdCom vote,Seeking Alpha,https://seekingalpha.com/news/3978291-biogen-stock-gains-fda-briefing-docs-alzheimers-drug-leqembi?utm_source=businessinsider&utm_medium=referral,positive,0.7853974103927612
1534,6/7/2023 5:49:39 PM,Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio,Benzinga,/news/stocks/thinking-of-buying-boston-properties-here-are-the-properties-and-tenants-you-d-add-to-your-portfolio-1032376482,neutral,0.9421291947364807
1535,6/7/2023 6:15:32 PM,Biogen (BIIB) Receives a Buy from Goldman Sachs,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-goldman-sachs-1032376813,positive,0.5906081199645996
1536,6/8/2023 9:00:45 AM,"Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-avita-medical-rcel-4d-molecular-therapeutics-fdmt-and-biogen-biib-1032377840,negative,0.6266195774078369
1537,6/8/2023 11:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Paycor HCM (PYCR), Crispr Therapeutics AG (CRSP) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-paycor-hcm-pycr-crispr-therapeutics-ag-crsp-and-biogen-biib-1032378180,neutral,0.9034797549247742
1538,6/8/2023 12:30:46 PM,"Analysts’ Top Healthcare Picks: HashiCorp (HCP), Astria Therapeutics (ATXS)",TipRanks,/news/stocks/analysts-top-healthcare-picks-hashicorp-hcp-astria-therapeutics-atxs-1032378374,positive,0.7583184242248535
1539,6/8/2023 3:01:55 PM,Expert Ratings for Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1032378489,neutral,0.834668755531311
1540,6/9/2023 11:35:15 AM,Biogen on hold for trading ahead of FDA AdCom vote on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3978902-biogen-stock-hold-trading-ahead-leqembi-adcom-vote?utm_source=businessinsider&utm_medium=referral,negative,0.6340027451515198
1541,6/9/2023 1:46:33 PM,SVB Securities Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-biogen-biib-1032380942,neutral,0.7309050559997559
1542,6/9/2023 7:59:23 PM,"FDA panel recommends full approval for Biogen, Esai Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3979004-fda-panel-recommends-full-approval-biogen-esai-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.6265135407447815
1543,6/9/2023 8:22:00 PM,"FDA panel recommends full approval for Biogen, Eisai Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3979004-fda-panel-recommends-full-approval-biogen-eisai-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.6105651259422302
1544,6/9/2023 9:05:25 PM,FDA Advisors Evaluate Whether Alzheimer's Drug Leqembi Should Get Full Approval ,RTTNews,/news/stocks/fda-advisors-evaluate-whether-alzheimer-s-drug-leqembi-should-get-full-approval-1032381522,neutral,0.7802136540412903
1545,6/10/2023 12:45:00 AM,FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease,PR Newswire,/news/stocks/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimer-s-disease-1032381697,positive,0.9034731388092041
1546,6/10/2023 1:50:34 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Zimmer Biomet Holdings (ZBH) and Innate Pharma SA (OtherIPHYF)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-biogen-biib-zimmer-biomet-holdings-zbh-and-innate-pharma-sa-otheriphyf-1032381720,negative,0.935036301612854
1547,6/11/2023 4:00:02 PM,Alzheimer’s disease market expected to reach $14B globally in 2030,Seeking Alpha,https://seekingalpha.com/news/3979065-biogens-leqembi-drive-alzheimers-market-2030?utm_source=businessinsider&utm_medium=referral,positive,0.8635393977165222
1548,6/12/2023 3:54:08 AM,FDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug Leqembi ,RTTNews,/news/stocks/fda-panel-recommends-full-approval-for-biogen-and-eisai-s-alzheimer-s-drug-leqembi-1032382258,positive,0.5854119658470154
1549,6/12/2023 10:30:26 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032383116,positive,0.552167534828186
1550,6/12/2023 12:10:29 PM,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-biogen-biib-1032383345,neutral,0.9119682908058167
1551,6/12/2023 12:31:44 PM,"Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), Humacyte (HUMA) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immunogen-imgn-humacyte-huma-and-biogen-biib-1032383456,neutral,0.9001039862632751
1552,6/12/2023 12:50:13 PM,"Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), Biogen (BIIB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-keros-therapeutics-kros-biogen-biib-1032383507,positive,0.7867993116378784
1553,6/12/2023 2:47:35 PM,BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing,InvestorPlace,/news/stocks/biib-stock-alert-biogen-resumes-trading-with-new-fda-backing-1032383860,neutral,0.8796477913856506
1554,6/12/2023 2:57:53 PM,Biogen stock doesn't see big boost from FDA panel endorsement of Leqembi,Seeking Alpha,https://seekingalpha.com/news/3979243-biogen-stock-doesnt-see-big-boost-fda-panel-endorsement-leqembi-alzheimers?utm_source=businessinsider&utm_medium=referral,positive,0.8505670428276062
1555,6/12/2023 3:09:45 PM,"Why Are Cruise Stocks CCL, RCL, NCLH Up Today?",InvestorPlace,/news/stocks/why-are-cruise-stocks-ccl-rcl-nclh-up-today-june-12th-1032383908,neutral,0.7814761996269226
1556,6/12/2023 8:01:12 PM,Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote,Benzinga,/news/stocks/prospects-for-full-approval-of-eisai-and-biogen-s-leqembi-shine-brighter-after-fda-committee-vote-1032384301,positive,0.8840839266777039
1557,6/12/2023 10:23:15 PM,"Biogen announces board changes, new date for annual meeting",Seeking Alpha,https://seekingalpha.com/news/3979391-biogen-announces-board-changes-new-date-for-annual-meeting?utm_source=businessinsider&utm_medium=referral,neutral,0.84663325548172
1558,6/13/2023 11:02:50 AM,Biogen's Leqembi may not be widely used for Alzheimer's in Europe - report,Seeking Alpha,https://seekingalpha.com/news/3979456-biogen-leqembi-not-widely-used-alzheimers-europe?utm_source=businessinsider&utm_medium=referral,neutral,0.9329445362091064
1559,6/13/2023 1:26:35 PM,Biogen in pact with NeuroSense for ALS biomarker study,Seeking Alpha,https://seekingalpha.com/news/3979522-neurosense-stock-rises-deal-with-biogen-als-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.5033447742462158
1560,6/13/2023 4:14:45 PM,Hot Stocks: AAPL falls on downgrade; MANU rises on Qatar bid expectations; TM gains; BIIB dips,Seeking Alpha,https://seekingalpha.com/news/3979590-hot-stocks-apple-falls-on-analyst-downgrade-manu-rises-on-qatar-bid-expectations-tm-gains-biib-dips?utm_source=businessinsider&utm_medium=referral,positive,0.6427229642868042
1561,6/13/2023 4:36:28 PM,"Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday",Benzinga,/news/stocks/methode-electronics-brookfield-renewable-partners-and-other-big-stocks-moving-lower-on-tuesday-1032386515,negative,0.9679405093193054
1562,6/14/2023 4:55:34 AM,SVB Securities Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-biogen-biib-1032387733,neutral,0.7309050559997559
1563,6/16/2023 1:35:50 AM,7 Undervalued S&P 500 Stocks to Buy in June,InvestorPlace,/news/stocks/7-undervalued-sp-500-stocks-to-buy-in-june-1032393185,positive,0.6796292066574097
1564,6/17/2023 1:50:22 AM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Grifols SA (GRFS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-grifols-sa-grfs-1032395288,neutral,0.902287483215332
1565,6/18/2023 8:56:10 PM,How to Retire Rich: Biotech Stocks Edition,InvestorPlace,/news/stocks/how-to-retire-rich-biotech-stocks-edition-1032395848,neutral,0.9189780354499817
1566,6/20/2023 11:14:33 PM,5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies,Benzinga,/news/stocks/5-biotech-stocks-that-could-soar-thanks-to-these-disruptive-healthcare-technologies-1032400340,neutral,0.6900235414505005
1567,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,negative,0.9452309608459473
1568,6/23/2023 11:25:08 AM,Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-hold-rating-on-biogen-biib-1032406651,neutral,0.9237781763076782
1569,6/23/2023 9:45:09 PM,Mizuho Securities Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-remains-a-buy-on-biogen-biib-1032407766,neutral,0.9223442077636719
1570,6/26/2023 6:45:43 AM,Biogen (BIIB) Receives a Buy from Robert W. Baird,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-robert-w-baird-1032408775,neutral,0.521748960018158
1571,6/29/2023 5:20:54 AM,FDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone Disease ,RTTNews,/news/stocks/fda-panel-votes-in-favor-of-ipsen-s-palovarotene-for-ultra-rare-bone-disease-1032416485,positive,0.5821017026901245
1572,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.9015730619430542
1573,6/30/2023 7:00:00 PM,"Catalyst Watch: BorgWarner, Biogen, iRobot and Coty are in the spotlight during holiday-shortened week",Seeking Alpha,https://seekingalpha.com/news/3984655-catalyst-watch-borgwarner-biogen-irobot-and-coty-are-in-the-spotlight-during-holiday-shortened-week?utm_source=businessinsider&utm_medium=referral,positive,0.6343396902084351
1574,7/1/2023 8:00:00 PM,"Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst",Seeking Alpha,https://seekingalpha.com/news/3984694-lilly-vertex-top-pharma-performers-h1-moderna-pfizer-worst?utm_source=businessinsider&utm_medium=referral,positive,0.6028407216072083
1575,7/3/2023 2:36:09 PM,Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment,Benzinga,/news/stocks/biogen-reports-new-spinraza-data-in-atrophy-patients-after-incomplete-response-to-novartis-treatment-1032423472,negative,0.9010288119316101
1576,7/4/2023 6:00:00 PM,FDA set to make decisions on several drug applications in July,Seeking Alpha,https://seekingalpha.com/news/3985059-fda-make-decisions-several-drug-applications-july?utm_source=businessinsider&utm_medium=referral,neutral,0.936848521232605
1577,7/6/2023 8:43:33 PM,3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True,InvestorPlace,/news/stocks/3-biotech-stocks-to-make-your-get-rich-dreams-come-true-1032431053,neutral,0.8534663319587708
1578,7/6/2023 9:10:18 PM,"Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi",Seeking Alpha,https://seekingalpha.com/news/3985739-biogen-eisai-win-full-fda-nod-alzheimers-drug-leqembi?utm_source=businessinsider&utm_medium=referral,positive,0.9154282212257385
1579,7/6/2023 10:28:00 PM,Quanterix launches LucentAD biomarker test for early Alzheimer's disease,Seeking Alpha,https://seekingalpha.com/news/3986112-quanterix-launches-lucentad-biomarker-test-for-early-alzheimers-disease?utm_source=businessinsider&utm_medium=referral,neutral,0.7426483035087585
1580,7/7/2023 12:05:18 AM,Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-buy-rating-for-biogen-biib-1032431149,neutral,0.6464465856552124
1581,7/7/2023 2:00:00 AM,FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease,PR Newswire,/news/stocks/fda-grants-traditional-approval-for-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimer-s-disease-1032431140,positive,0.9155845046043396
1582,7/7/2023 3:24:13 AM,FDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's Disease ,RTTNews,/news/stocks/fda-grants-traditional-approval-to-eisai-s-leqembi-to-treat-adult-patients-with-alzheimer-s-disease-1032431167,positive,0.9031243324279785
1583,7/7/2023 9:10:49 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), Biogen (BIIB) and Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-thermo-fisher-tmo-biogen-biib-and-boston-scientific-bsx-1032431744,negative,0.8441274762153625
1584,7/7/2023 10:25:07 AM,H.C. Wainwright Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/h-c-wainwright-remains-a-buy-on-biogen-biib-1032431929,neutral,0.9496791362762451
1585,7/7/2023 10:42:13 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-biogen-biib-and-crinetics-pharmaceuticals-crnx-1032432004,neutral,0.9090973734855652
1586,7/7/2023 11:05:09 AM,BMO Capital Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-biogen-biib-1032432030,positive,0.5420633554458618
1587,7/7/2023 11:50:52 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Simulations Plus (SLP),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-simulations-plus-slp-1032432089,negative,0.7481763362884521
1588,7/7/2023 12:05:30 PM,Jefferies Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/jefferies-remains-a-buy-on-biogen-biib-1032432153,neutral,0.9425736665725708
1589,7/7/2023 1:57:43 PM,BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug,InvestorPlace,/news/stocks/biib-stock-alert-what-to-know-as-fda-approves-biogens-alzheimers-drug-1032432459,neutral,0.9412599205970764
1590,7/7/2023 2:26:35 PM,Why Is Alibaba (BABA) Stock Up Today?,InvestorPlace,/news/stocks/why-is-alibaba-baba-stock-up-today-july-7th-1032432507,neutral,0.8013618588447571
1591,7/7/2023 3:00:29 PM,What 29 Analyst Ratings Have To Say About Biogen,Benzinga,/news/stocks/what-29-analyst-ratings-have-to-say-about-biogen-1032432286,neutral,0.9410464763641357
1592,7/7/2023 3:03:45 PM,FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today,InvestorPlace,/news/stocks/fslr-stock-alert-the-1-billion-reason-first-solar-is-up-today-1032432548,neutral,0.5690715909004211
1593,7/7/2023 6:16:21 PM,FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline,Benzinga,/news/stocks/fda-approves-biogen-s-alzheimer-s-drug-here-are-other-companies-with-treatments-in-the-pipeline-1032432660,neutral,0.9400222301483154
1594,7/7/2023 7:25:04 PM,Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts,Benzinga,/news/stocks/expanded-medicare-coverage-for-biogen-eisai-s-leqembi-signals-a-turning-point-in-alzheimer-s-treatment-analysts-1032432743,positive,0.927689790725708
1595,7/8/2023 8:15:26 AM,Needham Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/needham-reaffirms-their-buy-rating-on-biogen-biib-1032433066,neutral,0.7492828369140625
1596,7/8/2023 6:00:00 PM,Biogen/Eisai's Leqembi set to become Medicare's single highest drug spend,Seeking Alpha,https://seekingalpha.com/news/3986276-biogen-eisai-leqembi-medicare-single-highest-drug-spend?utm_source=businessinsider&utm_medium=referral,positive,0.8392616510391235
1597,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,positive,0.9371913075447083
1598,7/10/2023 7:10:50 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032434105,positive,0.552167534828186
1599,7/10/2023 12:20:21 PM,"Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Galapagos (GLPG) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-kalvista-pharmaceuticals-kalv-galapagos-glpg-and-biogen-biib-1032434788,neutral,0.9054373502731323
1600,7/11/2023 12:14:36 PM,ADC Therapeutics falls after pausing mid-stage trial for lead asset,Seeking Alpha,https://seekingalpha.com/news/3986713-adc-therapeutics-stock-falls-after-trial-pause?utm_source=businessinsider&utm_medium=referral,negative,0.9659664034843445
1601,7/11/2023 1:57:36 PM,Eisai executive behind Alzheimer’s therapy Leqembi retires,Seeking Alpha,https://seekingalpha.com/news/3986778-eisai-executive-behind-alzheimers-therapy-leqembi-retires?utm_source=businessinsider&utm_medium=referral,neutral,0.796785295009613
1602,7/13/2023 1:40:30 PM,"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Silence Therapeutics (SLN) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-silence-therapeutics-sln-and-biogen-biib-1032444674,neutral,0.9064680933952332
1603,7/13/2023 5:29:24 PM,7 Stocks That AI Says Will Make You a Millionaire by 2025,InvestorPlace,/news/stocks/7-stocks-that-ai-says-will-make-you-a-millionaire-by-2025-1032445565,neutral,0.8657408356666565
1604,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.4974316656589508
1605,7/17/2023 2:00:46 PM,Acumen stock rallies over 60% on Alzheimer's drug data,Seeking Alpha,https://seekingalpha.com/news/3988028-acumen-stock-rallies-on-alzheimers-drug-data?utm_source=businessinsider&utm_medium=referral,positive,0.9263291358947754
1606,7/17/2023 5:21:00 PM,Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab,Seeking Alpha,https://seekingalpha.com/news/3988105-eli-lilly-full-phase-3-data-confirms-benefit-alzheimers-donanemab?utm_source=businessinsider&utm_medium=referral,positive,0.6457033753395081
1607,7/18/2023 3:27:28 PM,Sanofi expands collaboration with Scribe on CRISPR genome editing,Seeking Alpha,https://seekingalpha.com/news/3988429-sanofi-expands-collaboration-scribe-crispr-genome-editing?utm_source=businessinsider&utm_medium=referral,positive,0.882541298866272
1608,7/20/2023 1:30:00 AM,Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023,PR Newswire,/news/stocks/eisai-presents-latest-analysis-of-lecanemab-s-effect-on-biomarker-changes-and-subcutaneous-dosing-at-the-alzheimer-s-association-international-conference-aaic-2023-1032460519,neutral,0.8832982182502747
1609,7/20/2023 3:55:25 PM,Robert W. Baird Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/robert-w-baird-sticks-to-their-buy-rating-for-biogen-biib-1032463372,neutral,0.8698599338531494
1610,7/24/2023 3:01:13 PM,Here's what to expect from Biogen's earnings report,Markets Insider Automation,/news/stocks/biogen-quarter-earnings-preview-q2-1032470095,neutral,0.924342691898346
1611,7/24/2023 3:02:24 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3990102-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.8660826683044434
1612,7/24/2023 4:15:09 PM,Biogen Q2 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3990118-biogen-q2-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.8310734629631042
1613,7/24/2023 10:50:38 PM,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Biogen (BIIB) and Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-biogen-biib-and-johnson-johnson-jnj-1032471681,negative,0.7018144726753235
1614,7/25/2023 11:14:52 AM,"Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M",Seeking Alpha,https://seekingalpha.com/news/3990474-biogen-non-gaap-eps-of-4_02-beats-0_26-revenue-of-2_46b-beats-100m?utm_source=businessinsider&utm_medium=referral,neutral,0.5333570837974548
1615,7/25/2023 12:26:12 PM,Biogen announces layoffs as focus turns to new products,Seeking Alpha,https://seekingalpha.com/news/3990514-biogen-announces-layoffs-as-focus-turns-to-new-products?utm_source=businessinsider&utm_medium=referral,negative,0.9598640203475952
1616,7/25/2023 12:30:54 PM,"Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alnylam-pharma-alny-biogen-biib-1032474293,positive,0.6176849603652954
1617,7/25/2023 1:30:49 PM,Biogen Q2 Results Top Estimates; Backs FY23 Outlook ,RTTNews,/news/stocks/biogen-q2-results-top-estimates-backs-fy23-outlook-1032473983,neutral,0.6634448170661926
1618,7/25/2023 1:35:46 PM,Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts,InvestorPlace,/news/stocks/biogen-layoffs-2023-what-to-know-about-the-latest-biib-job-cuts-1032474795,negative,0.8772264719009399
1619,7/25/2023 1:52:47 PM,MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage,InvestorPlace,/news/stocks/mbly-stock-alert-morgan-stanley-restarts-mobileye-coverage-1032474826,neutral,0.5188903212547302
1620,7/25/2023 2:07:55 PM,WMT Stock Alert: Is Walmart Really Worth $210?,InvestorPlace,/news/stocks/wmt-stock-alert-is-walmart-really-worth-210-1032475164,neutral,0.9305707812309265
1621,7/26/2023 4:20:16 AM,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-and-biogen-biib-1032476900,neutral,0.9015665650367737
1622,7/26/2023 7:50:18 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (IMGN) and Biogen (BIIB),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunogen-imgn-and-biogen-biib-1032478245,negative,0.701632559299469
1623,7/26/2023 10:20:25 AM,"Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Abbott Labs (ABT)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-abbott-labs-abt-1032478866,neutral,0.5014856457710266
1624,7/26/2023 11:10:43 AM,"Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Terns Pharmaceuticals (TERN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biogen-biib-terns-pharmaceuticals-tern-1032479065,positive,0.5178953409194946
1625,7/26/2023 4:00:50 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1032480458,neutral,0.9187624454498291
1626,7/26/2023 5:36:56 PM,Sage hits eight-month low as FDA decision on depression therapy nears,Seeking Alpha,https://seekingalpha.com/news/3991402-sage-stock-falls-ahead-fda-decision-depression-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8806376457214355
1627,7/27/2023 2:25:11 AM,Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-biogen-biib-1032481938,neutral,0.5527154803276062
1628,7/27/2023 5:00:41 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-27-2023-1032485469,neutral,0.4870787262916565
1629,7/28/2023 11:18:20 AM,Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B,Seeking Alpha,https://seekingalpha.com/news/3992756-biogen-agrees-to-buy-reata-pharmaceuticals-for-17250-a-share-in-cash?utm_source=businessinsider&utm_medium=referral,neutral,0.7436631321907043
1630,7/28/2023 1:34:08 PM,Biogen To Buy Reata Pharma In Around $7.3 Bln Deal; Stocks Move In Premarket ,RTTNews,/news/stocks/biogen-to-buy-reata-pharma-in-around-7-3-bln-deal-stocks-move-in-premarket-1032489687,positive,0.6076854467391968
1631,7/28/2023 2:23:41 PM,Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?,InvestorPlace,/news/stocks/why-is-reata-pharmaceuticals-reta-stock-up-53-today-1032490602,positive,0.8456966280937195
1632,7/28/2023 5:22:08 PM,"Larimar, Design higher as they benefit from Biogen deal for Reata",Seeking Alpha,https://seekingalpha.com/news/3993063-larimar-design-higher-benefit-biogen-deal-reata?utm_source=businessinsider&utm_medium=referral,positive,0.8833617568016052
1633,7/28/2023 5:56:18 PM,Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated,Benzinga,/news/stocks/reata-s-acquisition-fits-biogen-s-strategy-despite-high-cost-analyst-says-high-level-regulatory-scrutiny-not-anticipated-1032490800,neutral,0.5035783052444458
1634,7/29/2023 1:08:21 PM,Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil,InvestorPlace,/news/stocks/biotech-battlefields-3-stocks-to-watch-amid-wall-street-turmoil-1032491594,neutral,0.8893331289291382
1635,7/30/2023 7:00:57 PM,3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes,InvestorPlace,/news/stocks/3-millionaire-maker-biotech-stocks-to-buy-before-the-window-closes-1032492374,neutral,0.854169487953186
1636,7/31/2023 5:03:19 PM,"Rising Stars, Falling Trends: July's Industry ETF Winners And Losers",Benzinga,/news/etf/rising-stars-falling-trends-july-s-industry-etf-winners-and-losers-1032496121,negative,0.9192143082618713
1637,8/1/2023 4:20:13 PM,Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tg-therapeutics-tgtx-and-biogen-biib-1032502000,neutral,0.905144214630127
1638,8/1/2023 6:59:01 PM,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,InvestorPlace,/news/stocks/biotech-stocks-to-buy-3-1032502314,positive,0.931571364402771
1639,8/2/2023 7:17:56 PM,3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now,InvestorPlace,/news/stocks/3-strong-buy-biotech-stocks-you-should-be-loading-up-on-now-1032508396,positive,0.7262067794799805
1640,8/3/2023 11:40:27 AM,"Goldman in, Microsoft out of BofA Alpha Surprise Portfolio",Seeking Alpha,https://seekingalpha.com/news/3996317-goldman-in-microsoft-out-of-bofa-alpha-surprise-portfolio?utm_source=businessinsider&utm_medium=referral,neutral,0.6860989332199097
1641,8/4/2023 5:08:18 PM,"5 Healthcare Stocks to Buy Now, According to Analysts – August 2023",TipRanks,/news/stocks/5-healthcare-stocks-to-buy-now-according-to-analysts-–-august-2023-1032518928,neutral,0.8639002442359924
1642,8/4/2023 11:53:06 PM,"Sage, Biogen zuranolone OKd for postpartum, but not major, depression",Seeking Alpha,https://seekingalpha.com/news/3997942-sage-biogen-postpartum-depression-pill-zuranolone-wins-fda-approval?utm_source=businessinsider&utm_medium=referral,positive,0.5804174542427063
1643,8/5/2023 4:14:15 PM,Biogen : FDA Approves First Oral Treatment For Postpartum Depression ,RTTNews,/news/stocks/biogen-fda-approves-first-oral-treatment-for-postpartum-depression-1032519645,positive,0.5820498466491699
1644,8/6/2023 7:35:00 PM,2023 shaping up to be biggest year for biopharma M&A since pandemic,Seeking Alpha,https://seekingalpha.com/news/3997958-2023-shaping-up-to-be-biggest-year-for-biopharma-ma-since-pandemic?utm_source=businessinsider&utm_medium=referral,positive,0.858807384967804
1645,8/7/2023 9:16:13 AM,Biogen (BIIB) Receives a Hold from Barclays,TipRanks,/news/stocks/biogen-biib-receives-a-hold-from-barclays-1032523197,neutral,0.7176290154457092
1646,8/7/2023 9:20:25 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-becton-dickinson-bdx-and-regeneron-regn-1032523168,neutral,0.8969154357910156
1647,8/7/2023 10:06:02 AM,J.P. Morgan Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/j-p-morgan-sticks-to-its-hold-rating-for-biogen-biib-1032523290,neutral,0.7361335158348083
1648,8/7/2023 10:20:24 AM,"Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-foghorn-therapeutics-fhtx-aurinia-pharmaceuticals-auph-and-biogen-biib-1032523339,neutral,0.9155784249305725
1649,8/7/2023 11:39:26 AM,Sage plummets 46% after FDA declines zuranolone in major depression,Seeking Alpha,https://seekingalpha.com/news/3998064-sage-plummets-46-fda-declines-zuranolone-major-depression?utm_source=businessinsider&utm_medium=referral,negative,0.9552635550498962
1650,8/7/2023 12:10:37 PM,Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-horizon-therapeutics-hznp-and-biogen-biib-1032523648,neutral,0.891681969165802
1651,8/7/2023 2:50:03 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Pharvaris (PHVS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-pharvaris-phvs-1032524817,neutral,0.8946999311447144
1652,8/7/2023 4:34:23 PM,"PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories",Benzinga,/news/stocks/paypal-unveils-usd-backed-stablecoin-trucking-firm-yellow-corp-files-for-bankruptcy-fda-approves-first-oral-treatment-for-postpartum-depression-today-s-top-stories-1032524770,neutral,0.8963079452514648
1653,8/7/2023 6:06:57 PM,"FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says",Benzinga,/news/stocks/fda-s-rejection-of-sage-biogen-s-zuranolone-boosts-prospects-for-axsome-s-auvelity-analyst-says-1032525005,positive,0.9593117833137512
1654,8/7/2023 7:44:06 PM,What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead,Benzinga,/news/stocks/what-more-can-support-biogen-sage-s-zuranolone-resubmission-analysts-see-uncertain-road-ahead-1032525188,neutral,0.518332302570343
1655,8/7/2023 9:39:56 PM,"Wedbush cuts Sage to neutral, questions Biogen's future funding of zuranolone",Seeking Alpha,https://seekingalpha.com/news/3998702-wedbush-cuts-sage-to-neutral-questions-biogens-future-funding-of-zuranolone?utm_source=businessinsider&utm_medium=referral,negative,0.5386377573013306
1656,8/7/2023 10:15:31 PM,"RBC Capital cuts Sage to sector perform, calls FDA decision ""major setback""",Seeking Alpha,https://seekingalpha.com/news/3998721-rbc-capital-cuts-sage-to-sector-perform-calls-fda-decision-major-setback?utm_source=businessinsider&utm_medium=referral,negative,0.965493381023407
1657,8/8/2023 1:43:36 PM,DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/draftkings-to-rally-over-38-here-are-10-other-analyst-forecasts-for-tuesday-1032528487,neutral,0.9134270548820496
1658,8/8/2023 2:26:14 PM,"Lilly reaches all-time high on Q2 results, 2023 guidance boost",Seeking Alpha,https://seekingalpha.com/news/3999097-lilly-reaches-all-time-high-q2-results-2023-guidance-boost?utm_source=businessinsider&utm_medium=referral,positive,0.9195758104324341
1659,8/8/2023 10:12:18 PM,"BofA upgrades Axome to neutral, cites improved outlook for MDD drug",Seeking Alpha,https://seekingalpha.com/news/3999736-bofa-upgrades-axome-to-neutral-cites-improved-outlook-for-mdd-drug?utm_source=businessinsider&utm_medium=referral,positive,0.9503976702690125
1660,8/9/2023 4:20:17 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Caliber Imaging & Diagnostic (OtherLCDX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-caliber-imaging-diagnostic-otherlcdx-1032536088,neutral,0.9045464396476746
1661,8/11/2023 4:32:11 PM,Biogen/ Sage expected to hike price for new depression drug after narrow label,Seeking Alpha,https://seekingalpha.com/news/4001802-biogen-sage-expected-hike-price-new-depression-drug?utm_source=businessinsider&utm_medium=referral,positive,0.8708527684211731
1662,8/15/2023 8:20:35 PM,Sanofi was mystery suitor in Reata Pharma bidding war - report,Seeking Alpha,https://seekingalpha.com/news/4003207-sanofi-was-mystery-bidder-in-reata-pharma-bidding-war-report?utm_source=businessinsider&utm_medium=referral,neutral,0.7306932806968689
1663,8/16/2023 3:59:12 PM,"Wells Fargo starts GE HealthCare at overweight, sees increased imaging demand",Seeking Alpha,https://seekingalpha.com/news/4003527-wells-fargo-starts-ge-healthcare-at-overweight-sees-increased-imaging-demand?utm_source=businessinsider&utm_medium=referral,positive,0.9282436966896057
1664,8/16/2023 6:13:34 PM,"BofA upgrades Axsome to neutral, cites improved outlook for MDD drug",Seeking Alpha,https://seekingalpha.com/news/3999736-bofa-upgrades-axsome-to-neutral-cites-improved-outlook-for-mdd-drug?utm_source=businessinsider&utm_medium=referral,positive,0.9486755728721619
1665,8/23/2023 6:09:18 PM,Biogen's Leqembi set for strong uptake based on Baird physician survey,Seeking Alpha,https://seekingalpha.com/news/4005683-biogen-leqembi-alzheimers-strong-uptake-baird-physician-survey?utm_source=businessinsider&utm_medium=referral,positive,0.9065466523170471
1666,8/24/2023 1:31:49 PM,Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock,InvestorPlace,/news/stocks/insider-richard-barry-just-doubled-down-on-cassava-sava-stock-1032579999,neutral,0.45411574840545654
1667,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,neutral,0.9293889403343201
1668,8/24/2023 11:15:17 PM,FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri,Seeking Alpha,https://seekingalpha.com/news/4006231-fda-approves-sandoz-biosimilar-of-biogen-blockbuster-ms-drug-tysabri?utm_source=businessinsider&utm_medium=referral,positive,0.7177398800849915
1669,8/25/2023 10:50:39 AM,"Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Cooper Co (COO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-stericycle-srcl-biogen-biib-and-cooper-co-coo-1032582311,neutral,0.9064761996269226
1670,8/26/2023 6:00:00 PM,Crohn's disease drugmakers set to benefit from expected rise in cases,Seeking Alpha,https://seekingalpha.com/news/4006563-crohns-disease-drugmakers-benefit-expected-rise-cases?utm_source=businessinsider&utm_medium=referral,positive,0.9470041394233704
1671,8/28/2023 1:31:01 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032586128,positive,0.552167534828186
1672,8/29/2023 10:25:13 AM,RBC Capital Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-biogen-biib-1032588410,neutral,0.931504487991333
1673,8/29/2023 5:01:07 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1032589885,neutral,0.9187624454498291
1674,8/29/2023 7:24:04 PM,RBC Capital sees Biogen stock undervaluing Leqembi prospects,Seeking Alpha,https://seekingalpha.com/news/4007246-rbc-capital-sees-biogen-stock-undervaluing-leqembi-prospects?utm_source=businessinsider&utm_medium=referral,positive,0.879544198513031
1675,8/30/2023 9:20:13 AM,The 3 Most Promising Pharma Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-pharma-stocks-to-own-now-1032591971,neutral,0.6068359017372131
1676,8/31/2023 11:22:43 AM,Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch,Seeking Alpha,https://seekingalpha.com/news/4007938-sage-cuts-40-staff-in-portfolio-shake-up?utm_source=businessinsider&utm_medium=referral,negative,0.9502829909324646
1677,8/31/2023 12:30:53 PM,The 7 Most Promising Momentum Stocks to Own Now,InvestorPlace,/news/stocks/the-7-most-promising-momentum-stocks-to-own-now-1032596201,neutral,0.8393203020095825
1678,9/1/2023 10:29:00 PM,Biogen in $1.5B unsecured loan facility for Reata acquisition,Seeking Alpha,https://seekingalpha.com/news/4008672-biogen-15b-unsecured-loan-facility-reata-acquisition?utm_source=businessinsider&utm_medium=referral,neutral,0.6427655220031738
1679,9/4/2023 7:43:41 PM,The 3 Best Biotech Stocks to Buy Now: September 2023,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-now-september-2023-1032603521,neutral,0.9307847023010254
1680,9/6/2023 1:30:00 PM,Biogen Appoints Jane Grogan as Head of Research,GlobeNewswire,/news/stocks/biogen-appoints-jane-grogan-as-head-of-research-1032608530,neutral,0.9205115437507629
1681,9/6/2023 5:00:38 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-6-2023-1032609929,neutral,0.5207829475402832
1682,9/6/2023 6:27:04 PM,3 Healthcare Stocks to Sell in September Before They Crash & Burn,InvestorPlace,/news/stocks/3-healthcare-stocks-to-sell-in-september-before-they-crash-burn-1032610489,neutral,0.7820885181427002
1683,9/6/2023 8:45:28 PM,Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst,Benzinga,/news/stocks/denali-therapeutics-breakthrough-blood-brain-barrier-platform-a-game-changer-in-neurodegenerative-diseases-analyst-1032610481,neutral,0.6058497428894043
1684,9/7/2023 11:08:02 AM,7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth,InvestorPlace,/news/stocks/7-pharma-stocks-to-buy-for-groundbreaking-treatments-and-robust-revenue-growth-1032612381,positive,0.9394681453704834
1685,9/7/2023 3:04:48 PM,Researchers study weight loss drugs in dementia and addiction,Seeking Alpha,https://seekingalpha.com/news/4009962-researchers-test-weight-loss-drugs-dementia-addiction?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8902351260185242
1686,9/8/2023 7:00:57 PM,"Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates",Seeking Alpha,https://seekingalpha.com/news/4010342-catalyst-watch-arm-ipo-apple-event-and-senate-ai-forum-with-musk-zuckerberg-and-gates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9412830471992493
1687,9/10/2023 7:17:31 PM,"HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead",Seeking Alpha,https://seekingalpha.com/news/4010430-hsbc-bullish-on-iqvia-zoetis-bluebird-actinium-bearish-on-gilead?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5512138605117798
1688,9/11/2023 4:04:11 PM,Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara,Seeking Alpha,https://seekingalpha.com/news/4010646-sandoz-to-commercialize-biosimilar-to-jnj-blockbuster-drug-stelara?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.690517783164978
1689,9/12/2023 11:20:46 AM,Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-biogen-biib-1032622812,neutral,0.9099881052970886
1690,9/12/2023 5:26:27 PM,Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired,Seeking Alpha,https://seekingalpha.com/news/4011068-reata-pharmaceuticals-climbs-as-hsr-period-for-sale-to-biogen-expired?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8326119780540466
1691,9/12/2023 7:49:54 PM,Intas reportedly readying bid of up to $1B for Biogen biosimilars unit,Seeking Alpha,https://seekingalpha.com/news/4011091-intas-reportedly-readying-bid-of-up-to-1b-for-biogen-biosimilars-unit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7256180644035339
1692,9/21/2023 12:33:08 PM,"Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-boston-scientific-bsx-biogen-biib-1032646668,positive,0.4809814393520355
1693,9/21/2023 4:21:06 PM,Reata Pharma Stockholders Approve Acquisition By Biogen ,RTTNews,/news/stocks/reata-pharma-stockholders-approve-acquisition-by-biogen-1032647396,neutral,0.8471746444702148
1694,9/25/2023 7:02:57 AM,LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan,GlobeNewswire,/news/stocks/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimer-s-disease-in-japan-1032651556,positive,0.6795397996902466
1695,9/26/2023 2:59:54 PM,Biogen Completes Acquisition of Reata Pharmaceuticals,GlobeNewswire,/news/stocks/biogen-completes-acquisition-of-reata-pharmaceuticals-1032656039,neutral,0.7803244590759277
1696,9/26/2023 4:03:36 PM,Biogen Completes Acquisition Of Reata Pharmaceuticals; Plans To Update 2023 Guidance ,RTTNews,/news/stocks/biogen-completes-acquisition-of-reata-pharmaceuticals-plans-to-update-2023-guidance-1032656607,neutral,0.7035810351371765
1697,9/28/2023 10:36:22 AM,Prospects of Biogen’s Leqembi in Alzheimer’s Market: A Buy Rating Justification,TipRanks,/news/stocks/prospects-of-biogen-s-leqembi-in-alzheimer-s-market-a-buy-rating-justification-1032662347,neutral,0.6658858060836792
1698,9/29/2023 10:06:00 PM,"FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®",GlobeNewswire,/news/stocks/fda-approves-biogen-s-tofidence-tocilizumab-bavi-a-biosimilar-referencing-actemra-1032667597,positive,0.8127266764640808
1699,9/29/2023 11:03:10 PM,FDA Approves Biogen's Tofidence ,RTTNews,/news/stocks/fda-approves-biogen-s-tofidence-1032667644,neutral,0.7757477760314941
1700,10/3/2023 8:30:09 PM,Quant Ratings Updated on 74 Stocks,InvestorPlace,/news/stocks/100323-quant-ratings-1032675945,neutral,0.9231441617012024
1701,10/6/2023 1:45:35 AM,Biogen (BIIB) Receives a Buy from RBC Capital,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-rbc-capital-1032683178,neutral,0.5525236129760742
1702,10/11/2023 5:00:34 PM,Analyst Ratings for Biogen,Benzinga,/news/stocks/analyst-ratings-for-biogen-1032697359,neutral,0.9187624454498291
1703,10/11/2023 8:40:12 PM,7 Low-Volatility Stocks to Buy if You’re a Concerned Investor,InvestorPlace,/news/stocks/7-low-volatility-stocks-to-buy-if-youre-a-concerned-investor-1032698140,neutral,0.9172037839889526
1704,10/13/2023 10:43:53 AM,"Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), Biogen (BIIB) and Walgreens Boots Alliance (WBA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-biogen-biib-and-walgreens-boots-alliance-wba-1032703404,neutral,0.9192407727241516
1705,10/17/2023 8:30:51 PM,Quant Ratings Updated on 92 Stocks,InvestorPlace,/news/stocks/101723-quant-ratings-1032714183,neutral,0.9286938905715942
1706,10/19/2023 1:02:12 PM,"Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO), Biogen (BIIB) and REPRO-MED Systems (KRMD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bio-rad-laboratories-bio-biogen-biib-and-repro-med-systems-krmd-1032720976,neutral,0.9091927409172058
1707,10/19/2023 1:30:00 PM,Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting,GlobeNewswire,/news/stocks/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2023-meeting-1032720434,neutral,0.9141077995300293
1708,10/24/2023 3:30:00 PM,LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023,PR Newswire,/news/stocks/leqembi-lecanemab-irmb-named-one-of-time-s-best-inventions-of-2023-1032733700,positive,0.835797131061554
1709,10/24/2023 6:41:30 PM,An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week,Benzinga,/news/stocks/an-oversold-small-cap-industrial-that-insiders-are-buying-ahead-of-earnings-this-week-1032734632,negative,0.6606519222259521
1710,10/25/2023 8:56:34 AM,Positive Outlook for Biogen’s Leqembi subQ: An Analysis of Its Potential and Investment Opportunity,TipRanks,/news/stocks/positive-outlook-for-biogen-s-leqembi-subq-an-analysis-of-its-potential-and-investment-opportunity-1032740507,neutral,0.681944727897644
1711,10/25/2023 4:51:00 PM,New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/new-data-from-biogen-s-investigational-antisense-oligonucleotide-aso-targeting-tau-shows-promise-for-potential-new-generation-of-treatments-in-early-alzheimer-s-disease-1032739619,positive,0.9155515432357788
1712,10/25/2023 11:25:00 PM,EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITI...,PR Newswire,/news/stocks/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-study-results-and-clinical-improvement-data-in-earlier-stages-of-early-alzheimer-s-disease-from-additi-1032740584,neutral,0.6345851421356201
1713,10/25/2023 11:26:00 PM,Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From...,GlobeNewswire,/news/stocks/eisai-presents-new-leqembi-lecanemab-irmb-investigational-subcutaneous-formulation-interim-study-results-and-clinical-improvement-data-in-earlier-stages-of-early-alzheimer-s-disease-from-1032740595,neutral,0.5203167796134949
1714,10/26/2023 9:40:01 AM,Hold Rating on Biogen Amid Uncertainties in Alzheimer’s Treatment Market – An Analysis of Lecanemab’s Clinical Prospects,TipRanks,/news/stocks/hold-rating-on-biogen-amid-uncertainties-in-alzheimer-s-treatment-market-–-an-analysis-of-lecanemab-s-clinical-prospects-1032745745,neutral,0.5160365700721741
1715,10/26/2023 10:41:53 AM,Hold Rating on Biogen’s Leqembi: SubQ Formulation Shows Promising Results but Further Evaluation Needed,TipRanks,/news/stocks/hold-rating-on-biogen-s-leqembi-subq-formulation-shows-promising-results-but-further-evaluation-needed-1032745816,positive,0.9256635308265686
1716,10/26/2023 10:48:44 AM,Promising Alzheimer’s Drug Drives Morgan Stanley’s Buy Rating for Biogen,TipRanks,/news/stocks/promising-alzheimer-s-drug-drives-morgan-stanley-s-buy-rating-for-biogen-1032745873,positive,0.9020785689353943
1717,10/26/2023 11:05:30 AM,Hold Rating for Biogen: Evaluating the Potential and Challenges of SC Lecanemab and BIIB80,TipRanks,/news/stocks/hold-rating-for-biogen-evaluating-the-potential-and-challenges-of-sc-lecanemab-and-biib80-1032745897,neutral,0.8398599028587341
1718,10/26/2023 11:49:56 AM,"Biogen’s Stock Promising Future: Efficacy, Competitive Edge, and Convenience Bolster Buy Rating",TipRanks,/news/stocks/biogen-s-stock-promising-future-efficacy-competitive-edge-and-convenience-bolster-buy-rating-1032745957,positive,0.9458560347557068
1719,10/26/2023 12:30:07 PM,"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Universal Health (UHS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-biogen-biib-and-universal-health-uhs-1032746101,neutral,0.9173923134803772
1720,10/26/2023 1:03:39 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Alimera (ALIM) and Align Tech (ALGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-alimera-alim-and-align-tech-algn-1032746150,neutral,0.9025366306304932
1721,10/26/2023 1:21:47 PM,"Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Biogen (BIIB) and Roche Holding AG (OtherRHHVF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-community-health-cyh-biogen-biib-and-roche-holding-ag-otherrhhvf-1032746176,neutral,0.9033126831054688
1722,10/27/2023 12:25:46 AM,Needham Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/needham-reaffirms-their-buy-rating-on-biogen-biib-1032748570,neutral,0.7492828369140625
1723,10/27/2023 6:59:40 AM,Buy Rating for Biogen Upheld Based on Positive Leqembi Subcutaneous Formulation Results & Potential Commercial Opportunities,TipRanks,/news/stocks/buy-rating-for-biogen-upheld-based-on-positive-leqembi-subcutaneous-formulation-results-potential-commercial-opportunities-1032749746,positive,0.830558717250824
1724,10/27/2023 7:42:02 AM,Promising Developments Boost Biogen’s Prospects: An In-depth Analysis of Leqembi’s Position in Alzheimer’s Treatment Market,TipRanks,/news/stocks/promising-developments-boost-biogen-s-prospects-an-in-depth-analysis-of-leqembi-s-position-in-alzheimer-s-treatment-market-1032749771,positive,0.9280385375022888
1725,10/27/2023 7:58:35 AM,Promising Leqembi Data and Undervalued Stock: A Case for Buying Biogen,TipRanks,/news/stocks/promising-leqembi-data-and-undervalued-stock-a-case-for-buying-biogen-1032749853,neutral,0.7255722880363464
1726,10/27/2023 11:28:10 AM,Positive Outlook on Biogen’s Stock: Leqembi’s Promising Data and Strategic Management Decisions Fuel Buy Rating,TipRanks,/news/stocks/positive-outlook-on-biogen-s-stock-leqembi-s-promising-data-and-strategic-management-decisions-fuel-buy-rating-1032750176,positive,0.9501508474349976
1727,10/30/2023 9:50:50 AM,"Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-arcellx-inc-aclx-biogen-biib-1032755860,neutral,0.4989742338657379
1728,11/1/2023 10:40:09 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-biogen-biib-and-vertex-pharmaceuticals-vrtx-1032767548,neutral,0.902546763420105
1729,11/6/2023 6:18:52 AM,Potential Growth for Biogen: Exploring Upside Opportunities and Anticipating Skyclarys Success,TipRanks,/news/stocks/potential-growth-for-biogen-exploring-upside-opportunities-and-anticipating-skyclarys-success-1032783406,positive,0.598513126373291
1730,11/6/2023 1:30:00 PM,Biogen Appoints Monish Patolawala to its Board of Directors,GlobeNewswire,/news/stocks/biogen-appoints-monish-patolawala-to-its-board-of-directors-1032781556,neutral,0.9274607300758362
1731,11/6/2023 11:51:03 PM,3 Biotech Moonshots to Bet on the Future of Health,InvestorPlace,/news/stocks/3-biotech-moonshots-to-bet-on-the-future-of-health-1032784092,neutral,0.8782626390457153
1732,11/7/2023 3:01:13 PM,Here's what Wall Street expects from Biogen's earnings report,Markets Insider Automation,/news/stocks/biogen-q3-earnings-preview-stock-1032787623,neutral,0.8965476155281067
1733,11/8/2023 10:12:22 AM,"Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Biogen (BIIB) and Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bluebird-bio-blue-biogen-biib-and-johnson-johnson-jnj-1032796738,neutral,0.9149227142333984
1734,11/8/2023 1:20:41 PM,Biogen Inc. Q3 Earnings Summary,RTTNews,/news/stocks/biogen-inc-q3-earnings-summary-1032793896,neutral,0.6850086450576782
1735,11/8/2023 7:26:32 PM,"US Stocks Set To Snap Winning Streak, Treasuries Rally, Oil Tumbles: What's Driving Markets Wednesday?",Benzinga,/news/etf/us-stocks-set-to-snap-winning-streak-treasuries-rally-oil-tumbles-what-s-driving-markets-wednesday-1032796087,negative,0.6399989724159241
1736,11/9/2023 2:51:22 AM,"Hold Rating for Biogen: Revenue Decrease, Patent Expiry, and Delayed FDA Application Add Complexity to Financial Outlook",TipRanks,/news/stocks/hold-rating-for-biogen-revenue-decrease-patent-expiry-and-delayed-fda-application-add-complexity-to-financial-outlook-1032801230,negative,0.9690470099449158
1737,11/9/2023 2:54:00 AM,Hold Rating on Biogen: Balancing Prospects of Leqembi and Skyclarys Against Slow Alzheimer’s Market Build and Limited Growth Drivers,TipRanks,/news/stocks/hold-rating-on-biogen-balancing-prospects-of-leqembi-and-skyclarys-against-slow-alzheimer-s-market-build-and-limited-growth-drivers-1032801228,positive,0.8673112988471985
1738,11/9/2023 3:10:06 AM,Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-xenon-xene-and-biogen-biib-1032801619,neutral,0.8730619549751282
1739,11/9/2023 3:20:05 AM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Immatics (IMTX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-immatics-imtx-1032801661,neutral,0.8917721509933472
1740,11/9/2023 11:21:20 AM,"Best Stocks to Buy Now, 11/9/2023, According to Top Analysts",TipRanks,/news/stocks/best-stocks-to-buy-now-11-9-2023-according-to-top-analysts-1032802931,neutral,0.8569080829620361
1741,11/9/2023 11:30:23 AM,Analyst Projects Robust Sales Growth for Biogen Amid Rising Leqembi Demand and Upcoming Market Expansions,TipRanks,/news/stocks/analyst-projects-robust-sales-growth-for-biogen-amid-rising-leqembi-demand-and-upcoming-market-expansions-1032802918,positive,0.9537616968154907
1742,11/9/2023 11:41:16 AM,Fein’s Buy Rating on Biogen: Leqembi’s Potential Growth and Market Penetration,TipRanks,/news/stocks/fein-s-buy-rating-on-biogen-leqembi-s-potential-growth-and-market-penetration-1032802902,positive,0.8125081658363342
1743,11/9/2023 1:35:46 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Stryker (SYK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-stryker-syk-1032803039,positive,0.5827826261520386
1744,11/9/2023 6:00:30 PM,Expert Ratings for Biogen,Benzinga,/news/stocks/expert-ratings-for-biogen-1032802016,neutral,0.834668755531311
1745,11/9/2023 7:06:51 PM,Buy Recommendation for Biogen Amid Satisfactory 3Q23 Results and Strategic Accounting Adjustments,TipRanks,/news/stocks/buy-recommendation-for-biogen-amid-satisfactory-3q23-results-and-strategic-accounting-adjustments-1032805550,positive,0.9503572583198547
1746,11/9/2023 7:09:23 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Adicet Bio (ACET), Biogen (BIIB) and Ikena Oncology (IKNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-adicet-bio-acet-biogen-biib-and-ikena-oncology-ikna-1032805545,negative,0.9333593249320984
1747,11/9/2023 7:49:50 PM,These Analysts Revise Their Forecasts On Biogen After Q3 Results,Benzinga,/news/stocks/these-analysts-revise-their-forecasts-on-biogen-after-q3-results-1032802298,neutral,0.9143204689025879
1748,11/9/2023 9:03:57 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Acrivon Therapeutics, Inc. (ACRV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-acrivon-therapeutics-inc-acrv-1032806069,neutral,0.9129647016525269
1749,11/10/2023 11:16:02 AM,Strong Financial Performance and Cost Savings Potential: A Buy Rating for Biogen,TipRanks,/news/stocks/strong-financial-performance-and-cost-savings-potential-a-buy-rating-for-biogen-1032808199,positive,0.8966519832611084
1750,11/11/2023 1:15:23 AM,Barclays Reaffirms Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-biogen-biib-1032808891,neutral,0.7838815450668335
1751,11/13/2023 2:10:51 AM,"Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Biogen (BIIB) and Becton Dickinson (BDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bridgebio-pharma-bbio-biogen-biib-and-becton-dickinson-bdx-1032813337,neutral,0.8938168883323669
1752,11/17/2023 1:50:16 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Agilon Health (AGL) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-cigna-ci-agilon-health-agl-and-biogen-biib-1032831239,negative,0.8343841433525085
1753,11/21/2023 12:50:44 PM,"Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-agilent-a-henry-schein-hsic-and-biogen-biib-1032841047,neutral,0.8971436619758606
1754,11/21/2023 9:16:25 PM,"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others",Benzinga,/news/stocks/alzheimer-s-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-others-1032840637,positive,0.9230709075927734
1755,11/23/2023 2:30:14 AM,"Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-iqvia-holdings-iqv-biogen-biib-1032845842,neutral,0.6621273756027222
1756,11/28/2023 1:20:14 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-exact-sciences-exas-and-regeneron-regn-1032856675,neutral,0.8951032757759094
1757,12/1/2023 1:02:00 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-cybin-cybn-nevro-corp-nvro-and-biogen-biib-1032867880,negative,0.7453170418739319
1758,12/6/2023 10:11:43 AM,"Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Mayne Pharma Group (OtherMAYNF) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-replimune-group-repl-mayne-pharma-group-othermaynf-and-biogen-biib-1032879874,neutral,0.9064921736717224
1759,12/7/2023 5:17:14 AM,"UNH, HUM, BIIB: 3 Healthcare Stocks to Buy, Say Analysts",TipRanks,/news/stocks/unh-hum-biib-3-healthcare-stocks-to-buy-say-analysts-1032883124,neutral,0.7347010374069214
1760,12/7/2023 8:10:48 AM,"Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Crispr Therapeutics AG (CRSP) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sarepta-therapeutics-srpt-crispr-therapeutics-ag-crsp-and-biogen-biib-1032883420,neutral,0.9067538380622864
1761,12/7/2023 10:46:16 AM,Biogen’s Turnaround: Projecting Growth and Outperformance with New Therapies,TipRanks,/news/stocks/biogen-s-turnaround-projecting-growth-and-outperformance-with-new-therapies-1032883761,positive,0.9151709675788879
1762,12/7/2023 2:00:27 PM,The Latest Analyst Ratings for Biogen,Benzinga,/news/stocks/the-latest-analyst-ratings-for-biogen-1032881711,neutral,0.9380412101745605
1763,12/7/2023 6:17:59 PM,Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects,Benzinga,/news/stocks/why-this-biogen-analyst-is-turning-bullish-on-alzheimer-s-treatment-prospects-1032883111,neutral,0.7930379509925842
1764,12/8/2023 12:40:31 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032887030,positive,0.552167534828186
1765,12/12/2023 1:10:54 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Penumbra (PEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-penumbra-pen-1032895189,positive,0.7310383915901184
1766,12/14/2023 10:06:22 AM,These 3 stocks are Cowen’s best ideas for 2024 including Amazon and Biogen,TipRanks,/news/stocks/these-3-stocks-are-cowen-s-best-ideas-for-2024-including-amazon-and-biogen-1032902884,neutral,0.8287598490715027
1767,12/14/2023 12:30:00 PM,"ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.",GlobeNewswire,/news/stocks/zurzuvae-zuranolone-civ-a-landmark-oral-treatment-for-women-with-postpartum-depression-ppd-is-now-available-in-the-u-s-1032900508,positive,0.6099571585655212
1768,12/14/2023 1:12:17 PM,"Sage Therapeutics, Biogen Announce Availability Of ZURZUVAE In U.S. For PPD In Women ",RTTNews,/news/stocks/sage-therapeutics-biogen-announce-availability-of-zurzuvae-in-u-s-for-ppd-in-women-1032900656,positive,0.698015570640564
1769,12/15/2023 12:43:26 AM,Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential,InvestorPlace,/news/stocks/mind-bending-growth-3-psychedelic-stocks-with-trippy-potential-1032903102,negative,0.8007485866546631
1770,12/15/2023 3:05:25 PM,"CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease",GlobeNewswire,/news/stocks/chmp-issues-positive-opinion-for-biogen-s-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedreich-s-ataxia-a-rare-neurodegenerative-disease-1032904819,positive,0.9408803582191467
1771,12/15/2023 7:48:27 PM,Biogen's SKYCLARYS Gets CHMP Recommendation For Marketing Authorization ,RTTNews,/news/stocks/biogen-s-skyclarys-gets-chmp-recommendation-for-marketing-authorization-1032905825,positive,0.6475850343704224
1772,12/18/2023 10:25:31 AM,Biogen’s Buy Rating Affirmed: Skyclarys Approval Forecasts Growth and Turnaround by 2024,TipRanks,/news/stocks/biogen-s-buy-rating-affirmed-skyclarys-approval-forecasts-growth-and-turnaround-by-2024-1032910460,positive,0.9148285388946533
1773,12/19/2023 1:30:21 PM,Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission,GlobeNewswire,/news/stocks/centralized-marketing-authorizations-of-generic-versions-of-tecfidera-are-revoked-by-the-european-commission-1032912146,negative,0.7127839922904968
1774,12/19/2023 2:05:45 PM,Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA ,RTTNews,/news/stocks/biogen-says-european-commission-revokes-marketing-authorizations-for-generic-versions-of-tecfidera-1032912279,negative,0.839958131313324
1775,12/20/2023 12:00:58 PM,"Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Biogen (BIIB) and Ascendis Pharma (ASND)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-disc-medicine-iron-biogen-biib-and-ascendis-pharma-asnd-1032917668,neutral,0.9031761288642883
1776,12/26/2023 1:14:10 AM,Top 3 Healthcare Stock Picks for the New Year,InvestorPlace,/news/stocks/top-3-healthcare-stock-picks-for-the-new-year-1032925142,neutral,0.9152405261993408
1777,12/27/2023 10:31:53 PM,Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness,InvestorPlace,/news/stocks/healthcare-heroes-3-stocks-innovating-in-medicine-and-wellness-1032928865,neutral,0.8069815635681152
1778,12/31/2023 10:08:42 AM,Biogen (BIIB) Receives a Hold from BTIG,TipRanks,/news/stocks/biogen-biib-receives-a-hold-from-btig-1032934232,neutral,0.8793240189552307
1779,1/2/2024 2:13:14 PM,BTIG Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/btig-sticks-to-its-hold-rating-for-biogen-biib-1032938245,neutral,0.8191681504249573
1780,1/2/2024 6:57:42 PM,3 Biotech Stocks at the Forefront of the Quest for Eternal Youth,InvestorPlace,/news/stocks/3-biotech-stocks-at-the-forefront-of-the-quest-for-eternal-youth-1032937827,neutral,0.7953880429267883
1781,1/9/2024 10:06:03 AM,Maintaining Hold on Biogen: Balancing New Product Potential Against Market and Pipeline Uncertainties,TipRanks,/news/stocks/maintaining-hold-on-biogen-balancing-new-product-potential-against-market-and-pipeline-uncertainties-1032955161,positive,0.5440393686294556
1782,1/9/2024 10:15:33 PM,Optimistic Buy Rating for Biogen on Robust Drug Launches and Strategic Growth Initiatives,TipRanks,/news/stocks/optimistic-buy-rating-for-biogen-on-robust-drug-launches-and-strategic-growth-initiatives-1032956132,positive,0.9511848092079163
1783,1/10/2024 1:30:40 PM,Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-icon-iclr-and-biogen-biib-1032958071,neutral,0.8951762318611145
1784,1/10/2024 8:29:43 PM,"Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments",Benzinga,/news/stocks/analyst-assesses-cell-programming-focused-ginkgo-bioworks-positioning-amid-revenue-surge-program-adjustments-1032958430,positive,0.9251823425292969
1785,1/13/2024 7:05:25 PM,"BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?",TipRanks,/news/stocks/biib-zts-exas-which-strong-buy-healthcare-stock-is-best-1032965194,neutral,0.8941326141357422
1786,1/23/2024 8:25:28 AM,Barclays Reaffirms Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-biogen-biib-1032987159,neutral,0.7838815450668335
1787,1/24/2024 1:54:54 PM,Biogen slips as UBS cuts to Neutral on Alzheimer’s drug uptake,Seeking Alpha,https://seekingalpha.com/news/4057849-biogen-stock-slips-ubs-downgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.89500892162323
1788,1/24/2024 2:00:13 PM,Critical Insights From Biogen Analyst Ratings: What You Need To Know,Benzinga,/news/stocks/critical-insights-from-biogen-analyst-ratings-what-you-need-to-know-1032992038,neutral,0.937703549861908
1789,1/24/2024 8:55:14 PM,"Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts",Benzinga,/news/stocks/slow-market-penetration-for-biogen-s-another-alzheimer-s-drug-ubs-highlights-risks-forecasts-1032993934,negative,0.896992564201355
1790,1/25/2024 1:42:45 PM,AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday,Benzinga,/news/stocks/at-t-to-rally-around-44-here-are-10-top-analyst-forecasts-for-thursday-1032996432,neutral,0.9222627878189087
1791,1/26/2024 10:36:11 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033000843,positive,0.552167534828186
1792,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8954368233680725
1793,1/29/2024 1:12:01 PM,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Corbus Pharmaceuticals (CRBP)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-corbus-pharmaceuticals-crbp-1033006474,positive,0.7315669655799866
1794,1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7358655333518982
1795,1/31/2024 1:30:00 PM,Biogen to Realign Resources for Alzheimer's Disease Franchise,GlobeNewswire,/news/stocks/biogen-to-realign-resources-for-alzheimer-s-disease-franchise-1033014619,neutral,0.7436037063598633
1796,1/31/2024 2:29:25 PM,Biogen Decides To Discontinue Development Of Alzheimer's Drug Aduhelm ,RTTNews,/news/stocks/biogen-decides-to-discontinue-development-of-alzheimer-s-drug-aduhelm-1033014921,neutral,0.5918433666229248
1797,1/31/2024 2:54:28 PM,"Biogen scraps Aduhelm, will focus on other Alzheimer's drugs",Seeking Alpha,https://seekingalpha.com/news/4060667-biogen-scraps-aduhelm-will-focus-on-other-alzheimers-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9034826755523682
1798,2/6/2024 1:16:25 PM,Optimistic Outlook for Biogen’s Leqembi Sales Despite Slow Initial Uptake,TipRanks,/news/stocks/optimistic-outlook-for-biogen-s-leqembi-sales-despite-slow-initial-uptake-1033036114,positive,0.9475810527801514
1799,2/6/2024 2:20:34 PM,"Analysts Are Bullish on Top Healthcare Stocks: SurModics (SRDX), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-surmodics-srdx-biogen-biib-1033036335,positive,0.6707468032836914
1800,2/7/2024 10:35:41 AM,Strong Demand and Expanding Provider Network Justify Buy Rating for Biogen,TipRanks,/news/stocks/strong-demand-and-expanding-provider-network-justify-buy-rating-for-biogen-1033040775,positive,0.9064339995384216
1801,2/7/2024 12:55:59 PM,Oppenheimer Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-keeps-their-buy-rating-on-biogen-biib-1033041885,neutral,0.9158653020858765
1802,2/8/2024 9:10:42 PM,7 Biotech Stocks Fighting America’s Deadliest Diseases,InvestorPlace,/news/stocks/7-biotech-stocks-fighting-americas-deadliest-diseases-1033048253,neutral,0.7001750469207764
1803,2/9/2024 4:57:10 PM,Aptar Inks Enterprise Agreement With Biogen ,RTTNews,/news/stocks/aptar-inks-enterprise-agreement-with-biogen-1033051865,positive,0.8561633229255676
1804,2/9/2024 8:00:09 PM,"Catalyst Watch: Coca-Cola earnings, Instacart lockup, 13F filings and more NYCB drama",Seeking Alpha,https://seekingalpha.com/news/4065216-catalyst-watch-coca-cola-earnings-instacart-lockup-13f-filings-and-more-nycb-drama?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5400354862213135
1805,2/12/2024 11:20:00 AM,3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good,InvestorPlace,/news/stocks/3-millionaire-maker-stocks-to-buy-while-the-gettin-is-good-1033056423,neutral,0.7638309001922607
1806,2/12/2024 3:01:13 PM,Biogen earnings: here's what to expect,Markets Insider Automation,/news/stocks/biogen-stock-q4-earnings-preview-1033056955,neutral,0.9404481053352356
1807,2/12/2024 3:43:06 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4065562-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8660826683044434
1808,2/12/2024 4:21:47 PM,Biogen Q4 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4065594-biogen-q4-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8594914078712463
1809,2/12/2024 9:46:59 PM,Biogen gets EU approval for Friedrich's ataxia drug,Seeking Alpha,https://seekingalpha.com/news/4065790-biogen-gets-eu-approval-for-friedrichs-ataxia-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7097007036209106
1810,2/12/2024 10:06:00 PM,"Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia",GlobeNewswire,/news/stocks/biogen-received-european-commission-approval-for-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedreich-s-ataxia-1033058551,positive,0.9219944477081299
1811,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6178929805755615
1812,2/13/2024 2:43:45 AM,Biogen's Skyclarys Approved In Europe For Friedreich's Ataxia Treatment ,RTTNews,/news/stocks/biogen-s-skyclarys-approved-in-europe-for-friedreich-s-ataxia-treatment-1033058757,positive,0.6512297987937927
1813,2/13/2024 9:57:39 AM,Maintaining Hold on Biogen Amid Revenue Decline and Strategic Uncertainties,TipRanks,/news/stocks/maintaining-hold-on-biogen-amid-revenue-decline-and-strategic-uncertainties-1033060684,negative,0.928621232509613
1814,2/13/2024 12:18:36 PM,Biogen misses top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4065966-biogen-misses-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9523285627365112
1815,2/13/2024 12:59:24 PM,Biogen slips as outlook disappoints amid flat Leqembi sales,Seeking Alpha,https://seekingalpha.com/news/4065981-biogen-stock-slips-2024-outlook-disappoints?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9644381999969482
1816,2/13/2024 1:14:36 PM,"Biogen Inc. Q4 Profit Decreases, misses estimates",RTTNews,/news/stocks/biogen-inc-q4-profit-decreases-misses-estimates-1033060582,negative,0.9712603092193604
1817,2/13/2024 1:25:34 PM,Biogen’s Leqembi Drives Growth: Michael Yee’s Bullish Buy Rating Amid Rising Sales and Patient Adoption,TipRanks,/news/stocks/biogen-s-leqembi-drives-growth-michael-yee-s-bullish-buy-rating-amid-rising-sales-and-patient-adoption-1033062242,positive,0.9382194876670837
1818,2/13/2024 1:30:37 PM,"Analysts Are Bullish on Top Healthcare Stocks: Encompass Health (EHC), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-encompass-health-ehc-biogen-biib-1033062313,positive,0.7762318253517151
1819,2/13/2024 1:34:33 PM,"Biogen Sees Higher Adj. EPS, Weak Revenues In FY24; Stock Down In Pre-market ",RTTNews,/news/stocks/biogen-sees-higher-adj-eps-weak-revenues-in-fy24-stock-down-in-pre-market-1033060650,negative,0.9731167554855347
1820,2/13/2024 1:50:38 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033062393,positive,0.552167534828186
1821,2/13/2024 6:00:34 PM,Breaking Down Biogen: 8 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-biogen-8-analysts-share-their-views-1033062434,neutral,0.897786557674408
1822,2/13/2024 8:13:50 PM,"Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?",Benzinga,/news/stocks/markets-tumble-vix-up-8-on-hot-inflation-data-dollar-yields-jump-as-traders-unwind-rate-cut-bets-what-s-driving-markets-tuesday-1033062710,negative,0.7374973297119141
1823,2/13/2024 10:35:18 PM,Biogen’s Buy Rating Affirmed on Strong EPS Growth and Promising New Therapy Launches,TipRanks,/news/stocks/biogen-s-buy-rating-affirmed-on-strong-eps-growth-and-promising-new-therapy-launches-1033063348,positive,0.9555699229240417
1824,2/14/2024 11:38:52 AM,Hold Rating on Biogen Amidst Early Alzheimer’s Treatment Adoption and Moderate Growth Outlook,TipRanks,/news/stocks/hold-rating-on-biogen-amidst-early-alzheimer-s-treatment-adoption-and-moderate-growth-outlook-1033066816,positive,0.928859293460846
1825,2/14/2024 11:50:15 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Ironwood Pharma (IRWD) and Healthequity (HQY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-ironwood-pharma-irwd-and-healthequity-hqy-1033066885,neutral,0.8956640958786011
1826,2/14/2024 12:20:13 PM,"Analysts Are Bullish on These Healthcare Stocks: QuidelOrtho (QDEL), Abbott Labs (ABT)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-quidelortho-qdel-abbott-labs-abt-1033067335,neutral,0.6399168372154236
1827,2/14/2024 12:51:10 PM,"Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Madrigal Pharmaceuticals (MDGL) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbott-labs-abt-madrigal-pharmaceuticals-mdgl-and-biogen-biib-1033067461,neutral,0.9086591005325317
1828,2/14/2024 1:49:59 PM,Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/citigroup-to-rally-over-19-here-are-10-top-analyst-forecasts-for-wednesday-1033066215,neutral,0.9171735644340515
1829,2/14/2024 2:35:10 PM,Scotiabank Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/scotiabank-sticks-to-its-buy-rating-for-biogen-biib-1033067826,neutral,0.737128734588623
1830,2/14/2024 2:50:29 PM,"Wells Fargo downgrades Biogen to equal weight, cites Skyclarys sales",Seeking Alpha,https://seekingalpha.com/news/4066789-wells-fargo-downgrades-biogen-to-equal-weight-cites-skyclarys-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8189947605133057
1831,2/14/2024 3:33:07 PM,DOJ issues subpoena for info on Biogen's foreign operations,Seeking Alpha,https://seekingalpha.com/news/4066828-doj-issues-subpoena-for-info-on-biogens-foreign-operations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9042156934738159
1832,2/14/2024 9:11:57 PM,"Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says",Benzinga,/news/stocks/biogen-could-engage-in-1b--2b-deals-to-fill-revenue-shortfall-gaps-analyst-says-1033068148,positive,0.7524489760398865
1833,2/15/2024 6:41:31 AM,"Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Biogen (BIIB) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-haemonetics-hae-biogen-biib-and-axsome-therapeutics-axsm-1033070678,neutral,0.8980287909507751
1834,2/15/2024 9:16:04 AM,Optimistic Outlook for Biogen: Buy Rating Upheld Amid Growth Trajectory and Pipeline Potential,TipRanks,/news/stocks/optimistic-outlook-for-biogen-buy-rating-upheld-amid-growth-trajectory-and-pipeline-potential-1033071292,positive,0.9469341039657593
1835,2/15/2024 11:40:13 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: American Well (AMWL), Biogen (BIIB) and Insmed (INSM)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-american-well-amwl-biogen-biib-and-insmed-insm-1033072022,negative,0.7738081216812134
1836,2/15/2024 9:13:52 PM,7 Contrarian Biotech Stocks to Consider Amid Sector Weakness,InvestorPlace,/news/stocks/7-contrarian-biotech-stocks-to-consider-amid-sector-weakness-1033073521,neutral,0.7290653586387634
1837,2/19/2024 6:46:20 PM,From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024,InvestorPlace,/news/stocks/from-zero-to-hero-7-stock-losers-that-could-turn-things-around-in-2024-1033080868,neutral,0.6696564555168152
1838,2/21/2024 8:20:05 AM,"Analysts Are Bullish on These Healthcare Stocks: Johnson & Johnson (JNJ), Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-johnson-johnson-jnj-vertex-pharmaceuticals-vrtx-1033087099,positive,0.5155606269836426
1839,2/21/2024 7:33:22 PM,"10 worst performing Nasdaq 100 stocks of 2024 so far, including Tesla and Intel",Seeking Alpha,https://seekingalpha.com/news/4069829-10-worst-performing-nasdaq-100-stocks-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9621149301528931
1840,2/22/2024 11:00:53 PM,"3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024",InvestorPlace,/news/stocks/3-biotech-stocks-to-turn-10000-into-1-million-february-2024-1033095198,neutral,0.8369854688644409
1841,2/23/2024 12:59:52 PM,Biogen granted EU backing for ALS therapy,Seeking Alpha,https://seekingalpha.com/news/4071013-biogen-granted-eu-backing-als-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8895061016082764
1842,2/23/2024 1:00:26 PM,"Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP",GlobeNewswire,/news/stocks/biogen-s-qalsody-tofersen-the-first-therapy-to-treat-rare-genetic-form-of-als-received-positive-opinion-from-chmp-1033097037,positive,0.9434910416603088
1843,2/23/2024 2:21:09 PM,Biogen's Qalsody Receives Positive Opinion From CHMP ,RTTNews,/news/stocks/biogen-s-qalsody-receives-positive-opinion-from-chmp-1033097292,positive,0.9274958372116089
1844,2/27/2024 12:27:19 PM,RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-biogen-biib-1033108298,neutral,0.7063238024711609
1845,2/29/2024 11:00:45 PM,Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit),Benzinga,/news/stocks/top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-here-s-what-investors-think-about-them-wall-street-vs-reddit-1033120683,neutral,0.9334502816200256
1846,3/4/2024 7:09:42 PM,iShares BBB Rate Corporate Bond ETF declares monthly distribution of $0.3050,Seeking Alpha,https://seekingalpha.com/news/4075539-ishares-bbb-rate-corporate-bond-etf-declares-monthly-distribution-of-03050?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8787883520126343
1847,3/4/2024 9:09:21 PM,Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits,InvestorPlace,/news/stocks/biotechs-on-the-rise-3-stocks-to-buy-for-a-shot-of-profits-1033130269,neutral,0.7510853409767151
1848,3/4/2024 10:15:57 PM,Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting,GlobeNewswire,/news/stocks/biogen-highlights-new-data-at-the-international-conference-on-alzheimer-s-and-parkinson-s-diseases-ad-pd-2024-annual-meeting-1033130351,neutral,0.8935292363166809
1849,3/5/2024 4:00:46 PM,A Closer Look at 21 Analyst Recommendations For Biogen,Benzinga,/news/stocks/a-closer-look-at-21-analyst-recommendations-for-biogen-1033133592,neutral,0.9015387296676636
1850,3/6/2024 4:15:07 AM,RBC Capital Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-biogen-biib-1033136135,neutral,0.9115294814109802
1851,3/6/2024 1:30:51 PM,New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy,GlobeNewswire,/news/stocks/new-biomarker-data-add-further-evidence-supporting-the-potential-benefit-of-spinraza-nusinersen-in-infants-and-toddlers-with-unmet-clinical-needs-after-gene-therapy-1033137169,positive,0.9279215931892395
1852,3/7/2024 2:59:39 PM,"Biogen Alzheimer’s drug off to a slower rollout in U.S., partner Eisai says",Seeking Alpha,https://seekingalpha.com/news/4077221-biogen-alzheimers-drug-off-slower-rollout-us?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4630180299282074
1853,3/8/2024 12:07:44 PM,Eli Lilly slips as FDA delays decision on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4077577-eli-lilly-stock-slips-fda-decision-alzheimers-drug-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9297435283660889
1854,3/8/2024 3:35:32 PM,Fed Rate Cut Expectations Rise After February Jobs Report: Friday's Stock Movers,Benzinga,/news/etf/fed-rate-cut-expectations-rise-after-february-jobs-report-friday-s-stock-movers-1033146527,negative,0.44008415937423706
1855,3/11/2024 12:01:55 PM,Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-onconova-therapeutics-ontx-and-biogen-biib-1033151741,neutral,0.8890613913536072
1856,3/11/2024 4:23:20 PM,AbCellera gains on antibody collaboration with Biogen,Seeking Alpha,https://seekingalpha.com/news/4078071-abcellera-gains-antibody-collaboration-biogen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.937811553478241
1857,3/13/2024 6:11:38 AM,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biogen-biib-merck-company-mrk-1033158508,positive,0.48281052708625793
1858,3/14/2024 11:20:30 AM,Biotech group backs anti-China bill; part ways with WuXi AppTec,Seeking Alpha,https://seekingalpha.com/news/4079392-biotech-group-backs-anti-china-bill-splits-wuxi-apptec?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5961117148399353
1859,3/15/2024 8:08:53 PM,"Biogen chief medical officer departs, joins Alto Neuroscience board",Seeking Alpha,https://seekingalpha.com/news/4080162-biogen-chief-medical-officer-departs-joins-alto-neuroscience-board?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.753943920135498
1860,3/19/2024 12:40:34 PM,Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-crinetics-pharmaceuticals-crnx-and-biogen-biib-1033177442,neutral,0.896727979183197
1861,3/20/2024 1:00:32 PM,Labcorp expands Alzheimer's testing portfolio with new diagnostic,Seeking Alpha,https://seekingalpha.com/news/4081545-labcorp-expands-alzheimers-test-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8395876288414001
1862,3/22/2024 12:50:49 PM,EU delays decision on Eisai-Biogen Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4082599-eu-delays-decision-on-eisai-biogen-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8145773410797119
1863,3/25/2024 12:25:44 PM,Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-biogen-biib-1033193932,neutral,0.5527154803276062
1864,3/25/2024 6:00:14 PM,Forecasting The Future: 18 Analyst Projections For Biogen,Benzinga,/news/stocks/forecasting-the-future-18-analyst-projections-for-biogen-1033194215,neutral,0.9358155727386475
1865,3/25/2024 7:00:00 PM,Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich-1033194514,neutral,0.9046082496643066
1866,3/27/2024 12:20:27 PM,"Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-aprea-therapeutics-apre-biogen-biib-and-mesoblast-limited-othermeobf-1033202031,neutral,0.903069794178009
1867,3/30/2024 4:13:00 PM,Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues,Seeking Alpha,https://seekingalpha.com/news/4084974-eli-lilly-tops-the-growth-chart-for-the-sp-500-index-in-q1-as-the-sector-gains-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.653032124042511
1868,4/1/2024 2:49:49 AM,Eisai Submits Leqembi SBLA For IV Maintenance Dosing In Early Alzheimer's Disease ,RTTNews,/news/stocks/eisai-submits-leqembi-sbla-for-iv-maintenance-dosing-in-early-alzheimer-s-disease-1033210002,neutral,0.8325610756874084
1869,4/1/2024 9:26:37 AM,Hold Rating on Biogen Amidst Leqembi’s Regulatory Challenges and Competitive Pressures,TipRanks,/news/stocks/hold-rating-on-biogen-amidst-leqembi-s-regulatory-challenges-and-competitive-pressures-1033210829,negative,0.53659588098526
1870,4/1/2024 10:04:15 AM,Eisai submits sBLA for monthly maintenance dose of Alzheimer's drug Leqembi,Seeking Alpha,https://seekingalpha.com/news/4085471-eisai-submits-sbla-monthly-maintenance-dose-alzheimers-drug-leqembi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8950710892677307
1871,4/1/2024 12:10:28 PM,Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-4d-molecular-therapeutics-fdmt-and-biogen-biib-1033211725,neutral,0.8845738768577576
1872,4/1/2024 1:45:57 PM,Buy Rating on Biogen: Focused on Leqembi’s IV Dosing Amidst SQ Formulation Delay,TipRanks,/news/stocks/buy-rating-on-biogen-focused-on-leqembi-s-iv-dosing-amidst-sq-formulation-delay-1033212065,neutral,0.866741955280304
1873,4/2/2024 3:36:00 PM,Biotech Roundtable: Who will bring the next CRISPR drug to market?,Seeking Alpha,https://seekingalpha.com/news/4083199-biotech-roundtable-who-will-bring-the-next-crispr-drug-to-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8740512132644653
1874,4/7/2024 12:00:00 PM,"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",Seeking Alpha,https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9427610039710999
1875,4/9/2024 10:30:27 AM,"Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-harmony-biosciences-holdings-hrmy-recursion-pharmaceuticals-rxrx-1033233534,neutral,0.4890331029891968
1876,4/11/2024 10:00:53 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-kalvista-pharmaceuticals-kalv-and-ptc-therapeutics-ptct-1033241096,neutral,0.905910313129425
1877,4/11/2024 7:01:02 PM,Where Biogen Stands With Analysts,Benzinga,/news/stocks/where-biogen-stands-with-analysts-1033242166,neutral,0.9221560955047607
1878,4/12/2024 4:02:53 PM,GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma,Seeking Alpha,https://seekingalpha.com/news/4089307-glp-1s-benefit-parkinsons-barclays-sees-biopharma-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6429068446159363
1879,4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7529379725456238
1880,4/16/2024 7:31:20 PM,Biogen’s Alzheimer's drug to cost $3.5B for Medicare in 2025: report,Seeking Alpha,https://seekingalpha.com/news/4090212-biogens-alzheimers-drug-medicare-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8129854202270508
1881,4/19/2024 11:50:22 AM,"Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-gilead-sciences-gild-biogen-biib-1033266718,positive,0.5696873068809509
1882,4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9310646057128906
1883,4/22/2024 12:28:17 PM,Piper Sandler Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-biogen-biib-1033271990,neutral,0.8194357752799988
1884,4/23/2024 2:25:34 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/4092543-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.855887770652771
1885,4/23/2024 3:01:13 PM,Here's what Wall Street expects from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-q1-earnings-preview-1033275940,neutral,0.9258308410644531
1886,4/23/2024 3:01:17 PM,Biogen Q1 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4092573-biogen-q1-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.843289852142334
1887,4/24/2024 9:42:10 AM,"Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-day-one-biopharmaceuticals-dawn-biogen-biib-and-neurocrine-nbix-1033281644,neutral,0.9168521165847778
1888,4/24/2024 10:51:46 AM,"Biogen Non-GAAP EPS of $3.67 beats by $0.21, revenue of $2.29B misses by $30M",Seeking Alpha,https://seekingalpha.com/news/4092998-biogen-non-gaap-eps-of-3_67-beats-0_21-revenue-of-2_29b-misses-30m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7370980978012085
1889,4/24/2024 12:00:21 PM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and BioMarin Pharmaceutical (BMRN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-biomarin-pharmaceutical-bmrn-1033283046,neutral,0.8891050815582275
1890,4/24/2024 12:03:47 PM,Biogen says uptake for Alzheimer’s therapy is improving,Seeking Alpha,https://seekingalpha.com/news/4093061-biogen-stock-gains-q1-earnings-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9481522440910339
1891,4/24/2024 1:10:48 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Boston Scientific (BSX) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-boston-scientific-bsx-and-biogen-biib-1033283380,negative,0.9204069375991821
1892,4/24/2024 1:15:54 PM,"Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook ",RTTNews,/news/stocks/biogen-q1-adj-eps-tops-estimates-but-sales-miss-reaffirms-fy24-outlook-1033281174,positive,0.6871333718299866
1893,4/24/2024 3:53:28 PM,"BIIB Stock Earnings: Biogen Beats EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/biib-stock-earnings-biogen-for-q1-of-2024-1033283357,positive,0.847701370716095
1894,4/24/2024 7:40:58 PM,"Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?",Benzinga,/news/stocks/treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-what-s-driving-markets-wednesday-1033283702,negative,0.8183841705322266
1895,4/25/2024 9:40:44 AM,"Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Biogen (BIIB) and Molina Healthcare (MOH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-thermo-fisher-tmo-biogen-biib-and-molina-healthcare-moh-1033287812,neutral,0.9080461263656616
1896,4/25/2024 11:02:58 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-evolent-health-evh-and-biomarin-pharmaceutical-bmrn-1033288722,neutral,0.8947010636329651
1897,4/25/2024 11:10:34 AM,Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-biogen-biib-1033288696,neutral,0.5527154803276062
1898,4/25/2024 11:32:46 AM,"Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Universal Health (UHS)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biomarin-pharmaceutical-bmrn-universal-health-uhs-1033288863,positive,0.5610986948013306
1899,4/25/2024 11:56:20 AM,Jefferies Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/jefferies-keeps-their-buy-rating-on-biogen-biib-1033288960,neutral,0.9166783690452576
1900,4/26/2024 3:36:02 AM,"Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19 ",RTTNews,/news/stocks/biogen-s-tofidence-gets-positive-chmp-opinion-for-rheumatoid-arthritis-juvenile-arthritis-covid-19-1033290866,positive,0.9311685562133789
1901,4/26/2024 5:58:43 AM,Biogen’s Financial Upswing: Strong Q1 Performance and Market Penetration Justify Buy Rating,TipRanks,/news/stocks/biogen-s-financial-upswing-strong-q1-performance-and-market-penetration-justify-buy-rating-1033292879,positive,0.946601152420044
1902,4/26/2024 6:09:35 AM,Biogen’s Surpassing Performance and Positive Outlook Affirm Buy Rating,TipRanks,/news/stocks/biogen-s-surpassing-performance-and-positive-outlook-affirm-buy-rating-1033292931,positive,0.9067649841308594
1903,4/26/2024 6:22:26 AM,Buy Rating Justified: Biogen’s Promising Drug Launches and Strategic Growth Initiatives,TipRanks,/news/stocks/buy-rating-justified-biogen-s-promising-drug-launches-and-strategic-growth-initiatives-1033292994,positive,0.9132458567619324
1904,4/26/2024 9:50:44 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-dexcom-dxcm-and-herbalife-hlf-1033293992,neutral,0.906337559223175
1905,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6158697009086609
1906,4/29/2024 11:58:04 AM,Oppenheimer Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-biogen-biib-1033301129,neutral,0.9442697167396545
1907,4/29/2024 2:03:13 PM,7 Retirement Stocks to Buy at a 52-Week Low in April,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-at-a-52-week-low-in-april-1033300969,negative,0.8338459134101868
1908,4/29/2024 7:01:08 PM,The Analyst Landscape: 27 Takes On Biogen,Benzinga,/news/stocks/the-analyst-landscape-27-takes-on-biogen-1033301640,neutral,0.9168171882629395
1909,5/1/2024 3:44:29 PM,"AbCellera partners with PE firms to develop antibody drugs, company creation",Seeking Alpha,https://seekingalpha.com/news/4097439-abcellera-partners-private-equity-firms-develop-antibody-drugs-company-creation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.509709894657135
1910,5/2/2024 1:30:00 PM,Biogen Reports Progress on Corporate Responsibility Priorities,GlobeNewswire,/news/stocks/biogen-reports-progress-on-corporate-responsibility-priorities-1033319198,positive,0.935441792011261
1911,5/6/2024 6:42:11 PM,Why Is Nuvo Group (NUVO) Stock Up 200% Today?,InvestorPlace,/news/stocks/why-is-nuvo-group-nuvo-stock-up-200-today-1033334984,positive,0.7551090717315674
1912,5/7/2024 1:38:29 PM,Eli Lilly Alzheimer’s therapy set for June FDA AdCom meeting,Seeking Alpha,https://seekingalpha.com/news/4101160-eli-lilly-alzheimers-drug-set-june-fda-adcom?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9474264979362488
1913,5/9/2024 10:30:00 AM,The 3 Most Undervalued Pharma Stocks to Buy in May 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-may-2024-1033355189,neutral,0.7523892521858215
1914,5/11/2024 12:00:00 PM,3 S&P 500 Stocks to Rival Nvidia’s 2023 Performance in the Second Half of 2024,InvestorPlace,/news/stocks/3-sp-500-stocks-to-rival-nvidias-2023-performance-in-the-second-half-of-2024-1033365119,positive,0.9429292678833008
1915,5/15/2024 1:33:37 AM,Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track...,GlobeNewswire,/news/stocks/eisai-initiates-rolling-biologics-license-application-to-us-fda-for-leqembi-lecanemab-irmb-for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimer-s-disease-under-the-fast-track-1033379017,positive,0.6776726245880127
1916,5/15/2024 3:03:29 AM,Eisai Initiates Rolling BLA To FDA For LEQEMBI For Early Alzheimer's Disease Treatment ,RTTNews,/news/stocks/eisai-initiates-rolling-bla-to-fda-for-leqembi-for-early-alzheimer-s-disease-treatment-1033379051,neutral,0.6145710945129395
1917,5/15/2024 11:44:07 AM,Biogen partner Eisai begins FDA submissions for injectable Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/4106396-eisai-begins-fda-submissions-injectable-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.776604175567627
1918,5/15/2024 12:21:04 PM,"Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-taysha-gene-therapies-tsha-biogen-biib-1033385532,neutral,0.5026521682739258
1919,5/15/2024 1:01:49 PM,"Analysts Are Bullish on These Healthcare Stocks: scPharmaceuticals (SCPH), Optinose (OPTN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-scpharmaceuticals-scph-optinose-optn-1033385804,neutral,0.478259414434433
1920,5/15/2024 4:52:06 PM,Eisai projects major growth for Alzheimer's therapy Leqembi,Seeking Alpha,https://seekingalpha.com/news/4106735-eisai-projects-major-growth-for-alzheimers-therapy-leqembi-biogen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8975977897644043
1921,5/16/2024 11:36:25 AM,Biogen (BIIB) Receives a Buy from Truist Financial,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-truist-financial-1033393835,neutral,0.558030366897583
1922,5/16/2024 1:00:18 PM,Biogen and Ionis drop ALS candidate after trial setback,Seeking Alpha,https://seekingalpha.com/news/4107328-biogen-stock-ionis-stock-drop-als-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.963778555393219
1923,5/16/2024 1:30:14 PM,Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis,GlobeNewswire,/news/stocks/biogen-and-ionis-announce-topline-phase-1-2-study-results-of-investigational-drug-in-amyotrophic-lateral-sclerosis-1033392311,neutral,0.6615080237388611
1924,5/16/2024 5:47:53 PM,Biogen also drops collaboration with Ionis on Angelman syndrome candidate,Seeking Alpha,https://seekingalpha.com/news/4107659-biogen-also-drops-collaboration-with-ionis-on-angelman-syndrome-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8779821991920471
1925,5/16/2024 10:55:29 PM,Biogen: A Balanced View Amidst Setbacks and Alzheimer’s Drug Potential,TipRanks,/news/stocks/biogen-a-balanced-view-amidst-setbacks-and-alzheimer-s-drug-potential-1033395354,neutral,0.7848695516586304
1926,5/17/2024 10:15:00 AM,Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ,InvestorPlace,/news/stocks/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-may-2024-1033398565,positive,0.7998301982879639
1927,5/17/2024 9:26:48 PM,"Ionis, Biogen Down on Ending Development of ALS Drug",Benzinga,/news/stocks/ionis-biogen-down-on-ending-development-of-als-drug-1033400654,negative,0.9207988381385803
1928,5/20/2024 10:17:01 PM,Larimar stock rallies 24% on FDA removal of partial clinical hold,Seeking Alpha,https://seekingalpha.com/news/4108572-larimar-stock-rallies-on-fda-removal-of-partial-clinical-hold?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8574681878089905
1929,5/21/2024 8:39:04 PM,Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug,Benzinga,/news/stocks/larimar-therapeutics-friedreich-s-ataxia-investigational-drug-differentiated-from-biogen-s-marketed-drug-1033408750,neutral,0.7388636469841003
1930,5/22/2024 12:42:49 PM,Biogen inks $1.8B deal to acquire immune drug developer HI-Bio,Seeking Alpha,https://seekingalpha.com/news/4109272-biogen-inks-18b-deal-to-acquire-immune-drug-developer-hi-bio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5526325106620789
1931,5/22/2024 1:15:23 PM,Biogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ Rating,TipRanks,/news/stocks/biogen-s-strategic-acquisition-of-hi-bio-and-diversification-into-orphan-drug-market-prompt-buy-rating-1033412779,positive,0.8539541959762573
1932,5/22/2024 1:30:00 PM,"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences",GlobeNewswire,/news/stocks/biogen-bolsters-late-stage-pipeline-expands-immunology-portfolio-with-agreement-to-acquire-human-immunology-biosciences-1033411159,positive,0.9284027218818665
1933,5/22/2024 2:11:37 PM,Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln ,RTTNews,/news/stocks/biogen-to-buy-human-immunology-biosciences-in-deal-valued-at-up-to-1-8-bln-1033411333,neutral,0.5956004858016968
1934,5/22/2024 3:44:10 PM,IGM Biosciences up 40% following Biogen HI-Bio buy,Seeking Alpha,https://seekingalpha.com/news/4109393-igm-biosciences-up-40-following-biogen-hi-bio-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9226755499839783
1935,5/22/2024 4:00:24 PM,Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings),Benzinga,/news/stocks/deep-dive-into-biogen-stock-analyst-perspectives-17-ratings-1033412168,neutral,0.791338324546814
1936,5/23/2024 8:03:03 AM,Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-walgreens-boots-alliance-wba-and-biogen-biib-1033415382,neutral,0.9072046279907227
1937,5/23/2024 8:10:31 AM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Walgreens Boots Alliance (WBA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-walgreens-boots-alliance-wba-1033415375,neutral,0.8989835381507874
1938,5/23/2024 10:25:28 AM,Biogen’s Buy Rating Bolstered by Strategic Acquisition and Promising Pipeline Expansion,TipRanks,/news/stocks/biogen-s-buy-rating-bolstered-by-strategic-acquisition-and-promising-pipeline-expansion-1033415905,positive,0.952258825302124
1939,5/23/2024 11:11:00 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-incyte-incy-1033416355,negative,0.6925205588340759
1940,5/23/2024 11:15:51 AM,Buy Rating Affirmed for Biogen on Strategic Acquisition and Promising Pipeline,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-on-strategic-acquisition-and-promising-pipeline-1033416427,positive,0.9363638758659363
1941,5/23/2024 11:31:06 AM,"Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Biogen (BIIB) and Clene (CLNN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-scholar-rock-holding-srrk-biogen-biib-and-clene-clnn-1033416523,neutral,0.914570689201355
1942,5/23/2024 11:46:30 AM,Biogen (BIIB) Gets a Buy from Oppenheimer,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-oppenheimer-1033416576,neutral,0.6016966700553894
1943,5/24/2024 5:48:32 AM,Strategic Acquisitions and Clinical Catalysts Bolster Biogen’s Buy Rating,TipRanks,/news/stocks/strategic-acquisitions-and-clinical-catalysts-bolster-biogen-s-buy-rating-1033419160,positive,0.9542121887207031
1944,5/24/2024 5:51:58 AM,Biogen’s Strategic Diversification and Financial Strategy Garner Outperform Rating,TipRanks,/news/stocks/biogen-s-strategic-diversification-and-financial-strategy-garner-outperform-rating-1033419150,positive,0.9289629459381104
1945,5/28/2024 10:50:08 AM,"Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-inari-medical-nari-biogen-biib-and-sophia-genetics-soph-1033427210,neutral,0.9125716686248779
1946,5/29/2024 10:46:18 AM,RBC Capital Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-biogen-biib-1033431930,positive,0.49897974729537964
1947,5/30/2024 9:30:28 PM,EU approves Biogen treatment for genetic form of ALS,Seeking Alpha,https://seekingalpha.com/news/4111789-eu-approves-biogen-treatment-for-genetic-form-of-als?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7881863117218018
1948,5/30/2024 10:51:04 PM,"Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS",GlobeNewswire,/news/stocks/biogen-receives-european-commission-approval-for-qalsody-tofersen-the-first-therapy-to-treat-a-rare-genetic-form-of-als-1033437921,positive,0.8931410908699036
1949,5/31/2024 3:00:47 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-gilead-sciences-gild-biogen-biib-and-argenx-se-argx-1033439823,negative,0.7460076212882996
1950,5/31/2024 4:16:30 AM,"Biogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis ",RTTNews,/news/stocks/biogen-eu-approves-qalsody-to-treat-rare-genetic-form-of-amyotrophic-lateral-sclerosis-1033438119,positive,0.8882882595062256
1951,6/3/2024 1:30:00 PM,Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel,GlobeNewswire,/news/stocks/biogen-and-delta-flight-products-to-collaborate-with-advocates-and-patients-to-inform-the-future-of-accessible-air-travel-1033445284,neutral,0.586448073387146
1952,6/4/2024 1:30:16 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033450734,positive,0.552167534828186
1953,6/5/2024 10:50:14 AM,"Analysts Offer Insights on Healthcare Companies: Evolent Health (EVH), Biogen (BIIB) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-evolent-health-evh-biogen-biib-and-axsome-therapeutics-axsm-1033453768,neutral,0.9047881960868835
1954,6/5/2024 5:10:12 PM,Biogen favored at RBC as Eli Lilly awaits FDA AdCom on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113279-biogen-stock-favored-rbc-lilly-awaits-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7142055034637451
1955,6/6/2024 11:09:15 AM,"Novartis, Roche facing Italy antitrust probe over Lucentis biosimilar",Seeking Alpha,https://seekingalpha.com/news/4113515-novartis-roche-facing-italy-antitrust-probe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.933568000793457
1956,6/6/2024 12:20:10 PM,"Analysts’ Top Healthcare Picks: Addus Homecare (ADUS), Biogen (BIIB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-addus-homecare-adus-biogen-biib-1033458446,positive,0.7766286134719849
1957,6/6/2024 2:09:40 PM,FDA suggests safety warning for Eli Lilly Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113676-eli-lilly-alzheimers-drug-should-come-safety-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5038936734199524
1958,6/6/2024 9:23:47 PM,The 3 Most Undervalued Pharma Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-june-2024-1033459382,neutral,0.752024233341217
1959,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8829658031463623
1960,6/8/2024 6:00:00 PM,"Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030",Seeking Alpha,https://seekingalpha.com/news/4114265-lillys-donanemeb-remternetug-set-dominate-alzheimers-treatment-2030?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7012607455253601
1961,6/10/2024 1:37:43 AM,FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/fda-accepts-eisai-s-filing-of-leqembi-lecanemab-irmb-supplemental-biologics-license-application-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimer-s-disease-1033463760,positive,0.8232174515724182
1962,6/10/2024 2:48:43 AM,Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment ,RTTNews,/news/stocks/eisai-fda-accepts-sbla-on-leqembi-for-early-alzheimer-s-treatment-1033463768,positive,0.8807733058929443
1963,6/10/2024 9:35:50 AM,Buy Rating for Biogen Justified by Competitive Edge and FDA Insights on Safety Profiles,TipRanks,/news/stocks/buy-rating-for-biogen-justified-by-competitive-edge-and-fda-insights-on-safety-profiles-1033465471,positive,0.9044403433799744
1964,6/10/2024 4:09:47 PM,"Biogen, Eisai get January 2025 FDA action date for monthly Leqembi",Seeking Alpha,https://seekingalpha.com/news/4114537-biogen-eisai-get-january-2025-fda-action-date-monthly-leqembi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9272090792655945
1965,6/10/2024 7:35:10 PM,"Lilly's donanemab effective for Alzheimer's disease, FDA advisors say (updated)",Seeking Alpha,https://seekingalpha.com/news/4114590-lilly-donanemab-effective-alzheimers-disease-fda-advisors-say?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8593550324440002
1966,6/11/2024 11:40:29 AM,"Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Perspective Therapeutics (CATX) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-dianthus-therapeutics-dnth-perspective-therapeutics-catx-and-biogen-biib-1033469615,neutral,0.9029496312141418
1967,6/11/2024 8:19:11 PM,"Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst",Benzinga,/news/stocks/eli-lilly-s-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-says-bofa-analyst-1033470262,positive,0.9560290575027466
1968,6/12/2024 11:27:47 AM,Scotiabank Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/scotiabank-sticks-to-their-buy-rating-for-biogen-biib-1033473285,neutral,0.8032987117767334
1969,6/12/2024 6:24:16 PM,4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024,InvestorPlace,/news/stocks/4-best-stocks-to-buy-and-3-best-stocks-to-sell-june-2024-1033474011,neutral,0.9411122798919678
1970,6/15/2024 7:37:28 PM,ALS therapy market seen increasing to nearly $1.3B by 2029,Seeking Alpha,https://seekingalpha.com/news/4116487-als-therapy-market-seen-increasing-nearly-13b-2029?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8988732695579529
1971,6/15/2024 8:00:00 PM,The 3 Best Healthcare Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-june-2024-1033481338,neutral,0.8791823983192444
1972,6/22/2024 3:00:00 PM,GLP-1 drugs linked to reduced dementia risk: study,Seeking Alpha,https://seekingalpha.com/news/4118147-glp-1-drugs-linked-reduced-dementia-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.640005350112915
1973,6/24/2024 10:20:41 AM,Wells Fargo Remains a Hold on Biogen (BIIB),TipRanks,/news/stocks/wells-fargo-remains-a-hold-on-biogen-biib-1033500002,neutral,0.7848069071769714
1974,6/24/2024 10:20:55 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-sharecare-shcr-amylyx-pharmaceuticals-inc-amlx-and-biogen-biib-1033499999,negative,0.8151580691337585
1975,6/24/2024 11:15:35 AM,Biogen (BIIB) Receives a Buy from Scotiabank,TipRanks,/news/stocks/biogen-biib-receives-a-buy-from-scotiabank-1033500543,positive,0.6623258590698242
1976,6/24/2024 2:22:26 PM,Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications ,RTTNews,/news/stocks/biogen-says-european-commission-grants-tofidence-biosimilar-approval-for-multiple-indications-1033499732,positive,0.77357017993927
1977,6/26/2024 10:27:45 AM,Biogen (BIIB) Gets a Buy from RBC Capital,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-rbc-capital-1033507625,neutral,0.6299070119857788
1978,6/26/2024 6:01:29 PM,Forecasting The Future: 19 Analyst Projections For Biogen,Benzinga,/news/stocks/forecasting-the-future-19-analyst-projections-for-biogen-1033508641,neutral,0.9388151168823242
1979,6/26/2024 6:57:45 PM,Is the Options Market Predicting a Spike in Biogen Stock?,Benzinga,/news/stocks/is-the-options-market-predicting-a-spike-in-biogen-stock-1033508781,neutral,0.5120108723640442
1980,6/28/2024 1:39:36 AM,“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China,GlobeNewswire,/news/stocks/leqembi-lecanemab-for-the-treatment-of-alzheimer-s-disease-launched-in-china-1033513260,positive,0.5216047763824463
1981,6/28/2024 9:41:06 AM,"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Black Diamond Therapeutics (BDTX) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-black-diamond-therapeutics-bdtx-and-biogen-biib-1033514855,neutral,0.9136390686035156
1982,6/28/2024 10:17:57 AM,"Biogen, Eisai launch Alzheimer's drug Leqembi in China",Seeking Alpha,https://seekingalpha.com/news/4120477-biogen-eisai-launch-alzheimers-drug-leqembi-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7916646599769592
1983,6/28/2024 5:49:34 PM,Denali Outperforms Industry in 3 Months: Here's Why,Benzinga,/news/stocks/denali-outperforms-industry-in-3-months-here-s-why-1033515983,neutral,0.6632882952690125
1984,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7290327548980713
1985,7/2/2024 3:16:51 PM,Biogen Completes Acquisition of Human Immunology Biosciences,GlobeNewswire,/news/stocks/biogen-completes-acquisition-of-human-immunology-biosciences-1033523081,neutral,0.842694878578186
1986,7/2/2024 5:54:29 PM,Eli Lilly wins FDA approval of donanemab for Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/4121800-eli-lilly-wins-fda-approval-donanemab-alzheimers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9159002900123596
1987,7/3/2024 5:09:17 PM,Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst,Seeking Alpha,https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5239052772521973
1988,7/3/2024 6:13:19 PM,Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst,Benzinga,/news/stocks/eli-lilly-s-alzheimer-s-therapy-s-broad-label-reflects-regulatory-confidence-in-anti-amyloid-antibodies-analyst-1033527516,positive,0.580621063709259
1989,7/5/2024 10:20:00 AM,3 Highly Rated Biotech Stocks for Your July Buy List,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-for-your-july-buy-list-1033531559,neutral,0.9089598059654236
1990,7/10/2024 8:58:44 AM,Barclays Remains a Hold on Biogen (BIIB),TipRanks,/news/stocks/barclays-remains-a-hold-on-biogen-biib-1033543032,neutral,0.9156948328018188
1991,7/12/2024 10:37:33 AM,Biogen (BIIB) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-piper-sandler-1033550505,positive,0.6729490160942078
1992,7/12/2024 5:00:44 PM,Key Takeaways From Biogen Analyst Ratings,Benzinga,/news/stocks/key-takeaways-from-biogen-analyst-ratings-1033551005,neutral,0.9103500247001648
1993,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8902468085289001
1994,7/15/2024 4:03:52 PM,Lexeo stock drops 24% amid Friedreich Ataxia study results,Seeking Alpha,https://seekingalpha.com/news/4124338-lexeo-stock-drops-amid-friedreich-ataxia-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9673236012458801
1995,7/16/2024 11:05:23 AM,Biogen’s Strategic Acquisitions and Growth Potential: An Analyst’s Hold Rating Justification,TipRanks,/news/stocks/biogen-s-strategic-acquisitions-and-growth-potential-an-analyst-s-hold-rating-justification-1033559878,neutral,0.7704211473464966
1996,7/16/2024 3:10:14 PM,"Viridian, Pharvaris said to be among prime M&A targets for Biogen",Seeking Alpha,https://seekingalpha.com/news/4124646-viridian-pharvaris-among-prime-ma-targets-for-biogen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6242343783378601
1997,7/17/2024 3:06:53 PM,Hold Rating on Biogen Amid Uncertain Sales Projections for Leqembi and Skyclarys,TipRanks,/news/stocks/hold-rating-on-biogen-amid-uncertain-sales-projections-for-leqembi-and-skyclarys-1033565140,negative,0.9526786804199219
1998,7/17/2024 3:12:06 PM,Analysts Conflicted on These Healthcare Names: UnitedHealth (UNH) and Biogen (BIIB),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-unitedhealth-unh-and-biogen-biib-1033565127,neutral,0.4870237410068512
1999,7/17/2024 5:48:19 PM,Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data,Benzinga,/news/stocks/lexeo-down-despite-upbeat-rare-disease-gene-therapy-data-1033564826,negative,0.4935845136642456
2000,7/20/2024 9:05:29 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), Biogen (BIIB) and Sartorius (GB:0NIR)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-novartis-ag-six-swiss-ch-novn-biogen-biib-and-sartorius-gb-0nir-1033573773,negative,0.8051184415817261
2001,7/22/2024 7:04:27 PM,Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst,Benzinga,/news/stocks/ionis-rare-development-disorder-drug-candidate-could-be-differentiated-from-peer-ultragenyx-analyst-1033578984,neutral,0.753426730632782
2002,7/23/2024 10:39:42 AM,Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-biogen-biib-1033582772,neutral,0.8047587275505066
2003,7/24/2024 11:43:43 AM,"Biogen, Sage discontinue neuro candidate after mid-stage setback",Seeking Alpha,https://seekingalpha.com/news/4127414-biogen-stock-sage-stock-fall-trial-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5334715247154236
2004,7/24/2024 12:56:01 PM,"Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails ",RTTNews,/news/stocks/sage-therapeutics-biogen-say-phase-2-kinetic-2-study-of-sage-324-in-essential-tremor-fails-1033587799,neutral,0.6125013828277588
2005,7/25/2024 3:27:05 PM,Sage Therapeutics cut to Neutral at J.P. Morgan on pipeline concerns,Seeking Alpha,https://seekingalpha.com/news/4128442-sage-stock-cut-neutral-jp-morgan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7588080763816833
2006,7/26/2024 11:22:32 AM,Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle,Seeking Alpha,https://seekingalpha.com/news/4128882-biogen-stock-slips-lecanemab-rebuffed-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8742020130157471
2007,7/26/2024 1:20:38 PM,Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union,GlobeNewswire,/news/stocks/update-on-regulatory-review-of-lecanemab-for-early-alzheimer-s-disease-in-the-european-union-1033599726,neutral,0.9004918336868286
2008,7/26/2024 1:25:31 PM,Buy Rating on Biogen: Anticipating Positive Reversal and Global Market Strength for Lecanemab,TipRanks,/news/stocks/buy-rating-on-biogen-anticipating-positive-reversal-and-global-market-strength-for-lecanemab-1033601433,positive,0.9523976445198059
2009,7/26/2024 3:18:45 PM,AbbVie exits Alzheimer’s program on lack of differentiation,Seeking Alpha,https://seekingalpha.com/news/4129035-abbvie-axes-alzheimers-drug-mid-stage-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7185729742050171
2010,7/28/2024 12:00:00 PM,"Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4129069-earnings-week-ahead-msft-amzn-aapl-meta-qcom-pfe-mcd-sbux-ma-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9346819519996643
2011,7/29/2024 9:45:41 AM,Japanese Stocks: Eisai Shares Plummet as EU Rejects Alzheimer’s Drug,TipRanks,/news/stocks/japanese-stocks-eisai-shares-plummet-as-eu-rejects-alzheimer-s-drug-1033605987,negative,0.9527818560600281
2012,7/29/2024 11:17:30 AM,Truist Financial Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-biogen-biib-1033606901,neutral,0.9005795121192932
2013,7/29/2024 6:34:08 PM,Dr. Reddy's gets positive EMA opinion for rituximab biosimilar,Seeking Alpha,https://seekingalpha.com/news/4129672-dr-reddys-gets-positive-ema-opinion-for-rituximab-biosimilar?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.939415454864502
2014,7/30/2024 1:30:00 PM,"Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease",GlobeNewswire,/news/stocks/biogen-beckman-coulter-and-fujirebio-to-collaborate-on-blood-based-biomarkers-and-test-for-tau-pathology-in-alzheimer-s-disease-1033611267,neutral,0.5903645753860474
2015,7/30/2024 2:11:36 PM,Sage adds another downgrade as TD Cowen cuts after mid-stage setback,Seeking Alpha,https://seekingalpha.com/news/4130170-sage-stock-cut-hold-td-cowen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9578845500946045
2016,7/30/2024 3:03:36 PM,Novo’s older obesity drug benefits Alzheimer’s patients in small trial,Seeking Alpha,https://seekingalpha.com/news/4130198-novos-obesity-drug-benefits-alzheimers-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8379794359207153
2017,7/30/2024 4:10:28 PM,"Biogen, Beckman Coulter, Fujirebio To Develop Tau Pathology Blood Test For Alzheimer's Disease ",RTTNews,/news/stocks/biogen-beckman-coulter-fujirebio-to-develop-tau-pathology-blood-test-for-alzheimer-s-disease-1033612781,neutral,0.8542914390563965
2018,7/30/2024 9:58:53 PM,"Biogen, Eisai present positive three-year use data for Leqembi",Seeking Alpha,https://seekingalpha.com/news/4130719-biogen-eisai-present-positive-three-year-use-data-for-leqembi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9334141612052917
2019,7/30/2024 11:15:17 PM,New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The...,GlobeNewswire,/news/stocks/new-clinical-data-demonstrates-three-years-of-continuous-treatment-with-dual-acting-leqembi-lecanemab-irmb-continues-to-significantly-benefit-early-alzheimer-s-disease-patients-presented-at-the-1033614127,positive,0.950742244720459
2020,7/31/2024 2:10:27 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/4131090-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.882573127746582
2021,7/31/2024 2:54:40 PM,Vaccinex stock plunges 24% on mixed results for Alzheimer's study,Seeking Alpha,https://seekingalpha.com/news/4131127-vaccinex-stock-plunges-on-mixed-results-for-alzheimers-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9643994569778442
2022,7/31/2024 3:01:13 PM,What Wall Street expects from Biogen's earnings,Markets Insider Automation,/news/stocks/biogen-stock-price-q2-earnings-preview-1033617993,neutral,0.9294326305389404
2023,7/31/2024 4:02:07 PM,Biogen Q2 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4131214-biogen-q2-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.834174394607544
2024,8/1/2024 11:08:28 AM,"Biogen Non-GAAP EPS of $4.02 misses by $0.01, revenue of $2.46B beats by $70M",Seeking Alpha,https://seekingalpha.com/news/4132080-biogen-non-gaap-eps-of-4_02-misses-0_01-revenue-of-2_46b-beats-70m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.540040910243988
2025,8/1/2024 12:23:00 PM,Strong Q2 Performance and Raised Guidance Secure Biogen a Buy Rating,TipRanks,/news/stocks/strong-q2-performance-and-raised-guidance-secure-biogen-a-buy-rating-1033627788,positive,0.9534943699836731
2026,8/1/2024 12:50:29 PM,Biogen posts Q2 beat as sales from Alzheimer’s drug pick up,Seeking Alpha,https://seekingalpha.com/news/4132262-biogen-stock-focus-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9461408853530884
2027,8/1/2024 1:09:23 PM,Biogen’s Strong Q2 Performance and Promising Outlook Justify Buy Rating,TipRanks,/news/stocks/biogen-s-strong-q2-performance-and-promising-outlook-justify-buy-rating-1033628199,positive,0.9299951195716858
2028,8/1/2024 1:11:42 PM,Biogen Performance Analysis: A Balanced Hold Recommendation Amid Mixed Developments,TipRanks,/news/stocks/biogen-performance-analysis-a-balanced-hold-recommendation-amid-mixed-developments-1033628191,positive,0.9378700256347656
2029,8/1/2024 1:13:42 PM,"Analysts Conflicted on These Healthcare Names: Cencora (COR), Schrodinger (SDGR) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-cencora-cor-schrodinger-sdgr-and-biogen-biib-1033628328,negative,0.7385167479515076
2030,8/1/2024 1:23:58 PM,Wedbush Reaffirms Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/wedbush-reaffirms-their-hold-rating-on-biogen-biib-1033628267,neutral,0.7914790511131287
2031,8/1/2024 1:30:57 PM,Biogen Q2 Results Top Estimates; Boosts FY24 Outlook ,RTTNews,/news/stocks/biogen-q2-results-top-estimates-boosts-fy24-outlook-1033625919,positive,0.9342552423477173
2032,8/1/2024 2:45:00 PM,Biogen hosts conference call for investors,Markets Insider Automation,/news/stocks/biogen_conference-1029994202,neutral,0.9421575665473938
2033,8/2/2024 1:35:44 AM,Buy Rating Affirmed for Biogen: Strong Financials and Promising Alzheimer’s Drugs Drive Growth Outlook,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-strong-financials-and-promising-alzheimer-s-drugs-drive-growth-outlook-1033630120,positive,0.9511468410491943
2034,8/2/2024 8:47:26 AM,Barclays Remains a Hold on Biogen (BIIB),TipRanks,/news/stocks/barclays-remains-a-hold-on-biogen-biib-1033631618,neutral,0.9156948328018188
2035,8/2/2024 10:28:08 AM,Optimistic Outlook on Biogen’s Leqembi for Alzheimer’s: Buy Rating Justified by EMA Prospects and Positive Long-Term Data,TipRanks,/news/stocks/optimistic-outlook-on-biogen-s-leqembi-for-alzheimer-s-buy-rating-justified-by-ema-prospects-and-positive-long-term-data-1033632175,positive,0.9499666094779968
2036,8/2/2024 10:40:24 AM,RBC Capital Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-biogen-biib-1033632126,positive,0.49897974729537964
2037,8/2/2024 11:34:12 AM,"Analysts’ Top Healthcare Picks: Altimmune (ALT), Exact Sciences (EXAS)",TipRanks,/news/stocks/analysts-top-healthcare-picks-altimmune-alt-exact-sciences-exas-1033632912,neutral,0.5922757983207703
2038,8/2/2024 11:49:07 AM,Truist Financial Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-biogen-biib-1033633012,neutral,0.881507396697998
2039,8/2/2024 12:29:21 PM,Buy Rating Affirmed: Biogen’s Growth Momentum and Strategic Developments Fuel Positive Outlook,TipRanks,/news/stocks/buy-rating-affirmed-biogen-s-growth-momentum-and-strategic-developments-fuel-positive-outlook-1033633271,positive,0.9456193447113037
2040,8/2/2024 12:31:04 PM,Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-reaffirms-their-buy-rating-on-biogen-biib-1033633257,neutral,0.8345329165458679
2041,8/4/2024 11:00:05 AM,"Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid ",RTTNews,/news/stocks/weekly-biotech-buzz-fgen-cuts-jobs-fda-oks-adap-s-groundbreaking-cell-therapy-me-rebuffs-ceo-bid-1033634796,neutral,0.5439768433570862
2042,8/5/2024 6:20:54 AM,Buy Rating Affirmed for Biogen Amid Strong Core Performance and Strategic Growth Initiatives,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-amid-strong-core-performance-and-strategic-growth-initiatives-1033637858,positive,0.9521369934082031
2043,8/5/2024 6:27:36 AM,Buy Rating Affirmed for Biogen on Solid Financials and Promising Product Sales Trajectory,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-on-solid-financials-and-promising-product-sales-trajectory-1033637947,positive,0.9545155167579651
2044,8/11/2024 5:00:29 PM,"Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-enanta-pharmaceuticals-enta-hyperfine-hypr-and-biogen-biib-1033672081,neutral,0.9035071730613708
2045,8/19/2024 9:15:17 AM,Optimistic Outlook for Biogen’s Dapirolizumab Pegol Despite Past Setbacks,TipRanks,/news/stocks/optimistic-outlook-for-biogen-s-dapirolizumab-pegol-despite-past-setbacks-1033703838,positive,0.948575496673584
2046,8/22/2024 9:34:54 AM,Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain,Seeking Alpha,https://seekingalpha.com/news/4142646-biogeneisais-alzheimers-drug-wins-marketing-authorization-in-great-britain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9257237911224365
2047,8/22/2024 11:54:36 AM,Eisai And Biogen : Leqembi Approved In Great Britain For Early Alzheimer's Disease ,RTTNews,/news/stocks/eisai-and-biogen-leqembi-approved-in-great-britain-for-early-alzheimer-s-disease-1033713984,neutral,0.6424999237060547
2048,8/22/2024 5:10:58 PM,"Biogen, Eisai new Alzheimer’s drug considered too costly in Britain",Seeking Alpha,https://seekingalpha.com/news/4143014-biogen-eisai-alzheimers-drug-deemed-costly-uk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.664700984954834
2049,8/24/2024 5:16:09 PM,Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report,Seeking Alpha,https://seekingalpha.com/news/4143531-eli-lilly-alzheimers-drug-face-uk-rejection?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8033480048179626
2050,9/3/2024 11:48:48 AM,Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-reaffirms-their-buy-rating-on-biogen-biib-1033744313,neutral,0.8345329165458679
2051,9/4/2024 7:45:34 AM,Barclays Keeps Their Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/barclays-keeps-their-hold-rating-on-biogen-biib-1033746544,neutral,0.9206183552742004
2052,9/4/2024 10:16:43 AM,Biogen’s Upward Trajectory: A Buy Rating on Alzheimer’s and Pipeline Progress,TipRanks,/news/stocks/biogen-s-upward-trajectory-a-buy-rating-on-alzheimer-s-and-pipeline-progress-1033747283,positive,0.6285220980644226
2053,9/4/2024 12:07:19 PM,Biogen announces trial win for higher Spinraza doze,Seeking Alpha,https://seekingalpha.com/news/4146670-biogen-posts-trial-win-higher-spinraza-doze?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8662126064300537
2054,9/4/2024 1:30:34 PM,"Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA",GlobeNewswire,/news/stocks/biogen-announces-positive-topline-results-from-study-of-higher-dose-regimen-of-nusinersen-showing-significant-benefit-in-treatment-of-sma-1033746686,positive,0.9536566734313965
2055,9/4/2024 2:16:03 PM,Biogen Reports Positive Topline Data From DEVOTE Study Of Higher Dose Regimen Of Nusinersen In SMA ,RTTNews,/news/stocks/biogen-reports-positive-topline-data-from-devote-study-of-higher-dose-regimen-of-nusinersen-in-sma-1033746892,positive,0.9516392946243286
2056,9/4/2024 9:28:01 PM,"QIAGEN, Lilly to develop Alzheimer's risk detection test",Seeking Alpha,https://seekingalpha.com/news/4147100-qiagen-lilly-to-develop-alzheimers-risk-detection-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7123451828956604
2057,9/5/2024 10:57:23 AM,Optimistic Buy Rating for Biogen on Strategic Cost-Cutting and Growth Asset Prioritization,TipRanks,/news/stocks/optimistic-buy-rating-for-biogen-on-strategic-cost-cutting-and-growth-asset-prioritization-1033751252,positive,0.8808171153068542
2058,9/12/2024 1:30:00 PM,Biogen Board Appoints Two New Independent Directors,GlobeNewswire,/news/stocks/biogen-board-appoints-two-new-independent-directors-1033766497,neutral,0.9088627696037292
2059,9/12/2024 7:58:36 PM,"Jones Research starts Larimar at Buy, cites lead asset nomlabofusp",Seeking Alpha,https://seekingalpha.com/news/4149251-jones-research-starts-larimar-at-buy-cites-lead-asset-nomlabofusp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9211065173149109
2060,9/15/2024 10:16:14 AM,Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen,TipRanks,/news/stocks/cautious-optimism-amidst-growth-deceleration-and-rising-competition-for-biogen-1033772046,positive,0.7183666825294495
2061,9/19/2024 10:45:53 AM,RBC Capital Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-biogen-biib-1033783558,neutral,0.9115294814109802
2062,9/20/2024 2:33:27 PM,"Samsung Bioepis, Biogen Announce Positive CHMP Recommendation For OPUVIZ In Europe ",RTTNews,/news/stocks/samsung-bioepis-biogen-announce-positive-chmp-recommendation-for-opuviz-in-europe-1033786277,positive,0.9458803534507751
2063,9/24/2024 7:00:00 AM,UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024,GlobeNewswire,/news/stocks/ucb-and-biogen-announce-positive-topline-results-from-phase-3-study-of-dapirolizumab-pegol-in-systemic-lupus-erythematosus-and-are-initiating-second-phase-3-study-in-2024-1033792176,positive,0.6458583474159241
2064,9/24/2024 7:30:31 AM,Biogen: Phase 3 PHOENYCS GO Study With Dapirolizumab Pegol Meets Primary Endpoint ,RTTNews,/news/stocks/biogen-phase-3-phoenycs-go-study-with-dapirolizumab-pegol-meets-primary-endpoint-1033792211,positive,0.5919501781463623
2065,9/24/2024 10:22:45 AM,Eli Lilly's Alzheimer's therapy approved in Japan,Seeking Alpha,https://seekingalpha.com/news/4152449-eli-lillys-alzheimers-therapy-approved-in-japan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8382624387741089
2066,9/24/2024 10:41:53 AM,"Biogen, UCB mark late-stage trial win for autoimmune disease therapy",Seeking Alpha,https://seekingalpha.com/news/4152462-biogen-ucb-mark-trial-win-sle-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.917751133441925
2067,9/24/2024 12:45:25 PM,Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-on-promising-phase-3-results-and-strategic-development-plans-for-lupus-drug-dapi-1033794572,positive,0.951043963432312
2068,9/24/2024 3:25:18 PM,Buy Rating Affirmed for Biogen Amid Surprising Success of Lupus Drug Dapirolizumab Pegol,TipRanks,/news/stocks/buy-rating-affirmed-for-biogen-amid-surprising-success-of-lupus-drug-dapirolizumab-pegol-1033794885,positive,0.9472943544387817
2069,9/25/2024 9:36:14 AM,Hold Rating on Biogen Amidst Positive Lupus Trial Data and Pending Developments,TipRanks,/news/stocks/hold-rating-on-biogen-amidst-positive-lupus-trial-data-and-pending-developments-1033796699,neutral,0.8617604374885559
2070,9/25/2024 9:48:39 AM,Biogen’s Promising Lupus Drug Garners Buy Rating: A Financial Analysis of Dapirolizumab Pegol’s Market Potential,TipRanks,/news/stocks/biogen-s-promising-lupus-drug-garners-buy-rating-a-financial-analysis-of-dapirolizumab-pegol-s-market-potential-1033796759,neutral,0.7848135828971863
2071,9/25/2024 10:25:33 AM,Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market,TipRanks,/news/stocks/maintaining-hold-on-biogen-amid-uncertain-efficacy-and-competitive-sle-market-1033796906,negative,0.8761796355247498
2072,9/25/2024 11:05:17 AM,Biogen’s Clinical Triumph Spurs Buy Rating Amidst Market Opportunity,TipRanks,/news/stocks/biogen-s-clinical-triumph-spurs-buy-rating-amidst-market-opportunity-1033797390,positive,0.8649438619613647
2073,9/26/2024 10:48:17 AM,"Roche, Biogen kidney disease drug hits main goal in late-stage study",Seeking Alpha,https://seekingalpha.com/news/4153575-roche-biogen-post-late-stage-win-for-kidney-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.808631956577301
2074,9/26/2024 11:20:47 AM,Biogen to end Sage deal for neuro candidate,Seeking Alpha,https://seekingalpha.com/news/4153606-sage-stock-slips-biogen-ends-partnership?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6887378096580505
2075,9/26/2024 2:10:48 PM,Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal ,RTTNews,/news/stocks/sage-to-resume-full-ownership-of-sage-324-program-as-biogen-terminates-collaboration-deal-1033800396,neutral,0.9277837872505188
2076,10/1/2024 6:35:38 AM,Buy Rating Justified by Biogen’s Strategic Positioning and Strong Financial Outlook,TipRanks,/news/stocks/buy-rating-justified-by-biogen-s-strategic-positioning-and-strong-financial-outlook-1033810349,positive,0.9075183868408203
2077,10/3/2024 3:26:24 PM,Larimar started at outperform by Wedbush on FA drug candidate,Seeking Alpha,https://seekingalpha.com/news/4156088-larimar-started-at-outperform-by-wedbush-on-fa-drug-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9207695126533508
2078,10/7/2024 7:31:09 AM,Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Biogen (BIIB),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-and-biogen-biib-1033824143,neutral,0.8960067629814148
2079,10/8/2024 1:30:00 PM,"New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA",GlobeNewswire,/news/stocks/new-higher-dose-nusinersen-efficacy-and-safety-data-presented-at-world-muscle-society-congress-highlight-potential-to-maximize-benefit-of-nusinersen-in-sma-1033827598,positive,0.9098399877548218
2080,10/9/2024 12:30:36 PM,Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-biogen-biib-and-traws-pharma-traw-1033832538,negative,0.5548499822616577
2081,10/9/2024 1:30:00 PM,Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients,GlobeNewswire,/news/stocks/biogen-receives-u-s-fda-breakthrough-therapy-designation-for-felzartamab-for-the-treatment-of-antibody-mediated-rejection-in-kidney-transplant-recipients-1033831336,positive,0.9356107115745544
2082,10/9/2024 2:15:56 PM,Biogen: Felzartamab Receives Breakthrough Therapy Designation - Quick Facts ,RTTNews,/news/stocks/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-1033831487,positive,0.8286773562431335
2083,10/9/2024 3:28:05 PM,Biogen’s kidney transplant rejection candidate gets FDA breakthrough designation,Seeking Alpha,https://seekingalpha.com/news/4157326-biogen-kidney-transplant-rejection-candidate-gets-fda-breakthrough-designation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8245179653167725
2084,10/10/2024 6:01:49 PM,Biogen reinstated at market perform at Raymond James on Leqembi disappointment,Seeking Alpha,https://seekingalpha.com/news/4157670-biogen-reinstated-market-perform-raymond-james-leqembi-disappointment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8843379616737366
2085,10/11/2024 12:35:44 PM,Morgan Stanley Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-biogen-biib-1033839284,neutral,0.8121581077575684
2086,10/12/2024 1:16:30 PM,Maintaining Hold on Biogen Amid Modest Growth and Cautious Outlook,TipRanks,/news/stocks/maintaining-hold-on-biogen-amid-modest-growth-and-cautious-outlook-1033840012,negative,0.5337591767311096
2087,10/14/2024 2:19:01 PM,Eight stocks positioned for short sales – Oppenheimer Asset Management,Seeking Alpha,https://seekingalpha.com/news/4158231-eight-stocks-positioned-for-short-sales-oppenheimer-asset-management?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9314119219779968
2088,10/21/2024 10:31:40 AM,"Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-cvs-health-cvs-vertex-pharmaceuticals-vrtx-1033864750,neutral,0.6276834011077881
2089,10/22/2024 1:30:00 PM,Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024,GlobeNewswire,/news/stocks/biogen-announces-late-breaker-and-new-data-presentations-at-american-society-of-nephrology-asn-kidney-week-2024-1033870058,neutral,0.9421694874763489
2090,10/22/2024 10:48:32 PM,Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report,Seeking Alpha,https://seekingalpha.com/news/4192946-lilly-alzheimers-drug-not-to-be-covered-by-uks-nhs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9389773011207581
2091,10/23/2024 10:05:20 AM,"Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports",TipRanks,/news/stocks/eli-lilly-alzheimer-s-drug-rejected-as-too-expensive-by-uk-s-nhs-ft-reports-1033878329,negative,0.861038863658905
2092,10/23/2024 10:08:26 AM,Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use,Seeking Alpha,https://seekingalpha.com/news/4193722-eli-lillys-alzheimers-drug-donanemab-rejected-for-nhs-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5665563344955444
2093,10/23/2024 11:40:06 AM,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Sangamo Biosciences (SGMO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-and-sangamo-biosciences-sgmo-1033879422,neutral,0.8913983702659607
2094,10/23/2024 11:55:37 AM,Oppenheimer Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-reaffirms-their-buy-rating-on-biogen-biib-1033879559,neutral,0.8345329165458679
2095,10/24/2024 1:30:00 PM,Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference,GlobeNewswire,/news/stocks/biogen-to-present-new-data-at-the-clinical-trials-on-alzheimer-s-disease-ctad-2024-annual-conference-1033885479,neutral,0.9135732650756836
2096,10/25/2024 4:58:20 PM,Key Biogen Tecfidera patent upheld by European Patent Office,Seeking Alpha,https://seekingalpha.com/news/4206165-key-biogen-tecfidera-patent-upheld-european-patent-office?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7243767380714417
2097,10/27/2024 2:15:00 AM,Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024,GlobeNewswire,/news/stocks/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-nephropathy-at-american-society-of-nephrology-asn-kidney-week-2024-1033896096,positive,0.9340481758117676
2098,10/27/2024 1:13:38 PM,Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy ,RTTNews,/news/stocks/biogen-s-phase-2-study-shows-promising-results-for-felzartamab-in-iga-nephropathy-1033896499,positive,0.9473844170570374
2099,10/27/2024 8:15:05 PM,Biogen presents results from Phase 2 IGNAZ study of Felzartamab in IgAN,TipRanks,/news/stocks/biogen-presents-results-from-phase-2-ignaz-study-of-felzartamab-in-igan-1033896851,neutral,0.869572103023529
2100,10/28/2024 12:26:42 PM,Biogen’s Strategic Shift: Felzartamab’s Promise in IgAN and Beyond Fuels Buy Rating,TipRanks,/news/stocks/biogen-s-strategic-shift-felzartamab-s-promise-in-igan-and-beyond-fuels-buy-rating-1033902694,positive,0.846653401851654
2101,10/28/2024 12:45:40 PM,"Biogen CFO Michael McDonnell to retire, Robin Kramer to succeed",TipRanks,/news/stocks/biogen-cfo-michael-mcdonnell-to-retire-robin-kramer-to-succeed-1033902910,neutral,0.9131036996841431
2102,10/28/2024 1:30:00 PM,"Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025",GlobeNewswire,/news/stocks/michael-mcdonnell-executive-vice-president-and-chief-financial-officer-to-retire-in-february-2025-1033901354,neutral,0.8721948862075806
2103,10/28/2024 2:51:17 PM,Biogen Appoints Robin Kramer As CFO To Replace Michael MCDonnell ,RTTNews,/news/stocks/biogen-appoints-robin-kramer-as-cfo-to-replace-michael-mcdonnell-1033901821,neutral,0.892024576663971
2104,10/29/2024 11:17:35 AM,Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-biogen-biib-1033909671,neutral,0.5527154803276062
2105,10/29/2024 12:21:04 PM,Biogen appoints Quirk as Chief Medical Officer,TipRanks,/news/stocks/biogen-appoints-quirk-as-chief-medical-officer-1033910411,neutral,0.9236396551132202
2106,10/29/2024 12:33:15 PM,Biogen names former Bristol-Myers executive as medical chief,Seeking Alpha,https://seekingalpha.com/news/4217750-biogen-names-medical-chief-from-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9377938508987427
2107,10/29/2024 1:00:00 PM,"Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer",GlobeNewswire,/news/stocks/biogen-appoints-daniel-quirk-md-as-chief-medical-officer-1033908481,neutral,0.913630485534668
2108,10/29/2024 2:04:01 PM,Biogen Names Daniel Quirk Chief Medical Officer And Head Of Medical Affairs - Quick Facts ,RTTNews,/news/stocks/biogen-names-daniel-quirk-chief-medical-officer-and-head-of-medical-affairs-quick-facts-1033908935,neutral,0.9439651966094971
2109,10/29/2024 3:49:34 PM,Biogen Q3 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4219089-biogen-q3-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8303654789924622
2110,10/29/2024 6:00:55 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033911969,neutral,0.9220908284187317
2111,10/29/2024 10:00:29 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4219928-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9330109357833862
2112,10/29/2024 10:05:14 PM,"Biogen, Neomorph announces multi-target research collaboration",TipRanks,/news/stocks/biogen-neomorph-announces-multi-target-research-collaboration-1033912545,neutral,0.8848841786384583
2113,10/29/2024 10:41:34 PM,"Sage stock plunges 18% post-market following business update, earnings",Seeking Alpha,https://seekingalpha.com/news/4221566-sage-stock-plunges-post-market-following-business-update-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9520096182823181
2114,10/29/2024 11:00:23 PM,"Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases",GlobeNewswire,/news/stocks/biogen-and-neomorph-announce-multi-target-research-collaboration-to-discover-and-develop-molecular-glue-degraders-for-alzheimer-s-rare-and-immunological-diseases-1033912167,positive,0.8057509064674377
2115,10/29/2024 11:05:03 PM,"Biogen, Neomorph to collaborate on clinical candidates for Alzheimer's",Seeking Alpha,https://seekingalpha.com/news/4221625-biogen-neomorph-to-collaborate-on-clinical-candidates-for-alzheimers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6104676127433777
2116,10/30/2024 3:42:10 AM,Biogen And Neomorph Collaborate To Develop Molecular Glue Degraders For Alzheimer's And More ,RTTNews,/news/stocks/biogen-and-neomorph-collaborate-to-develop-molecular-glue-degraders-for-alzheimer-s-and-more-1033912735,neutral,0.6347403526306152
2117,10/30/2024 10:55:24 AM,"Biogen Non-GAAP EPS of $4.08 beats by $0.29, revenue of $2.46B beats by $30M",Seeking Alpha,https://seekingalpha.com/news/4222398-biogen-non-gaap-eps-of-4_08-beats-0_29-revenue-of-2_46b-beats-30m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5941526293754578
2118,10/30/2024 10:55:45 AM,"Biogen raises FY24 EPS view to $16.10-$16.60, consensus $16.19",TipRanks,/news/stocks/biogen-raises-fy24-eps-view-to-16-10--16-60-consensus-16-19-1033917899,positive,0.8476709723472595
2119,10/30/2024 10:56:59 AM,"Biogen reports Q3 EPS $4.08, consensus $3.79",TipRanks,/news/stocks/biogen-reports-q3-eps-4-08-consensus-3-79-1033917886,neutral,0.6367707848548889
2120,10/30/2024 12:15:36 PM,Biogen’s Strong Earnings and Growth Potential Support Buy Rating,TipRanks,/news/stocks/biogen-s-strong-earnings-and-growth-potential-support-buy-rating-1033919184,positive,0.9062157273292542
2121,10/30/2024 12:17:56 PM,Sage Therapeutics price target lowered to $8 from $9 at Oppenheimer,TipRanks,/news/stocks/sage-therapeutics-price-target-lowered-to-8-from-9-at-oppenheimer-1033919158,negative,0.7995071411132812
2122,10/30/2024 12:30:15 PM,Biogen Q3 Results Top Estimates; Boosts FY24 Adj. EPS Outlook ,RTTNews,/news/stocks/biogen-q3-results-top-estimates-boosts-fy24-adj-eps-outlook-1033916581,positive,0.9374334216117859
2123,10/30/2024 1:01:23 PM,Morning Movers: Caterpillar and Eli Lilly sink following quarterly reports,TipRanks,/news/stocks/morning-movers-caterpillar-and-eli-lilly-sink-following-quarterly-reports-1033919565,neutral,0.9493290185928345
2124,10/30/2024 4:06:44 PM,Biogen raises 2024 EPS guidance with strong Q3 results,Seeking Alpha,https://seekingalpha.com/news/4223140-biogen-raises-2024-eps-guidance-strong-q3-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9465446472167969
2125,10/30/2024 9:23:28 PM,Biogen Announces CFO Transition and Regulation FD Update,TipRanks,/news/stocks/biogen-announces-cfo-transition-and-regulation-fd-update-1033921712,neutral,0.8278504610061646
2126,10/30/2024 11:40:14 PM,Biogen/Eisai announce latest findings for Leqembi in Alzheimer’s disease,TipRanks,/news/stocks/biogen-eisai-announce-latest-findings-for-leqembi-in-alzheimer-s-disease-1033921961,neutral,0.86665940284729
2127,10/31/2024 12:30:12 AM,Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference,GlobeNewswire,/news/stocks/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at-the-17th-clinical-trials-for-alzheimer-s-disease-ctad-conference-1033921416,positive,0.5335143208503723
2128,10/31/2024 2:05:59 AM,Positive Outlook and Strong Performance Drive Buy Rating for Biogen,TipRanks,/news/stocks/positive-outlook-and-strong-performance-drive-buy-rating-for-biogen-1033922335,positive,0.9226160645484924
2129,10/31/2024 2:25:19 AM,"Biogen’s Growth Potential: Positive Outlook Supported by Strong EPS, Successful Launches, and Clinical Trials",TipRanks,/news/stocks/biogen-s-growth-potential-positive-outlook-supported-by-strong-eps-successful-launches-and-clinical-trials-1033922434,positive,0.9466804265975952
2130,10/31/2024 3:59:40 AM,Biogen Inc. Raises 2024 Financial Outlook Amid Product Launch Success,TipRanks,/news/stocks/biogen-inc-raises-2024-financial-outlook-amid-product-launch-success-1033925228,positive,0.8246251940727234
2131,10/31/2024 8:47:36 AM,Barclays Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/barclays-sticks-to-its-hold-rating-for-biogen-biib-1033927412,neutral,0.8449577689170837
2132,10/31/2024 8:50:21 AM,Biogen downgraded to Equal Weight from Overweight at Morgan Stanley,TipRanks,/news/stocks/biogen-downgraded-to-equal-weight-from-overweight-at-morgan-stanley-1033927373,positive,0.46556127071380615
2133,10/31/2024 9:46:26 AM,Cautious Neutrality: Biogen’s Mixed Performance and Uncertain Growth Outlook,TipRanks,/news/stocks/cautious-neutrality-biogen-s-mixed-performance-and-uncertain-growth-outlook-1033927950,negative,0.956706702709198
2134,10/31/2024 10:20:45 AM,Biogen price target lowered to $180 from $190 at Barclays,TipRanks,/news/stocks/biogen-price-target-lowered-to-180-from-190-at-barclays-1033928217,negative,0.6830191612243652
2135,10/31/2024 10:39:25 AM,Biogen (BIIB) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/biogen-biib-gets-a-hold-from-wells-fargo-1033928383,neutral,0.8496178388595581
2136,10/31/2024 10:51:01 AM,RBC Capital Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-biogen-biib-1033928557,positive,0.49897974729537964
2137,10/31/2024 11:41:32 AM,Biogen price target lowered to $275 from $300 at TD Cowen,TipRanks,/news/stocks/biogen-price-target-lowered-to-275-from-300-at-td-cowen-1033928939,negative,0.4538813531398773
2138,10/31/2024 11:56:18 AM,Biogen’s Promising Pharmaceutical Prospects: Buy Rating Backed by Lecanemab Success and Pipeline Diversification,TipRanks,/news/stocks/biogen-s-promising-pharmaceutical-prospects-buy-rating-backed-by-lecanemab-success-and-pipeline-diversification-1033929067,positive,0.8308561444282532
2139,10/31/2024 12:10:31 PM,Oppenheimer Keeps Their Buy Rating on Biogen (BIIB),TipRanks,/news/stocks/oppenheimer-keeps-their-buy-rating-on-biogen-biib-1033929515,neutral,0.9158653020858765
2140,10/31/2024 12:24:48 PM,Jefferies Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/jefferies-remains-a-buy-on-biogen-biib-1033929643,neutral,0.9425736665725708
2141,10/31/2024 4:01:23 PM,"Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz",TipRanks,/news/stocks/microsoft-reports-q1-beat-comcast-weighs-cable-networks-spinoff-morning-buzz-1033931015,neutral,0.8997287750244141
2142,11/4/2024 6:45:08 PM,Biogen call volume above normal and directionally bullish,TipRanks,/news/stocks/biogen-call-volume-above-normal-and-directionally-bullish-1033947025,positive,0.9160063862800598
2143,11/11/2024 9:21:12 PM,Needham biotech analysts hold an analyst/industry conference call,TipRanks,/news/stocks/needham-biotech-analysts-hold-an-analyst-industry-conference-call-1033994780,neutral,0.9411064386367798
2144,11/13/2024 9:15:54 PM,Biogen initiated with a Neutral at Citi,TipRanks,/news/stocks/biogen-initiated-with-a-neutral-at-citi-1034011806,neutral,0.8267605900764465
2145,11/14/2024 2:45:32 PM,"American upgraded, Regeneron initiated: Wall Street’s top analyst calls",TipRanks,/news/stocks/american-upgraded-regeneron-initiated-wall-street-s-top-analyst-calls-1034019984,neutral,0.8680362105369568
2146,11/14/2024 4:05:20 PM,Biogen up 5% after EMA recommends Leqembi for early Alzheimer’s disease,TipRanks,/news/stocks/biogen-up-5-after-ema-recommends-leqembi-for-early-alzheimer-s-disease-1034020226,positive,0.929523229598999
2147,11/14/2024 4:05:28 PM,EMA recommends Leqembi for treatment of early Alzheimer’s disease,TipRanks,/news/stocks/ema-recommends-leqembi-for-treatment-of-early-alzheimer-s-disease-1034020225,neutral,0.7639566659927368
2148,11/14/2024 4:20:29 PM,Biogen gains as Eisai wins EU nod for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4290948-biogen-stock-gains-eu-backs-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9076641201972961
2149,11/14/2024 4:32:32 PM,Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease,TipRanks,/news/stocks/eisai-receives-positive-chmp-opinion-for-lecanemab-in-early-alzheimer-s-disease-1034020289,positive,0.9372414350509644
2150,11/14/2024 5:23:15 PM,Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in-early-alzheimer-s-disease-1034019319,positive,0.9335229396820068
2151,11/14/2024 6:20:32 PM,Raymond James sees EU Leqembi uptake as more modest for Biogen than in U.S.,TipRanks,/news/stocks/raymond-james-sees-eu-leqembi-uptake-as-more-modest-for-biogen-than-in-u-s-1034020678,positive,0.7873296737670898
2152,11/14/2024 7:26:46 PM,"Gilead, Vertex initiated as new big biotech buys at Citi",Seeking Alpha,https://seekingalpha.com/news/4291773-gilead-vertex-initiated-new-big-biotech-buys-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.738814651966095
2153,11/14/2024 9:11:33 PM,Biogen initiated with a Peer Perform at Wolfe Research,TipRanks,/news/stocks/biogen-initiated-with-a-peer-perform-at-wolfe-research-1034021106,neutral,0.8745625615119934
2154,11/14/2024 11:50:19 PM,"Wolfe starts Biogen at Peer Perform, sees limited downside risk",TipRanks,/news/stocks/wolfe-starts-biogen-at-peer-perform-sees-limited-downside-risk-1034021600,neutral,0.7158408164978027
2155,11/15/2024 1:24:38 AM,Eisai Gets Positive Opinion From CHMP In European Union For Lecanemab In Early Alzheimer's Disease ,RTTNews,/news/stocks/eisai-gets-positive-opinion-from-chmp-in-european-union-for-lecanemab-in-early-alzheimer-s-disease-1034021131,positive,0.9268450140953064
2156,11/15/2024 10:26:02 AM,Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments,TipRanks,/news/stocks/cautious-optimism-for-biogen-hold-rating-amidst-european-approval-developments-1034023966,neutral,0.6561874151229858
2157,11/15/2024 11:36:39 AM,Biogen price target raised to $300 from $294 at Baird,TipRanks,/news/stocks/biogen-price-target-raised-to-300-from-294-at-baird-1034024543,positive,0.9409184455871582
2158,11/15/2024 12:56:50 PM,Biogen (BIIB) Gets a Buy from TD Cowen,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-td-cowen-1034025327,positive,0.4994063377380371
2159,11/15/2024 1:26:08 PM,Positive EMA Reversal Boosts Biogen’s Leqembi Prospects Despite Challenges,TipRanks,/news/stocks/positive-ema-reversal-boosts-biogen-s-leqembi-prospects-despite-challenges-1034025504,positive,0.9548599720001221
2160,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9049097299575806
2161,11/18/2024 10:18:26 AM,Needham downgrades Biogen (BIIB) to a Hold,TipRanks,/news/stocks/needham-downgrades-biogen-biib-to-a-hold-1034030275,negative,0.5336971282958984
2162,11/18/2024 10:20:13 AM,Biogen downgraded to Hold from Buy at Needham,TipRanks,/news/stocks/biogen-downgraded-to-hold-from-buy-at-needham-1034030271,neutral,0.8060740828514099
2163,11/18/2024 11:05:29 AM,Needham downgrades Biogen to Hold on lack of share catalysts,TipRanks,/news/stocks/needham-downgrades-biogen-to-hold-on-lack-of-share-catalysts-1034030581,negative,0.9488704800605774
2164,11/18/2024 1:51:52 PM,"Samsung Bioepis, Biogen Get European Commission Approval For Opuviz, A Biosimilar To Aflibercept ",RTTNews,/news/stocks/samsung-bioepis-biogen-get-european-commission-approval-for-opuviz-a-biosimilar-to-aflibercept-1034030019,positive,0.7486234903335571
2165,11/18/2024 2:35:30 PM,"Roku, Robinhood upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/roku-robinhood-upgraded-wall-street-s-top-analyst-calls-1034032295,neutral,0.7892583012580872
2166,11/18/2024 4:25:29 PM,"Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales",Seeking Alpha,https://seekingalpha.com/news/4303068-biogen-cut-to-hold-by-needham-on-lack-of-catalysts-slow-leqembi-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9313578605651855
2167,11/18/2024 5:00:22 PM,"Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz",TipRanks,/news/stocks/spirit-enters-into-bankruptcy-proceedings-cvs-names-new-directors-morning-buzz-1034032639,neutral,0.9092763662338257
2168,11/19/2024 7:00:14 AM,Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity,GlobeNewswire,/news/stocks/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity-1034034053,negative,0.8163355588912964
2169,11/19/2024 7:46:37 AM,UCB And Biogen: Dapirolizumab Pegol Meets Primary Endpoint In Phase 3 PHOENYCS GO Study ,RTTNews,/news/stocks/ucb-and-biogen-dapirolizumab-pegol-meets-primary-endpoint-in-phase-3-phoenycs-go-study-1034034183,positive,0.7577919363975525
2170,11/19/2024 10:55:23 AM,"UCB, Biogen present results from PHOENYCS GO study",TipRanks,/news/stocks/ucb-biogen-present-results-from-phoenycs-go-study-1034036364,neutral,0.9057342410087585
2171,11/19/2024 5:47:55 PM,"Biogen, UCB release phase 3 data on lupus candidate dapirolizumab",Seeking Alpha,https://seekingalpha.com/news/4307964-biogen-ucb-release-phase-3-data-lupus-candidate-dapirolizumab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8958980441093445
2172,11/21/2024 11:45:12 AM,Biogen price target lowered to $207 from $251 at Mizuho,TipRanks,/news/stocks/biogen-price-target-lowered-to-207-from-251-at-mizuho-1034049046,negative,0.8221713900566101
2173,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.757529079914093
2174,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9368929862976074
2175,11/23/2024 2:37:00 PM,"Notable analyst calls this week: Roku, Nvidia and Biogen among top picks",Seeking Alpha,https://seekingalpha.com/news/4321403-notable-analyst-calls-this-week-roku-palo-alto-and-biogen-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6780714392662048
2176,11/25/2024 3:26:15 PM,Jefferies Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/jefferies-remains-a-buy-on-biogen-biib-1034062331,neutral,0.9425736665725708
2177,11/26/2024 1:55:40 PM,Anavex gains after seeking EU marketing nod for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4335176-anavex-gains-seeking-eu-marketing-nod-alzheimer-s-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9270049929618835
2178,11/26/2024 4:15:09 PM,Biogen put volume heavy and directionally bearish,TipRanks,/news/stocks/biogen-put-volume-heavy-and-directionally-bearish-1034067745,negative,0.9400905966758728
2179,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8861560225486755
2180,11/28/2024 12:40:07 AM,"Eisai, Biogen launch Leqembi in South Korea",TipRanks,/news/stocks/eisai-biogen-launch-leqembi-in-south-korea-1034073833,neutral,0.9049132466316223
2181,11/28/2024 1:47:20 AM,RBC Capital Sticks to Its Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-biogen-biib-1034074001,positive,0.49897974729537964
2182,12/4/2024 11:45:10 PM,"Eisai, Biogen say LEQEMBI approved for treatment of early AD in Mexico",TipRanks,/news/stocks/eisai-biogen-say-leqembi-approved-for-treatment-of-early-ad-in-mexico-1034099563,positive,0.5772753953933716
2183,12/5/2024 2:02:36 AM,Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment ,RTTNews,/news/stocks/eisai-and-biogen-mexico-approves-leqembi-for-early-alzheimer-s-disease-treatment-1034099375,positive,0.6716170310974121
2184,12/5/2024 1:45:41 PM,GeneDx expands access to exome testing for pediatric epilepsy patients,TipRanks,/news/stocks/genedx-expands-access-to-exome-testing-for-pediatric-epilepsy-patients-1034103285,positive,0.8776916265487671
2185,12/5/2024 6:12:25 PM,"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alkermes-alks-biogen-biib-and-edwards-lifesciences-ew-1034104745,neutral,0.914422869682312
2186,12/9/2024 10:35:05 AM,Biogen downgraded to Hold from Buy at Jefferies,TipRanks,/news/stocks/biogen-downgraded-to-hold-from-buy-at-jefferies-1034113593,neutral,0.6204178929328918
2187,12/9/2024 10:35:18 AM,Biogen’s Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating,TipRanks,/news/stocks/biogen-s-modest-growth-prospects-and-revenue-challenges-highlighted-in-hold-rating-1034113591,neutral,0.6173272132873535
2188,12/9/2024 7:18:10 PM,"Biogen downgraded to hold by Jefferies, Ocrevus royalties cited",Seeking Alpha,https://seekingalpha.com/news/4379444-biogen-downgraded-to-hold-by-jefferies-ocrevus-royalties-cited?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8720489740371704
2189,12/10/2024 12:10:15 PM,Biogen reinstated with a Neutral at BofA,TipRanks,/news/stocks/biogen-reinstated-with-a-neutral-at-bofa-1034119668,neutral,0.8916740417480469
2190,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,neutral,0.8453128933906555
2191,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8290338516235352
2192,12/12/2024 10:37:54 PM,"Biogen ALS drug needs to be covered by MA plans, CMS says",Seeking Alpha,https://seekingalpha.com/news/4386075-biogen-als-drug-needs-to-be-covered-by-ma-plans-cms-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8757205009460449
2193,12/16/2024 11:21:05 AM,Biogen downgraded to Hold from Buy at Stifel,TipRanks,/news/stocks/biogen-downgraded-to-hold-from-buy-at-stifel-1034140578,neutral,0.8223469257354736
2194,12/16/2024 2:35:49 PM,"Netflix, MongoDB downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/netflix-mongodb-downgraded-wall-street-s-top-analyst-calls-1034142189,neutral,0.7343029379844666
2195,12/18/2024 12:00:22 PM,Eli Lilly Alzheimer's therapy approved in China,Seeking Alpha,https://seekingalpha.com/news/4387585-eli-lilly-alzheimers-therapy-approved-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5417210459709167
2196,12/19/2024 2:16:59 PM,PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone,Seeking Alpha,https://seekingalpha.com/news/4388085-ptc-therapeutics-submits-nda-for-friedreich-ataxia-treatment-vatiquinone?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8509451746940613
2197,12/20/2024 9:30:23 AM,Biogen downgraded to Market Perform from Outperform at BMO Capital,TipRanks,/news/stocks/biogen-downgraded-to-market-perform-from-outperform-at-bmo-capital-1034161195,negative,0.8419511914253235
2198,12/20/2024 6:07:44 PM,Biogen’s Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles,TipRanks,/news/stocks/biogen-s-challenges-and-cautious-outlook-hold-rating-amid-revenue-growth-struggles-and-neurology-market-hurdles-1034163849,negative,0.9556353092193604
2199,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9418226480484009
2200,1/2/2025 3:40:30 AM,Biotech Stocks Facing FDA Decision In January 2025 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2025-1034184979,neutral,0.9066577553749084
2201,1/2/2025 9:55:08 AM,Biogen downgraded to Neutral from Overweight at Piper Sandler,TipRanks,/news/stocks/biogen-downgraded-to-neutral-from-overweight-at-piper-sandler-1034186367,neutral,0.46647194027900696
2202,1/2/2025 2:40:57 PM,"Alphabet, Uber downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/alphabet-uber-downgraded-wall-street-s-top-analyst-calls-1034187799,negative,0.7434813976287842
2203,1/2/2025 5:06:06 PM,Tesla reports below-consensus deliveries: Morning Buzz,TipRanks,/news/stocks/tesla-reports-below-consensus-deliveries-morning-buzz-1034188108,neutral,0.8962764739990234
2204,1/2/2025 6:19:17 PM,Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds,Seeking Alpha,https://seekingalpha.com/news/4392088-biogen-stock-cut-piper-sandler?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7294816374778748
2205,1/6/2025 3:00:02 PM,"Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart",Seeking Alpha,https://seekingalpha.com/news/4392667-healthcare-sectors-2024-gainers-and-losers-intuitive-surgical-boston-scientific-tops-chart?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.76433265209198
2206,1/7/2025 1:30:25 PM,Biogen price target lowered to $231 from $260 at RBC Capital,TipRanks,/news/stocks/biogen-price-target-lowered-to-231-from-260-at-rbc-capital-1034201339,negative,0.8017409443855286
2207,1/7/2025 10:23:11 PM,Solid Biosciences stock jumps 11% post-market on FDA update,Seeking Alpha,https://seekingalpha.com/news/4393241-solid-biosciences-stock-jumps-post-market-on-fda-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8207141757011414
2208,1/8/2025 1:10:18 AM,Biogen price target lowered to $220 from $302 at Truist,TipRanks,/news/stocks/biogen-price-target-lowered-to-220-from-302-at-truist-1034202829,negative,0.42884403467178345
2209,1/8/2025 1:15:43 AM,Truist Financial Sticks to Their Buy Rating for Biogen (BIIB),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-biogen-biib-1034202852,neutral,0.7316833138465881
2210,1/9/2025 12:40:35 PM,Biogen appoints Feire as Head of Business Development and External Innovation,TipRanks,/news/stocks/biogen-appoints-feire-as-head-of-business-development-and-external-innovation-1034210742,neutral,0.9242650866508484
2211,1/10/2025 11:40:16 AM,Wells Fargo Issues a Hold Rating on Biogen (BIIB),TipRanks,/news/stocks/wells-fargo-issues-a-hold-rating-on-biogen-biib-1034214464,neutral,0.8999046683311462
2212,1/10/2025 11:55:19 PM,Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen,TipRanks,/news/stocks/sage-therapeutics-confirms-7-22-per-share-acquisition-proposal-from-biogen-1034216923,neutral,0.7112671136856079
2213,1/11/2025 1:34:40 PM,Sage confirms Biogen’s bid to acquire remaining stake,Seeking Alpha,https://seekingalpha.com/news/4394305-sage-stock-gains-biogens-buyout-offer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8275848627090454
2214,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8774528503417969
2215,1/13/2025 12:36:13 PM,Truist Financial Remains a Buy on Biogen (BIIB),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-biogen-biib-1034221440,neutral,0.9005795121192932
2216,1/13/2025 1:57:03 PM,Piper Sandler Sticks to Its Hold Rating for Biogen (BIIB),TipRanks,/news/stocks/piper-sandler-sticks-to-its-hold-rating-for-biogen-biib-1034221937,neutral,0.8267583250999451
2217,1/13/2025 2:06:33 PM,Morning Movers: Intra-Cellular surges following deal to be bought by J&J,TipRanks,/news/stocks/morning-movers-intra-cellular-surges-following-deal-to-be-bought-by-j-j-1034222103,neutral,0.6571653485298157
2218,1/13/2025 2:30:14 PM,BofA moves to No Rating on Sage Therapeutics after Biogen bid,TipRanks,/news/stocks/bofa-moves-to-no-rating-on-sage-therapeutics-after-biogen-bid-1034222315,neutral,0.8329285383224487
2219,1/13/2025 2:40:30 PM,"Biogen bid for Sage does not change narrative, says BMO Capital",TipRanks,/news/stocks/biogen-bid-for-sage-does-not-change-narrative-says-bmo-capital-1034222272,neutral,0.9398120045661926
2220,1/13/2025 2:41:12 PM,"Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist",TipRanks,/news/stocks/sage-therapeutics-takeover-bid-undervalues-zurzuvae-says-truist-1034222267,positive,0.9381135702133179
2221,1/13/2025 4:35:26 PM,"Sage takeout bid implies zero enterprise value, says Mizuho",TipRanks,/news/stocks/sage-takeout-bid-implies-zero-enterprise-value-says-mizuho-1034222619,negative,0.675452709197998
2222,1/13/2025 5:10:43 PM,"J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz",TipRanks,/news/stocks/j-j-to-acquire-intra-cellular-clearwater-to-buy-enfusion-morning-buzz-1034222650,neutral,0.9126174449920654
2223,1/14/2025 12:22:25 AM,FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatment,TipRanks,/news/stocks/fda-accepts-eisai-biogen-s-bla-for-leqembi-in-early-ad-treatment-1034223233,positive,0.5213785171508789
2224,1/14/2025 1:05:00 AM,FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/fda-accepts-leqembi-lecanemab-irmb-biologics-license-application-for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimer-s-disease-1034223051,positive,0.8733581900596619
2225,1/14/2025 2:07:15 AM,FDA Accepts Eisai And Biogen's BLA For Subcutaneous LEQEMBI For Early Alzheimer's Disease ,RTTNews,/news/stocks/fda-accepts-eisai-and-biogen-s-bla-for-subcutaneous-leqembi-for-early-alzheimer-s-disease-1034223139,neutral,0.6730489134788513
2226,1/14/2025 11:52:57 AM,"Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review",Seeking Alpha,https://seekingalpha.com/news/4394818-biogen-eisai-alzheimers-injection-gets-fda-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6458012461662292
2227,1/14/2025 8:57:54 PM,Biogen stock at lowest level since February 2013 following J.P. Morgan presentation,Seeking Alpha,https://seekingalpha.com/news/4395035-biogen-stock-at-lowest-level-since-february-2013-following-jp-morgan-presentation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9653680324554443
2228,1/14/2025 9:57:47 PM,"Sarepta, Biogen drugs with accelerated approval under fire in FDA report",Seeking Alpha,https://seekingalpha.com/news/4395072-sarepta-biogen-drugs-with-accelerated-approval-under-fire-in-fda-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8277693390846252
2229,1/15/2025 12:25:40 PM,Biogen’s Hold Rating: Navigating Challenges in Alzheimer’s Treatments and Pipeline Development,TipRanks,/news/stocks/biogen-s-hold-rating-navigating-challenges-in-alzheimer-s-treatments-and-pipeline-development-1034231194,neutral,0.8220357298851013
2230,1/16/2025 1:26:04 AM,Biogen Hold Rating: Balancing Promising Prospects with Market Uncertainties,TipRanks,/news/stocks/biogen-hold-rating-balancing-promising-prospects-with-market-uncertainties-1034232856,positive,0.9332897663116455
2231,1/17/2025 11:47:56 AM,Biogen (BIIB) Receives a Hold from Piper Sandler,TipRanks,/news/stocks/biogen-biib-receives-a-hold-from-piper-sandler-1034240175,neutral,0.6569689512252808
2232,1/17/2025 11:10:08 PM,Sage sues Biogen in wake of $469M buyout offer: report,Seeking Alpha,https://seekingalpha.com/news/4396363-sage-sues-biogen-in-wake-of-469m-buyout-offer-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6602106690406799
2233,1/18/2025 4:31:23 PM,Trending stocks as Wall Street bounces back with strong week,Seeking Alpha,https://seekingalpha.com/news/4396381-trending-stocks-as-wall-street-bounces-back-with-strong-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8051238656044006
2234,1/22/2025 7:01:21 PM,Biogen partner Eisai reportedly sees FY25 launch for home version of Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4397509-biogen-partner-sees-fy25-launch-leqembi-home-version?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6331828832626343
2235,1/23/2025 12:41:39 PM,"Biogen announces FDA, EMA accepted applications for higher dose of nusinersen",TipRanks,/news/stocks/biogen-announces-fda-ema-accepted-applications-for-higher-dose-of-nusinersen-1034260695,positive,0.8871389031410217
2236,1/23/2025 1:30:54 PM,FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA,GlobeNewswire,/news/stocks/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma-1034259210,positive,0.8554127812385559
2237,1/23/2025 1:48:39 PM,Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis,Seeking Alpha,https://seekingalpha.com/news/4397815-biogen-ionis-spinraza-being-reviewed-higher-dose-biib?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9447644352912903
2238,1/23/2025 2:01:22 PM,Biogen Says FDA And EMA Accept Applications For Higher Dose Regimen Of Nusinersen In SMA ,RTTNews,/news/stocks/biogen-says-fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma-1034259358,positive,0.878285825252533
2239,1/27/2025 12:20:04 AM,"FDA approves Eisai, Biogen’s sBLA for lecanemab-irmb IV dosing",TipRanks,/news/stocks/fda-approves-eisai-biogen-s-sbla-for-lecanemab-irmb-iv-dosing-1034269272,positive,0.5822617411613464
2240,1/27/2025 12:33:52 AM,FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease,GlobeNewswire,/news/stocks/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimer-s-disease-1034269223,positive,0.8248187303543091
2241,1/27/2025 2:13:58 AM,FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease ,RTTNews,/news/stocks/fda-approves-once-every-four-weeks-maintenance-dosing-of-leqembi-for-early-alzheimer-s-disease-1034269247,neutral,0.8079003095626831
2242,1/27/2025 11:45:39 AM,Biogen’s Hold Rating: Balancing Modest Gains and Strategic Uncertainty,TipRanks,/news/stocks/biogen-s-hold-rating-balancing-modest-gains-and-strategic-uncertainty-1034272055,positive,0.9138777256011963
2243,1/27/2025 2:26:04 PM,"Sage Therapeutics initiates strategic review, rejects Biogen proposal",TipRanks,/news/stocks/sage-therapeutics-initiates-strategic-review-rejects-biogen-proposal-1034273284,negative,0.7496810555458069
2244,1/27/2025 2:41:42 PM,"Sage Therapeutics rejects Biogen bid, starts strategic review",Seeking Alpha,https://seekingalpha.com/news/4398870-sage-therapeutics-rejects-biogen-bid-starts-strategic-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8898295164108276
2245,1/27/2025 3:11:39 PM,FDA approves Leqembi four-week maintenance dosing,Seeking Alpha,https://seekingalpha.com/news/4398864-fda-approves-leqembi-four-week-maintenance-dosing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5178614258766174
2246,1/27/2025 4:48:33 PM,"Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up ",RTTNews,/news/stocks/sage-therapeutics-explores-alternatives-rejects-biogen-s-proposal-stock-up-1034272655,neutral,0.8363507390022278
2247,1/27/2025 5:10:31 PM,"China’s DeepSeek sinks tech, AT&T reports Q4 beat: Morning Buzz",TipRanks,/news/stocks/china-s-deepseek-sinks-tech-at-t-reports-q4-beat-morning-buzz-1034273722,neutral,0.7775600552558899
2248,1/28/2025 11:36:46 AM,Biogen price target lowered to $160 from $190 at Citi,TipRanks,/news/stocks/biogen-price-target-lowered-to-160-from-190-at-citi-1034277153,negative,0.7762544751167297
2249,1/29/2025 12:27:14 PM,Biogen (BIIB) Gets a Buy from RBC Capital,TipRanks,/news/stocks/biogen-biib-gets-a-buy-from-rbc-capital-1034283473,neutral,0.6299070119857788
2250,1/29/2025 9:10:13 PM,Larimar started at buy by Truist on Friedreich's ataxia drug,Seeking Alpha,https://seekingalpha.com/news/4400041-larimar-started-at-buy-by-truist-on-friedreichs-ataxia-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8511669635772705
2251,1/29/2025 9:55:18 PM,Sage Therapeutics price target raised to $9 from $6 at Mizuho,TipRanks,/news/stocks/sage-therapeutics-price-target-raised-to-9-from-6-at-mizuho-1034284957,positive,0.9478965997695923
2252,1/30/2025 8:32:24 AM,"VOO ETF News, 1/30/2025",TipRanks,/news/stocks/voo-etf-news-1-30-2025-1034287469,neutral,0.940527081489563
2253,1/30/2025 11:51:04 AM,Biogen (BIIB) Gets a Hold from Piper Sandler,TipRanks,/news/stocks/biogen-biib-gets-a-hold-from-piper-sandler-1034288615,neutral,0.8682826161384583
2254,1/31/2025 11:40:32 AM,Biogen provides update on EU regulatory review of lecanemab in Alzheimer’s,TipRanks,/news/stocks/biogen-provides-update-on-eu-regulatory-review-of-lecanemab-in-alzheimer-s-1034294808,neutral,0.9153403043746948
2255,1/31/2025 12:09:30 PM,"Biogen, Eisai Alzheimer’s drug review delayed in EU",Seeking Alpha,https://seekingalpha.com/news/4401328-biogen-stock-focus-alzheimers-drug-review-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8348605632781982
2256,1/31/2025 12:30:52 PM,Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union,GlobeNewswire,/news/stocks/update-on-regulatory-review-of-lecanemab-for-early-alzheimer-s-disease-in-the-european-union-1034294765,neutral,0.9004918336868286
2257,2/1/2025 7:36:00 PM,"Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more",Seeking Alpha,https://seekingalpha.com/news/4401274-key-deals-this-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9281123280525208
2258,2/1/2025 11:45:00 PM,"Notable Healthcare headlines for the week: Moderna, AbbVie, Thermo Fisher, J&J in focus",Seeking Alpha,https://seekingalpha.com/news/4400864-notable-healthcare-headlines-for-the-week-moderna-thermo-fisher-jj-in-focus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9122067093849182
2259,2/7/2025 12:05:24 PM,"QQQ ETF Update, 2/7/2025 ",TipRanks,/news/stocks/qqq-etf-update-2-7-2025 -1034326992,neutral,0.9336649775505066
